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Group 3 medulloblastoma (MBGroup3) is a highly aggressive tumour characterised by MYC 
amplification and elevated expression (17% of MBGroup3). MYC amplification confers a dismal 
prognosis, and there is an urgent unmet need for novel therapeutic approaches. The 
identification and targeting of MYC’s biological dependencies thus represent a promising 
strategy to treat MYC-driven MBGroup3 tumours.  
Methods 
Three independent MYC-regulable isogenic MBGroup3 cell lines, in which MYC expression can 
be directly regulated by shRNA, were used to characterise MYC-dependency in these novel 
models of MBGroup3 tumours. The lines were used to investigate the role of MYC in drug 
resistance and sensitivity by characterising the MYC-dependent response to a panel of cancer 
therapeutics and small molecule inhibitors, to identify drugs whose efficacy is MYC-
dependent, or which synergise with MYC knockdown. Three indirect MYC-targeting strategies 
(targeting MYC transcription and MYC mRNA translation) were assessed using candidate 
drugs, alongside undertaking a high-throughput compound screen (HTCS) (>500 inhibitors) 
using the models.  
Results 
Data from the MYC-dependent lines was used to identify MYC-dependent differences in drug-
sensitivity between MYC-overexpressing and MYC-knockdown cell lines after inhibition of 
specific proteins. This approach identified several specific druggable dependencies (e.g. cell 
cycle regulators, DNA-damage response controllers, mitotic control machinery) with potential 
for the development of treatments against MBGroup3. Integration of drug-sensitivity results 
with data on MYC transcriptional (by RNA-seq) and biological (by whole-genome CRISPR 
screening) dependencies in the models, identified BRD4, PLK1, CHK1 and AURK as specific 
molecular targets. Subsequent validation of target inhibition revealed MYC-dependent 
effects, associated with downregulation of MYC and target-dependent pathways, across 






These findings support the development of PLK1, CHK and AURK inhibition as therapeutic 
approaches against MYC-dependent MBGroup3. Future work is now essential to validate our 
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Cancer is a group of genetic diseases characterised by uncontrolled cell proliferation, leading 
to the accumulation of fast-growing abnormal cells with the ability to invade surrounding 
tissues, and disseminate throughout the body. Cancer is a complex disease that involves 
progressive dynamic changes in cells’ genome to progressively acquire the mechanisms that 
will direct their transformation from normal human cells into malignant derivatives (Hanahan 
and Weinberg, 2000). 
Tumour development and progression requires the acquisition of specific cellular capabilities, 
including sustained proliferative signalling, evasion of growth suppressors, cell death 
resistance, replicative immortality, induction of angiogenesis, activation of invasion and 
metastatic mechanisms, deregulation of cellular energetics and the ability to bypass the 
immune system (Figure 1)(Hanahan and Weinberg, 2000). Acquisition of these multiple 
hallmarks is dependent on the acquisition of a succession of genetic alterations that affect 
genes involved in the biological processes mentioned above, which is promoted by genomic 
instability and a tumour-promoting microenvironment (Hanahan and Weinberg, 2000, 
Hanahan and Weinberg, 2011). 
 
Figure 1.1. Hallmarks of cancer.Illustrative representation of the 12 hallmarks of cancer as described 






Despite great efforts and advances over the last ten years to understand this complex disease, 
cancer is still one of the biggest health problems worldwide, and one of the greatest 
challenges faced by science and medicine. Over the last ten years, cancer incidence rates have 
increased by 20% in the United Kingdom, with a yearly average of 364,000 new cancer cases 
in the UK (CRUK, 2016). Despite the diversity and disparity of cancer types, breast, prostate, 
lung and bowel cancers account for 53% of all cancers diagnosed (Figure 1.2). 
 
Figure 1.2. Incidence (%) of most common cancer in the United Kingdom. NHL, Non-hodgkin’s 





















1.2 Paediatric cancer 
Paediatric cancer is rare (an average of 1900 new cases per year in the United Kingdom), 
accounting for less than 1% of all new cancer diagnosis (CRUK, 2016). Recent decades have 
seen cancer incidence rates among children and adolescents increase, whilst death rates have 
experienced an overall reduction of 63%, as a result of major advances in cancer diagnosis and 
treatments (Hudson et al., 2015).  
Leukaemia, central nervous system (CNS) tumours, and lymphomas are the most common 
types of cancer diagnosed in children, accounting for more than two thirds of all paediatric 
cancers (Figure 1.3). Despite ranking second in terms of incidence, brain, CNS, and intracranial 
tumours are the most frequent cause of death amongst children (CRUK, 2016). 
Despite all the progress made, current therapy causes long-term sequelae and related 
toxicities (Calaminus et al., 2007). The substantial progress on survival rates for the majority 
of childhood cancers indicates the need for continued advances and research to find effective 
treatments to further reduce childhood cancer mortality and the treatment-related toxicities 
that accompany it (Landier et al., 2015).  
 
Figure 1.3. Incidence (%) rates of childhood cancers in the United Kingdom. NHL, Non-hodgkin’s 
lymphoma. (CRUK, 2016).  
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1.2.1 Tumours of the CNS  
The most commonly diagnosed type of CNS tumours are gliomas. Gliomas arise in the glial 
cells of either the brain or the spine, of which astrocytomas are the most frequent subtypes. 
Embryonal tumours account for approximately 19% of all childhood brain cases, and are the 
second most frequent form of malignant tumours. This group includes atypical 
teratoid/rhabdoid tumours (AT/RT), primitive neuroectodermal tumours of the central 
nervous system (CNS-PNETs) and medulloblastoma (MB). Embryonal CNS tumours are 
extremely aggressive tumours and are associated with higher mortality rates and long-term 
side effects for the survivors. They are the most common form of malignant brain tumour, of 






Tumours of the central nervous system (CNS) and brain are the second most common solid 
malignancies diagnosed in children, comprising 25-30% of childhood cancer diagnoses (Ward 
et al., 2014)(Figure 1.4). Medulloblastomas are the most frequent malignant brain tumours 
(WHO grade IV), accounting for 10% of all paediatric deaths from cancer (Pizer and Clifford, 
2009) 
 
Figure 1.4. MRI of a medulloblstoma.Sagittal view of a cranial MRI image of a patient with 
medulloblatoma, indicated by the arrow. Image provided by Prof. Simon Bailey (PBTG, Newcastle). 
 
MB defines a heterogeneous group of intracranial embryonal tumours, with a male to female 
predominance (1.8:1) and a peak incidence at 4-7 years of age. However, they can occur at 
any age from infants to elderly patients, although they are far more rare in adulthood. MB 
commonly arise in the cerebellum in the posterior fossa of the cranium, and are characterised 
by a tendency to disseminate (~35% of cases at diagnosis) commonly via cerebrospinal fluid 
(CSF) pathways (Smoll and Drummond, 2012, Pizer and Clifford, 2008).  
Insights into MB biology, based on histopathological features and molecular signatures have 
enabled the sub-classification of this heterogeneous disease and now inform treatment 
strategies. However, despite huge advances in understanding the disease biology, over 30% 
of MB patients will experience disease recurrence, from which current survival rates are under 




1.3.2 Diagnosis and staging 
The diagnosis of MB is based on clinical symptoms, magnetic resonance imaging (MRI) of the 
brain and a lumbar puncture of CSF cytology, to assess the presence of primary tumour and 
metastasis (Northcott et al., 2019).   
Patients with MB usually present with symptoms that are a direct effect of the tumour 
localisation in the brain, with obstruction of CSF and increased intracranial pressure (Pizer and 
Clifford, 2008). Some of these symptoms include vomiting, headaches, speech and optical 
disturbances, and ataxia.  
Clinical staging of the disease involves MRI of the brain and CSF cytology at the time of 
diagnosis. Staging of MB uses the modified Chang’s classification (Chang et al., 1969) to 
determine the metastatic state of the disease, which ranges from M0 to M4 (Table 1.1).  
Metastatic stage Definition 
M0 no evidence of metastasis 
M1 presence of tumour cells in CSF 
M2 Intracranial metastasis 
M3 spinal metastasis 
M4 metastasis outside the CNS 
 
Table 1.1. Metastatic staging of Medulloblstoma. Adapted from Chang et al., 1969. 
 
Current protocols for clinical trials and patient management group patients into two main risk 
categories, standard and high risk, in order to adjust treatment according to the extent of the 
disease.  
Standard-risk children are those over the age of 3, with no evidence of metastatic spread at 
diagnosis, with complete or almost-total tumour resection. High-risk patients are those 
presenting any of the above risk factors, thus requiring intensified therapy, including higher 
doses of chemotherapy, hyperfractionated radiotherapy (HFRRT) and stem cell rescue (Table 
1.2) (Ellison, 2010, Ramaswamy et al., 2016). All children under 3 years of age are now 
classified as high-risk as they do much worse after treatment.  
Incorporation of risk stratification schemes in the clinical setting based on disease risk has 
underpinned a dramatic improvement in survival rates in the last three decades, where 
around 80% of standard risk patients survive over 5 years, and between 60-65% of those with 
high-risk features (Juraschka and Taylor, 2019).   
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Parameters  Standard Risk Group  High Risk Group  
Age Patients older than 3 years of age Patients younger than 3 years of age 
Extent of previous 
surgical resection 
<1.5 cm² residual tumour 
after resection 
Subtotal resection or >1.5 cm² 
residual tumour after resection 
Tumour stage M0 stage confirmed by MRI and CSF sampling 
M1-M3 stage or presence of 
leptomeningeal seeding 
 
Table 1.2. Parameters used to risk stratify children with medulloblastoma.  
 
1.3.3 Prognostic factors  
Before the identification of MB subgroups, patient risk stratification was based on metastatic 
stage (Chang’s classification), age at diagnosis, histological variant and extent of resection to 
divide patients into high- and standard-risk schemes for treatment adjustment.  
The molecular characterisation of MB allowed the incorporation of subgroup and molecular 
characteristics to the clinicopathological variants to stratify the disease to adjust therapeutic 
regimes according to patients’ prognosis. 
This features are currently being used in the risk stratification schemes for the pan-European 
PNET5 and the United States clinical trial for medulloblastoma (Pizer and Clifford, 2009, 
Gottardo et al., 2014, Ramaswamy et al., 2016). Current disease stratification factors used in 
ongoing clinical trials are summarised in Table 1.3.   
 
Table 1.3. Pathological and clinical biomarkers used for clinical trials. M+, metastatic disease; R+, 
subtotal resection; LCA, large-cell/anaplastic histology;  MBWNT, WNT medulloblastoma; MBSHH, SHH 
medulloblastoma;  SIOP, International Society of Paediatric Oncology; HR, high-risk; PNET, primitive 
neuro ectodermal tumours. 
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1.3.4 Histological subtypes 
Accurate MB diagnosis can be difficult since the posterior fossa is a common location for other 
types of tumours to arise, which can present with similar features to MB. Therefore, 
integrated histopathological and molecular analysis alongside brain imaging is essential for 
MB diagnosis.  
According to the 2016 World Health Organization (WHO) classification of tumours of the CNS, 
MB comprises four main biological subtypes: classic (CLA), desmoplastic/nodular (DN), 
medulloblastoma with extensive nodularity (MBEN) and large-cell/anaplastic (LCA, a 
combined category)(Figure 1.5)(Villa et al., 2018, Gilbertson and Ellison, 2008, Ellison, 2010).  
Classic MB is the most common histological subtype, present in 70% of all cases; LCA and 
DN/MBEN each represent between 10-15% of patients. Distribution of histological variants 
varies depending on age and partially correlates with the molecular subgroups, which can 
often be used as prognostic factors to risk stratify the disease (Gajjar and Robinson, 2014).  
In the WHO classification 2016, an adaptation was made to jointly diagnose large-cell and 
anaplastic medulloblastomas  as large-cell/anaplastic (LCA) medulloblastomas, since both rare 
entities showed mixed cellular composition and were difficult to differentiate from one 
another (Pietsch and Haberler, 2016). LCA histology can be found in all subgroups, and it is 
indicative of aggressive tumours with the ability to metastasise. LCA is used as prognostic 
marker to identify patients with high-risk disease. 
On the other hand, DN/MBEN histology is linked to a much more favourable prognosis in 




Figure 1.5. Histological subtypes of medulloblastoma. Microscopy images showing the different 
histological features that MBs present. a) Classic MB is characterised by packed cells surrounded by 
very little cytoplasm, with high mitotic and apoptotic activity. b) DN MB are characterised by the 
variable presence of nodules (N) of differentiated neurocytic cells. Among the nodules desmoplastic 
internodular (IN) regions are interspersed. c) MBEN MB are characterised by large and irregular 
areas of nodules with internodular desmoplasia in sparse. d) LCA MB are characterised by nuclear 
pleomorphism accompanied by cell wrapping and frequent mitotic and apoptotic figures. 
Abbreviations: DN, desmoplastic nodular; LCA, large cell/anaplastic; MBEN, medulloblastoma with 
extensive nodularity. Scale x20. (Adapted from Gupta, 2017) 
1.3.5 Treatment of Medulloblastoma 
The past 20 years have seen significant improvements in MB risk stratification that have led 
to overall increased survival rates up to 80% with little to no change in the treatment protocol 
of standard care established for MB  (Juraschka and Taylor, 2019).  Generally, therapy is based 
on a multimodal treatment that consists of surgical resection and radiotherapy followed by 
chemotherapy. Depending on the presence of risk factors at diagnosis the intensity of 
adjuvant therapy varies (Gandola et al., 2009, Packer et al., 2006, Lannering et al., 2012, von 
Bueren et al., 2016). 
With this approach, the estimated 5-year overall survival is around 80% for non-infants, 
without metastasis, and gross total resection (GTR) of the tumour, and 60% for children 
presenting metastasis at diagnosis and/or subtotal resection (STR)(where a residual portion 
of the tumour, >1.5cm2, is left). Survival estimates have remained stable for the last couple of 
decades (Oyharcabal-Bourden et al., 2005, Packer et al., 2006, Gajjar et al., 2006, Lannering et 




Surgical resection of the tumour is an essential part of MB treatment. The main objectives of 
surgery are to achieve a total gross resection of the primary tumour and to re-establish CSF 
circulation before administration of radio- and chemotherapy (Gerber, 2014). The importance 
of the extent of tumour resection remains a prognostic factor in the molecular era, where GTR 
or near-total resection (NTR; residual portion of the tumour is <1.5cm2) are consistently 
associated with better prognosis, compared to STR (Gerber et al., 2014, Thompson et al., 2016, 
Albright et al., 1996).    
The prognostic significance of subtotal resection, however, remains controversial. Recent 
studies have reported similar prognosis for patients that have GTR or NTR, which leaves the 
surgeons to weigh the potential of leaving residual tumour in order to avoid extensive 
neurological damage (Thompson et al., 2018, Schreiber et al., 2017, Gajjar et al., 1996).     
Aside from primary tumour removal, an important goal of surgery is to provide tissue for 
histological and molecular analysis, which is essential for risk stratification of the disease and 




After neurosurgery, patients are given a localised boost of radiation to the site of the primary 
tumour in the posterior fossa to prevent MB spread in the CSF (Ivanov et al., 2016). 
Craniospinal irradiation (CSI) dose is risk stratified. For standard risk patients, a CSI dose of 
23.4Gy is given in 13 fractions followed by administration of a tumour bed boost of 54-55.8Gy. 
High-risk patients are irradiated with CSI doses of 36Gy, followed by a tumour bed boost to 
55-55.8Gy (Gajjar et al., 2006, Thomas and Noël, 2019, Ivanov et al., 2016). 
Considering that the brains of younger patients are in a stage of rapid development, radiation 
has major consequences for infants and children, it is therefore not recommended in patients 
<3 years of age, but either reduction or omission of radiotherapy have failed to increase 
patient outcomes (Ashley et al., 2012).   
Despite widespread side effects, radiation prolongs survival of patients with MB, which clearly 
implies the need to effectively risk-classify patients in order to lower radiation dosages in 
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those patients with lower risk of dissemination and tumour recurrence. Current studies are 
investigating alternative ways of delivering radiation treatment, such as modulation of 
radiation intensity or use of proton beams, to minimise exposure of normal tissue and avoid 
overexposure (Mulhern et al., 2005, St Clair et al., 2004, Vatner et al., 2018, Yock et al., 2016, 
Deutsch et al., 1996).  
In this regard, the Phase III clinical trial ACNS0331 conducted by the Children’s Oncology Group 
was designed to test whether a 5.4Gy reduction in the CSI dose (total of 18Gy) and boost 
volume resulted in differential overall or event-free survival rates. Administration of 18Gy 
radiation dose with an in-field boost from posterior fossa to tumour bed did not change event 
free survival or overall survival of patients, whereas a reduction of CSI dose resulted in inferior 
survival rates and increased risk of recurrence (Michalski et al., 2016). 
1.3.5.3 Adjuvant Chemotherapy  
Chemotherapy is the second adjuvant in MB treatment, established to increase survival and 
reduce the intensity of radiation by using chemotherapeutic agents (Deutsch et al., 1996, 
Evans et al., 1990). The most widely used chemotherapeutic agents are cisplatin, carboplatin, 
vincristine, cyclophosphamide, and lomustine (Packer et al., 2013, Dhall et al., 2008, Taylor et 
al., 2003). 
The optimal chemotherapeutic regime, as per multi-drug regime and number of cycles 
administrated, has yet not been strictly defined, it remains highly variable between clinical 
trials, which makes the systematic assessment of combinatorial therapy effects hard to 
determine and improve for those patients categorised as high-risk. Nonetheless, the primary 
goal of current chemotherapy regimens are to deliver the minimum required dose with the 
least toxic agents possible for maximal disease control (Northcott et al., 2019).    
MB has always been considered sensitive to chemotherapeutic agents, and standard-risk 
patients under this adjuvant treatment have been reported to have increased event-free 
survival. Drugs listed and dosages are well established in this population of MB patients, but 
adverse side effects are still prevalent. To advance the effectiveness of adjuvant 
chemotherapy regimes in MB, exploration of new and conventional chemotherapeutic agents 
in accordance to molecular subtypes might dictate better responsiveness to therapy with 
fewer or reduced side effects, and improve the management of the disease (Gajjar et al., 2006, 
Packer et al., 2006, Sirachainan et al., 2011, Martirosian and Neman, 2019). 
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1.3.5.4 Treatment side effects  
The effectiveness of the multimodal treatment comes at the expense of long-term sequelae 
and side effects that have a tremendous effect on survivors’ quality of life. Many MB survivors 
experience long term neurocognitive impairments that worsen over time, with a direct effect 
on intelligence quotient (Frange et al., 2009, Edelstein et al., 2011, Ribi et al., 2005).  
Several studies performed over the years have established the importance of radiation 
therapy volume and age at treatment on intelligence quotient (IQ). Despite the use of lower 
CSI doses for standard-risk patients, radiation is still severely detrimental to younger patients 
(<8.8 years), where several studies have reported up to 12 and 14-point IQ deficit for patients 
treated with radiation in comparison to those who did not receive it. Also, lower IQ points 
after cranial irradiation was seen in younger patients in comparison to those who were older 
at treatment (>8.8 years)(Palmer et al., 2003, Palmer et al., 2007, Gottardo and Gajjar, 2006). 
Resection in itself can be problematic and the main cause of neurological deficits, with 
cerebellar mutism syndrome occurring in approximately 25% of patients. As a result of 
radiation and adjuvant chemotherapy patients develop neuroendocrine disorders, 
orthopaedic impairments, gonadal alterations, hormonal dysfunctions, along with the 
development of secondary malignancies (Law et al., 2012, Kennedy et al., 2014, Chevignard et 
al., 2017, Camara-Costa et al., 2014). 
These long-term side effects reflect the clear need to keep improving therapy stratification in 
an attempt to reduce treatment side effects in standard-risk patients, to increase survival in 
high-risk disease, and to move forward to use novel targeted agents that could reduce the 








1.3.6 Cancer predisposition syndromes 
The association observed between numerous hereditary cancer predisposition syndromes 
and MB was the first step towards insights into the molecular biology of MB. The development 
of MB brain tumours in patients with Gorlin syndrome (PTCH1 mutations – SHH signalling 
pathway), Turcot syndrome (APC mutations – WNT signalling pathway) and Li-Fraumeni 
syndrome (TP53 mutations), led early research studies to focus on understanding how these 
signalling pathways were disrupted in these syndromes and their association with MB 
tumourigenesis (Smith et al., 2014, Brugières et al., 2012, Taylor et al., 2002, Kool et al., 2014). 
Comprehensive genetic predisposition studies have linked germline mutations in APC (Turcot 
syndrome), PTCH1 (Gorlin syndrome), SUFU and TP53 (Li-Fraumeni) to be primary risk factors 
for the development of MB (Figure 1.6). Waszak et al., associated the presence of biallelic 
mutations or heterozygous mutations in BRACA2 and PALB2¸ observed in 1% and <1% of all 
MB cases respectively, with increased risk of MB in patients with germline predisposition 
mutations (Waszak et al., 2018, Twigg et al., 2016, Vladoiu et al., 2019). Previous studies have 
found a 5% risk of medulloblastoma in Gorlin syndrome. In 2014, Smith et al. provided 
evidence that SUFU mutations can cause classical Gorlin syndrome, and that those presenting 
with SUFU mutations have 20x higher risk (33%) of developing medulloblastoma than those 
with PTCH1 mutations (<2%)(Smith et al., 2014).  
 
Figure 1.6. Medulloblastoma genetic predisposition.Germline mutations in six genes have been 
associated with increased risk of MB, which are TP53 (Li-Fraumeni syndrome), APC (Turcot 
syndrome; familial adenomatous polyposis syndrome), PTCH1 (Gorlin syndrome), SUFU, TP53 (Li-
Fraumeni), PALB2 and BRCA2 (Fanconi anemia). Other syndromes associated with increased risk of 
MB in rare cases include Curry-Jones syndrome (CJS; SMO mutations), Greig cephalopolysyndactyly 
syndrome (GCPS; GLI3 mutations), ataxia telangiectasia (ATM mutations) and Bloom syndrome (BS; 
BLM mutations) (Adapted from Northcott, et al., 2019)  
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1.3.7 Molecular subgroups 
Advances in molecular genetics and epigenetics has enabled the molecular profiling of 
tumours, which has shed light on heterogeneous MB biology, and has become the standard 
methodology for subgroup determination and sub-classification within each subgroup. In 
2012, a consensus was reached based on transcriptomic and methylomic data, describing that 
MB comprises four different molecular subgroups: Wnt (MBWNT), Shh (MBSHH), Group 3 
(MBGroup3) and Group 4 (MBGroup4), each of them associated with distinct prognosis, molecular 
alterations, and demographics (Northcott et al., 2012b, Kool et al., 2012, Taylor et al., 2012, 
Schwalbe et al., 2013). 
In 2016, the WHO classification of tumours of the central nervous system officially adopted 
these four molecular subgroups, and since then further refinement of the subgroups has been 
possible allowing the determination of substructures within each subgroup (Northcott et al., 
2017, Schwalbe et al., 2017, Cavalli et al., 2017). 
The four distinct molecular subgroups present substantial biological and survival differences 
(Figure 1.7), which is still present within the sub-classification of each subgroup.  
 
Figure 1.7. Overall survival of patients with MB.Kaplan-Meier plot of overall survival in MB, 
according to molecular subgroup. MBWNT (WNT; blue), MBSHH (red; SHH), MBGroup3 (yellow; Group 3), 




1.3.7.1 WNT subgroup 
MBWNT is the least common subgroup, accounting for approximately 10% of all MB cases.  
MBWNT predominantly affects older children but can occur at all ages, with a peak incidence 
between 6-13 years of age and usually presenting with classic histology (Taylor et al., 2012). 
Tumours that fall in this category are characterised by loss of chromosome 6 (80-85% of 
patients) and hyper-activation of the WNT signalling pathway. Over 85% of MBWNT tumours 
harbour a point mutation in exon 3 of the gene encoding for β-catenin, CTNNB1, leading to 
the constitutive activation of the WNT signalling pathway (Northcott et al., 2012b, Northcott 
et al., 2017, Juraschka and Taylor, 2019). Aberrant activation of the WNT pathway causes β-
catenin stabilisation and consequent nuclear accumulation, which triggers the transcription 
of pro-tumourigenic genes, including MYC and cyclin D1, promoting proliferation.  
Recent studies have shown that the majority of MBWNT tumours that lack CTNNB1 mutations 
correspond to patients with germline APC mutations (Waszak et al., 2018). Other recurrent 
genetic alterations include mutations in DDX3X (36%), SMARCA4 (19%), TP53 (14%), CSNK2B 
(14%), PIK3CA (11%), and EPHA7 (8%)(Figure 1.8)(Jones et al., 2012, Northcott et al., 2017, 
Pugh et al., 2012, Robinson et al., 2012) .    
 
Figure 1.8. WNT subgroup. MBWNT are characterised by alterations in genes involved in the canonical 
wingless (WNT) signalling pathway. Upon binding of Wnt protein to its receptor Frizzled (FZD), 
dishevelled (DSH) is activated which prevents the degradation of β-catenin through the disruption 
of the protein complex APC/AXIN/GSK3β. β-catenin is translocated to the nucleus and activates the 
expression of downstream target genes, including MYC and cyclin D1. When the pathway is inactive, 
β-catenin is phosphorylated and bound to the APC/AXIN/GSK3β protein complex, which mediates 
its proteasomal degradation. The percentage values denote the proportion of patients of MBWNT 




MBWNT confers the best prognosis of all subgroups, with a much lower metastatic spread and 
with survival rates at five years above 95% in patients under 16 years of age. The association 
of <16 years of age and favourable prognosis was not seen in the SJMB12 study performed by 
St. Jude Children's Research Hospital, with 100% survival for all WNT patients.     
The high overall survival (OS) of patients with MBWNT includes those patients presenting high 
risk factors like LCA phenotype or TP53 mutations (summarised in Figure 1.9) (Kool et al., 2012, 
Taylor et al., 2012, Lindsey et al., 2011). 
Current multicentre clinical trials for MB have incorporated subgroup and risk features to 
stratify patients in order to adjust therapy intensity according to their biomarkers, in an 
attempt to reduce treatment toxicity and long-term side effects (NCT02724579; 
NCT02066220; NCT01878617)(Pizer and Clifford, 2009). Currently, only the SJMB12 trial 
enrols high-risk patients on a biologically informed basis, and there are no open trials for high-




Figure 1.9. Summary of the main clinical and molecular features of WNT subgroup.Values for the 
proportion of cases, age, histology 5-year overall survival (OS), frequent mutations and cytogenetics 
of MBWNT. CLA, classic histology; LCA, large-cell/anaplastic histology; DN, desmoplastic nodular 






1.3.7.2 SHH subgroup 
MBSHH accounts for approximately 30% of MB cases, and together with MBWNT, are the best 
defined and understood subgroups. MBSHH tumours are very heterogeneous diseases in terms 
of pathology, response to therapy, and outcome.  
MBSHH often present with nodular/desmoplastic histology, with all MBEN cases belonging 
exclusively to this subtype. MBSHH affects males and females equally, with a bimodal age 
distribution, occurring most commonly in infants less than 3 years of age and in patients 
greater than 16 years old (Summarised in Figure 1.11).   
The subgroup is characterised by alterations in genes involved in the SHH signalling pathway. 
Common alterations found within MBSHH subgroup are mutations in PTCH1 (43%), SUFU (10%), 
and SMO (9%), and amplifications of GLI1 or GLI2 (9%), and MYCN (7%) (Figure 1.10). Most 
adult SHH cases present mutations at the TERT promoter region (39%). Another frequently 
observed alteration is the mutation of TP53, occurring in 9.4% of MBSHH, which confer an 
extremely poor prognosis (Northcott et al., 2012b, Juraschka and Taylor, 2019, Lindsey et al., 
2014, Zhukova et al., 2013).  In a very few cases MBSHH patients have metastatic spread at 
diagnosis and in general have an intermediate prognosis. Despite OS rates around 70%, 
patients with either GLI2 amplifications, chromosome 14 loss, 10q deletions, MYCN 
amplifications and particularly those with TP53 mutations have a poor prognosis and overall 
survival of 41% (Pezzolo et al., 2011, Pugh et al., 2012, Zhukova et al., 2014). 
Four different subtypes have so far been described within MBSHH (SHHα, SHHβ, SHHγ and 
SHHδ)(Cavalli et al., 2017). SHHα has the worst prognosis, which primarily presents with GLI2 
and MYCN amplifications, and mutations in TP53. SHHβ and SHHγ are both infant subtypes, 
with distinct biology and outcome. SHHβ are generally metastatic and harbour multiple focal 
amplifications and focal PTEN deletions, whereas SHHγ are associated with MBEN histology 
and fewer copy number alterations, which have better outcomes than SHHβ. Lastly, the SHHδ 
subtype affects mainly adults and is characterised by TERT promoter mutations (Cavalli et al., 





Figure 1.10. SHH subgroup. MBSHH are characterised by alterations in genes involved in the sonic 
hedgehog (SHH) signalling pathway. When inactive, Ptch receptors (PTCH1) prevent the 
translocation of smoothened receptors (SMO) to the cilium, which mediates the activation of SUFU, 
who binds to GLI1 and GLI2 transcription factors in the cytoplasm preventing their translocation to 
the nucleus, mediating their degradation. Upon binding of SHH to PTCH1, PTCH1 ceases to repress 
SMO, liberating SUFU from binding the Gli proteins, which can then translocate to the nucleus and 
activate the transcription of target genes. The percentage values denote the proportion of patients 
of MBWNT who have the genetic mutation. LOF, loss-of-function (adapted from Northcott, et al., 
2019). 
 
Most advances in targeted therapies have been made in the MBSHH subgroup, where inhibitors 
of the SHH signalling pathway are in phase I/II clinical trials (Romer and Curran, 2005, Gajjar 
et al., 2013). Importantly, resistance to treatment has emerged after exposures to SMO 
inhibitors, which has led to the targeting of CK2 instead (downstream target of SMO in the 
SHH pathway) for durable remission. A phase I/II trial is recruiting patients with recurrent 




Figure 1.11. Summary of the main clinical and molecular features of SHH subgroup. Values for the 
proportion of cases, age, histology 5-year overall survival (OS), frequent mutations and cytogenetics 
of MBSHH. CLA, classic histology; LCA, large-cell/anaplastic histology; DN, desmoplastic nodular 










1.3.7.3 Group 3 subgroup 
MBGroup3 comprise 25% of MBs and carry the worst prognosis of all subgroups, with overall 
survival at 5 years less than 60%. MBGroup3 affect mostly infants and children, with a 2:1 male 
to female predominance. Tumours within this subgroup exhibit LCA or classic histology and 
are characterised by metastatic disease at diagnosis (47%)(Taylor et al., 2012, Jones et al., 
2012, Northcott et al., 2012a). 
Despite having the poorest prognosis, unlike SHH and WNT subgroups, a common driver 
pathway has not yet been identified, and it is the most poorly understood in regards to its 
biology. MBGroup3 present unstable genomes, but the most common recurring alteration is the 
amplification or over-expression of the c-MYC oncogene (c-MYC is hereafter referred to as 
MYC), accounting for 17% of MBGroup3 cases. Clifford and colleagues have shown that the 
gravest prognosis in infant MBGroup3 is defined by the amplification of MYC (copy number ≥5; 
~91% of patients) with patients with this aberration succumbing to disease within 1 year 
(PBTG, unpublished)(Taylor et al., 2012, Northcott et al., 2012b). 
MBGroup3 exhibit tetraploidy, and present several copy number alterations, the most recurrent 
being the loss of chromosomes 17p (~40-45%), 8, 10q and 16q; and gain of chromosomes 1q, 
7, and 18. Chromothripsis is a form of genome structural variation that frequently occurs in 
MYC-amplified MBGroup3. Upregulation GFI1 and GFI1B has been seen in around 15-20% of MB 
cases as a consequence of structural variations placing the coding sequences of both genes 
next to super-enhancers, instigating their activity (‘enhancer hijacking’)(Northcott et al., 2014, 
Northcott et al., 2017, Jones et al., 2012, Taylor et al., 2012, Northcott et al., 2012b, Lee et al., 
2019). 
Somatic mutations are less common in this subgroup, events occurring in only 5% of patients. 
Only 4 genes are recurrently mutated: SMARCA4, KBTBD4, CTDNEP1 and KMT2D. The 
amplification of the OTX2 (2%) and MYCN (5%) can also be seen in a small subset of these 
tumours.  
Like in the other subgroups, several MBGroup3 subtypes have been proposed. In 2017, Schwalbe 
et al., using DNA methylation data, divided MBGroup3 into a high-risk and a low-risk subtype, 
with MYC amplification/overexpression and LCA histology being high-risk features associated 
with shorter progression free survival (summarised in Figure 1.12)(Schwalbe et al., 2017, 





Figure 1.12. Summary of the main clinical and molecular features of Group 3 subgroup. Values for 
the proportion of cases, age, histology 5-year overall survival (OS), frequent mutations and 
cytogenetics of MBGroup3. CLA, classic histology; LCA, large-cell/anaplastic histology; DN, 









1.3.7.4 Group 4 subgroup 
MBGroup4 is the most common subgroup, comprising ~ 40% of all MB diagnosis. MBGroup4 can 
occur at all ages, but is less common in infants, affecting males more frequently (3:1 ratio). 
Despite frequently presenting with CLA histology and metastasis at diagnosis (35-40% of 
cases), patients with MBGroup4 have an intermediate prognosis (Taylor et al., 2012, Northcott 
et al., 2012b). 
Similarly to MBGroup3, the underlying molecular mechanism of this subgroup is poorly 
understood. Gene-level somatic mutations are rare (6-9% of cases), occurring more commonly 
in KDM6A, ZMYM3, KTM2C and KBTBD4, genes encoding for chromatin modifying proteins. 
Common genomic aberrations involve the amplification of MYCN, OTX2 and CDK6 (all 
comprising 6% of cases), and enhancer-hijacking-mediated overexpression of GFI1 and GFI1B 
(5-10%), and PRMD6 (17%)(Figure 1.13). MBGroup4 can also present with large chromosomal 
alterations, especially gains of chromosome 7 and 17q, and the loss of chromosome 8, 11 and 
17p (Northcott et al., 2012b, Northcott et al., 2017, Taylor et al., 2012, Kool et al., 2012). 
As with MBGroup3, the MBGroup4 subgroup was further subdivided into two subtypes, low- and 
high-risk. Features conferring high-risk status are metastatic disease and gain of chromosome 
7; whereas, in a MBGroup4 specific context MYCN amplification and LCA histology did not confer 
a poorer prognosis (Summarised in Figure 1.14)(Schwalbe et al., 2017).      
 
Figure 1.13. Main molecular characteristics of Group 4 subgroup. MBGroup4 tumours present little 
single gene mutations, with overexpression of PRDM6 as a consequence of its translocation 
downstream SNCAIP, promoting its overexpression. The percentage values denote the proportion 





Figure 1.14. Summary of the main clinical and molecular features of Group 4 subgroup. Values for 
the proportion of cases, age, histology 5-year overall survival (OS), frequent mutations and 
cytogenetics of MBGroup4. CLA, classic histology; LCA, large-cell/anaplastic histology; DN, 










1.4 MYC  
he MYC family of oncogenes consists of c-MYC, MYCN and MYCL, which encode c-Myc, N-Myc 
and L-Myc (Nesbit et al., 1999). This family of genes are multifunctional transcription factors 
with helix-loop-helix leucine zipper motifs that regulate the expression of up to 15% of the 
entire genome (Fernandez et al., 2003, Conacci-Sorrell et al., 2014). MYC proteins act as 
transcription amplifiers of effectors involved in multiple cellular processes, including cell-cycle 
progression, metabolism, ribosome biogenesis and protein synthesis (Figure 1.15). The major 
involvement of MYC in controlling such fundamental biological processes requires its strict 
regulation at the expression and functional level (Tansey, 2014). 
 
Figure 1.15. Cellular processes regulated by MYC.As a transcription factor, MYC regulates the 
expression of genes whose effectors are involved in a broad range of cellular functions, including 









1.4.1 MYC structure 
MYC is situated on human chromosome 8q24, and comprises three exons, with one of them 
being non-coding. The two coding exons translate into three different isoforms; the one 
starting at a canonical AUG codon in exon 2 (size 64kDa) is the most studied one, referred to 
as MYC (Hann et al., 1994). MYC proteins are characterised by a highly conserved N-terminal 
region, containing a transactivation domain comprised of two MYC boxes (I and II), essential 
for DNA-binding and MYC’s role as a transcriptional regulator (Ryan and Birnie, 1996). At the 
C-terminal region lies the basic-helix-loop-helix leucine zipper (bHLHZ), required for binding 
to specific DNA sequences (enhancer boxes; E-Box) (Figure 1.16)(Dang, 1999). 
 
 
Figure 1.16. MYC structure and functional domains of human MYC. Schematic representation of 
MYC gene and the structure of its resultant protein products. The sites of the gene’s promoters are 
indicated as P0, P1, P2 and P3. The initiation sites for the translation of the two MYC isoforms are 
shown as codons of the initial amino acids (CUG; AUG); NL, nuclear localization; BR, basic region; 











1.4.2 Transcriptional control of MYC 
MYC regulates transcription of its target gene by dimerization with its protein partner MAX. 
Interaction with MAX is done through the common BR-HLH-LZ motif, which enables the 
formation of a MYC/MAX complex with the ability to bind to the conserved DNA sequence 
(CACGTG) found in E-box elements of target genes. Upon recognition and binding to these 
specific sequences, MYC/MAX heterodimer recruits a chromatin remodelling complex (TRRAP, 
GCN5, TIP60 and TIP48) that allows the stimulation of gene expression (Adhikary and Eilers, 
2005, Pelengaris et al., 2002, Chen et al., 2018b). Alternatively, repression of transcription can 
also occur upon binding with MIZ1 (Figure 1.17). Activation of MYC expression upon mitogenic 
stimuli recruits Miz1 to interact with the MYC/MAX heterodimer to repress transcription of 
MYC target genes. The ratio of Myc and Miz1 bound to E-boxes of gene promoters guide the 
direction of the transcription response (Vo et al., 2016)(Figure 1.16).  
 
Figure 1.17. Interaction of MYC with MAX and MIZ1 to promote/repress genes expression. 
Schematic of the MYC-MAX-MIZ1 interactions to stimulate/repress gene expression. A) Formation 
of the heterodimer MYC/MAX complex promotes gene expression (+) upon binding to Enhancer box 
regions (E-box). B) When Miz1 is recruited to E-boxes with the MYC/MAX heterodimer, MYC 
represses gene transcription (Adapted from Vo et al., 2016) 
 
 
In addition, MAX can also form complexes with the bHLHZ-Mad family proteins, Mga and Mnt, 
which bind to E-box consensus sequences and repress transcription through the recruitment 
of histone deacetylase complexes (Grandori et al., 2000). Cellular differentiation and growth 
arrest has been associated with increased expression of Mad protein, suggesting their 
function as tumour suppressor proteins. To date, Mxi-1 (Mad2) protein is the only Mad family 






1.4.3 MYC protein stability 
It is not surprising, given the importance of MYC as a transcriptional regulator able to 
determine cell fate (proliferation and apoptosis), that sophisticated mechanisms are in place 
to ensure proper levels of MYC expression, at the transcriptional (initiation and elongation), 
post-transcriptional (mRNA stability) and translational level (protein stability)(Sears, 2004). 
MYC protein stability is regulated by several post-translational modifications, which include 
phosphorylation, acetylation, glycosylation and ubiquitination. MYC-stability is mediated by 
its phosphorylation at two specific residues within the N-terminal region, Threonine 58 (T58) 
and Serine 62 (S62), upon mitogenic activation of the Ras-dependent signalling cascade 
(Adhikary and Eilers, 2005). Activation of Ras results in the ERK-mediated phosphorylation of 
MYC at S62, which increases MYC protein stability. By contrast, phosphorylation of the MYC 
Thr58 site by GSK-3β through the PI3K/AKT signalling pathway destabilises MYC and facilities 
the de-phosphorylation of MYC at Ser62. Phosphorylation of the T58 residue is recognised by 
the E3 ubiquitin ligase SCFfbw7, which stimulates the Ub-dependent proteasomal degradation 
of MYC (Figure 1.18). Therefore, MYC stability is granted by the Ras-dependent inhibition of 
GSK-3β, preventing MYC phosphorylation at T58 and its concomitant proteasomal 
degradation (Tansey, 2014, Sears, 2004, Vervoorts et al., 2006). 
 
Figure 1.18. Transcriptional regulation of MYC.MYC protein stability is regulated by its 
phosphorylation at  Serine 62 (S62) and Threonine 58 (T58) of its conserved N-terminal domain, by 
the Ras-dependent signalling cascade. Following mitogen stimulation, Ras is activated, which 
stabilises MYC through its phosphorylation at S62 through the MAPK/ERK pathway and 
phosphorylation at T58 by inhibition of GSK-3β through the PI3K/AKT signalling pathway. 
Phosphorylation of MYC at T58 is recognised by the prolyl isomerase (PIN1), which enables the 
removal of the phosphate residue at S62 by the phosphatase-2A (PP2A). MYC phosphorylation at 
T58 is recognised by the ubiquitin ligase SCFfbw7, which marks MYC for proteasomal degradation 
(adapted from Adhikary and Eilers, 2005).  
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1.4.4 Biological functions of MYC 
1.4.4.1 Cell cycle and proliferation 
One of the key biological functions of MYC is its ability to promote and regulate cell-cycle 
progression. Upon mitogenic stimuli, MYC proteins have the capacity to activate and repress 
genes involved in the process, expediting the entry of both G1 and G2 phases of the cell cycle, 
speeding cells’ cycling rate whilst reducing their requirements for growth factors to sustain it 
(Pelengaris et al., 2002, Tansey, 2014).This is most likely due to the ability of MYC to directly 
upregulate gene expression of cyclin-dependent kinases (cyclin D2, D3, E1, E2, CDC25A, E2F1 
and E2F2) and downregulate those involved in cell cycle arrest (p15,  p21, p27) (Dominguez-
Sola and Gautier, 2014). 
 
1.4.4.2 Apoptosis 
It is now widely acknowledged that programmed cell death by apoptosis is a natural 
impediment during neoplastic transformation. Over the past decade much effort has been 
spent on unravelling MYC-driven apoptosis mechanisms to convert oncogenic levels of MYC 
from pro-survival to pro-apoptotic (McMahon, 2014). 
Oncogenes like MYC activate the apoptotic signalling pathway in a cell-specific context in the 
absence of appropriate survival signals (Figure 1.19). MYC can induce apoptosis by affecting 
the transcription of downstream effectors of the apoptotic pathway, causing an imbalance 
between pro-apoptotic and anti-apoptotic proteins (Tansey, 2014, Pelengaris et al., 2002). 
MYC can regulate the expression of members of the BH3-only category of Bcl-2 family 
proteins, stimulating the expression of Bim (Bcl2 antagonist) whilst inhibiting the expression 
of the pro-apoptotic proteins Bcl-2 and Bcl-XL (Eischen et al., 2001, Pelengaris et al., 2002). 
Bim promotes the release of cytochrome c from the mitochondria causing the induction of 
apoptosis by associating with apoptotic protease-activating factor 1 (APAF1) protein to create 
the apoptosome, which activates the downstream caspase-dependent effectors cascade 





Nonetheless, the ARF-MDM2-p53 axis is the most common pathway by which MYC induces 
apoptosis. Upregulation of expression of the tumour suppressor ARF leads to the 
destabilisation and inactivation of the ubiquitin ligase MDM2, which targets p53 for 
degradation. Induction of p53 leads to the activation of its broad tumour suppressive 
apoptotic response (Soucie et al., 2001, Tansey, 2014). The importance of the ARF/p53 
pathway to combat the tumorigenic capacity of MYC is reflected by the frequent loss of the 
tumour suppressor p53 in human cancers (Phesse et al., 2014). 
 
Figure 1.19. Pathways associated with MYC induced apoptosis. MYC can induce apoptosis through 
several pathways. MYC can stabilise p53 through the induction of p19ARF. Alternatively, MYC can 
directly regulate the expression of the pro-apoptotic BH3-only protein BIM, whilst blocking the 
expression of anti-apoptotic proteins BCL2 and BCL-XL, which both lead to the release of cytochrome 
c from the mitochondria. Another mechanism by which MYC potentially induces apoptosis is through 
its ability to induce genomic instability - DNA damage (DNA double-strand breaks (DSBs)(Adapted 
from Adhikary and Eilers, 2005).  
 
1.4.4.3 Differentiation 
Normal tissues constrain cell growth by driving cell differentiation, which is an irreversible 
post-mitotic state. Inhibition of cell differentiation was one of the first MYC activities to be 
described (Leon et al., 2009). MYC-dependent cell cycle progression is generally incompatible 
with terminal differentiation; suppression of MYC expression has been shown to trigger 
negative growth inhibitory signals that are essential to exit the cell cycle and undergo 
differentiation (Oster et al., 2002). Moreover, severe downregulation of MYC and its 




Several studies have established the importance of the MYC-MAX-Mad network in regulating 
cell proliferation and differentiation (Grandori et al., 2000). MAD protein members MAD1, 
MXI1, MAD3, and MAD4 have been linked to terminal differentiation and inhibition of cell 
cycle progression by antagonising MYC-MAX function as transcriptional activators. MAX-MAD 
heterodimers repress transcription by recruiting class I histone deacetylases to target gene 
promoters, thereby decreasing the accessibility of activator factors to the DNA (Amati et al., 
2001, Pelengaris et al., 2002).   
 
1.4.4.4 Genomic instability  
Neoplastic transformation occurs with the progressive acquisition of changes in the genome, 
conferring upon them selective advantages that lead to their clonal expansion. Under normal 
circumstances, a complex array of DNA monitoring and repair is in place in order to maintain 
genomic integrity, preventing mutation events occurring (Hanahan and Weinberg, 2000). 
The main mechanism by which MYC causes genomic instability is by promoting replication 
stress (Felsher and Bishop, 1999). MYC promotes the rapid turnover of cells by activating the 
transcription of genes involved in cell cycle progression and DNA synthesis, which is in need 
of a rapid replication process. Upregulation of MYC expression coupled with the loss of tumour 
suppressor genes like TP53, prevents cells from sensing DNA damage and its consequent 
repair (Dominguez-Sola and Gautier, 2014, Mazouzi et al., 2014). MYC activation allows cells 
to bypass the checkpoint controls of the cell cycle, allowing the aberrant replication and 
survival of cells with genetic load, which confer a selective advantage to normal cells (Oster et 
al., 2002, Kumari et al., 2017) 
Alternatively, MYC can promote genetic instability by inducing DNA damage through the 
accumulation of reactive oxygen species (ROS)(Vafa et al., 2002). Upregulated MYC expression 
leads to elevated cellular metabolic activity and mitochondrial biogenesis that causes an 






1.5 MYC deregulation in cancer 
MYC has the ability to regulate most of the cellular processes in the body. It is no surprise, that 
under normal circumstances, MYC expression is stringently controlled to ensure cellular 
homeostasis. Deregulation of the strict regulatory control of MYC activity can provide the basis 
to acquire the fundamental traits needed for neoplastic transformation (Dang, 2012). 
In cancer, MYC is the most frequently deregulated oncogene, partly due to the fact that unlike 
other oncoproteins such as Ras, its coding sequence does not need to be changed in order to 
unleash its oncogenic potential  (Grotzer et al., 2009). In fact, most human cancers show 
increased MYC expression, which is correlated with tumour aggressiveness (Vita and 
Henriksson, 2006). Although point mutation and c-MYC locus rearrangements have been 
reported, mostly in Burkitt’s lymphoma, their prevalence is low in other cancers (Schmitz et 
al., 2014).    
MYC deregulation in cancer cells can occur through a series of direct and indirect mechanisms. 
MYC activation can occur through the direct regulation of the cellular mechanisms that 
maintain MYC-expression control, or through the activation of upstream signalling cascades 
that enhance MYC stability (Oster et al., 2002). The most common mechanism to acquire 
constitutive overexpression of MYC is through gene amplification, which can take the form of 
small or large focal amplifications, or in the form of double-minute chromosomes, as an 
extrachromosomal gene amplification (Vita and Henriksson, 2006). 
An additional documented process that can result in oncogene amplification is chromothripsis 
(Figure 1.20). Chromothripsis occurs when cells fail to properly segregate chromosomes 
during mitosis, causing chromosomes to break into multiple fragments causing the 
accumulation of damaged DNA in the cell. When this occurs, the generation of DNA double-
strand breaks triggers the DNA damage response as an attempt to re-join the fragmented 
chromosomal pieces, primarily through the non-homologous end-joining (NHEJ) repair 
mechanism (Rode et al., 2016, Holland and Cleveland, 2012). Through the repair process, 
chromosomes can be randomly joined together, losing those pieces that cannot bind a 
centromere during cell division, whilst some chromosomal fragments might fuse together 
generating a derivative chromosome called a double-minute (Dmin) (Alseraye et al., 2009, 
Koltsova et al., 2019). Dmin containing oncogenes that confer a selective advantage amongst 




Figure 1.20.Chromothripsis as a mechanism of gene amplification. The shattering of chromosomes 
are rearranged and stuck back together through the non-homologous end-joining repair mechanism, 
leading to chromosomes with complex rearrangements. Fragments that are not reincorporated can 
be either lost or ends fused together to form circular, derivative chromosomes (double minute; 
Dmin). Dmin harbouring oncogenes are frequently amplified resulting in increased copy number of 
DNA fragments on these chromosomes. (Adapted from Holland and Cleveland, 2012)  
 
Sustained high levels of MYC have a dramatic impact on cell proliferation, growth, metabolism, 
DNA replication, cell cycle progression, cell differentiation, and metastasis. The genomic 
instability caused by MYC accelerates the multistep tumorigenic process by facilitating the 
acquisition of the set of genetic changes required to maintain the hallmarks of malignancy 
(Gabay et al., 2014). Despite being the most commonly activated oncogene implicated in the 
pathogenesis of human cancers, upregulation of MYC expression alone is incapable of driving 
neoplastic transformation (Gabay et al., 2014). This has led to increased interest in elucidating 
the biological context-specific role of MYC in tumorigenesis, and its complex interacting 
network of genes to identify those who synergise with MYC to promote malignant 
transformation (Meyer and Penn, 2008). 
It is well established that enhanced expression of MYC proteins contribute to almost every 
aspect of tumour biology, hence its involvement in most human cancers. The entire MYC 
family of oncoproteins has been found to be overexpressed in a diverse set of neoplastic 
malignancies, including blood, skin, breast, colon, and brain, becoming a representative 
malignant signature for  each type (Nesbit et al., 1999). The fact that MYC depletion causes 
growth arrest and tumour regression supports the feasibility of MYC targeting as a new 
therapeutic strategy for most, if not all, oncological diseases (Wang et al., 2008). 
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1.6 Role of MYC in Medulloblastoma 
Childhood medulloblastomas are extremely heterogeneous. Highly aggressive MB tumours 
frequently harbour MYC or MYCN amplification and/or expression. MYC and MYCN 
amplifications have been correlated with poor clinical outcomes and are currently accepted 
as adverse prognostic factors in MB (Kool et al., 2012, Ryan et al., 2012). 
However, MYC proteins relate differently to each medulloblastoma subgroup, accentuating 
the importance of considering the molecular subgrouping of the disease for patient risk-
stratification, and the need to clarify the relationship of MYC to MB prognosis.  
1.6.5 MYC in MBWNT subgroup  
Paediatric patients with MBWNT have a favourable prognosis, with >95% survival at 5 years. 
This is despite the frequent occurrence of TP53 mutations in this group, and elevated 
expression of MYC (poor prognostic markers)(Roussel and Robinson, 2013). Noteworthily, 
amplification of the MYC family of oncogenes almost never occur in MBWNT. In this subgroup, 
elevated expression of MYC proteins occurs as a direct consequence of the constitutive 
activation of the WNT signalling pathway, in which MYC is a downstream target, and thus a 
marker of enhanced WNT pathway activity. Therefore, the high levels of MYC expression in a 
subgroup with an excellent prognosis further confirms the notion that MYC expression alone 
is a poor prognosticator (Northcott et al., 2019). 
1.6.6 MYC in MBSHH subgroup  
There is substantial biological heterogeneity within MBSHH. MYCN and MYCL1 are found to be 
uniformly highly expressed in this subgroup, whilst MYC amplification is very rare in this group. 
Activation of the SHH signalling pathway promotes the expression and stabilisation of MYCN, 
which leads to its elevated expression. Moreover, MYCN amplifications are frequently 
observed in MBSHH, specifically in older children and adolescents (SHHα subtype), and are 
predictive of prognosis. Amplification of MYCN is commonly coupled with TP53 mutations and 
LCA histology, high-risk features conveying poor prognosis and significantly worse outcome 




1.6.7 MYC in MBGroup3 subgroup  
MYC is more intricately linked to MBGroup3 than any other subgroup, becoming its defining 
feature. MYC is significantly more highly expressed compared to MBSHH and MBGroup4 (similar 
levels to MBWNT), but its aberrant amplification occurs at a much higher frequency. MYCN 
amplifications are less common in MBGroup3, and occur in a mutually exclusive fashion to  the 
amplification of MYC, suggesting overlapping functions in a subgroup-specific manner 
(Roussel and Robinson, 2013). Recent MB subgroup subclassification divides MBGroup3 into 
high-risk and a low-risk subtypes, in which the high-risk subgroup is associated with MYC 
amplification or overexpression (Figure 1.12).  
1.6.8 MYC in MBGroup4 subgroup  
As in Group 3 tumours, MYCN amplification is a recurrent alteration in MBGroup4. Group 4 
tumours generally present lower expression of the genes MYC and MYCN when compared to 
the other MB subgroups. Contrary to MBGroup3, MBGroup4 patients with MYCN amplification are 
subclassified as low-risk and its amplification does not correlate with decreased survival rates 















1.7 Role of MYC and TP53 in Medulloblastoma   
Medulloblastoma is a very heterogeneous entity and most of its molecular features need to 
be studied in the context of subgroup specificity. A particular example has been the role of 
the tumour suppressor gene TP53 in the oncogenesis of MB (Ramaswamy et al., 2016), which 
has been widely scrutinised in the recent years.  
p53 is one of the most important molecules involved in the pathogenesis of cancers. Tumour 
suppression by TP53 occurs via both transcription-dependent and a transcription-
independent manner (Stiewe, 2007). Transcription-dependent activities occur in the nucleus 
by which p53 regulates transcription of genes involved in the cell cycle, apoptosis, DNA repair, 
transcription, and metabolism. Transcription-independent activities induce apoptosis and 
autophagy in the cytoplasm (Ho et al., 2005, Yu et al., 2019).  In response to cellular stress, 
activation of p53 mediates the upregulation of genes involved in apoptosis, cell-cycle arrest 
and senescence (Riley et al., 2008). Therefore, mutations in TP53 and dysregulation of the 
pathway are important in the pathogenesis of many human cancers, including MB. 
It has been hypothesised that MYC acts co-ordinately and tightly with p53 to mediate 
responses to stresses, where p53 levels accumulate whilst MYC levels are reduced, and vice-
versa. Synchronised up and downregulation of MYC and TP53 determine whether the cells will 
undergo apoptosis or senesce, and important cell fate in cancer and tumourigenesis 
(Ramaswamy et al., 2016).   
TP53 has different roles in medulloblastoma, and the prognostic value of somatic mutations 
in this tumour suppressor gene is subgroup dependent. Patients with WNT tumours 
harbouring somatic TP53 mutations have an excellent prognosis, whereas the prognosis of 
patients with SHH tumours with TP53 mutations is dismal (Zhukova et al., 2013). Children with 
SHHα subtype constitute a high-risk group of patients and have the worst prognosis. This 
subtype primarily presents with GLI2 and MYCN amplifications, and mutations in TP53, and its 
associated with treatment failures and relapse after radiotherapy (Doussouki et al., 2019) 
On the other hand, TP53 mutations are rarely observed in patients with MBGroup3 and MBGroup4 
tumours, but they can be observed at relapse, and are usually associated with MYC 
amplification (Hill et al., 2015, Kool et al., 2014) . Although mutations are not frequent, these 
two subgroups usually present with the loss of one copy of TP53 as a result of the deletion of 
chromosome 17p.  
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1.8 Study of MYC in MBGroup3 context  
Despite the aggressive treatment, over the past two decades survival rates for paediatric 
patients with MB have not increased. Subgroups with dismal prognosis, namely those with 
SHH with TP53 mutations and Group 3 with MYC amplification, respond poorly to therapy, 
usually relapse and are essentially incurable. Therefore, the best opportunity to cure MB is by 
improving frontline therapy efficacy. To increase cure rates, it is of crucial importance to 
develop new targeted therapy strategies and combinational approaches with current 
chemotherapeutic agents for high-risk MB patients. 
Despite this, MBGroup3 driver pathways have not yet been identified, MYC oncogene 
amplification or overexpression is the most common recurring alteration (accounting for 17% 
of MBGroup3 cases), and it is a high-risk factor for this subgroup (Figure 1.21) (Kool et al., 2012, 
Ryan et al., 2012). There is an urgent need to better understand the biology of Group 3 MB 
disease and to elucidate MYC’s role in its pathogenesis and aggressiveness, in order to 
translate this knowledge into the development of new treatment strategies to improve 
survival rates of children with these tumours.   
 
 
Figure 1.21. Prognosis of MYC amplification in Group 3 medulloblastoma. Kaplan-Meier survival 
comparing the progression free survival of children with Group 3 medulloblastoma with and without 







1.9 Therapeutic strategies to target MYC 
In principle, MYC-driven cancers could be targeted by affecting MYC at the molecular level or 
by targeting some of the unique properties that MYC confers upon cancer cells for the 
maintenance of the malignant phenotype (Tansey, 2014). 
Despite the undisputable therapeutic opportunity that MYC offers, MYC inhibitors have yet to 
become clinically available. For a long time, MYC was thought to be undruggable; the main 
reason being MYC’s global implication in cells gene regulation, which its complete inhibition 
could cause severe toxicity and adverse side effects to normal tissues. MYCs structure as a 
transcription factor is another major challenge, due to its lack of an enzymatic active site that 
could be efficiently targeted by small molecule inhibitors (McKeown and Bradner, 2014). In 
addition, its nuclear localisation, which makes it harder to reach than membrane or 
cytoplasmic molecular targets, and the fact that the MYC family includes three different 
proteins with redundancy in some of their function, has posed a challenge in delivering a 
specific and efficient MYC inhibitor (Beaulieu et al., 2019, Whitfield et al., 2017). The technical 
difficulties with targeting MYC directly created the need to develop alternative strategies to 
inhibit its action, which explain the broad range of indirect targeting strategies developed over 
the years (Figure 1.22).  
 
Figure 1.22. MYC-targeting strategies. Schematic representation of current strategies to target MYC 




1.9.1 Direct targeting of MYC 
A great number of researchers have been addressing these difficulties in recent years, and 
have shown the feasibility of developing small molecules that can directly bind to and inhibit 
MYC activity (Han et al., 2019a). Strategies aiming to directly inhibit MYC focus on interfering 
with its production (promoter accessibility and/or recruitment of transcription factors) or 
function (preventing its interaction with MAX, or binding to DNA).  
 
1.9.1.1 G-quadruplex stabilisers 
G-quadruplex are secondary guanine-rich structures formed in nucleic acids, which reside 
upstream of transcriptional start sites, inhibiting expression. The NHIII(1) region of the MYC 
promoter forms G-quadruplexes. Small molecule ligands can be used to specifically stabilise 
G-quadruplex structures on MYC promoters to supress MYC expression at the mRNA and 
protein levels (Whitfield et al., 2017) (Allen-Petersen and Sears, 2019). The small molecule 
compounds GQC-05, CZ1, IZCZ-3 and DC-34 have been seen to stabilise MYC G-quadruplex 
and repress MYC expression (Calabrese et al., 2018, Das et al., 2018). So far, CX-3543 is the 
only G-quadruplex stabiliser that has reached clinical trials (Chen et al., 2014). 
 
1.9.1.2 MYC/MAX disruption 
Most inhibitors developed for the direct targeting of MYC expression have focused on 
disrupting MYC/MAX dimerization, or their interaction with E-box motifs to reduce MYC 
expression (Shalaby and Grotzer, 2016). MYC’s bHLHZ domain is essential for MYC 
dimerization with its partner MAX and subsequent binding to E-box sequences in gene 
promoters to activate transcription of target genes. Several peptide mimetic compounds have 
so far been developed, and despite being highly selective, most of them display low potency 
and off-target effects, lacking in vivo efficacy (Mo and Henriksson, 2006, Kiessling et al., 2006).   
Recently it has been reported that a new MYC/MAX inhibitor, MYCMI-6, binds directly within 
the conserved bHLHZ domain and disrupts the formation of the MYC/MAX complex at a low 
micromolar range. Its utilisation in in vivo studies of MYCN amplified neuroblastoma cell lines 
significantly reduced proliferation whilst inducing apoptosis. Treatment with MYCMI-6 did not 




Another promising compound found to stabilise MAX/MAX homodimers and decrease MYC 
protein levels is KI-MS2-008. Struntz et al demonstrated the efficacy of the compound in 
perturbing the MYC-driven transcriptional program, exhibiting preliminary in vivo efficacy by 
reducing tumour volume in hepatocellular carcinoma murine models (Struntz et al., 2019). 
 
1.9.1.3 OmoMyc 
The therapeutic promise of using peptide compounds to directly disrupt MYC activity has led 
to the optimisation and development of compounds for better clinical applicability. Great 
advances have been made with the compounds Omomyc, a dominant negative molecule 
consisting of the MYC dimerisation domain with four mutations in the MYC leucine zipper, 
which prevents its binding to all MYC family member promoters. Omomyc has the ability to 
form dimers with MYC, preventing MYC/MAX association and binding to E-box for 
transcriptional activation, supressing MYC-dependent transcription (Savino et al., 2011) 
(Soucek et al., 2002, Soucek et al., 2004, Jung et al., 2017). 
More recently, the use of purified Omomoyc protein was proven to penetrate cell membranes 
and effectively interfere with MYC transcriptional activity, in glioma and non–small cell lung 
cancer in vitro and in vivo models (Wang et al., 2019a, Beaulieu et al., 2019) 
There is great promise for small molecule peptides that directly interact with MYC and disrupt 
its transcriptional activity. Results published so far are encouraging researchers to further 
optimise these compounds for clinical application of MYC-targeted peptides (Figure 1.23).   
 
Figure 1.23. Direct targeting of MYC.  MYC activity can be directly disrupted by interfering with the 
accessibility of transcription factors to its promoter (e.g. CX-3543 small molecule inhibitor) or by 
disrupting MYC/MAX dimerization to inhibit translation of MYC-target genes (e.g. Omomyc, MYCMI-
6, KI-MS2-008 inhibitors)(adapted from Posternak et al., 2016). 
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1.9.2 Indirect targeting of MYC 
The evident challenge that direct MYC targeting has presented, has led to many researchers 
taking indirect approaches to target MYC transcriptional regulation in MYC-driven cancers.  
Indirect approaches have focused on targeting MYC transcriptional regulation, or modulating 
its stability and activity (Figure 1.24)(Whitfield et al., 2017).  
 
Figure 1.24. Indirect targeting of MYC.  MYC activity can be indirectly disrupted by affecting its 
transcription, translation and protein stability. MYC expression at the transcriptional level can be 
inhibited by the use of BRD4, CDK7 and CDK9 small molecule compounds. Translation of MYC mRNA 
can be downregulated by inhibiting the PI3K/AKT/mTOR signalling pathway using BEZ235, INK-128 
and AZD2014 small molecule compounds. MYC inhibition at the post-translational level can be 
achieved by affecting MYC protein stability with AURKA and PLK1 inhibitors (e.g. MLN8237, 
BI2536)(adapted from Chen et al., 2018).  
 
1.9.2.1 Targeting MYC transcription  
MYC transcription requires local and global epigenetic changes that control the ability of the 
transcriptional machinery to interact with promoters and enhancers of genes to be 
transcribed (You and Han, 2014). Disruption of epigenetic modifications has become a strategy 
of great interest to reduce MYC expression and activity.  
Inhibitors of histone deacetylases, histone methyltransferases, histone demethylases, 
bromodomain, and extra-terminal motif (BET) bromodomain inhibitors have shown efficacy 
against MYC (Allen-Petersen and Sears, 2019). 
43 
 
1.9.2.1.1 BET bromodomain inhibition  
MYC/MAX dimerisation and consequent binding to E-boxes of target gene promoters initiates 
the organisation of histone acetyl transferases, which promote accessible chromatin for the 
transcriptional machinery to interact with gene promoters.   
Bromodomain proteins function as chromatin readers by recognising acetylated lysine 
residues on N-terminal tails of histones of active promoter regions, usually associated with an 
open chromatin state and therefore transcriptional activation. The bromodomain and extra-
terminal domain (BET) family of proteins is composed of four members: BRD2, BRD3, BRD4, 
and BRDT, which exclusively recognise histone acetylation motifs. Interaction with acetylated 
residues enables the assembly of chromatin complexes and transcription activators at specific 
promoter sites of genes (Florence and Faller, 2001, Choi et al., 2016, Barone et al., 2013, 
Sakaguchi et al., 2018). 
It is well established that through the recruitment of the multiprotein complex positive 
transcription elongation factor b (P-TEFb), BRD4 regulates gene transcription. P-TEFb is a 
cyclin dependent kinase with catalytic (CDK9) and regulatory (CDKT) subunits, and it is 
constituted by several other polypeptides. BRD4 has a high affinity for binding to CDK9 
contained within P-TEFb. Upon interaction, P-TEFb is recruited to promoters to activate RNA 
polymerase II (pol II) through phosphorylation at serine 2 at the carboxyl-terminal domain, 
resulting in transcriptional elongation (Chen et al., 2018b, Henssen et al., 2013, Stathis and 
Bertoni, 2018, Florence and Faller, 2001, Sims et al., 2004).  
BRD4 regulates MYC transcription through interaction with the heterodimers MYC/MAX and 
recruitment of P-TEFb on MYC enhancer and super-enhancer regions to promote 
transcriptional activation (Rahl and Young, 2014, Fowler et al., 2011, Levens, 2008, Yang et al., 
2005).  
BET bromodomain inhibitors have shown potent anti-tumorigenic effects in multiple MYC-
driven models, in both in vitro and in vivo studies, displaying potent downregulation of MYC 
transcriptional programs. The small molecule inhibitor JQ1 (BRD4 inhibitor) is the most 
studied BET inhibitor, which preferentially decreases MYC transcription by preventing the 
binding of BRD4 to acetylated histones within the MYC promoters and enhancers (Figure 1.25) 
(Allen-Petersen and Sears, 2019). 
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There are more than 15 different BET inhibitors under current clinical assessment. However, 
most of them have shown limited clinical response. Current studies suggest that BET inhibitors 
lack power as single agents, but in combination with other drugs like kinase inhibitors, could 
potentially achieve more durable responses in the clinic (Gerlach et al., 2018, Bolin et al., 
2018).  
 
Figure 1.25. Indirect targeting of MYC through BET bromodomain inhibition.MYC activity can be 
indirectly disrupted by affecting its transcription. MYC expression at the transcriptional level can be 
inhibited by the use of BRD4, CDK7 and CDK9 small molecule compounds (e.g. JQ1, PC585 and 
THZ1)(adapted from Chen et al., 2018).  
 
1.9.2.1.2 Inhibition of cyclin dependent kinases 7 and 9  
For MYC target genes to be transcribed, the multiprotein complex P-TEFb has to be recruited 
at gene promoters to phosphorylate RNA polymerase II and to initiate transcription.  
The cyclin dependent kinase 7 is part of the transcription factor II Human (TFIIH) protein 
complex. TFIIH is a component of the RNA Pol II preinitiation complex (PIC) assembled in gene 
promoters to aid RNA pol II travel to the promoters of those genes to be transcribed (Vannini 
and Cramer, 2012). CDK7, as part of its catalytic subunit, together with its cofactor cyclin H, 
phosphorylates the C-terminal domain of the RNA polymerase II at Ser5 to initiate 
transcription (Whittaker et al., 2017). 
Pol II pause release is stimulated through P-TEFb recruitment to promoters, which activates 
the polymerase through phosphorylation at Ser2 of its CTD domain. As explained above, CDK9 
is the catalytic subunit of P-TEFb, and becomes active upon phosphorylation by different 
kinases, one of them being CDK7 (Mbonye et al., 2018). 
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Numerous studies have demonstrated that inhibition of CDK7/9 results in a global reduction 
of MYC transcriptional programs. The use of THZ1 (CDK7 inhibitor) and PC585 (CDK9 inhibitor) 
on MYC-driven models of blood, lung and brain cancers showed potent anti-tumour effects, 
encouraging the pursuit of its targeting as a potential cancer treatment (Chipumuro et al., 
2014) (Garcia-Cuellar et al., 2014, Brisard et al., 2018). Despite the MYC-downregulatory effect 
of CDK7/9 inhibition, in vivo studies have raised awareness of the global effect on cell cycle 
and proliferation that the suppression of the activity of these kinases for extended periods of 
time can have (Ganuza et al., 2012, Posternak and Cole, 2016). 
 
1.9.2.2 Targeting MYC translation 
Another plausible approach to repress MYC activity is by blocking its translation. Once 
transcribed, MYC mRNA is exported to the cytoplasm under the direct control of mitogenic 
signals, and this process is coordinated by the eIF4F complex.  
The complex is formed by the eukaryotic initiation factors eIF4E, eIF4A and eIF4G, and recruits 
ribosomes to the 5’-cap of mRNA to initiate mRNA translation. Some mRNAs, like MYC, have 
an internal ribosomal entry site (IRES) at the 5’ end of the sequence, allowing the mRNA to be 
translated by both mechanisms (Castell and Larsson, 2015). 
The family of proteins 4E-BPs are negative regulators of translation, interfering with the 
assembly of the eIF4F complex by binding to eIF4E. Phosphorylation of 4E-BPs by mTORC1 
inactivates the inhibitors allowing the formation of the eIF4F complex and subsequent 
initiation of translation (Roux and Topisirovic, 2018). 
The central role of mTOR in mediating the translation of MYC mRNA has fuelled the 
development of small molecule compounds targeting mTOR complexes to downregulate MYC, 
with a large number of them being approved for clinical use. However, studies have shown 
that mTOR inhibition alone fails to inhibit MYC expression due to the activation of feedback 
loops that increase the expression of growth factor receptors and activate the MAPK signalling 
pathway, which consequently upregulates MYC mRNA expression (Carneiro et al., 2015, Yang 




In this regard, recent studies using the small molecule inhibitor CUDC-907, with dual targeting 
of PI3K and HDAC, resulted in the reduction of MYC transcription which translated into the 
inhibition of tumour growth in several MYC-dependent murine models (Sun et al., 2017). Its 
efficacy is currently being studied as part of Phase II clinical trials of patents with MYC 
alterations. Another dual-functioning compound showing great anti-tumour effects in MYCN 
amplified Neuroblastoma is SF2523, which targets PI3K and BRD4. SF2523 showed reduced 
toxicities compared to the individual inhibition of its main targets (Andrews et al., 2017). The 
potent effect of dual function compounds on MYC expression highlights the importance of 
combinational therapies to further develop strategies to treat MYC-dependent tumours.   
 
1.9.2.3 Targeting MYC protein Stability 
Regulation of MYC protein is a complex process. Even after synthesis, the protein itself is under 
complex control and it is subject to several post-translational modifications to establish 
particular states of MYC activity (Tansey, 2014). 
 
1.9.2.3.1 Ubiquitin-dependent degradation   
The ubiquitination of MYC plays a crucial role in its control. As mentioned in section 1.4.3, 
phosphorylation of MYC at Threonine 58 site acts as a tag for SCFfbw7 ubiquitin ligase to 
ubiquitinate MYC and stimulate its proteasomal degradation (Welcker et al., 2004). USP28, 
USP7, and USP36 are some of the deubiquitinases that counteract SCFfbw7 and help stabilise 
MYC protein (Wang et al., 2018). 
Numerous studies have proposed the use of inhibitors targeting deubiquitinating enzymes to 
increase MYC turnover (Chen et al., 2019). P22077, a small molecule inhibitor of USP7, 
supressed growth of MYCN-amplified neuroblastoma murine models (Tavana et al., 2016, Fan 







1.9.2.3.2 Aurora Kinase A   
Aurora Kinase A, apart from its role in cell cycle progression, is involved in the stabilisation of 
MYCN protein. Recent studies have shown that AURKA binds to MYCN forming a protective 
complex that prevents the MYCN SCFfbw7-mediated proteasomal degradation. In vitro and in 
vivo studies using the AURKA inhibitor MLN8237 (Alisertib) have demonstrated correlation 
between aurora A and MYCN expression levels, whereby inhibition of AURKA disrupts the 
complex formed by MYCN and AURKA, triggering MYCN degradation (Richards et al., 2016, Li 
et al., 2018). MLN8237 is currently being evaluated in multiple late phase clinical trials. These 
studies support the use of AURKA inhibitors as potential destabilisers of MYC. 
 
1.9.2.3.3 Polo-like kinase 1   
The polo-like kinases (PLK) family of proteins are kinases involved in the control of many 
biological processes, and have an essential role in mitosis and maintenance of genome 
stability. PLK1 is the best characterised PLK family member, due to its involvement in the 
regulation of multiple steps of the mitotic process (Strebhardt, 2010).   
Like AURKA, apart from being a downstream regulator of MYC expression signatures, it has 
been demonstrated that PLK1 also affects MYC stabilisation. Phosphorylation of SCFfbw7 by 
PLK1 triggers its auto-polyubiquitination and consequent degradation, inhibiting MYCN-
SCFfbw7 mediated degradation. Inhibition Fbw7 stabilises MYCN, which in turn directly 
promotes PLK1 transcription, constituting a positive feedback loop resulting in tumour 
proliferation (Sato et al., 2015, Xiao et al., 2016). 
The use of PLK1 inhibitors in models of MYCN-amplified neuroblastoma and small cell lung 
carcinomas, such as BI6727 or BI2536, consistently reduced MYCN expression and induced 
apoptosis of MYC-overexpressing cell lines. Recent studies have revealed synergy between 
PLK1 inhibition and BCL2 antagonism, validating the PLK1-SCFfbw7-MYC interconnected 





1.9.2.4 Targeting by synthetic lethality 
Advances in genome screening have intensified indirect approaches to target MYC-dependent 
tumours by synthetic lethality. It is well established that cancer cells develop a prime 
dependency on their overexpressed oncogene for the maintenance of the malignant 
phenotype and their survival (Weinstein and Joe, 2008). Indeed, downregulation of MYC in 
MYC-overexpressing cell lines results in tumour regression (Pei et al., 2012, Li et al., 2014b). 
Utilisation of whole genome screens has enabled the identification of pathways supporting 
oncogenic MYC transcriptional signalling that could be exploited to treat MYC-dependent 
cancers.  
Several studies have highlighted the dependency of MYC overexpressing cell lines on the 
expression of CDKs. Pharmacological inhibition of CDK2, CDK1 and CDK9 has been shown to 
selectively target MYC overexpressing cell lines (Whitfield et al., 2017). The CDK1 inhibitor 
purvalanol A greatly induced apoptosis in MYC-dependent hepatoblastoma and lymphoma 
murine models, through the upregulation of pro- and anti-apoptotic molecules (Kang et al., 
2014, Campaner et al., 2010). 
MYC deregulation increases cell replication, causing a state of replicative stress in the cell, 
promoting genome instability. CHK1 plays an important role in cell cycle progression and DNA 
damage control, which MYC-overexpressing tumours with rapid cell turnover are in need of 
for their survival. Indeed, pharmacological inhibition of CHK1 significantly increases genome 
instability and massive cell death in MYC-dependent models (Figure 1.26)(Murga et al., 2011). 
Many MYC-synthetic genes identified are involved in cell metabolism. The need of MYC-
dependent cancer cells for constant and proper metabolic support for cell growth and 
proliferation has led to the targeting of various metabolic enzymes like Glutaminase or LDHA, 
to inhibit tumour growth (Xiao et al., 2015, Chen et al., 2018b, Hsieh and Dang, 2016). CB-839, 
a selective glutaminase inhibitor, is currently under investigation for tumours with MYC 
upregulation (Grinde et al., 2019). 
Various other targets have been identified in MYC synthetic studies, some of them being PIM 
kinases, RNA polymerases or Aurora kinases. Recently, SUMOylation enzymes have been 




Figure 1.26. Example of strategies to target MYC-dependent tumours by synthetic lethality. CDK1 
(cell cycle), CHK1 (DNA-repair mechanisms) and GLS (cells metabolism) are essential genes for the 
survival of MYC-overexpressing cancerous cells. Pharmacological inhibition of CDK1, CHK1 and GLS 
specifically sensitises cells overexpressing MYC to apoptosis (synthetic lethal) over those expressing 
normal levels of MYC. (Adapted from Chen et al., 2018).    
 
 
1.10 Proposed MYC-targeting strategies for MBGroup3 
The expanding wealth of molecular data on MB, has allowed a thorough understanding of the 
molecular changes that characterise each subgroup, paving the way for targeted therapeutic 
strategies.  
Of all subgroups, MBGroup3 have the worst outcome and yet its molecular pathway of origin is 
still undefined, with few driver gene alterations identified in MBGroup3 tumorigenesis. Despite 
only accounting for 17% of MBGroup3 cases, the amplification and/or overexpression of MYC 
has been associated with poor clinical outcome, becoming the defining feature of this 
subgroup (Northcott et al., 2012b, Pizer and Clifford, 2009). 
The fact that MYC suppression causes tumour regression in MYC-driven murine MB models 
and its association with highly aggressive tumours, indicate that MYC plays a key role in 
MBGroup3 tumour development. This has led research to focus on developing strategies to 
disrupt MYC function in this specific cellular context (Pei et al., 2012, Roussel and Robinson, 
2013).    
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The incorporation of molecular and histopathological features for disease stratification has 
enabled small adjustments to the conventional MB therapy to reduce related toxicities. 
Current clinical studies are stratifying patients on the basis of molecular subgroups, which has 
enabled incorporation of SMO inhibitors for MBSHH patients and reduced treatment intensity 
of MBWNT patients presenting with low-risk features (NCT01878617)(Northcott et al., 2019). 
Unfortunately, no major changes have proceeded to enhance outcomes for, or palliate, 
MBGroup3 patients. However, the SJMB12 study is currently investigating the effect and 
tolerability of adding cycles of combined gemcitabine and pemetrexed to the conventional 
treatment of MBGroup3 and MBGroup4 patients with high-risk features (Morfouace et al., 2014). 
Results from pre-clinical studies are pointing to the combined use of HDAC and PI3K inhibitors 
(Figure 1.27), compounds with dual activity on PI3K-BRD4, CHK inhibitors with current 
cytotoxic chemotherapeutic agents, CDK inhibitors alone or in combination with cytotoxic 
agents, or targeting GFI1 and GF1B overexpression to treat patients with MBGroup3, but nothing 
has yet been translated to the clinic (Prince et al., 2016, Pei et al., 2016, Cook Sangar et al., 
2017, Faria et al., 2015, Lee et al., 2019, Song et al., 2019, Eckerdt et al., 2019, Juraschka and 
Taylor, 2019). 
Despite the vast knowledge and current understanding of MYC and its involvement in cancer 
development, there has been no systematic assessment of anti-MYC strategies in MYC-
dependent medulloblastoma models. The current lack of innovative treatments for patients 
with MBGroup3 requires further efforts be placed in the development of new combinational 
therapeutic strategies to establish and specifically target essential MYC-dependent 




Figure 1.27. HDAC and PI3K inhibition as potential strategy to target MBGroup3 tumours.Dual 
Inhibition of HDAC and PI3K using the CUDC-907 compound has been shown to downregulate MYC 
expression, and it has been proposed as a potential therapeutic strategy to target MYC-driven 
MBGroup3 tumours. The figure highlights the signalling pathways affected by the compound (adapted 
from Allen-Petersen et al., 2019).  
 
1.10.1 Isogenic MYC regulable MBGroup3 cell lines 
One way to study the underlying pathophysiology of MB biology is using cell-lines derived 
from MB patients. The use of established MB cell lines can certainly help gain a better 
understanding of the molecular and genetic mechanisms of those MB tumours that confer the 
worst prognosis and are resistant to treatment, like MBGroup3.  
For the large number of established MB cell lines there is little diversity regarding genetic 
features, and most cell lines modelling MBGroup3 harbour MYC amplifications (Xu et al., 2015, 
Clifford et al., 2006, Ivanov et al., 2016). To explore specific MYC-dependent biology and its 
potential for therapeutic targeting in a MBGroup3 context, the Paediatric Brain Tumour Group 
at Newcastle University has established three MYC-regulable isogenic cell lines (using D425, 
D283 and HDMB03 as hosts) in which MYC expression can be directly regulated experimentally 
(Dr. Shanel Swartz, PhD thesis).   
To the current day, this is the first time that regulable models of MYC in Group 3 
medulloblastoma are described. The utilisation of cell lines facilitates their manipulation to 
make regulable models of specific genes, which would result extremely challenging in patient 
derived xenografts (PDX) and genetically engineered mouse (GEM) models. The use of MYC-
regulable Group 3 medulloblastoma cell lines will allow the investigation of the MYC-
dependency of this subgroup of tumours.  
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1.10.1.1 Tet-inducible shRNA system for MYC knock down 
Short Haipirin RNA (shRNA) is one of the most used and well established techniques for 
efficient and stable knockdown of gene expression. shRNA techniques have long been used to 
study gene function by inducing temporary knockdown of genes that are essential for cell 
survival, where its knock out would otherwise be lethal (Frank et al., 2017).   
Selection of cell models was performed according to their MYC expression levels (Table 1.4). 
MB cell line subgroup was assigned using primary MB methylation data (process described in 
Dr. Shanel Swartz PhD thesis). D425 and HDMB03 harbour MYC amplification, which leads to 
increased mRNA expression and subsequent protein translation. On the other hand, D283 is a 
MYC-gained cell line containing an extra copy of the MYC gene (Dr. Shanel Swartz, PhD thesis).  
 
Cell lines Subgroup TP53 MYC 
D283 Group 3 WT Gain 
D425 Group 3 Mutant Amplified 
HDMB03 Group 3 WT Amplified 
 
Table 1.4. Genetic characteristics of medulloblstoma cell lines.Summary of MYC and TP53 status of 
the medulloblastoma cell lines selected for the study. WT, wild type.    
 
The cell lines were transduced with an inducible shRNA system (pLKO-Tet-On-Puro vector) to 
temporarily control and modulate MYC oncogene expression by the administration of 
doxycycline (DOX)(inducing agent) to the culture media. The lentiviral vector pLKO-Tet-On-
Puro contains all the necessary components of a TeT inducible shRNA expression system in 
the host cells (Wiederschain et al., 2009)(www.addgene.org). 
The pLKO vector contains a TetOperator (TetO) located in the H1 promoter (Figure 27), 
containing two Tet responsive elements (TRE) flanking a TATA box, which regulates the 
expression of the shRNA. The Tet repressor (TetR) is located downstream of the constitutive 
polymerase II hPGK promoter. Between the TetR and puromycin selection cassette, an IRES 





In the absence of the inducer DOX, the expression of the shRNA is blocked by the continued 
expression of TetR, which binds to TRE in the H1 promoter containing TetO, allowing intrinsic 
levels of MYC expression within the host cell. The addition of DOX to the culture media triggers 
the transcription of the shRNA construct by displacing TetR from the promoter, therefore 
targeting MYC mRNA expression inducing MYC gene knockdown (Figure 1.28)(Wiederschain 
et al., 2009).   
 
Figure 1.28. Tet-ON doxycycline inducible shRNA expression system. Mechanism of transcriptional 
control of TeT inducible shRNA expression system. The pLKO-Tet-On vector contains all the 
necessary elements for lentiviral insertion and inducible expression of shRNA in target cells. In the 
absence of inducer, the Tet repressor protein (TerR) blocks shRNA expression by binding to the Tet 
Response Element (TRE) at the H1 promoter. The system is activated by the addition of doxycycline, 
which binds to TerR and stimulates transcription of the shRNA, which targets specific mRNA for 
degradation (Adapted from Wiederschain et al., 2009).   
 
Each isogenic cell line generated has two experimental constructs targeting two different MYC 
sequences, called MYC2 and MYC3 (expressing shRNA to silence MYC), and a control construct 
(NS) expressing a non-silencing shRNA. Both experimental shRNAs target different positions 
of the third exon of MYC (Dr. Shanel Swartz, PhD thesis). 
The use of cells transfected with a non-targeting shRNA allows the use of the same pool of 
cells as controls, including studying the possible side effects of the insertion of the lentiviral 
vector, and of doxycycline addition.  
The generation of stable isogenic cell lines with a DOX-inducible system for MYC knockdown 
brings the opportunity for direct investigation of the nature and extent of MYC’s involvement 
in MBGroup3 pathogenesis, and its dependency. The use of these models could allow the 
identification of key pathways for the survival of MYC-overexpressing cells, and to identify and 
develop novel therapeutic strategies to bring into the clinic, providing a systematic and 




1.11 Summary and aims 
Over the last few years tremendous advances have been made in understanding the molecular 
underpinnings of MB, becoming one of the best molecularly characterised cancers. The 
discovery of specific genetic features that characterise each subgroup are already being 
translated directly into the clinic, for more precise treatment approaches that aim to keep 
improving survival of patients whilst reducing the extremely toxic side effects of current 
standard treatment (Northcott et al., 2019, Allen-Petersen and Sears, 2019). 
One of the greatest challenges remains in translating this wealth of molecular data into 
effective novel treatments for the high-risk patients with MBGroup3. MYC amplification and/or 
overexpression is the hallmark of MBGroup3, and its key association with MBGroup3 tumour 
development makes it a promising target to specifically treat patients with this subgroup of 
tumours (Northcott et al., 2012b, Pizer and Clifford, 2009, Pei et al., 2012, Roussel and 
Robinson, 2013). It is crucial to better understand the biological role of this prognostic marker 
in a subgroup specific context to better inform and design therapeutic regimens that would 
improve clinical outcomes and survival for high-risk patients.  
The major objective of this project is to gain a better understating of MYC’s role in MBGroup3 
pathogenesis, and to identify potential MYC-dependent targets for the development of new 
therapeutic strategies to treat high-risk MBGroup3 patients.  
1. The project aims to directly investigate the nature and extent of MYC’s involvement and 
dependency in MBGroup3 pathogenesis, using the newly generated MYC-regulable isogenic 
cell lines.  
- Validation of the effectiveness of MYC knockdown achieved with the inducible shRNA 
system, and establishment of any MYC-dependent phenotypes, will be performed to 
establish the suitability of the isogenic models as new tools to study MYC-dependent 
biology within human MBGroup3.  
 
2. The project will then focus on using the novel MYC-regulable isogenic cell lines to 
investigate the role of MYC amplification/gain in drug resistance and sensitivity; to identify 
drugs which show (i) greater efficacy in MYC expressing cells and (ii) potential synthetic 




- Candidate drugs (drugs chosen based on their published efficacy in MYC models, 
mechanism of action, pharmacological properties and potential for clinical use in the 
near future) targeting signalling pathways associated with MYC, will be tested in a 
MYC-dependent manner using the newly generated models.  
 
3. Alongside looking at candidate drugs, the project will take an unbiased approach by 
undertaking a high-throughput drug library screen on the isogenic cell-based models, to 
identify MYC-dependent therapies which could potentially be used to treat this subgroup 
of highly lethal paediatric tumours. 
- The MYC-modulable models will be exposed to hundreds of compounds to look for 
MYC-dependent drug-sensitivity effects. Integrative analysis of screen results with 
data on transcriptional and genetic MB dependencies will be used to identify 
compounds to specifically target MYC in MYC-driven MBGroup3 cell lines.  
 
4. Prioritised candidates will be validated individually by assessing their effects in MYC 
amplified/regulable MB cell lines, alongside non-amplified MBSHH models. MYC-dependent 
effects of inhibitors will be investigated, including impact on cell proliferation, apoptosis, 
cell cycle, and target and downstream pathway expression. Together, this data will be used 















2.1.1 Laboratory equipment  
Instrument  Manufacturer 
 2720 Thermal Cycler  Applied Biosystems  
Attune NxT flow cytometer  ThermoFisher Scientific 
Benchtop centrifuge 5424 Epppendorf 
Cell Irradiator  Gulmay Medical Ltd 
Centrifuge 5415 R Epppendorf 
Centrifuge 5804R (tissue culture use) Eppendorf 
CO2 incubator (MCO-230AICUV-PE) Panasonic 
Countess II FL Automated Cell Counter ThermoFisher Scientific 
FLUOstar Omega plate reader  BMG Labtech 
Heraeus Multifuge 3S Plus ThermoFisher Scientific 
Microcentrifuge technico Mini Labnet 
Microlab STAR platform Hamilton 
Mr Frosty Nalgene 
Multidrop Combi Reagent Dispenser ThermoFisher Scientific 
NanoDrop ND-1000 spectrophotometer ThermoFisher Scientific 
Nebauer-improved haemocytometer Marienfeld-Superior 
StoragePod Roylan Developments 
VICTOR Multilabel Plate Reader PerkinElmer 
ViiA 7  Applied Biosystems  
Wes Protein Simple 
Table 2.1. List of equipment   
 
2.1.2 Materials for tissue culture  
Tissue Culture Supplier 
Cell bind 96 well plate (3340) Corning  
clear 384 well plate (3701) Corning  
Countess Cell Counting Chamber Slides ThermoFisher Scientific 
ErgoOne Multi-Channel Pipettes StarLab 
ErgoOne Single-Channel Pipettes StarLab 
MACS SmartStrainers Miltenyibiotec 
Nebauer-improved haemocytometer Marienfeld-Superior 
Olympus CKX53 microscope Life Science 
TEVOS FL Cell Imaging System ThermoFisher Scientific 
white 384 well plate (3570) Corning  
white 96 well plate (3917) Corning  





2.1.3 Chemicals and reagents  
Item Supplier 
0.4% trypan blue BIO-RAD 
0.45µm filter Merck-Millipore 
Agarose Bioline 
BCA protein assay kit ThermoFisher Scientific 
Caspase3/7-Glo Promega 
CellTiter AQueous One Solution Promega 
CellTiter-Glo Promega 
Corning Tissue culture flasks (T25, T75, T150) Sigma-Aldrich 
Cryovials ThermoFisher Scientific 
Doxycycline hyclate Sigma-Aldrich 
Dymethyl Sulfoxide (DMSO) Cell signaling  
Eppendorf LoBind microcentrifuge tubes Sigma-Aldrich 
Gibco foetal calf serum ThermoFisher Scientific 
Halt Protease inhibitor Cocktail (100X) ThermoFisher Scientific 
High capacity cDNA reverse transcription kit Applied Biosystems 
L-Glutamine  Sigma Aldrich 
Lobind microfuge tubes VWR 
MEM Non- Essential Amino Acids Solution (100x) ThermoFisher Scientific 
Microfuge tubes Eppendorf 
Nuclease-Free water Ambion 
Platinum SYBR Green Super Mix UDG Applied Biosystems 
PowerUp SYBR Green Master Mix ThermoFisher Scientific 
Propidium iodide  Sigma-Aldrich 
Puromycin Dihydrochloride (10µg/ml) ThermoFisher Scientific 
QIAshredder QIAGEN 
RIPA buffer (10X) Sigma-Aldrich 
RNase A, DNase and protease-free (10mg/ml) ThermoFisher Scientific 
RNeasy mini Kit Qiagen  
Tet System Approved FBS Takara 
Triton (100X) Sigma-Aldrich 
Trypsin-EDTA solution (10X) Sigma-Aldrich 









2.1.4 RT-qPCR primers  
Gene Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
MYC TGAGGAGACACCGCCCAC CAACATCGATTTCTTCCTCA 
TBP GTATTAACAGGTGCTAAAGTCAG TTTTCAAATGCTTCATAAATTTCTGC 
Table 2.4. Primers for RT-qPCR. 
 
2.1.5 Small molecule compounds 
Compound Alternative name Target Vendor 
(+)-JQ1  BRD4 Selleckchem 
Adavosertib MK-1775 Wee1 Selleckchem 
Alisertib MLN8237 AURKA Selleckchem 
AZD7762  CHK1 Selleckchem 
BI2536  PLK1 Selleckchem 
CYC065  CDK9 Cyclacel Pharmaceuticals 
Milciclib PHA-848125 CDK2 Selleckchem 
Prexasertib LY2606368 CHK1/2 Selleckchem 
Sapanisertib INK128 mTORC1/2 Selleckchem 
SN38  DNA topoisomerase I Selleckchem 
Vistusertib AZD2014 mTORC1/2 Selleckchem 
YM155 Sepantronium Bromide BIRC5 Selleckchem 
















Target species Manufacturer 
GAPDH rabbit Cell Signaling 
CHK1 rabbit Abcam 
pCHK1 rabbit Cell Signaling 
PI3 Kinase p110α rabbit Cell Signaling 
Phospho-4E-BP1 (Thr37/46) rabbit Cell Signaling 
Phospho-S6 Ribosomal Protein (Ser235/236) rabbit Cell Signaling 
Phospho-MEK1/2 (Ser217/221) rabbit Cell Signaling 
PARP rabbit Cell Signaling 
Cleaved PARP (Asp214) rabbit Cell Signaling 
Aurora A/AIK rabbit Cell Signaling 
Phospho-Aurora A(Thr288)/AuroraB rabbit Cell Signaling 
CDK2 rabbit Cell Signaling 
PLK1 rabbit Cell Signaling 
Phospho-cdc25 (Ser216) rabbit Cell Signaling 
c-MYC rabbit Cell Signaling 
mTOR rabbit Cell Signaling 
MCL-1 rabbit Cell Signaling 
Phospho-GSK-3β (Ser9) rabbit Cell Signaling 
Table 2.6. List of antibodies used for protein detection with Wes.    
 
 
2.1.7 Software  
Software Owner/Developer 
Attune NxT flow cytometer 
(version 2.7) ThermoFisher Scientific 
FlowJo (version 10) FlowJo 
GENESys (version 1.5.1.0) SYNGENE 
Primer3 ELIXIR - European research infrastructure for biological information 
R (version 3.5.0) The R Foundation for Statistical Computing 
R studio (version 1.1.453) JJ Allaire 
QuantStudio Real-Time PCR System ThermoFisher Scientific 
Compass Protein Simple 
Prism8 GraphPad 
Table 2.7. List of software used for data analysis    
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2.2 Cell culture 
2.2.1 Cell line models 
Several Group 3 and SHH medulloblastoma cell line models were used in this study. D283Med, 
D425Med, D458Med, HDMB03 were used to model MBGroup3 tumour biology. DAOY and 
UW228.2 cell lines were used as MBSHH models. A list with information on the cell lines, their 
growth and tumour characteristics can be seen in Table 2.9.   
The isogenic MYC-regulable cell lines used D425, D283 and HDMB03 as hosts. Table 2.8 shows 
the genetic characteristics of the isogenic models.  
Cell lines Subgroup TP53 MYC 
D283 Group 3 WT Gain 
D425 Group 3 Mutant Amplified 
HDMB03 Group 3 WT Amplified 
 
Table 2.8. Genetic characteristics of medulloblstoma cell lines. Summary of MYC and P53 status of 
the medulloblastoma cell lines selected for the study. WT, wild type.    
 
2.2.2 Cell culture maintenance 
Cell lines used in this study were grown in the appropriate media (specified in Table 2.10) and 
incubated at 37oC with humidified atmosphere of 5% CO2. Cells were passaged when reaching 
70-80% confluence.  
In general, cell suspensions were collected and remaining adherent cells washed with 
phosphate buffered saline (PBS) and detached from the flask surface using 1x trypsin-EDTA. 
Trypsin was neutralised with a 2:1 ratio of concordant fresh culture media. Cell suspension 
was then centrifuged at 700xg for 5 minutes, supernatant removed and cell pellet re-
suspended. An appropriate volume of cell suspension was transferred to new flasks containing 
fresh pre-warmed growth medium.    








    Growth characteristics Patient Characteristics Tumour characteristics 
Cell line Subgroup Source Date published Growth  Doubling time 
age at 
diagnosis sex Line derived from 
DAOY SHH American Type Culture Collection (Manassas, VA, USA) 1985 adherent 48 hours 4 years Male 
Primary tumour (pre-
treatment) 
D283Med Group 3 American Type Culture Collection (Manassas, VA, USA) 1985 semi-adherent 52.55 hours 6 years Male 
Metastases from ascites and 
pertoneal implant (post-
radiotherapy) 
D425Med Group 3 Dr. D. Bigner (Duke University, Durham, NS, USA) 1991 semi-adherent 62 hours 6 years Male Primary tumour at diagnosis 
D458Med Group 3 Dr. D. Bigner (Duke University, Durham, NS, USA) 1991 semi-adherent 83 hours 6 years Male Metastases at relapse 
UW228.2 SHH 
Dr. J. Silber (Univeristy of 
Washington, Seattle, WA, 
USA). 
1995 adherent 25.2 hours 9 years Female Primary tumour (pre-treatment) 
HDMB03 Group 3 
Hedwig E. Deubzer (German 
Cancer Research Cemter 
(DKFZ)) 
2012 semi-adherent 72-96 hours 3 years Male Primary tumour (pre-treatment) 
Table 2.9. Information of primary MB cell lines used in this study. 
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Media Cell line Composition of media 
  1% L-Glutamine 
Dulbecco’s Modified Eagle’s 
Medium Isogenic D425Med 1μg/ml puromycin 
High glucose (DMEM – D6171 – 
Sigma Aldrich) Isogenic D283Med 
10% Tet-free foetal bovine 
serum 
  DMEM 
 D425 Med  
Dulbecco’s Modified Eagle’s 
Medium D283 Med 1% L-Glutamine 
High glucose (DMEM – D6171 – 
Sigma Aldrich) D458 Med 10% foetal bovine serum 
 DAOY DMEM 
 UW2281  
  1% L-Glutamine 
RPMI-1640  1% Non-essential amino acids 
(R5886 – Sigma-Aldrich) Isogenic HDMB03  1μg/ml puromycin 
  10% Tet-free foetal bovine 
serum 
  RPMI 1640 
  1% L-Glutamine 
RPMI-1640 HDMB03 1% Non-essential amino acids 
(R5886 – Sigma-Aldrich)  10% foetal bovine serum 
  RPMI 1640 
Table 2.10. Media used for culturing cell lines. 
 
  
2.2.3 Cell counting 
Cell density and viability was determined using the Countess Automated Cell Counter or a 
haemocytometer following trypan blue (BIO-RAD) staining. Trypan blue staining allows the 
counting of viable cells under the microscope, as they remain unstained whilst non-viable cells 
absorb the dye and become blue.   
An aliquot of the cell suspension was mixed with 0.4% Trypan blue in a 1:1 ratio, and 10μl of 
the mixture loaded to a chamber of the haemocytometer or countess slide. For manual 
counting, a percentage of viable cells was calculated by counting the number of unstained 
cells in the 4 corner counting quadrants. 
total cells/ml =  
nᵒcells counted x dilution factor




2.2.4 Cell collection 
For cell pellet collection, suspension cells were transferred to a 1.5ml Eppendorf tube and 
centrifuged at maximum speed for 2 minutes. The media was aspirated and cell pellet washed 
twice with ice-cold PBS. After the second wash, the tube containing only the cell pellet was 
stored at -80ᵒC for future use.    
 
2.2.5 Cell line cryopreservation and thawing  
Freezing media was made with 80% foetal bovine serum and 20% sterile DMSO. A suitable 
number of cells was centrifuged for 5 minutes at 250xg, supernatant aspirated and cell pellet 
resuspended in ice-cold FBS followed by the addition of the same amount of ice-cold freezing 
media. Cells were transferred into pre-labelled cryovials, left on ice for a few minutes before 
being transferred to a room temperature Mr. Frosty, and stored at -80ᵒC. The freezing 
container Mr. Frosty helps preserve cell viability by providing a gradual freezing rate of the 
vials (1ᵒC/min). For long-term storage, frozen cryovials were stored in a -150ᵒC freezer.  
To recover cell lines, cryovials were placed in a 37ᵒC water bath, and only when there was a 
small amount of ice remaining, vials were left on ice to completely thaw. Cell suspensions 
were then transferred to a Falcon tube and 5ml of appropriate pre-warmed media was added, 
dropwise, to ensure the slowly diffusion of DMSO from the cells. Cell suspension was gently 
mixed and transferred to a new flask with an appropriate amount of media, and left in the 
incubator overnight. After 48h, media was replaced to avoid possible toxic effects of the 
remaining DMSO in the media. For the isogenic cell lines, the media was changed to the one 








2.3 General Laboratory techniques 
2.3.1 Doxycycline treatment  
Doxycycline (DOX) is a tetracycline antibiotic used as inducer for pLKO-Tet-On shRNA 
expression system. DOX is stable in culture medium for 48h. In this study, DOX was added to 
cell culture at a final concentration of 1mg per ml for shRNA MYC knockdown.  
 
2.3.2 Proliferation Assay 
To assess the proliferative characteristics of the cells, cells were plated into either 384 or 96 
well plates at the appropriate cell density (dependent on cell lines and type of experiment), 
and left in the incubator at 37ᵒC for the desired amount of time. Cells bearing the MYC and NS 
shRNAs were pre-treated with DOX 24h before plating. DOX was then refreshed when seeding. 
For experimentations longer than 72h, DOX was refreshed accordingly to ensure continued 
MYC knockdown.  
Cell proliferation was assayed at the appropriate time with either CellTiter 96 AQueous One 
(CTA) for colorimetric assay or CellTiter-Glo (CTG) for luminescence assay. For the colorimetric 
assessment of cell proliferation, CTA reagent was added to the cells followed by 2h incubation 
at 37°C. After incubation, absorbance of each well was measured with FLUOstar Omega plate 
reader (BMG Labtech) at 490nm. For the luminescence assay, plates were left to equilibrate 
at room temperature before adding CTG reagent. Plates were left on a rocker for 10min at 
room temperature. The luminescence signal was then read using the Omega microplate 
reader. 
The optical density (OD) or relative luminescence units (RLU) were used as indicator of cell 
survival. The untreated control was used to normalise values obtained from treated cells. Data 







2.3.3 Protein extraction 
Eppendorf tubes containing the cell pellets were left to defrost on ice. The appropriate 
amount of cold RIPA buffer (used at 10X) was added to the cell pellet (approximately 250μl 
per 5x106 cells), and the mixture pipetted up and down to suspend the pellet until dissolved. 
The solution was supplemented with Halt protease inhibitor cocktail (100X), used at 1X 
concentration. Eppendorfs containing the solution were left on ice for 15min and cells sheared 
using a Bioruptor Plus sonication device (Diagenode), for 3 cycles of 10 seconds on / 10 
seconds off with 50% pulse. After sonication, samples were centrifuged at 112xg for 15min at 
4ᵒC. Total amount of protein was quantified right after centrifugation or samples were left at 
-80ᵒC for future use.  
 
2.3.4 Protein Quantification 
Pierce BCA Protein Assay Kit (ThermoFisher Scientific) was used for quantification of total 
protein according to manufacturer’s instructions. Briefly, protein concentrations were 
determined with reference to standards of diluted concentrations of bovine serum albumin 
(BSA) protein, based on a standard curve. Dilution of standards were prepared according to 
the manufacturer’s protocol. Between 1-5µl of sample and 25µl of each standard were 
pipetted into a 96-well plate, followed by the addition of 200µl of working solution reagent, 
made up at a 50:1 ratio of the kits reagents A:B. The plate was mixed for 30 seconds on a plate 
shaker and incubated for 30 minutes at 37°C. After incubation, the plate was cooled to room 
temperature and the absorbance measured using the FLUOstar Omega microplate reader 
(490nm) (BMG Labtech). The protein concentration of each sample was then determined 









2.3.5 Protein detection and analysis 
2.3.5.1 Simple Western Assay (Wes) 
Simple Western Assay (Wes) was used to identify and analyse proteins of interest. Wes 
(https://www.proteinsimple.com/wes.html) is a capillary electrophoresis-based western blot 
that offers automated steps equivalent to traditional western blots. Samples are processed in 
capillary columns were they are separated based on size and identified as they pass through 
a separation and stacking matrix. Proteins are immobilised onto the capillary wall by photo-
activated cross-linkage.  The washing step removes the matrix and target proteins are then 
identified using a primary antibody immunoprobed with a horseradish peroxide (HRP)-
conjugated secondary antibody. Similar to traditional western blotting, the resultant 
chemiluminescent signal generated by the HRP-catalysed reaction visualises the protein of 
interest. The resultant signals are automatically detected, quantified and converted to 
electropherograms and gel-like images by the Compass software.  
Protein and reagent preparation for the Wes assay were conducted according to 
manufacturer’s protocol (ProteinSimple).   
 
2.3.6 Cell Irradiation 
To study the effect of MYC on radioresistance, exponentially growing MYC-regulable cells 
were induced with and without DOX for MYC knockdown. 24h after DOX induction, an 
appropriate number of cells was seeded onto 96 well plates and allowed to recover for 24h. 
Cells in each plate were irradiated using a D3300 X-Ray system (Gulmay Medical Ltd., Surrey, 
UK). Cell lines underwent single doses of irradiation of either 2, 5, 10, 15 or 50Gy. Control 
plates received no irradiation. D425 NS was used as negative control to compare to those 
D425 cells bearing a MYC-knockdown construct being exposed to DOX treatment. 
After irradiation, plates were incubated at 37°C and cell viability assessed at 72h using the 
colorimetric CellTiter 96 AQueous One reagent. Absorbance of each well was read with a 





2.3.7 Drug testing 
2.3.7.1 Drug handling 
Drugs were diluted in dimethyl sulfoxide (DMSO) to a final concentration of 10mM and stored 
at -80°C. Before treatment, all drugs were freshly diluted in media to the desired working 
concentration.  
2.3.7.2 Drug sensitivity assay 
To assess the effect of the inhibitors on cell proliferation, cells were seeded in plates 24h prior 
to treatment. Drugs were added to the cells at the final required concentration and left in the 
incubator for the required time of exposure. For data normalisation, cells were grown with 
equivalent volumes of DMSO-containing media without drug. At the end of each treatment, 
CTG or CTA was added to the plate and read as previously described. The effect of drugs on 
cell viability was determined by comparing growth results of untreated cells.  
2.3.7.3 Time pulse cell viability assay 
To assess the effect of CYC065 inhibitor on the cell cycle and its overall effect on cell viability, 
cells were seeded in cell bind 96 well plates 24h prior to treatment for cells to recover. For 
MYC-silencing, cells were pre-induced with DOX 24h before seeding to start drug treatment 
when maximum MYC knockdown was achieved. Cells were exposed to decreased 
concentrations of CYC065, 1:3 serial dilutions from 100µM to 0.03µM, for 1h, 2h, 4h and 8h. 
For data normalisation, cells grown with serial dilutions of DMSO served as controls.  
After the specified time of exposure, drug-containing media from the plates was removed and 
refreshed with drug-free media. Cells were left in the incubator to grow for 72h, at which point 
cell viability was assessed with CTG. Data was analysed with Prism and presented as 
percentage of viable cells compared to the untreated control for each respective construct 
and cell line.   
2.3.7.4 Protein analysis for time pulse assays 
To assess the effect of CYC065 at the protein level, cells were seeded in cell bind 6 well plates 
24h prior to drug treatment to allow recovery. For MYC-silencing, cells were pre-induced with 
DOX 24h before seeding to ensure drug treatment started when MYC was completely knocked 
down. Cells were exposed to 1x, 2x and 4x the IC50 of CYC065, for 1h, 2h and 8h. For data 
normalisation, cells grown with an equal volume of DMSO were used as controls.  
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After the specified times of exposure, cell pellets were collected and washed two times with 
ice-cold PBS and stored at -80°C until required. Protein analysis and quantification was done 
with Wes.  
2.3.7.5 Determination of half-maximal inhibitory concentration (IC50)  
IC50 are a measure of a drug’s efficiency that indicate the quantity of drug needed to inhibit a 
biological process by half. To assess the effect of the inhibitors on cell growth, cells were 
seeded in either 96 or 384 well plates 24 hours prior to treatment with a titration (10 fold 
dilutions from 10pM-10μM) of the drugs. For data normalisation, cells were grown with 
equivalent volumes of DMSO-containing media. At 72h, cell proliferation was measured.   
Values were analysed and growth curves created with Prism8 (GraphPad) using the 
log(inhibitor) vs. normalized response curve [Y=100/(1+10^((X-LogIC50)))]. Each experiment 
was performed in triplicate and repeated independently at least three times.  
2.3.7.6 Rescue assays 
To confirm reduced cell viability caused by treatment with the inhibitors, appropriate numbers 
of cells, previously grown in the presence and absence of DOX for MYC knockdown, were 
seeded in cell bind 96 well plates and left overnight in the incubator to recover. Drugs were 
added to the plates the following day, to the desired final concentration. At day 5 post 
treatment, media-containing drug was removed from plates using a multi-channel pipette and 
replaced with drug-free media. Cell viability was assessed with CellTiter-Glo (CTG) at 3, 5, 10 
and 14 days following initial drug exposure. Relative luminescence units (RLU) were used as 
an indicator of cell survival (metabolically active cells). Luminescence readings were analysed 









2.3.8 High-throughput compound screen 
The liquid handling of the small molecule inhibitor high-throughput screen was done using a 
Microlab STAR robotic platform (Hamilton), with the exception of cell seeding. Compounds 
were stored in 100% DMSO as 10mM stocks, and further diluted in DMSO to obtain a final 
concentration in each well of the 384-well plate of 0.5nM, 1nM, 5nM, 10nM, 100nM, 500nM, 
1000nM or 0.5nM, 5nM, 50nM and 500nM, depending on the compound library (Library 
content described in Chapter 5, Appendix 5.1, Appendix 5.2 and Appendix 5.3). Final DMSO 
concentration in all wells was 0.2% (v/v). Inhibitors were stored in a StoragePod, (Roylan 
Developments) under nitrogen atmosphere. Compounds on the screen were assessed in 
triplicate on separate plates to avoid plate to plate variations.  
48h prior to drugging, doxycycline (DOX) was added to flasks containing cell lines for MYC 
knockdown (cell lines cloned with NS shRNA constructs included). The day before the screen 
1000-2000 cells in 25μl of media were seeded in a 384-well assay plate using a Multi-Drop 
combi. To ensure single cell suspensions, cells were passed through 30µm MACS cell strainers 
when diluting to the appropriate number and volume required. Plates were then left in the 
incubator for 24h to recover. After the incubation time, compounds were freshly diluted in 
the Microlab STAR platform (Hamilton) (to the final titration explained above) and 25μl of the 
aliquoted drugs were added to the plates. Cells were cultured in the presence of the inhibitors 
for five days. After treatment, cell viability was assessed using CellTiter-Glo (CTG), by adding 
20μl to the media. After 10 minutes of gentle incubation on a shaker, luminescence signal was 
captured using a Victor X-light plate reader.     
An untreated control (no compound or DMSO) alongside positive and negative controls 50% 
DMSO only or camptothecin) were included on every assay plate for data normalisation. Signal 
from each well was normalised to the median of the negative controls (software analysis as 






2.3.9 Gene expression quantification  
2.3.9.1 RNA extraction 
RNA was extracted from frozen pellets using the QIAGEN RNeasy Mini Kit. To lyse the cells, 
samples were resuspended in 300μl of RLT buffer and transferred to a QIAshredder column. 
After a 2min centrifugation at 20000xg, the resultant elution was homogenised with 300μl of 
70% ethanol and transferred to a RNeasy column, which was then centrifuged for 30sec at 
8000xg. Sequential washings with 700μl RW1 and 500μl RPE buffer, followed by 15s 
centrifugation at 8000xg after each step, were performed to remove contaminants from RNA 
bound in the columns. 30μl of RNAse-free water was used to elute the RNA from the RNeasy 
columns. The final RNA concentration was immediately quantified using a 
nanospectrophotometer, which provided with the 260/280 ratio to assess the quality of the 
RNA extracted. RNA was then stored at -80°C until required.  
2.3.9.2 cDNA synthesis 
The high capacity cDNA reverse transcription kit (Applied Biosystems) was used to synthesise 
cDNA from extracted RNA. Following the manufacture’s protocol, up to 5.8μl of sample was 
mixed with 4μl of reaction mix and 1μl of reverse transcriptase, and made up to a total volume 
of 20μl with nuclease-free water, to produce 50ng/μl of cDNA. After the reverse transcription, 
cDNA was stored at -20°C. 
2.3.9.3 Quantitative reverse transcription PCR (RT-qPCR) 
To quantify mRNA expression of genes of interest, PowerUp SYBR Green Master Mix kit 
(Applied Biosystems) was used to amplify cDNA synthesised from samples RNA. The use of the 
SYBR green dye enables the quantification of DNA as it intercalates between DNA bases of 
double-stranded DNA, emitting fluorescent signal upon excitation. Resultant fluorescence is 
used as a measure of total DNA amplified. Primers for our target genes (summarised in table 
2.4) were designed using Primer3Plus software.  
A volume of 4μl of cDNA at a final concentration of 1ng/μl, was mixed with the reverse and 
forward primers alongside the SYBR master mix and the water. Components of the master mix 







SYBR Green Mix 5.1μl 
Forward primer (10μM) 0.2μl 
Reverse primer (10μM) 0.2μl 
Sample 4μl 
Nuclease-free H2O 0.5μl 
 
Table 2.11. Components of the SYBR Green assay for RT-qPCR 
 
Total volumes of 10μl reactions were run in triplicate on 384-well plates in a ViiA7 machine 
using TBP as internal control (reference gene). RT-qPCR cycling conditions used can be seen in 
Table 2.12.  
Condition Temperature (°C) Time 
Hold stage 
step 1 50 2 min 
step 2 95 10 min 
PCR stage (40 cycles) 
step 1 95 15 sec 
step 2 60 1 min 
Melt Curve stage 
step 1 95 15 sec 
step 2 60 1 min 
step 3 95 15 sec 
Table 2.12. Thermal cycling conditions for RT-qPCR SYBR assay 
 
Data produced was analysed with QuantStudio Real-Time PCR System (Applied Biosystems), 
and the comparative Ct method was used, which assumes uniform amplification efficiency of 
100% across samples. The housekeeping gene was used to normalise the expression of each 
gene of interest, yielding a ∆Ct value, which was then used to compare the non-drug treated 
control and the experimental sample. The resultant ∆∆Ct value was then linearised to obtain 
relative mRNA expression.   
 
Differential gene expression was calculated as follows: 
∆Ct = (Ct target gene – Ct reference gene) 
∆∆Ct = (∆Ct target gene - ∆Ct reference gene) 




2.3.10 Flow cytometry  
Flow cytometry analysis was used to assess cell cycle phases of cells of interest. Samples were 
harvested, washed twice with ice cold PBS and fixed by adding drop wise cold 70% ethanol 
while vortexing. Cells were kept at 4°C until required.  
For cell cycle analysis, samples were spun at 850xg in a 4°C centrifuge for 5min. Ethanol was 
carefully aspirated to minimise cell loss. Cell pellet was resuspended in 0.5ml of PBS. Cells 
were treated with 50μl of 100µg/ml RNase A (pre-heated at 100°C for 10 mins) to ensure only 
DNA content of cells was stained. To lyse and stain the cells, 250μl of 1:10 mix of Propidium 
iodide (PI) and triton (100X) was added to each sample. Cells were analysed using the Attune 
NxT Flow Cytometer (ThermoFisher Scientific) and data was processed and cell cycle 
distribution verified using FlowJo software.  Percentage of cells in each cell cycle phase was 









MYC’s involvement in MBGroup3 pathogenesis is well established (Chapter 1). As explained in 
Chapter 1, the MYC oncogene family members are super-transcription factors that have the 
ability to regulate 15% of the entire genome. Downstream effects of MYC involve key 
biological functions like cell proliferation, differentiation and survival, being of crucial 
importance to tightly regulate its expression. Several studies have demonstrated that 
inactivation of MYC can translate into an anti-tumorigenic effect. Tumour addiction to MYC 
thus offers a therapeutic window to target oncological diseases (Dang et al., 2006, Hutter et 
al., 2017). 
Despite several attempts to target MYC directly, single drug development has proven to be 
challenging and no drugs for its direct targeting are clinically available yet. Indirect targeting 
of MYC has been widely investigated over the last decade, making it clear that therapeutic 
strategies aiming to alter MYC abundance or disrupt key MYC functions are going to be 
required in order to target the effects of this master cell regulator (Vita and Henriksson, 2006, 
Shalaby and Grotzer, 2016). 
A few studies using small interference RNA (siRNA) strategies (von Bueren et al., 2009, Ćwiek 
et al., 2015) have been done in MBGroup3 to try and elucidate MYC´s role in MB tumour biology 
and identify druggable genetic dependencies, but none have yet explored it in a context-
specific MYC-dependent manner. To specifically explore the role of MYC in MBGroup3, the 
Paediatric Brain Tumour Group (PBTG) at Newcastle University has established three MYC-
regulable MBGroup3 cell lines, using D425, D283 and HDMB03 as hosts, where MYC can be 
silenced through the DOX-induced expression of shRNA. MYC knockdown is achieved by the 
addition of DOX to the media, which triggers the expression of the shRNA construct 
transduced into the cells knocking down MYC expression. The expression vector system is 
described in Chapter 2. 
The host cell lines used inherently express different levels of MYC. D425 and HDMB03 have 
MYC amplification, whereas D283 has gained an extra copy of the MYC gene. Each set of 
isogenic cell lines generated have two experimental constructs targeting two different MYC 
sequences, called MYC2 and MYC3 (expressing shRNA to silence MYC), and a non-silencing 
control construct (NS) expressing a non-silencing shRNA (Dr. Swartz, PhD thesis)(constructs 
and shRNA system is explained in Chapter 2).  
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The generation of stable isogenic cell lines with a DOX-inducible system for MYC knockdown 
brings the opportunity for direct investigation of the nature and extent of MYC’s involvement 
in MBGroup3 pathogenesis, and its dependency. The use of these models could allow the 
identification of key pathways for the survival of MYC-overexpressing cells, and to identify and 
develop novel therapeutic strategies to bring into the clinic, which is a promising strategy to 
























To the present day, this is the first time that MYC-regulable MBGroup3 cell models have been 
generated. The aim of this chapter is to validate the effectiveness of MYC knockdown achieved 
with the inducible shRNA system, and to independently characterise phenotypic changes 
associated with MYC knockdown in these three sets of isogenic cell lines. Corroboration of 
achievement of MYC-silencing by the shRNA system, and MYC-dependent cancer phenotypes, 
will establish the suitability of these models as new tools to study the MYC-dependent biology 




















3.3 Validation of DOX-inducible MYC-regulable MBGroup3 cell lines 
3.3.1 Validation of MYC knockdown at the protein level 
The modelling principle on which this thesis is based is the ability to experimentally regulate 
MYC expression in MBGroup3 cell lines. Therefore, prior to experimentation, testing the 
reproducibility of MYC knockdown by doxycycline (DOX) in each host cell line was necessary.  
The DOX concentration selected for experimentation was based on previous optimisation 
work done in the PBTG (Dr. Swartz, PhD thesis), where it was established that 1µg/ml was the 
minimum dose required to achieve maximum MYC knockdown with minimal effects on MYC 
expression caused by DOX alone in control cells. Therefore, it was decided to start validation 
experiments with a concentration of a 1µg/ml to determine if each shRNA targeting MYC could 
knock it down at the chosen concentration in each host cell line.  
Initial experiments to determine the time course of MYC knockdown over 96h were only 
carried out in D425. To confirm MYC knockdown at the protein level, D425 cells bearing the 
NS, MYC2 and MYC3 constructs were cultured in the presence and absence of DOX (1µg/ml) 
(Figure 3.1) and harvested at different time points (24, 48, 72, 96h).The NS construct was used 
as a negative control for the function of the shRNA and to determine the specific effects of 
the silencing constructs on the cell lines.  
 
 
Figure 3.1. Overview of the isogenic working system. Schematic representation of the isogenic 
shRNA model system. The D425 MBGroup3 cell line has been transduced with a non-silencing (NS), 
MYC2 and MYC3 shRNA construct for silencing MYC expression. Expression of the shRNA system and 
the consequent silencing of MYC is triggered by the addition of doxycycline (DOX+) to the media. 
Constructs need to be grown separately to avoid mixing. For DOX-treated conditions, cells from the 





Cell lysates from DOX-treated cells were collected, protein quantified and protein detected 
with a simple western Assay (Wes) as described in Chapter 2.  
Protein quantification of D425 with Wes validated that maximum MYC knockdown was 
achieved at 72h by the MYC2 and MYC3 constructs (Figure 3.2), showing no significant 
differences in MYC protein levels at later time points (MYC2 p=0.787; MYC3 p=0.525), thus 
confirming prolonged MYC knockdown throughout the time course of DOX induction. 
Treatment of D425 NS with DOX did not have an effect on the cells or in MYC protein 
expression levels. Time course experiments of DOX induction independently validated the 
concentration of DOX previously determined to use to achieve maximum MYC knockdown 
(1µg/ml), and the time at which this is achieved (72h).   
Considering maximum MYC knockdown was achieved at 72h, validation of MYC knockdown in 
D283 and HDMB03 was only performed at this single time point. 
 
 
Figure 3.2. Time course of MYC knockdown in D425 MBGroup3 cell line.Simple western assay (Wes) 
of MYC protein levels (~75kDa) expressed by D425 cells transduced with the NS, MYC2 and MYC3 
shRNA constructs, cultured in the presence of doxycycline (DOX) for 96h. Protein levels were 
assessed at 0, 24, 48, 72 and 96h. D425 NS was used as a non-targeting control for shRNA. DOX-
induced MYC knockdown was achieved at 72h in the MYC2 and MYC3 construct. GAPDH (~40kDa) 










3.1.1.1 Establishment of the level of MYC knockdown achieved 
Next, D425, D283 and HDMB03 isogenic cell lines cloned with the NS, MYC2 and MYC3 
constructs were cultured with DOX for 72h to induce the expression of the shRNA constructs 
for MYC knockdown. Un-treated cells were used as controls for each construct. For data 
normalisation, MYC protein levels were normalised to the expression levels of GAPDH. 
After DOX treatment, no changes in MYC protein expression levels were seen for any of the 
NS controls when cultured in the presence and absence of DOX. In the presence of DOX, a 
decrease in MYC protein levels was seen in MYC2 and MYC3 constructs across cell lines when 
compared to their correspondent un-treated controls (Figure 3.3). Triggering the expression 
of D425 MYC2 and MYC3 shRNA caused a reduction in MYC protein levels of 73% for MYC2 
and 60% for MYC3 (% of the average of two replicates), when compared to their respective 
DOX-untreated control, in both cases statistically significant (p=0.0081; p=0.042, respectively). 
Similarly, D283 MYC2 and MYC3 shRNA significantly reduced MYC protein expression by 72.1% 
and 65.3%, respectively (p=0.014; p=0.023). Treatment with DOX also triggered the expression 
of HDMB03 MYC2 and MYC3 shRNA constructs, reducing MYC protein levels by 51.6% in 
MYC2, and 37% in MYC3 (only significant in MYC2, p=0.012), when compared to their 
untreated counterparts (Figure 3.3). Results from all 3 cell lines indicate that the MYC2 shRNA 
construct is the most efficient in knocking down MYC expression, achieving an average of 65% 
MYC knockdown across cell lines.      
In summary, MYC knockdown at the protein level was successfully reproduced with the 
addition of the established doxycycline concentration (1µg/ml) to the media. DOX triggered 
the expression of the MYC2 and MYC3 shRNA constructs across cell lines, achieving a 
reduction of MYC protein levels of 65% on average. These experimental conditions were taken 








Figure 3.3. Validation of MYC knockdown at the protein level by inducible shRNA constructs in 
D425, D283 and HDMB03 MB cells.  D425, D283 and HDMB03 cell lines cloned with the NS, MYC2 
(M2) and MYC3 (M3) constructs, were cultured for 72h in the presence (+DOX) and absence (-DOX) 
of doxycycline for MYC knockdown. Cells were harvested at 72h, protein extracted and protein levels 
analysed with Wes. The image shows automated western blots and densitometry analysis of MYC 
protein expression in A)D425, B)D283 and C)HDMB03. GAPDH was used as internal loading control. 
MYC protein expression was normalised to GAPDH protein expression levels. Graphs show the 
comparison of MYC protein levels between MYC overexpressing cell lines (blue: -dox; MYC ON) and 
those with MYC knockdown (red: +dox; MYC OFF). Densitometry results are shown as means ± SEM 
of two independent experiments and the significance determined by paired student’s t-test 






3.3.2 Validation of MYC knockdown at the RNA level 
Following confirmation of shRNA-mediated silencing of MYC protein expression, we sought to 
examine if MYC knockdown was also observed at the mRNA level.  
D425 and D283 isogenic cell lines were grown in the presence of DOX for DOX-inducible MYC 
knockdown, harvested at 3 and 7 days after DOX induction and RNA extracted for 
quantification of mRNA expression by quantitative real-time PCR.  
DOX-induced MYC knockdown was also identified at the mRNA level. No differences in MYC 
mRNA levels were observed for the NS constructs, consistent with results at the protein 
expression level. Both targeting shRNA constructs caused a significant decrease in MYC mRNA 
expression with 3 days of DOX treatment in both cell lines.  
In D425, after 3 days, MYC knockdown caused a significant reduction of MYC mRNA expression 
in MYC2 and MYC3 cells when compared to the DOX-untreated control (day 0). A decrease of 
60% in MYC2 and 19% in MYC3 was observed within 3 days of DOX treatment (MYC2 p=0.0004; 
MYC3 p=0.007). A further decrease in MYC mRNA expression was seen with prolonged 
treatment with DOX (day 7) when compared to un-induced counterparts, by 74% and 47% in 
MYC2 and MYC3 respectively (MYC2 p=0.0017; MYC3 p=0.0025) (Figure 3.5, A). 
Triggering of shRNA expression in D283 MYC2 and MYC3 also caused a significant decrease in 
MYC mRNA levels when compared to the control, of 41% and 19% respectively for both 
constructs (MYC2 p=0.011; MYC3 p=0.03). MYC mRNA levels were further reduced when 
exposed to DOX for 7 days (relative to control), by 57% in MYC2 and 39% in MYC3 (MYC2 
p=0.023; MYC3 p=0.01) (Figure 3.4, B). 
The same effect was seen in HDMB03 cell line. MYC knockdown caused a significant decrease 
in MYC mRNA levels after 3 days of DOX exposure, for both constructs (MYC2 p=0.0293; MYC3 
p=0.0113). A further decrease in MYC mRNA levels were seen after 7 days of DOX exposure, 
by 48.4% in MYC2 and 27.7% in MYC3, only significant for MYC2 construct (MYC2 p=0.0131; 
MYC3 p=0.0542). 
Overall, MYC-knockdown was also seen at the mRNA level in both sets of isogenic cell line 
models. DOX-induced MYC knockdown caused a decreased in MYC mRNA expression levels 
after 3 days of exposure to DOX. Prolonged induction with doxycycline further significantly 





Figure 3.4. Validation of MYC knockdown at the mRNA level by inducible shRNA constructs in 
D425, D283 and HDMB03 MB cells.RT-qPCR result showing MYC mRNA expression levels of the NS, 
MYC2 (M2) and MYC3(M3) constructs in A) D425, B) D283 and C)HDMB03 cells. Isogenic cell lines 
were cultured in the presence of DOX for 3 and 7 days. Changes in MYC mRNA expression levels are 
compared to the untreated control (no DOX) for each construct (day 0). Data represents the mean 
(±SEM) of triplicates. Expression fold change was calculated relative to TBP expression (control 




3.4 Effect of MYC knockdown on cell proliferation 
The proliferative consequences of knocking down MYC by shRNA was assessed next, in order 
to determine whether the cell lines retained their addiction to the oncogene.  
To study the proliferative effect of MYC knockdown, cell growth of D425, D283 and HDMB03 
cell lines following reduction of MYC expression was studied. Cell proliferation was assessed 
using CellTiter-Glo (CTG) assay, as described in Chapter 2, every 24h for 6 consecutive days. 
Luminescence measurements, as an estimation of cell number, were used to generate growth 
curves. Growth curves generated for each construct of each cell line were compared according 
to MYC-expression levels (Figure 3.5, 3.6 and 3.7). 
A significant decrease in cell proliferation was seen across all cell lines following MYC 
knockdown. MYC-silencing significantly reduced MYC2 and MYC3 cells proliferation by 72h 
when compared to their counterparts not exposed to DOX (i.e. expressing high levels of MYC), 
in all three host cell lines. DOX itself did not have a reproducible effect on cell proliferation, 
(NS shRNA cells). The effect of MYC knockdown was consistent in D425, D283 and HDMB03. 
Statistical significance of the comparisons performed are summarised in Table 3.1.   
Cell lines selected for use in this study were thus characterised by their addiction to MYC and 




Figure 3.5. Growth curves of MYC-amplified D425 cells following MYC knockdown.  Growth curves 
of D425 NS, MYC2 and MYC3 cell lines grown in the absence (-DOX) and presence (+DOX) of DOX for 
MYC knockdown. Cell proliferation was assessed with CTG every 24h for a total of 6 days. Cell 
proliferation is presented as relative luminescence units (RLU). A) Growth curve of D425 NS cells in 
the absence (-dox; MYC ON) and presence (+dox; MYC OFF) of DOX. No difference in proliferation 
was observed between conditions. B) & C) Growth curves of D425 MYC2 and MYC3 cells in the 
absence (-dox; MYC ON) and presence (+dox; MYC OFF) of DOX. MYC knockdown (+DOX) caused a 
significant decrease in MYC2 and MYC3 proliferation across cell lines. D) Summary of doubling times 
for D425 cells following MYC knockdown. Results are shown as means (±SEM) of at least three 






Figure 3.6. Growth curves of MYC-amplified D283 cells following MYC knockdown  Growth curves 
of D283 NS, MYC2 and MYC3 cell lines grown in the absence (-DOX) and presence (+DOX) of DOX for 
MYC knockdown. Cell proliferation was assessed with CTG every 24h for a total of 6 days. Cell 
proliferation is presented as relative luminescence units (RLU). A) Growth curve of D283 NS cells in 
the absence (-dox; MYC ON) and presence (+dox; MYC OFF) of DOX. No difference in proliferation 
was observed between conditions. B), C) Growth curves of D283 MYC2 and MYC3 cells in the absence 
(-dox; MYC ON) and presence (+dox; MYC OFF) of DOX. MYC knockdown (+DOX) caused a significant 
decrease in MYC2 and MYC3 proliferation across cell lines. D) Summary of doubling times for D283 
cells following MYC knockdown. Results are shown as means (± SEM) of at least three individual 




Figure 3.7. Growth curves of MYC-amplified HDMB03 cells following MYC knockdown. Growth 
curves of HDMB03 NS, MYC2 and MYC3 cell lines grown in the absence (-DOX) and presence (+DOX) 
of DOX for MYC knockdown. Cell proliferation was assessed with CTG every 24h for a total of 6 days. 
Cell proliferation is presented as relative luminescence units (RLU). A) Growth curve of HDMB03 NS 
cells in the absence (-dox; MYC ON) and presence (+dox; MYC OFF) of DOX. No difference in 
proliferation was observed between conditions. B), C) Growth curves of HDMB03 MYC2 and MYC3 
cells in the absence (-dox; MYC ON) and presence (+dox; MYC OFF) of DOX. MYC knockdown (+DOX) 
caused a significant decrease in MYC2 and MYC3 proliferation across cell lines. D) Summary of 
doubling times for HDMB03 cells following MYC knockdown. Results are shown as means (± SEM) of 






Table 3.1. Evaluation of cell proliferation according to MYC expression levels. Growth of NS, MYC2 
and MYC3 D425, D283 and HDMB03 cell lines grown in the presence (+DOX) and absence (-DOX) of 
doxycycline were compared to assess differences in cell proliferation according to MYC-expression 
levels. Table summarises the statistical analysis of the growth comparison of cells with MYC 
knockdown (+DOX) compared to their untreated counterparts (-DOX). Significance was determined 
















3.5 Effect of MYC knockdown on the cell cycle  
In order to understand the mechanism by which cell growth was reduced upon MYC 
knockdown, flow cytometry-based cell cycle analysis was performed for every variant of D425, 
D283 and HDMB03. Following the same methodology, cells grown in the presence and 
absence of DOX were harvested for cell cycle analysis at 72h. Staining of DNA content was 
performed using propidium iodide (PI) and analysed using the Attune NxT Flow Cytometer 
(ThermoFisher Scientific), as described in Chapter 2.  
Cell cycle analysis identified no significant differences in cell cycle distribution for D425, D283 
and HDMB03 cloned with the control NS construct. MYC silencing with shRNA caused an 
increase in cell numbers in G1 phase and a decrease in the number of cells in the S phase of 
the cell cycle when compared to controls (no DOX); these changes in cell cycle distribution 
seen across all host cell lines.  
 
In D425, MYC knockdown caused a significant increase in cells in G1 phase for both MYC2 and 
MYC3 cells, when compared to cells overexpressing MYC (MYC2 p=0.0164; MYC3 p=0.0094). 
This increase of cell numbers in G1 was accompanied by a significant decrease in cells in S 





Figure 3.8. Cell cycle distribution of D425 MB cell line upon MYC knockdown.Cell cycle distribution 
of D425 NS, MYC2 and MYC3, grown in the presence (+DOX) and absence (-DOX) of DOX for MYC 
knockdown. A) Percentage of D425 NS, MYC2 (M2) and MYC3 (M3) cells at G0-G1, G2-M, S, and sub-
G1 phases of the cell cycle. Graphs B), C) and D) show the percentage of cells in each phase of the 
cell cycle, for NS, MYC2 and MYC3 respectively. B)No significant changes were seen in the cell cycle 
distribution of D425 NS. C) MYC knockdown (red: +dox) caused a significant increase in the number 
of cells in G0-G1 phase and a significant decrease of cells in S phase in MYC2 cells when compared to 
controls cultured with no DOX (blue: -dox). D) MYC knockdown (orange: +dox) caused a significant 
increase in the number of cells in G0-G1 phase and a significant decrease of cells in S phase in MYC3 
cells when compared to controls cultured with no DOX (green: -dox). Results are shown as means ± 














For D283, despite a noticeable increase in cells on the G1 phase of the cell cycle upon MYC 
knockdown, it was only significant for MYC2 (p=0.0210). Nevertheless, a significant decrease 
in the number of cells in the S phase of the cell cycle was seen for both MYC2 and MYC3 (MYC2 
p=0.0241; MYC3 p=0.0271)(Figure 3.9). 
 
 
Figure 3.9. Cell cycle distribution of D283 MB cell line upon MYC knockdown. Cell cycle distribution 
of D283 NS, MYC2 and MYC3, grown in the presence (+DOX) and absence (-DOX) of DOX for MYC 
knockdown. A) Percentage of D283 NS, MYC2 (M2) and MYC3 (M3) cells at G0-G1, G2-M, S, and sub-
G1 phases of the cell cycle. Graphs B), C) and D)show the percentage of cells in each phase of the cell 
cycle, for NS, MYC2 and MYC3 respectively. B)No significant changes were seen in the cell cycle 
distribution of D283 NS. C) MYC knockdown (red: +dox) caused a significant increase in the number 
of cells in G0-G1 phase and a significant decrease of cells in S phase in MYC2 cells when compared to 
controls cultured with no DOX (blue: -dox). D)MYC knockdown (orange: +dox) caused a significant 
increase in the number of cells in G0-G1 phase and a significant decrease of cells in S phase in MYC3 
cells when compared to controls cultured with no DOX (green: -dox). Results are shown as means ± 









Although the same pattern was seen in HDMB03, differences in cell cycle distribution of MYC2 
and MYC3 were non-significant. Only the comparison of cell numbers of MYC2 cells in S phase 
of the cell cycle resulted to be statistically significant (p=0.0428) (Figure 3.10).   
 
 
Figure 3.10. Cell cycle distribution of HDMB03 MB cell line upon MYC knockdown.Cell cycle 
distribution of HDMB03 NS, MYC2 and MYC3, grown in the presence (+DOX) and absence (-DOX) of 
DOX for MYC knockdown. A) Percentage of HDMB03 NS, MYC2 (M2) and MYC3 (M3) cells at G0-G1, 
G2-M, S, and sub-G1 phases of the cell cycle. Graphs B), C) and D) show the percentage of cells in 
each phase of the cell cycle, for NS, MYC2 and MYC3 respectively. B) No significant changes were 
seen in the cell cycle distribution of HDMB03 NS. C) MYC knockdown (red: +dox) caused an increase 
in the number of cells in G0-G1 phase (not significant) and a significant decrease of cells in S phase in 
MYC2 cells when compared to controls cultured with no DOX (blue: -dox). D)MYC knockdown 
(orange: +dox) caused an increase in the number of cells in G0-G1 phase and a decrease of cells in S 
phase in MYC3 cells when compared to controls cultured with no DOX (green: -dox)(not significant). 
Results are shown as means ± SEM of three individual experiments, and significance determined by 







3.6 Effect of MYC knockdown on apoptosis  
To gain a better understanding of the mechanism by which MYC knockdown was reducing cell 
growth rates, apoptosis assays using the Caspase-Glo 3/7 reagent were performed D425 and 
D283 to study the effect of MYC silencing on apoptosis in a time-dependent manner (methods 
described in Chapter 2). Since HDMB03 apoptotic levels had already been established by Dr. 
Shanel Swartz as part of her PhD thesis, the effect of MYC knockdown on apoptosis was only 
investigated in D425 and D283 isogenic cell lines (Dr. Shanel Swartz, PhD thesis). 
Caspase 3/7 activity was assessed in D425 and D283 transduced with NS, MYC2 and MYC3 
shRNA after 72h of DOX treatment (apoptosis levels at all time points can be seen in Appendix 
3.1). Non-treated cells for each construct were used as control for comparison. NS cells were 
used as internal control to account for possible effects of DOX treatment.  
MYC knockdown in D425 MYC2 and MYC3 caused a significant decrease in apoptosis at 72h of 
DOX induction when compared to the corresponding untreated control (0h) (MYC2 p<0.0001; 
MYC3 p=0.0001). No significant changes in apoptotic markers were seen for D425 MYC2 cells 
expressing high levels of MYC (no DOX) between 0 and 72h. Following MYC knockdown, a 
significant decrease in apoptosis was seen in MYC2 cells when compared to the levels of 
apoptosis at 0h (Figure 3.11, A).  A slight increase in apoptosis was seen in D425 MYC3 
expressing high levels of MYC when compared the correspondent control (0h), however, this 
did not reach statistical significance. In D425 NS, apoptosis seemed to decline in a time 
dependent manner. Despite the slight decrease detected, changes observed were not 
statistically significant (Figure 3.11, A).   
A significant decrease in apoptosis was also observed in D283 MYC2 and MYC3 cells following 
MYC silencing with shRNA at 72h, when compared to their correspondent control 
counterparts (0h) (MYC2 p=0.0006; MYC3 p=0.0214) (Figure 3.11, B). 72h after DOX-induction, 
a less marked but consistent increase in apoptosis was seen at 72h in MYC2 and MYC3 cells 
when expressing high levels of MYC (no DOX) in comparison to 0h (not statistically significant). 
No significant changes in apoptotic signal were seen in D283 NS, between both time points 





Figure 3.11.Effect of MYC knockdown on apoptosis in D425 and D283 regulable MBGroup3 cell 
lines.Time dependent effect of MYC knockdown on apoptosis A) D425 and B) D283 MYC-regulable 
cell lines. Cells cloned with NS, MYC2 and MYC3 constructs were cultured with DOX for 72h (+DOX). 
Un-treated cells (-dox) were used as controls for each construct. A) At 72h, MYC knockdown (+dox) 
caused a significant decrease in apoptosis in D425 MYC2 and MYC3 cells. B)  A significant decrease 
in apoptosis was observed following MYC knockdown in D283 MYC2 and MYC3 cells for both cell 
lines. Results are shown as means ±SEM of three individual experiments, values expressed as 









3.7 Effect of radiation on MYC-driven cell lines 
Radiation plays a pivotal role in MB treatment (Ashley et al., 2012, Bloom, 1982). Patients with 
MBGroup3 tumours respond poorly to treatment and those with MYC overexpression or 
amplification are associated with a significantly worse outcome (Schwalbe et al., 2017). 
Bueren et al. analysed how MYC expression determined the response of MB cell lines to radio- 
and chemotherapy. They studied the response of DAOY and UW228 (MBSHH) cell lines 
engineered to express different levels of MYC mRNA to irradiation (2Gy, 5Gy or 10Gy). They 
found that higher levels of MYC expression sensitise MB cell lines to radiation treatment (von 
Bueren et al., 2011).  
To study if similar effects are observed in a Group 3 background and further characterise 
phenotypes in our models, D425 cells cloned with the NS, MYC2 and MYC3 regulable-
constructs were induced with DOX to knockdown MYC and exposed to ionising radiation (IR). 
Preliminary experiments with IR were only performed in D425. 
 
 
3.7.1 MYC sensitises D425 MB cells to radiation 
To examine whether MBGroup3 sensitivity to radiation was MYC-dependent, radio-sensitivity 
assays were performed on D425 MYC-regulable cell line. 
D425 NS, MYC2 and MYC3 cells were induced with DOX 48h before IR treatment to ensure 
maximum MYC knockdown when irradiating. DOX was refreshed before seeding to maintain 
MYC knockdown throughout the experiment. Cells in each plate were irradiated with single 
doses of either 2, 5, 10, 15 or 50Gy (described in Chapter 2). Control plates received no 
irradiation. D425 NS were used as negative control to compare to those D425 cells bearing 
also a construct and being exposed to DOX treatment. Cell viability was assessed 72h after 






A reduction in cell viability was observed after treatment with different concentrations of IR, 
which was more markedly pronounced in cells expressing high levels of MYC than in cells with 
MYC knockdown. 72h after IR treatment, no differences in cell viability between D425 NS cells 
treated with and without DOX were seen (Figure 3.12, A), showing that DOX treatment has a 
minimum effect on cell viability (p=0.7633). MYC knockdown reduced MCY2 and MYC3 cells 
susceptibility to IR when compared to cells expressing high levels of MYC, difference only 
significant in D425 MYC2 (MYC2 p=0.0488; MYC3 p=0.1031) (Figure 3.12, B and C). IR of 10Gy 
reduced MYC2 and MYC3 cells viability by 44.88% and 41.55% respectively, compared to a 
reduction of only 13.3% and 19.3% following MYC knockdown.  
Overall, D425 cells expressing high levels of MYC were found to be more susceptible to IR, 
causing a decrease in cell viability in a dose-dependent manner. MYC knockdown increased 





Figure 3.12. Radiation sensitivity of D425 NS, MYC2 and MYC3 cells. Dose-response curves of D425 
NS, MCY2 and MYC3 cells response to single doses of ionising radiation (2, 5, 10, 15, 50Gy) after 72h 
post-treatment. A) Dose response curve of D425 NS in the absence (-dox; MYC ON) and presence 
(+dox; MYC OFF) of DOX. No differences in cell viability were seen after IR treatment when treated 
with and without DOX. B) Dose response curve of D425 MYC2 in the absence (-dox; MYC ON) and 
presence (+dox; MYC OFF) of DOX. Cell viability of MYC overexpressing cells (-dox; MYC ON) was 
significantly reduced after IR treatment, compared to cells with MYC knockdown (+dox; MYC OFF). 
C) Dose response curve of D425 MYC3 in the absence (-dox; MYC ON) and presence (+dox; MYC OFF) 
of DOX. Expression of high levels of MYC caused a decrease in cell viability after IR treatment 
compared to cells with MYC knockdown (+dox; MYC OFF), did not reach statistical significance. 
Curves are presented as log(concentration) vs response. Data is shown as percentage of the mean 
(±SEM) of three independent experiments. Statistical significance determined by paired students t-







To study the role of MYC within MBGroup3, the Paediatric Brain Tumour Group generated three 
isogenic cell lines in which MYC expression can be directly regulated with the expression of 
shRNA. The use of MYC-regulable MBGroup3 cell lines could give better insight on the direct role 
of MYC in MBGroup3 biology and to enable the identification of targetable genetic pathways 
cooperating with MYC to promote tumorigenesis for the development of new therapeutic 
approaches.   
Since the project is based on the inducible knockdown of MYC in MBGroup3 cell lines, this 
chapter establishes and validates the MYC-dependent phenotypes of these MYC-regulable 
models. Automated Western blot analysis was performed to validate the induction of MYC 
knockdown in cells exposed to DOX, which showed the expected effective MYC knockdown at 
72 hours and its prolonged effect at longer time exposures. Reproducibility of MYC knockdown 
was seen across all cell lines; D425, D283 and HDMB03. Knockdown of MYC at the protein 
level was also observed and validated at the mRNA level.  
 
To assess the proliferative consequences of knocking down MYC by shRNA, and determine if 
the cell lines retained their addiction to MYC and MYC-dependent phenotypes, cell growth of 
D425, D283 and HDMB03 cell lines following reduction of MYC expression was studied. 
Knockdown of MYC caused a significant decrease in cells proliferation when compared to cells 
expressing MYC, and a decrease in apoptotic markers. Results concur with previous studies 
showing the involvement of MYC in cell proliferation and MYC-dependency of MYC-amplified 
MB (Felsher, 2010, Swartling et al., 2010). 
MYC is a master regulator of key components of cell cycle progression, controlling 
proliferation and apoptosis. MYC is one of the most robust agents regulating programmed cell 
death through various mechanisms. MYC causes genome instability that triggers a signalling 
cascade that culminates in the expression of pro-apoptotic genes such as BAX, 






MYC addicted cells present a rapid cell turnover, which consequently have higher rates of cell 
death when compared to those having MYC knockdown. The higher doubling time of cells 
expressing high levels of MYC could explain the increase in apoptotic markers seen in MBGroup3 
cell lines at 72h. Under normal circumstances, MBGroup3 cells grow rapidly and after a few days 
in culture, the increased cell confluence affects cells ability to grow and the apoptotic 
response is triggered to limit unchecked cell growth. These results coincide with historical 
findings of cells presenting both a high mitotic index and a significant fraction of apoptotic 
cells (Topham and Taylor, 2013, McMahon, 2014). 72-96h after MYC knockdown, cell growth 
starts to slow down and plateau, associated with G0/G1 arrest and reduced apoptosis. 
Reduction of MYC expression levels could be inhibiting MYC-induced apoptosis by arresting 
cell growth at G1 phase of the cell cycle, suggesting that cells are entering a senescent phase 
instead of going to an apoptotic state. Alongside arrest at G1 phase of the cell cycle upon MYC 
knockdown, previous studies on the cell lines have shown an increase in the expression of the 
gene Cyclin Dependent Kinase Inhibitor 1A (CDKN1A)(Dr. Swartz, PhD thesis). The protein 
encoded by CDKN1A, p21, binds and inhibits CDKs blocking cell cycle progression. Inhibition 
of the gene encoding for this particular protein has been found to be frequently supressed in 
MYCN amplified tumours like Neuroblastoma (Westermann et al., 2008, Ryl et al., 2017).  
Results presented coincide with a preceding study done on MBGroup3 cell lines, where MYC 
knockdown by siRNA resulted in inhibition of cell proliferation and reduction of apoptosis (von 
Bueren et al., 2009). Moreover, in conformance with the literature, these results indicate that  
reduction in MYC expression levels results in a G1 cell cycle arrest, leaving cells in a 
metabolically activate state but without being actively growing (Florea et al., 2013, Schorl and 
Sedivy, 2003, Garcia-Gutierrez et al., 2019, Ćwiek et al., 2015). 
As mentioned before, MYC has the ability to control both proliferation and apoptosis. Under 
cellular stress, such as exposure to radiation, apoptosis can be induced by MYC deregulation. 
The important implication of radiation in MB therapy has led several studies to investigate 
how MYC alters cells response to radiation in MYC-driven cancers (Bucci et al., 2005, von 
Bueren et al., 2009, von Bueren et al., 2011, Rieken et al., 2015).  
To further investigate the models, cells were treated with radiation to simulate treatment of 
MBGroup3 patients. A decrease in radiation-sensitivity was seen upon MYC knockdown, in 
comparison to D425 with higher levels of MYC. The findings are supported by studies showing 
that MYC is necessary for damaged-induced apoptosis. MYC triggers replication stress and 
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increased genomic instability, sensitising cancer cells overexpressing MYC to radiation 
(Dobbelstein and Sorensen, 2015, Taylor et al., 1997). 
MBs are strikingly sensitive to DNA-damaging therapies. Higher levels of MYC expression have 
been found to sensitise MB cell lines to radiation treatment (von Bueren et al., 2011). But 
highly aggressive MB tumours, like Group 3 and SHHα, are associated with therapeutic failure 
and short patient survival, which often present with combined TP53-MYC defects.  
MYC and TP53 modulate each other’s activity, since they are involved in many of the same 
cellular processes, therefore affecting similar targets. Loss of p53 function prevents the 
transcriptional repression of MYC, which potentiates MYC-induced oncogenesis by decreasing 
tumour cell apoptosis and increasing cells proliferative rate (Ho et al., 2005). This could explain 
the faster growth of D425 cell line (TP53 mutant) in comparison to D283 and HDMB03 growth 
(TP53 wild type).  
It is important to consider the mutational status of TP53 of our cell models when conducting 
experiments. The ability of p53 to promote apoptosis and cell cycle arrest is of extreme 
importance for its tumour suppression function. A halt of cell proliferation to allow time for 
the repair of damaged DNA is fundamental to avoid increased mutational load and genomic 
instability (Crowther et al., 2016). Studies on MB have shown that p53 function in triggering 
the apoptotic pathway is essential for treatment effectiveness, which could be the reason why 
patients with combined MYC-TP53 alterations respond poorly to treatment, since loss of p53 
has been seen to result in a reduction of treatment-induced apoptosis in medulloblastoma cell 
lines (Rausch et al., 2012, Ivanov et al., 2016). In this regard, D425’s response to radiotherapy 
might differ from the D283 and HDMB03 response (both have functional TP53). Sensitivity to 
irradiation should be studied in the other cell lines to better understand the interplay of MYC 
and TP53 in response to current therapeutic regimens. Moreover, the role of the tumour 
suppressor gene TP53 and the burden of its mutational status should be taken into 
consideration when performing future experiments testing small molecule inhibitors, as cells 
sensitivity might differ.   
Through the establishment of the knockdown system in our models, we have established that 
downregulation of MYC expression triggers cell cycle arrest at G0/G1 over apoptosis. A possible 
explanation why MYC-dependent tumours are nonresponsive to treatment could be that 
decreased MYC expression in MYC-dependent MBGroup3 tumours leads to the production of 
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quiescent cells with the ability to survive the aggressive nature of MB treatment (radiation 
and DNA-damaging agents), re-emerging again after its administration. Therefore, it is pivotal 
that therapeutic strategies targeting this subgroup of tumours aim at molecular dependencies 
that sensitise MYC-overexpressing cells to the induction of apoptosis, rather than solely 
downregulating MYC expression.  
 
Taken together, the MYC knockdown effect on cell proliferation further reinforces the notion 
of the reliance of MBGroup3 on MYC to sustain rapid cell turnover for tumour growth and the 
reality of MYC oncogenic addiction in MBGroup3 (Swartling et al., 2010). 
Despite seeing consistent effects in achieving MYC knockdown at the protein and mRNA level, 
MYC2 construct achieved better knockdown on MYC expression across cell lines when 
compared to the one achieved with MYC3 construct. This could be due to differences in the 
targeted position within the third exon of MYC of both constructs. Efficiency of MYC3 
constructs ability to achieve MYC knockdown could partially mask MYC-dependent effects, so 
should be taken into consideration when analysing results of future experiments.     
Sensitisation of MYC-overexpressing MBGroup3 cells to ionising radiation further exemplifies the 
appropriateness of using the newly generated MYC-regulable cell lines as models to study 








Appendix 3.1. Effect of MYC knockdown on apoptosis in MBGroup3 cell lines. Time dependent effect 
of MYC knockdown on caspase 3/7 activity in two MB cell lines A) D425 and B) D283. MYC knockdown 
caused a decrease in apoptotic markers. In the presence of high levels of MYC, levels of caspase 3/7 
increase throughout time. The results are shown as means ± SEM of three individual experiments, 












Overexpression and amplification of MYC family genes is commonly observed in MB, with each 
subgroup having different expression levels of c-MYC and N-MYC (Chapter 1). MBGroup3 is 
characterised by MYC amplifications (~17%) and overexpression, which is linked to aggressive 
biological behaviour and reduced patient survival (Jones et al., 2012). MYC offers an ideal 
therapeutic target for this specific subgroup of tumours, to help improve survival rates. 
Despite numerous attempts over recent decades to develop drugs targeting MYC directly, 
none have yet been developed clinically. Efforts have been directed at therapeutic strategies 
targeting MYC indirectly, by compromising its transcription, translation, protein stability and 
its dependence on downstream pathways (Chapter 1)(Shalaby and Grotzer, 2016, Chen et al., 
2018b). 
   
4.1.1 Targeting MYC mRNA translation through the PI3K/Akt/mTOR signalling pathway 
The phosphoinositide-3-kinase (PI3K)/Akt signalling pathway is one of the most important 
intracellular signalling cascades for cell regulation, as it controls survival, growth, metabolism, 
motility and cellular angiogenesis (Porta et al., 2014). This signalling cascade is aberrantly 
altered in various cancers, including MB. Independent of subgroup type, numerous alterations 
involving the PI3K/AKT signalling have been reported in MB, which is fundamental for its 
proliferation, maintenance and metastasis (Baryawno et al., 2010, Hartmann et al., 2006, 
Eckerdt et al., 2019). Genetic and epigenetic abnormalities affecting components of this 
signalling pathway are frequent events in cancer; including copy number gain and 
amplification of growth factor receptors (EGFR), or loss-of-function mutations of the PTEN 
tumour suppressor gene (Chalhoub and Baker, 2009). These alterations lead to aberrant 
activation of the pathway, which is correlated with high-risk subgroups and tumour resistance, 








As MYC is considered directly undruggable, interfering with the phosphorylation and 
activation of appropriate kinases within the PI3K/mTOR pathway to affect MYC protein 
stability has been exploited as an alternative strategy. Several mTOR/PI3K inhibitors used in 
neuroblastoma murine models have been shown to successfully destabilise MYCN (Cage et 
al., 2015). Inhibition of PI3K has been shown to promote apoptosis and morphological changes 
in DAOY MB cell lines (Frasson et al., 2015). Its inhibition, in combination with inhibition of 
hedgehog (HH), increased sensitivity of MYC-driven MBGroup3 cell lines to cisplatin treatment 
(Aldaregia et al., 2018, Chaturvedi et al., 2018). 
Additionally, gene expression profiling of our inducible isogenic models of MYC-driven 
MBGroup3 before and after MYC silencing was used to identify differences in gene networks and 
pathways following MYC silencing. RNAseq results and subsequent analysis revealed that MYC 
knockdown caused the downregulation of genes involved in cell cycle progression at G2/M 
phase and mTORC1 signalling pathway (Figure 4.1)(Dr. Swartz, PhD thesis).  
The assessment of mTOR inhibition in a MYC-dependent manner using the MYC-regulable 
isogenic cell lines will allow us to investigate the relationship between mTOR and MYC, and 
the potential of using inhibitors targeting components of the PI3K signalling pathway to 
therapeutically exploit the MYC-dependency of MBGroup3. 
 
 
Figure 4.1. GSEA enrichment plot of mTORC1 signalling upon MYC knockdown.GSEA enrichment 
plot of MTORC1 signalling, showing a negatively enriched plot in MYC knockdown (A) and positively 
enriched in MBGroup3 primary tumours (B). The enrichment score (ES) indicates the extent of which a 
gene is represented within the ranked gene list. The leading edge subsets indicates genes that 
contribute most to the enrichment score within the gene set, and is represented by the vertical lines. 
The ranked list metric shows the value of the ranking metric moving down the list of ranked genes, 




4.1.2 Targeting MYC transcription through BRD4 inhibition 
Bromodomain (BRD) proteins are epigenetic modifiers that exclusively recognise and interact 
with histone acetylation motifs enabling the assembly of chromatin complexes and 
transcriptional activators at specific promoter sites of genes (Donati et al., 2018). As explained 
in Chapter 1, BRD4 regulates MYC transcription through interaction with the heterodimers 
MYC/MAX and recruitment of P-TEFb on MYC enhancer and superenhancer regions to 
promote transcriptional activation (Rahl and Young, 2014, Fowler et al., 2011, Levens, 2008, 
Yang et al., 2005).  
Inhibition of the BET bromodomain by JQ1 has been proven to greatly diminish MYC 
expression and downregulate MYC/MYCN-associated transcriptional activity in several 
cancers. Various studies have used this strategy in MYC-driven cancers like MB and NB, where 
not only a decrease in the expression of MYC-associated proteins was observed, but treatment 
with JQ1 also significantly reduced cell proliferation, inducing apoptosis and senescence 
(Henssen et al., 2013, Bandopadhayay et al., 2014, Puissant et al., 2013, Venkataraman et al., 
2014, Delmore et al., 2011). 
With the aim to explore the potential therapeutic effect of targeting MYC transcription in a 
MBGroup3 subgroup and MYC-dependent context, JQ1 was used on our isogenic models to 
assess the possibility of MYC downregulation through BET inhibition. Assessment of the effect 
of MYC modulation will enable the comparison to the effect inhibiting BRD4 has on MYC 










4.1.3 Targeting MYC transcription through CDK9 inhibition 
In recent years, the use of gene silencing techniques has enabled the identification of 
components of the MYC-interactome, and the targeting of those pathways have emerged as 
an alternative therapeutic strategy to target MYC-oncogenic-signalling (Cermelli et al., 2014). 
CDK9 has been found in several studies of different cancers as a key component for MYC 
expression, and its targeting opens a new therapeutic window to affect cells capabilities of 
proliferation and survival (Ma et al., 2019, Wang et al., 2019b, Kinoshita et al., 2018, Li et al., 
2019, Wang et al., 2019c).  
As previously stated, CDK9 is the catalytic subunit of the P-TEFb complex, which is essential to 
control the expression of MYC. Upon phosphorylation, CDK9 becomes active and 
phosphorylates the C-terminal domain of RNA Pol II, a hallmark of transcriptional pause-
release and transcriptional elongation of most protein coding genes (Rahl and Young, 2014). 
Inability of CDK9 to phosphorylate RNA Pol II blocks transcriptional elongation, supressing the 
transcription of genes related to cell cycle and the synthesis of anti-apoptotic proteins 
(including MCL1), thereby sensitising cancerous cells to apoptotic stimuli. Overall, BRD4 
recruitment of P-TEFb in the MYC promoter region is key for allowing transcription and 
concomitant MYC-effector genes (Wang et al., 2019c, Lu et al., 2015, Wang and Fischer, 2008). 
CYC065 is a highly selective second-generation inhibitor of CDK2 and CDK9, with oral and 
intravenous availability. Mechanistically, CYC065 binds to cyclins 2 and 9 preventing the 
occurrence of their dependent cell cycle regulation and gene transcription mechanisms. 
CDK9/2 inhibition leads to apoptosis induction through the downregulation of genes involved 
in DNA repair and survival pathways (Saladino et al., 2015, Chen et al., 2018c). CDK9 inhibition 
by CYC065 successfully downregulated MYCN expression and caused tumour regression in NB 
cell models and xenografts (Poon et al., Childhood Cancer Meeting 2016, Abs. 1-19).  
The sensitivity of the compound displayed in cell models of other MYC-driven tumours 






The use of the regulable D425, D283 and HDMB03 cell lines, developed and validated in 
Chapter 2, provides the opportunity to study the effects of MYC overexpression in MBGroup3 
and its potential for therapeutic targeting.  
The aim of this Chapter is to investigate the role of MYC amplification or gain in drug resistance 
and sensitivity in MBGroup3 using the MYC-regulable isogenic cell lines. The potential of 
pharmacologically manipulating MYC-dependent signalling pathways to treat high-risk 
patients with MBGroup3 will be assessed by undertaking two indirect pharmacological anti-MYC 
strategies (targeting MYC transcription through BRD4 and CDK9 inhibition, and MYC mRNA 
translation through mTOR inhibition). Candidate drugs targeting signalling pathways 
associated with MYC will be assessed in a MYC-dependent manner to investigate the 
therapeutic potential of exploiting the MYC-dependency of MBGroup3 tumours as a therapeutic 
strategy to treat MYC-driven cancers.  
Results from this Chapter will prove the specific MYC-downregulatory effect of mTOR, BRD4 
and CDK9, previously shown to downregulate MYC transcriptional signature in other MYC-
driven cancers, and undercover its potential use in combinatorial approaches for patients in 











4.3 Targeting MYC translation   
4.3.1 Effect of mTOR inhibition on cell viability in MBGroup3 cell lines 
Several studies have already reported the connection between the mTOR signalling pathway 
and MYC driven cancers. From previous studies, our group has RNAseq data available for all 
isogenic cell lines with MYC modulated by shRNA, and primary MB tumour expression data 
from samples of known subgroups and known MYC status. mTOR signalling pathway was 
shown to be downregulated by MYC, when expression data of primary tumours was compared 
to the RNAseq data of isogenic cell lines with MYC knockdown.  
To further explore the interplay between MYC protein regulation and the PI3K signalling 
pathway in context of MBGroup3, two small molecule compounds, INK128 (Sapanisertib) and 
AZD2014 (Vistusertib), that act as ATP-competitive inhibitors of mTOR were used on the 
isogenic models. Both drugs are potent selective mTORC1/2 inhibitors which act in an ATP-
dependent manner, and are highly selective toward several isoforms of PI3K.  
Only the D425 isogenic cell line was used in preliminary experimentation to examine if the 
inhibitors had an effect on MYC expression. Growth-inhibitory assays were performed in order 
to determine the dose of drug required to give half-maximal response (IC50) over 72h. D425 
NS, D425 MYC2 and D425 MYC3 were treated with a 10-fold dilution series of these drugs for 
72h, and cell viability was measured with CellTiter-Glo (CTG) at 72h, as explained in Chapter 
2. Values obtained were analysed with Prism8.  
In the presence of high levels of MYC expression, D425 MYC2 and D425 MYC3 presented a 
similar cellular sensitivity to INK128 when compared to the non-silencing control. Significant 
differences in growth inhibition were seen when MYC was knocked down, where D425 MYC2 
and D425 MYC3 appeared to be less sensitive to INK128 (Students t-test, p=0.0005; p=0.03, 
respectively)(Figure 4.2). 
Similarly, in the presence of high levels of MYC expression, cells bearing both MYC2 and MYC3 
constructs presented a similar response to AZD2014 when compared to the NS control. Cell 
sensitivity to the inhibitor changed when MYC was knocked down in the presence of DOX, 
where MYC2 and MYC3 cell lines displayed decreased sensitivity to the drug (Figure 4.3). The 
inhibitor caused greater growth-inhibitory effect in the presence of high levels of MYC 
compared to the knockdown state, only reaching statistical significance in D425 MYC2, not 




Figure 4.2. Growth-inhibitory curves of D425 in response to the mTOR inhibitor INK128. Growth-
inhibitory curves of A)D425 NS, B)D425 MYC2 and C)D425 MYC3 isogenic MBGroup3 cells treated with 
the mTOR inhibitor INK128. Cells were cultured in the presence (+dox; MYC OFF) and absence (-dox; 
MYC ON) of doxycycline for MYC knockdown. Values are shown as percentage of cell viability in three 
independent experiments relative to untreated cells, along with the fitting curve. The curve is 
presented as log(concentration) vs response. The growth inhibitory effect of the drug on MYC-
overexpressing cell lines versus MYC knockdown was compared by paired student’s t-test (statistical 
significance denoted by *; *p<0.05). D)Table summarising the half maximal inhibitory concentration 
(IC50) calculated from dose response curves. Significant differences between cells expressing high (-
dox: MYC ON) and low (+dox: MYC OFF) levels of MYC was calculated with a ratio paired student’s t-




Figure 4.3. Growth-inhibitory curves of D425 to the mTOR inhibitor AZD2014.Growth-inhibitory 
curves of A)D425 NS, B)D425 MYC2 and C)D425 MYC3 isogenic MBGroup3 cells treated with the mTOR 
inhibitor AZD2014. Cells were cultured in the presence (+dox; MYC OFF) and absence (-dox; MYC 
ON) of doxycycline for MYC knockdown. Values are shown as percentage of cell viability in three 
independent experiments relative to untreated cells, along with the fitting curve. The curve is 
presented as log(concentration) vs response. The growth inhibitory effect of the drug on MYC-
overexpressing cell lines versus MYC knockdown was compared by paired student’s t-test (statistical 
significance denoted by *; *p<0.05). D)Table summarising the half maximal inhibitory concentration 
(IC50) calculated from the dose response curves. Significant differences between cells expressing high 
(-dox: MYC ON) and low (+dox: MYC OFF) levels of MYC was calculated with a ratio paired student’s 
t-test (p-value). P-value is shown with the SD and SEM. 
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To validate the IC50, D425 was exposed for 72h to 10 and 50nM of each drug to study its effect 
on cell viability. To compare the effect of the inhibitors on cell viability, cells which were not 
exposed to these compounds were used as controls. Cells bearing the NS construct were used 
as internal control to account for changes due to the shRNA constructs, and DOX-treated to 
normalise the effect of DOX on the cell line. As expected, no significant differences were seen 
in cell proliferation between D425 cells cloned with the NS, MYC2 and MYC3 shRNA constructs 
under normal growth conditions (MYC expressing)(Figure 4.4, A). 
D425 exhibited a high sensitivity to mTOR inhibition by INK128. In the presence of high levels 
of MYC (MYC expression levels established in Chapter 3), D425 MYC2 and MYC3 exhibited a 
significant decrease in cell proliferation when exposed to 10nM of INK128 (p<0.0001 for both 
constructs) when compared to the untreated control. Further reduction in cell viability was 
observed when dosed with 50nM when compared to the un-treated controls. Following MYC 
knockdown, exposure to 10nM and 50nM of INK128 further reduced D425 NS, D425 MYC2 
and D425 MYC3 cell viability although it was not as clear compared to MYC-overexpressing 
cells (Figure 4.4, B and C).  
The same effect on D425 cell viability was observed when treated with AZD2014 (Figure 4.5). 
In this case, D425 MYC2 and D425 MYC3 cells with MYC knockdown showed no significant 
differences in cell viability when treated with 10nM and 50nM of the inhibitor when compared 
to the untreated control. Only cells overexpressing MYC showed a statistically significant 
decrease in cell viability upon treatment. MYC knockdown caused increased resistance to 
inhibition of mTOR.    
 
In summary, mTOR inhibition by INK128 and AZD2014 had a MYC-dependent drug-sensitivity 
effect on D425. Inhibition of mTOR resulted in differential drug sensitivity between MYC-
overexpressing and MYC-knockdown cell lines, where higher levels of MYC sensitised the cells 





Figure 4.4.D425 viability in response to AZD2014 inhibitor.Graphs show INK128 effect on viability 
of A)D425 NS, B)D425 MYC2 and C)D425 MYC3, in the presence (-dox; MYC ON) and absence (+dox; 
MYC OFF) of high levels of MYC expression. Cells were exposed to 10nM and 50nM of mTOR 
inhibitor. Data is shown as means (±SEM) of three independent experiments. Statistical significance 





Figure 4.5. D425 viability in response to AZD2014 inhibitor.Graphs show AZD2014 effect on viability 
of A)D425 NS, B)D425 MYC2 and C)D425 MYC3, in the presence (-dox; MYC ON) and absence (+dox; 
MYC OFF) of high levels of MYC expression. Cells were exposed to 10nM and 50nM of the mTOR 
inhibitor. Data is shown as means (±SEM) of three independent experiments. Statistical significance 




4.3.2 Effect of AZD2014 and INK128 at the protein level  
After testing the MYC-dependent growth-inhibitory effect of the inhibitors, the next objective 
was to examine if mTOR inhibition caused downregulation of MYC protein expression. To 
evaluate this effect at the protein level, considering the short half-life of MYC, cells were 
treated with 10nM of each inhibitor for 15, 30, 60 and 120min. After drug exposure, cells were 
harvested and protein was extracted to perform a simple western assay (Wes; ProteinSimple) 
for protein quantification, as explained in Chapter 2. 
Despite exhibiting a growth-inhibitory MYC-dependent effect, none of the drugs had a direct 
downregulatory effect on MYC protein levels (Figure 4.6 and 4.7). When quantified, MYC 
protein levels were increased after drug incubation. The use of mTOR inhibitors led to a slight 
reduction in MYC protein at early time points with a subsequent increase at later exposures, 
where a rapid upregulation of MYC protein was seen after only 1h.  
An increase in MYC protein levels was seen with shorter exposures (15-30min) of both 
inhibitors following MYC knockdown. After 1 hour of drug exposure, protein levels of MYC 
were reduced on average by 22% in both D425 MYC2 and D425 MYC3 after treatment with 
INK128, when compared to the untreated control. Similarly a reduction of 35%, was observed 
in D425 MYC2 and D425 MYC3 when exposed to AZD2014 (Figure 4.7). Downregulation of 
MYC protein levels was only seen in cells with MYC knockdown and at later time points, which 
indicates a synergistic effect of the inhibitor with MYC knockdown.   
Alongside the quantification of MYC protein levels, downstream effectors of the mTOR 
signalling pathway were analysed. INK128 caused a time-dependent decrease in 
phosphorylation of the kinase S6 at Ser2356/236, a direct downstream target of mTOR. This 
indicates that the inhibitor efficiently inhibited mTORC1, thus affecting the subsequent 
phosphorylation of the downstream effector, S6. The decrease in the phosphorylated form of 







Variable levels of PI3 kinase p110α (PI3K110α) protein were seen after treatment with 10nM 
of INK128 for all constructs and conditions, as seen in Figure 4.6. INK128 is supposed to inhibit 
the phosphorylation of PI3K110α, through the suppression of mTOR. The inconsistency in the 
levels of pPI3K110α across constructs was observed in two different biological repeats, which 
indicate that the concentration of inhibitor used for the experiment may not have been 
sufficient to inhibit its phosphorylation.  
 
 
Figure 4.6. Effect of INK128 inhibitor at the protein level.Automated Western Blot (WES) analysis 
of c-MYC expression after treatment with INK128 inhibitor. D425 NS, MYC2 and D425 MYC3, with 
and without MYC-silencing by DOX (+), were treated with 10nM of the inhibitor for 15min, 30min, 
60min and 120min. At each time point, MYC protein expression levels were examined alongside 
downstream effectors of the mTOR signalling pathway (pS6, PI3K p110α , p4E-BP1). Protein levels of 
GAPDH were used as internal control. The same effect of IN128 on downstream effectors of the 





The same time-dependent downregulation of pS6 across D425 constructs with and without 
MYC knockdown was also observed after exposure to AZD2014 in two biological repeats. A 
reduction in total protein levels of mTOR was seen at later time points following MYC 
knockdown (Figure 4.7). No change in total protein levels of mTOR was observed in D425 cells 




Figure 4.7. Effect of AZD2014 inhibitor at the protein level.Automated Western Blot (Wes) analysis 
of c-MYC expression after treatment with AZD2014 inhibitor. D425 NS, D425 MYC2 and D425 MYC3, 
with and without MYC-silencing by DOX (+), were treated with 10nM of the inhibitor for 15min, 
30min, 60min and 120min. MYC protein expression levels were examined alongside downstream 
effectors of the mTOR signalling pathway (pS6, mTOR) at each time point. Protein levels of GAPDH 
were used as internal control.   
 
 
In summary, mTOR inhibition with AZD2014 and INK128 had no clear effects on MYC protein 
expression. A slight reduction of MYC protein was observed at shorter exposure times (0-
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30min) followed by an increase after incubation of over 1h was seen across D425 constructs. 
The same trend was seen using either AZD2014 or INK128. The opposite effect was seen when 
MYC was knocked down, where MYC protein levels increased during the first 30min of 
incubation and further increased at later time points.   
Despite the slight additive effect of the inhibitors with MYC knockdown, further studies using 
these inhibitors were not pursued since no clear effects on MYC protein expression were 
observed. The main purpose of this study was to find a compound that had a clear effect on 
MYC expression which could be used as a therapeutic strategy to target MYC-driven MBGroup3 
tumours. Therefore, other targeting strategies were explored instead of attempting to 
elucidate the effect of mTOR signalling in controlling MYC translation in MBGroup3 cell lines, 












4.4 Targeting MYC transcription  
4.4.1 BRD4 inhibition  
4.4.1.1 Effect of BRD4 inhibition in MBGroup3 cells viability  
To explore the effect of BRD4 inhibition in MBGroup3 cell lines, MYC-regulable D425 and D283 
were chosen for analysis. The use of a MYC amplified and a MYC gained cell line (described in 
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Chapter 2 and 3) will enable a better understanding of the effect of JQ1 treatment in the 
presence of different levels of MYC expression in the context of MBGroup3. 
Cells sensitivity to pharmacological inhibition of BRD4 with JQ1 was examined in growth 
inhibition studies. D425 and D283 isogenic cell lines induced with DOX prior to 
experimentation were treated with 10-fold dilutions of JQ1 for 72h (methodology described 
in Chapter 2). Cell viability after treatment was measured using CTG and resultant 
luminescence values analysed with Prism8 to generate a dose-response inhibition curve to 
calculate the IC50.  
Treatment with JQ1 caused a MYC-dependent growth-inhibitory effect on the D425 cell line 
(Figure 4.8). D425 NS, D425 MYC2 and D425 MYC3 cells overexpressing MYC exhibited higher 
sensitivity to the inhibitors when compared to cell lines with MYC knockdown. Exposure to 
JQ1 caused a significant reduction in D425 MYC2 and D425 MYC3 cells viability (p=0.01, 
p=0.02, respectively) when compared to their controls with reduced MYC expression. 
Summary table with IC50 values can be seen in Figure 4.8, G).   
BRD4 inhibition by JQ1 selectively inhibited the growth of D283 cells expressing higher levels 
of MYC compared to those with MYC knockdown by shRNA. A significant reduction in D283 
MYC2 and D283 MYC3 cell viability was observed when compared to their counterparts with 
MYC silenced (p=0.0049, p=0.0313, respectively)(Figure 4.8, A, B, C). Therefore, MYC 
knockdown caused a decrease in cell sensitivity to the JQ1.   
No differences in growth inhibition were seen for the NS construct of cell lines, when grown 






Figure 4.8. Growth-inhibitory curves of D283 and D425 to JQ1 inhibitor. Dose-response inhibition 
curves of D283 (A)NS, B)MYC2, C)MYC3) and D425 (D)NS, E)MYC2, F)MYC3) MBGroup3 cell lines treated 
with JQ1 (BRD4 inhibitor) for 72 hours, in the absence (-dox; MYC ON) and presence (+dox; MYC 
OFF) of DOX. Cells were exposed to 10-fold dilutions of the drug for 72 hours to determine the IC50 
concentration (nM). Cell viability was measured with CellTiter-Glo (CTG). Results are shown as a 
percentage of cell viability of three independent experiments relative to cells grown in the presence 
of DMSO. Values obtained were analysed with Prism8 to generate a dose-response inhibition curve 
fitting a non-linear regression model. Curve is presented as log concentration versus response. 
Significance was determined by paired student’s t-test (*p<0.05) G)Table summarising the half 
maximal inhibitory concentration (IC50) of each cell lines calculated from the dose response curves. 
Significant differences between cells expressing high (-dox: MYC ON) and low (+dox: MYC OFF) levels 







To further explore differences in response to JQ1 following MYC knockdown by shRNA, D425 
and D283 were treated with different JQ1 concentrations around the IC50 range (10nM, 50nM, 
100nM, 150nM, 200nM, 250nM, 300nM, 350nM). Cell viability after 72h of drug exposure was 
analysed for comparison.  
Cell line with MYC overexpression appeared to be more sensitive to JQ1 treatment compared 
to cells with MYC knockdown. No differences in cell viability were seen for the NS constructs 
cultured in the presence and absence of DOX in response to JQ1 treatment. DOX did not affect 
responsiveness to the inhibitor, showing the expected 50% reduction of cells’ proliferation by 
200-250nM doses. The viability of cells with MYC knockdown was not affected by JQ1 




Figure 4.9. Effect of BRD4 inhibition on D425 and D283 viability.Cell viability of D283 (A)NS, 
B)MYC2, C)MYC3) and D425 (D)NS, E)MYC2, F)MYC3) after JQ1 treatment. Cells were cultured in the 
absence (-dox; MYC ON) and presence (+dox; MYC OFF) of doxycycline (DOX) for MYC knockdown. 
Cells were treated with 10nM, 50 nM, 100nM, 150nM, 200nM, 250nM, 300nM and 350nM of JQ1 
for 72 hours. Cell viability was assessed with CTG. Untreated cells (no drug) were used for each 
condition (+/-DOX) as controls (ctrl). Data was blank-corrected to DMSO-containing wells. Data is 





4.4.1.2 Effect of JQ1 treatment on D425 and D283 apoptosis 
To gain a better understanding of the mechanism by which JQ1 was compromising cell 
viability, apoptosis assays were performed on D425 and D283 cloned with the MYC2 shRNA 
constructs, expressing high levels of MYC and with MYC knockdown.  
Caspase 3/7 activity was assessed in D425 and D283 MYC2 cells (methodology explained in 
Chapter 2), overexpressing MYC and with MYC knockdown, after treatment with 0.2 µM and 
0.5µM of JQ1 (Figure 10). Although no major differences were seen in overall signals, JQ1 
treatment resulted in a significant increase in apoptosis in D425 MYC2 and D283 MYC2 when 
compared to the untreated counterpart of each cell line (p<0.0001 for both). A significant 
increase in apoptosis was seen when 0.2µM and 0.5µM treatments were compared only for 
D425 MYC2 (p=0.0064). Consistent with the growth inhibition results, BRD4 inhibition did not 
induce apoptosis in cells with MYC knockdown. JQ1 treatment caused increased apoptosis in 




Figure 4.10. Effect of the JQ1 inhibitor on apoptosis in D425 and D283 cell models.Measurement 
of luminescent signal from the apoptotic executors caspase 3/7 in A)D425 MYC2 and B)D283 MYC2 
after JQ1 treatment, in the absence (-dox; MYC ON) and presence (+dox; MYC OFF) of doxycycline 
for MYC knockdown. Cells were treated with 0.2µM and 0.5µM of JQ1 for 72h. Data is shown as 
means ±SEM of three independent experiments. Statistical significance determined by unpaired 





4.4.1.3 Effect of BRD4 inhibition on MYC protein levels  
The effect of JQ1 treatment on MYC and related proteins was then examined. D425 and D283 
cell lines cloned with MYC2 and MYC3 shRNA constructs were treated with a range of 
concentrations of JQ1 (0.1µM, 0.2µM, 0.4µM, 1µM and 2µM) to test whether MYC expression 
was affected by BRD4 inhibition (Figure 4.11).  
JQ1 treatment reduced MYC protein levels in the D425 and D283 cell lines in a dose-
dependent manner. Quantification analysis of D425 MYC protein levels with automated 
western blot revealed a reduction of MYC protein by 50% with 0.2µM, 0.4µM and 1µM of 
inhibitor. At the highest concentration (1µM), MYC expression was reduced by 80%.  
Although MYC protein levels were reduced following JQ1 treatment in D425 when the 
expression of shRNA was induced by DOX, the combinatory effect of JQ1 with MYC knockdown 
did not further reduce MYC protein levels to the same extent as observed by JQ1 treatment 
alone in MYC overexpressing cells. Interestingly, JQ1 treatment did not contribute to a 
decrease in MYC protein levels following knockdown (Figure 4.11, A). Treatment within the 
nM range only reduced protein levels by 20%, compared to a 65% reduction on MYC protein 
levels at the micromolar range. Overall, JQ1 had a greater effect in reducing MYC protein levels 
when cells were over-expressing MYC than in a MYC knockdown state.  
A similar dose-dependent downregulation of MYC was seen in the D283 isogenic cell line. JQ1 
inhibitor reduced MYC protein levels in a dose dependent manner, irrespective of MYC 
expression levels (MYC-overexpressing/MYC knockdown) (Figure 4.11, B). Protein 
quantification analysis with Wes after treatment with 0.2µM of JQ1 revealed a reduction in 
MYC protein levels by 65% in MYC2 and 58% in MYC3 cells which were each overexpressing 
MYC. Following MYC knockdown, BRD4 inhibition only downregulated MYC protein levels 
when treated at the highest dose.  
Reduction in MYC protein was seen alongside a dose-dependent increase of levels of the anti-
apoptotic protein MCL1, and a decrease in levels of total PARP for both cell lines. These effects 







Figure 4.11. Effect of JQ1 inhibitor on D425 and D283 at the protein level.Automated Western Blot 
analysis of MYC protein levels express by A)D425 and B)D283 after 72 hours treatment with JQ1 
inhibitor. D425 and D283 MYC2 and MYC3, with and without MYC-silencing by doxycycline (DOX), 
were treated with 0.1µM, 0.2µM, 0.4µM, 1µM and 2µM of the inhibitor for 72 hours. MYC protein 
levels were analysed alongside protein levels of the anti-apoptotic markers MCL1 and PARP. Protein 
levels of GAPDH were used as internal control. Protein quantification was performed in two 





4.4.1.4 Effect of BRD4 inhibition in gene expression of D425 and D283  
To see if the downregulation of MYC protein expression was correlated with a decrease in 
MYC expression at the mRNA level, expression of MYC in D425 MYC2 and D283 MYC3 was 
studied following JQ1 treatment (Figure 4.12). MYC mRNA expression of D425 MYC2 and D283 
MYC2 cell lines decreased with JQ1 treatment (by 38.6% and 29.3%, respectively), although 
the reduction was not as profound as the reduction which was achieved by shRNA knockdown. 
Combination of JQ1 and DOX-induced MYC silencing resulted in a greater reduction of MYC 
mRNA expression for both D425 and D283 cell lines, 61.2% and 70.7% (data from Jemma 
Castle, MRes Project).  
 
Figure 4.12. Effect of JQ1 inhibitor on MYC expression levels in D425 and D283 MYC2.Analysis of 
changes in MYC mRNA expression levels by RT-qPCR of D425 and D283 in response to treatment 
with JQ1. Cells cultured with (+) and without (-) DOX for MYC knockdown were treated with JQ1 for 
comparison. Expression fold change was calculated relative to the control cells with no DOX and no 
JQ1 of the respective cell line. Data represents the mean (±SEM) of triplicates of two biological 
repeats. Expression fold change was calculated relative to TBP expression (control gene). 
Significance is denoted by *p≤0.05, **p≤ 0.01, ***p≤0.001, ****p≤0.0001). Data kindly provided by 







4.4.2 Cyclin-dependent kinase 9 inhibition 
4.4.2.1 Effect of CDK9 inhibition on D425 and D283 cell viability  
As previously shown, targeting MYC transcription through BRD4 inhibition with JQ1 resulted 
in the downregulation of MYC protein expression in our regulable models. Following the same 
indirect strategy, CYC065 (CDK9 inhibitor) was tested on D425 and D283 to compare which 
anti-MYC targeting strategy was more effective in downregulating MYC in our MBGroup3 cell 
lines. 
The growth inhibitory effect of pharmacological CDK9 inhibition was examined in D425 and 
D283 isogenic cell lines, transduced with NS, MYC2 and MYC3 shRNA constructs. Cells were 
induced with DOX prior to experimentation for maximum MYC knockdown, and treated with 
10-fold dilutions of CYC065 to determine the IC50, as described in Chapter 2. Cell viability was 
measured at 72h using CTG and resultant luminescence values analysed with Prism8 to 
generate a dose-response inhibition curves (Chapter 2).  
MBGroup3 cell lines overexpressing MYC exhibited higher sensitivity to CYC065, when compared 
to those with MYC knockdown (Figure 4.13). A MYC-dependent growth inhibitory effect was 
seen in both D425 and D283. CDK9 inhibition caused a significant reduction in viability of D425 
and D283 cells expressing high-levels of MYC when compared to those with MYC knockdown 
by shRNA (D425 MYC2 p=0.0109; D425 MYC3 p=0.0206; D283 MYC2 p=0.0109; D283 MYC3 
p=0.0259). No differences in growth inhibition were seen for cell lines cloned with the NS 
shRNA construct when grown in the presence and absence of DOX (D425 NS p=0.3172; D283 
NS p=0.3237).  
D283 NS, D283 MYC2 and D283 MYC3 cells gave similar IC50 values of around 200nM (Figure 
4.13, G). Cell sensitivity to the inhibitor decreased when MYC was knocked down, increasing 
IC50 values to around 1 and 5µM when compared to the control. Similar IC50 values were seen 
for all constructs of D425, with values around 120nM. MYC knockdown by DOX caused an 
increase in resistance to the inhibitor, increasing the IC50 value to the micromolar range. When 
IC50 values were compared for both cell lines as a measure of sensitivity to the inhibitor, D425 






Figure 4.13. Growth-inhibitory curves of D283 and D425 to CYC065 inhibitor. Dose-response 
inhibition curves of D283 (A)NS, B)MYC2, C)MYC3) and D425 (D)NS, E)MYC2, F)MYC3) MBGroup3 cell 
lines treated with CYC065 (CDK9 inhibitor) for 72h, in the absence (-dox; MYC ON) and presence 
(+dox; MYC OFF) of DOX. Cells were exposed to 10-fold dilutions of the drug for 72h to determine 
the IC50 (nM). Cell viability was measured with CellTiter-Glo (CTG). Results are shown as percentage 
of cell viability of three independent experiments relative to cells grown in the presence of DMSO. 
Values obtained were analysed with Prism8 to generate a dose-response inhibition curve that fits a 
non-linear regression model. Curve is presented as log(concentration) vs response. The significance 
was determined by paired student’s t-test (*p<0.05) G)Table summarising the half maximal 
inhibitory concentration (IC50) of each cell line calculated from the dose response curves. Significant 
differences between cells expressing high (-dox: MYC ON) and low (+dox: MYC OFF) levels of MYC 




Considering that CDK9 is a short-lived protein with a half-life of 4-7h depending on the cell 
type (Hellvard et al., 2016), D425 and D283 MYC2 were incubated with CYC065 for shorter 
time periods to observe direct effects of CDK9 on cell viability (Garriga et al., 2003). After each 
time point, the drug was removed, and the media was refreshed. Cell viability was assessed 
after 72h to allow cells to recover and enable a complete round of cell division if cells remained 
viable.  
CYC065 showed good efficacy in MBGroup3. D283 and D425 were extremely sensitive to CDK9 
inhibition, significantly reducing cell viability with an exposure of 8h with CYC065 (Figure 4.14). 
Comparison of cell viability at each time point after drug exposure was statistically significant, 
showing a reduction in cell viability in a time dependent manner. When MYC was knocked 
down in D425, a clear difference in sensitivity to the inhibitor was only observed after 8h of 
exposure when compared to MYC2 control, where lower levels of MYC expression were 
associated with resistance to the inhibitor in D425 cells. The same trend was seen for D283. 
D283 MYC2 cells cultured in the presence of DOX exhibited greater resistance to the inhibitor, 




Figure 4.14. Effect of CDK9/2 inhibition on D425 and D283 cell viability. Dose-response curves of 
D425 and D283 MBGroup3 cell lines treated with CYC065 (CDK9 inhibitor) for 1h, 2h, 4h, and 8h, in the 
presence and absence of DOX for MYC silencing. Cells were exposed to decreased 1:3 serial dilution 
concentrations of CYC065 (from 100µM to 0.03µM). Cell viability was measured with CTG. Values 
are shown as percentage of cell viability of three biological repeats of three independent 
experiments relative to cells grown in the presence of DMSO. Values obtained were analysed with 
Prism to generate a dose-response inhibition curve fitting a non-linear regression model. Curve is 










4.4.2.2 Effect of CDK9 inhibition on D425 and D283 apoptosis 
To assess whether CYC065 was compromising cell viability through the induction of apoptosis, 
the caspase-Glo 3/7 assay was performed on D425 MYC2 and D283 MYC2 after treatment with 
0.2µM and 0.5µM of CYC065 as described in Chapter 2. The apoptotic signals of cells with MYC 
knockdown were also measured for comparison.  
Inhibition of CDK9 caused a significant increase in apoptosis (p<0.0001), in both conditions 
with and without MYC knockdown (Figure 4.15). Similar levels of apoptosis were seen 
between D425 and D283. Treating MYC expressing cells with CYC065 resulted in a significant 
increase in cell apoptosis of around 6-fold and 10-fold when compared to the untreated 
controls. When MYC was silenced, apoptosis was significantly increased by around 2-fold and 
4-fold for both cell lines. When compared, the increase in apoptosis seen in both cell lines 
after CYC065 treatment was significantly different between cells overexpressing MYC and with 
MYC knockdown (p<0.0001)(Figure 4.15). 
Results indicate that MYC-driven MBGroup3 cell lines are sensitive to CDK9 inhibition in a MYC-
dependent manner, where CYC065 preferentially targets MYC-overexpressing cell lines, 
compromising their viability through the induction of cell apoptosis. 
 
 
Figure 4.15. Effect of CYC065 inhibitor on D283 and D425 apoptosis.  Measurement of apoptotic 
executors caspase 3/7 on D425 and D283 after JQ1 treatment, in the presence and absence (+; MYC 
knockdown) of high levels of MYC expression. Cells were treated with 0.2µM and 0.5µM of CYC065 
for 72h. Data is shown as means ±SEM of three independent experiments. Statistical significance 





4.4.2.3 Effect of CYC065 treatment on D425 and D283 at the protein level 
The effect of CDK9 inhibition at the protein level was examined to identify if decrease in cell 
viability was associated with alteration of MYC expression. D425 and D283 cells with the NS 
and MYC2 construct were exposed to 1x, 2x and 4x the IC50 of CYC065, for 1 hour, 2 hours and 
8 hours, as explained in Chapter 2.  
When analysed at the protein level with Wes, CYC065 successfully reduced MYC protein 
expression in a time and dose-dependent manner (Figure 4.16). CDK9 inhibition by CYC065 
caused a rapid downregulation of MYC expression in both cell lines, which was accentuated 
with longer exposures and higher doses of the inhibitor. Densitometry analysis showed that, 
with only 2h of exposure, CYC065 caused a reduction in MYC protein expression of almost 50% 
with 4xIC50, when compared to untreated control. Treatment with IC50 concentration reduced 
MYC protein by 40% after 2h and 4h, reaching 55% reduction in just 8h of exposure.  
 
 
Figure 4.16. Effect of CYC065 inhibitor on D425 and D283 at the protein level. Automated Western 
Blot analysis of MYC protein levels expressed by A)D283 and B)D425 after 72h treatment with JQ1 
inhibitor. D425 MYC2 and D283 MYC2, with and without MYC-silencing by doxycycline (DOX), were 
treated with 0.1µM, 0.2µM, 0.4µM, 1µM and 2µM of the inhibitor for 72 hours. MYC protein 
expression levels were examined alongside protein levels of the anti-apoptotic markers MCL1 and 
PARP After treatment. Protein levels of GAPDH were used as internal control. Protein quantification 





The combination of CYC065 and MYC-silencing with doxycycline had an additive effect and 
caused a further reduction of MYC in both cell lines (Figure 4.16). Protein quantification with 
Wes revealed a reduction in MYC protein levels of D283 by 50% with only 2h of exposure to 
the drug, abrogating MYC protein levels completely with time and dose. CYC065 had a similar 
effect on D425 MYC2. Protein was reduced around 55% with exposures to IC50 for 2h. The 
largest reduction in MYC protein levels was observed in D425 with MYC knockdown after 
CYC065 treatment (Figure 4.16, B).   
As expected CDK9/2 inhibition by CY065 induced a rapid downregulation of MCL1 protein 
levels. An upregulation of PARP protein was also induced in a time and dose dependent 
manner. Both proteins were seen to be up and downregulated in the same way when MYC 
















4.4.2.4 Effect of CDK9 inhibition by CYC065 on D425 and D283 gene expression  
To see if the downregulation of MYC protein expression was correlated with a decrease in 
MYC expression at the mRNA level, expression of MYC in D425 MYC2 and D283 MYC3 was 
studied following CYC065 treatment. 
A MYC-dependent reduction of MYC mRNA expression levels was seen after treatment with 
CYC065 in D425 and D283 (Figure 4.17). CDK9 inhibition significantly decreased MYC mRNA 
expression of D425 and D283 MYC2 cell lines overexpressing MYC, by 49.22% and 57% 
respectively, when compared to untreated cells (D425 MYC2 p=0.0002; D283 MYC2 
p=0.0003). Following MYC knockdown, CYC065 had no significant effect on MYC mRNA 
expression in either cell lines (p=0.1495 and p=0.566, for D425 and D283, respectively)(data 
from Jemma Castle, MRes Project).  
 
Figure 4.17. Effect of CYC065 inhibitor on MYC expression levels in D425 and D283 MYC2.  Analysis 
of changes in MYC mRNA expression levels by RT-qPCR of D425 and D283 in response to treatment 
with CYC065. Cells cultured with (+) and without (-) DOX for MYC knockdown were treated with 
CYC065 for comparison. Expression fold change was calculated relative to the control cells with no 
DOX and no CYC065 of the respective cell line. Data represents the mean (±SEM) of triplicates of two 
biological repeats. Expression fold change was calculated relative to TBP expression (control gene). 
Significance is denoted by *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001).  Data kindly provided by 








4.5.1 MYC sensitises MBGroup3 cell lines to mTOR inhibition  
The PI3K/AKT/mTOR signalling pathway has a key role in controlling and regulating cellular 
maintenance. It is well established that this signalling cascade is aberrantly altered in various 
cancers, including MB. Independent of subgroup type, numerous alterations involving the 
PI3K/AKT signalling have been reported in MB, which is fundamental for MB proliferation, 
maintenance and metastasis. Its aberrant activation is usually associated with high-risk 
subgroups and tumour resistance, making it an ideal target for new therapeutic approaches 
(Baryawno et al., 2010, Hartmann et al., 2006, Eckerdt et al., 2019).  
Previous studies have shown the effectiveness of targeting this signalling pathway in MB using 
mTOR inhibitors. Moreover, inhibiting the PI3K/AKT/mTOR pathway with small molecule 
inhibitors has been shown to destabilise MYC and MYCN proteins. As mTOR is a downstream 
target of MYC upregulation, it is a good candidate for therapeutic targeting  (Pei et al., 2016, 
Cage et al., 2015, Buonamici et al., 2010). 
The potential effect of mTORC1/2 inhibition using INK128 and AZD2014 against MYC-driven 
MB cells was examined in this study. D425 MBGroup3 cells showed different sensitivities to 
mTOR inhibition following MYC knockdown. D425 MYC2 treated with DOX for MYC 
knockdown showed greater resistance to the mTOR inhibitors when compared to both the NS 
control and untreated D425 MYC2 expressing MYC. In contrast, D425 MYC3 showed a trend 
of decreased sensitivity following MYC knockdown, but this was not statistically significant. In 
general, D425 cells expressing high levels of MYC exhibited greater sensitivity to INK128 and 
AZD2014 than cells with MYC knockdown, showing a clear MYC-dependent sensitivity to 
mTOR inhibition.    
Despite MYC-dependent sensitivity to mTOR inhibitors, treatment with INK128 and AD2014 
did not cause downregulation of MYC protein levels. In fact, re-expression of MYC was 
observed after 1-2 hours of drug exposure. Although no effects were seen on MYC protein 
levels, a MYC-independent reduction in S6 phosphorylation was observed, indicating the 
efficacy of the inhibitors. A MYC-dependent reduction of total levels of mTOR was seen in cell 
lines with MYC knockdown at later time points after treatment with AZD2014. The results 




The PI3K/AKT/mTOR signalling pathway involves crosstalk nodes with other pathways, 
numerous feedback loops and compensatory pathways. The complexity of the network brings 
many opportunities for cancerous cells to circumvent PI3K inhibition, limiting its therapeutic 
efficacy (Yang et al., 2019). It has been reported that the interaction between mTORC1 and 
S6K, mediates potent negative feedback loops that affect upstream signalling of several 
tyrosine kinases (TRKs) and insulin receptors in addition to promoting growth signalling in 
normal and cancerous cells. mTORC1 inhibitors cause compensatory activation of the PI3K and 
AKT nodes when supressing the feedback loops, causing enhanced activation of upstream 
signalling of pro-oncogenic and survival pathways (MEK/ERK), thus opposing the anti-
proliferative effects of the inhibitors (Rozengurt et al., 2014, Guri and Hall, 2016). 
Several studies exposing different cancer types to selective mTOR inhibitors have shown them 
to induce over activation of ERK, a kinase member of the Ras-Raf-ERK signal transduction 
cascade. Ras is an oncogene that plays a pivotal role in cell growth. Ras activation stimulates 
the effector kinases MEK and ERK that activate key transcription factors for mitogenesis. This 
compensatory mechanism could explain the rebound in MYC expression after drug treatment 
with mTOR inhibitors, a way cells have to circumvent PI3K inhibition and promote MYC 
transcription (Mendoza et al., 2011, Asati et al., 2016).  
Evidence shows that PI3K/mTOR inhibition increases MYC expression through activation of 
the NOTCH signalling pathway. Muellner et al. showed a reduction in Bez-235 inhibitor efficacy 
(dual PI3K/mTOR inhibitor) through activation of NOTCH-MYC signalling (Shepherd et al., 
2013, Muellner et al., 2011, Dey et al., 2015). These studies offer another explanation of an 
alternative mechanism by which MYC-driven MBGroup3 cell lines could upregulate MYC 
expression when downstream effectors of the PI3K signalling pathway are affected, to 
maintain high levels of MYC expression.   
Although the use of AZD2014 and INK128 did not have a direct effect on MYC expression in 
MYC-driven MBGroup3 cell lines, further investigation at the mRNA and protein level should 
include more time points and varied concentrations to properly evaluate the effect of mTOR 
inhibition. Gene expression alterations are dynamic and therefore time-dependent, making 
experimental approaches often challenging to capture in detail this time-dependent biological 
process. In this regard, some changes in gene expression might have been missed, since only 
short time periods were considered as a preliminarily approach to investigate the effect these 
inhibitors had on MYC expression.  
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Downstream effectors of the apoptotic signalling pathway should also be studied to 
understand the mechanism by which AZD2014 and INK128 reduced the viability of D425 cells. 
In summary, mTOR inhibition did not result in downregulation of MYC expression, and due to 
time constraints, mTOR inhibition in MBGroup3 cell lines was not pursued, and alternative drugs 
and signalling pathways were investigated.   
 
4.5.2 BRD4 inhibition decreases MYC expression 
The BET family of proteins has become a promising target for epigenetic therapy. Involvement 
of BRD4 in regulating MYC expression and the transcription of MYC-targeted genes has been 
seen as a promising new anti-cancer therapeutic approach to use on MYC-driven cancers.  
JQ1 has previously been shown to reduce MYC expression and downregulate MYC-associated 
transcriptional activity in MB and NB MYC-driven cancers (Henssen et al., 2013, 
Bandopadhayay et al., 2019, Bandopadhayay et al., 2014, Venkataraman et al., 2014). 
Currently, this is the first study assessing the efficacy of JQ1 and MYC dependency in Group 3 
medulloblastoma.  
In accordance to these published studies, treatment with JQ1 did destabilise MYC and caused 
a reduction in its expression, both at the protein and mRNA level in a MYC-dependent manner 
in our regulable models. JQ1 treatment caused a MYC-dependent growth-inhibitory effect on 
the MB regulable models, where a significant difference between the IC50 concentrations was 
seen when compared cells overexpressing MYC with its MYC-silenced counterparts. 
Reduction of MYC expression levels through BRD4 inhibition caused a reduction in cell 
proliferation. Interference with MYC translation through JQ1 treatment seemed to cause a 
similar effect to MYC-silencing with doxycycline, reducing cellular proliferation but without 
inducing cell death. This correlates with small differences seen in expression of the apoptosis 
executors caspase 3 and 7 following treatment with JQ1. Results are in accordance with other 
studies reporting the involvement of BRD4 in regulating cancer cell proliferation through 
induction of cellular senescence (Dong et al., 2018).    
JQ1 treatment upregulated the expression of MCL1, resulting in an increase in MCL1 protein 
levels after JQ1 treatment. JQ1-induced upregulation of the anti-apoptotic protein MCL1 has 
been previously linked to resistance to JQ1. BRD4 has a role in non-homologous end joining 
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(NHEJ) DNA damage repair. Inhibition of BRD4 with JQ1 has been shown to increase DNA 
damage by inhibiting DNA repair. 
Increased levels of MCL1 trigger anti-apoptotic signalling pathways, arresting cell cycle 
progression to prevent cells sustaining DNA damage from replicating (Fujise et al., 2000, Zhang 
et al., 2018b). The decrease seen in the expression levels of PARP, a protein involved in DNA 
repair, indicates that increased MCL1 levels might occur to ensure cells bearing damaged DNA 
do not replicate. This could explain the maintenance of some viable cells following JQ1 
treatment, as after 72h 50% of the cells were still viable at the highest tested concentration 
of the inhibitor. 
Stability of MCL1 is tightly regulated through phosphorylation and ubiquitination by various 
oncogenic signalling pathways, including the MAPK pathway. These oncogenic signalling 
cascades promote rapid increase of MCL1 to promote cell survival and escape the apoptotic 
signal (Williams and Cook, 2015, Basu and Sridharan, 2017). These studies are in agreement 
with the upregulation of the RNA expression of genes involved in the MAPK signalling pathway 
seen in the regulable models, which could explain the increase in levels of MCL1 protein after 
JQ1 treatment.   
Further study of drug response should include the analysis of cell cycle and gene expression 
of genes involved in the apoptotic and senescence-signalling pathway, to better determine 
the mechanism by which JQ1 reduced proliferation and cell viability in MBGroup3.   
JQ1 development offered a new therapeutic strategy to treat cancer through targeting the 
transcription of critical oncogenes driving tumorigenic processes. The mechanism of action of 
JQ1 has been key to establish proof of principle of BET inhibition as a target strategy for many 
human cancers. However, the short half-life of the compound has made it challenging to 
identify an effective dosage range in vivo without going above physiologic safety levels. In fact, 
clinical JQ1-related toxicities have already been reported and its exact mechanism of toxicity 
is still unknown, it may be due to its broad target spectrum across the BET family members 
(Bakshi et al., 2018, Stathis and Bertoni, 2018). 
The pharmacokinetic and pharmacodynamic properties and molecule structure of JQ1 has 
become a model for the development of new drugs with increased bioavailability and reduced 
neurocognitive related toxicities. Many BET inhibitors (like OTX015 and I-BET76) have been 
approved for clinical studies, but unfortunately initial evaluation has reported toxic side 
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effects associated with treatment in various different cancers (Piha-Paul et al., 2019, Blum et 
al., 2018, Aftimos et al., 2017, Hottinger et al., 2016, Amorim et al., 2016, Patnaik et al., 2018) 
Current literature and the results of this study indicate that BET inhibition is a promising 
anticancer strategy to compromise MYC expression in MYC-driven tumours. Administration of 
BET inhibitors alone may not be sufficient to kill MYC-driven MB cell lines, as attenuation of 
MYC expression does not trigger the apoptotic pathway, but a combination of BET inhibitors 
and compounds affecting the expression of anti-apoptotic proteins could be a good strategy 
to induce cell death in MB (Miller et al., 2019).  
 
4.5.3 CDK9 inhibition results in inhibition of MYC transcription  
MYC is a potent oncogenic driver, and its overexpression induces the upregulation of gene 
transcription, protein translation and DNA replication, resulting in aberrant cell proliferation 
that gives a competitive advantage. In recent years, much effort has been directed in 
developing strategies to target MYC function indirectly. Targeting MYC transcription through 
BRD4 inhibition has shown great promise. The use of BET inhibitors has demonstrated great 
potential in supressing MYC transcriptional activity, and overall good anti-tumour properties. 
JQ1 treatment on MBGroup3 isogenic models successfully reduced MYC expression both at the 
mRNA and protein level. However, despite JQ1’s great efficacy, the use of pan-BRD inhibitors 
has been shown to be toxic in pre-clinical models (Alqahtani et al., 2019), and its lack of 
selectivity against MYC transcription is still a concern. 
Published data indicates that recruitment of the P-TEFb complex to the MYC promoter region 
by BRD4 is essential to control MYC expression. CDK9 is the catalytic subunit of the P-TEFb, 
which is tempting to speculate that direct inhibition of P-TEFb through CDK9 inhibition would 
produce a similar or greater effect in inhibiting MYC transcription, which would in turn induce 
growth arrest in MYC addicted cell lines (Lu et al., 2015, Blake et al., 2019). Therefore, efficacy 
of CDK9 inhibition in disrupting MYC-dependent transcription was explored in MBGroup3 as an 
alternative therapeutic approach to target MYC transcription. The CDK9 inhibitor CYC065 
(Cyclacel), was chosen for the study because of its great potential seen in NB (Chen et al., 
2018b, Hashiguchi et al., 2019). 
MYC-expressing MBGroup3 cell lines demonstrated enhanced susceptibility to CYC065. 
Treatment with CYC065 caused a reduction in cell counts alongside reduced viability. The role 
140 
 
of CDK9 as a global regulator of gene transcription, and its particular role in regulating MYC 
expression directly, may explain why its inhibition caused a reduction in D425 and D283 
proliferative capacity. 
CDK9 has been shown to be an intermediary involved in MYC phosphorylation at Ser62, an 
important contributor to subsequent MYC degradation and apoptosis, which could explain the 
decreased in cell viability seen in MYC over-expressing MBGroup3 cell lines (Hashiguchi et al., 
2019).   
MYC expression levels positively correlated with sensitivity to the CDK9 inhibitor CYC065. 
MYC-overexpressing D425 and D283 were more sensitive to CDK9 inhibition when compared 
to its MYC-silenced counterparts. Although not as pronounced, differences between cell line 
sensitivities were observed, with D425 being more sensitive to CDK9 inhibition. Differences in 
CYC065 sensitivity may be explained by differences in intrinsic levels of MYC expression. D425 
is a MYC over-expressing cell line, whereas D283 has only gained one additional copy of MYC 
(Chapter 1, section 1.7.1.1), the difference in overall MYC expression levels might affect 
response to treatment with CYC065.  
CDK9 regulates both MYC transcription and MYC protein stability in a MYC-dependent 
manner. As expected, its inhibition resulted in downregulation of MYC at the mRNA and 
protein level. CYC065 successfully reduced protein expression levels of MYC and MCL1, 
oncogenic drivers whose transcription is directly regulated by CDK9. Downregulation of MYC 
and MCL1 protein expression with CYC065 was greater in D425 than in D283. As mentioned, 
overall expression levels of MYC could explain differences in the efficiency by which MYC 
protein levels were downregulated after CDK9 inhibition. Higher levels of MYC expression in 
D425 would translate into more transcription of MYC target genes in comparison to D283.  
Inhibition of CDK9 by CYC065 shows great promise as a new therapeutic strategy to target 
MYC-dependent MBGroup3 tumours. CYC065 significantly reduced MYC expression both at the 
protein level, reducing proliferation and cell viability in D425 and D283 MBGroup3 cell lines in a 
MYC-dependent way. Further studies involving cell cycle analysis and apoptotic assays should 
be pursued to elucidate the mechanism by which the inhibitor is affecting cell viability. 
All things considered, the results of this Chapter provide a degree of validation to use CDK9 
inhibition as a therapeutic strategy to downregulate MYC transcription in MYC-dependent 




This chapter outlines the pursuit of two different pharmacological strategies to indirectly 
target MYC in two MYC-regulable MBGroup3 cell lines. The use of the isogenic models enabled 
the testing of candidate drugs targeting MYC-associated signalling pathways in a MYC-
dependent manner.  
Despite MYC being a downstream effector of the PI3K/AKT/mTOR signalling pathway, mTOR 
inhibition did not downregulate MYC expression. The rebound of MYC expression following 
inhibition has been linked to acquired resistance to PI3K inhibitors. The complexity of 
underlying compensatory feedback loops that malignant cells use to circumvent the effect of 
PI3K inhibition, necessitates deeper understanding to overcome drug resistance. Until the 
underlying mechanism of the signalling pathway is well established in a tissue-specific context, 
it is clear that single-agent targeting of this signalling cascade is not the best approach to treat 
MYC-dependent MBGroup3 tumours. Combinational approaches would be better options to 
treat MB to increase treatment efficacy and reduce treatment resistance (Yang et al., 2019, 
Vora et al., 2014).  
Targeting MYC transcription holds the promise for a better strategy to directly downregulate 
MYC expression. MBGroup3 cell lines are specifically sensitive to CDK9 and BRD4 inhibition in a 
MYC-dependent fashion, and have shown great efficacy in destabilising MYC protein levels, 
decreasing cell proliferation and inducing apoptosis. When compared, CYC065 had a greater 
effect in reducing MYC protein levels than JQ1.  
Despite CDK9 inhibition causing a general reduction in expression of most human genes, the 
induction of MYC expression upon prolonged pharmacological inhibition of CDK9 has been 
previously reported (Lu et al., 2015). BRD4 recruits P-TEFb at the MYC enhancer and 
superenhancer regions to promote its transcription. It has been found that binding between 
BRD4 and P-TEFb protects CDK9 from drug inhibition, which would explain the induction of 
MYC expression to maintain the transcription of key genes for cell survival and to compensate 
for the loss of CDK9 (Lu et al., 2015).  
Work presented in this chapter identifies MBGroup3 MYC-overexpressing cell lines to be more 
sensitive to the candidate inhibitors. As shown in Chapter 3, MYC knockdown downregulates 
cell cycle and proliferation, which could mask the effect of the inhibitors.  To discern whether 
the sensitives to the inhibitors identified are MYC-dependent or a consequence of reduced 
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cell turnover, the recapitulation of the experiments using alternative non-MYC amplified 
MBGroup3 cell lines or MBGroup3 lines expressing lower levels of MYC would be key to understand 
the contribution of MYC overexpression to the drug sensitivity observed. Testing of the 
inhibitors on alternative MBGroup3 cell lines would be key to differentiate MYC-dependent 
sensitivities from those susceptibilities identified as a direct result from downregulation of cell 
proliferation upon MYC-knockdown.   
 
Results presented in this chapter, indicate that targeting of BRD4 and CDK9, alone or in 
combination, is a potential therapeutic strategy to treat MYC overexpressing MBGroup3 
tumours. The potential of simultaneous inhibition of BRD4 and CDK9 should be further 














High-throughput genomic and proteomic methods have had a huge impact on our 
understanding of cancer biology, paving the way for major improvements in cancer 
therapeutics. Integration of ‘omic’ data sets have aided in the identification of targetable 
molecular mechanisms altered in a particular cancer, with the aim of developing new 
therapeutic approaches to increase survival rates and reduce adverse effects of current 
standard therapy (Hajare et al., 2013). 
The need for major improvements in personalised medicine has driven the acceleration of the 
process of identifying new antitumoural drugs for translational research. Combination of 
bioinformatics, combinatorial chemistry and automation of cell-based assays has created a 
more effective platform to accelerate the drug discovery process (Entzeroth et al., 2009). 
An important drug discovery methodology is compound screening, which is the process of 
assaying the effect of chemical compounds on biological models of interest and measuring 
phenotypic effects such as growth. The establishment of laboratory robots and automated 
machinery has facilitated the emergence of high-throughput screening (HTS) approaches, 
whereby large numbers of compounds can be assayed in a very time- and cost-efficient 
manner (Xia and Wong, 2012, Shukla, 2016).   
Availability of a compound library is a prerequisite for HTS. Chemical libraries can vary from 
being broad (with a huge variety of small molecules with diverse targeting) to more specific 
(tailored to a family of related targets). Usually, a compound library is chosen to be as diverse 
as possible to assay for potential effects without pre-conceived assumptions (Szymanski et al., 
2012). 
HTS, performed by means of automated miniaturised cell-based assays, enables the 
evaluation of hundreds of potential drug targets at a time by functionally assessing their 
efficacy in biological models of interest. In this regard, cell-based phenotypic screening is 
usually used in academic research to compare the effect of several compounds on cell 





The application of HTS technologies has required the parallel development of informatic 
systems in order to analyse and interpret the large amounts of data generated. Computational 
analysis of data generated through HTS has facilitated its integration with other platforms, 
allowing the connection of basic research with preclinical and clinical data providing new 
avenues for cancer treatment (Szymanski et al., 2012). 
Whilst working on the candidate drug list described in Chapter 4, the opportunity to run a high 
throughput compound screen (HTCS) as part of a collaborative project (INSTINCT) with the 
Institute of Cancer Research (ICR) London arose.  
Although, there has been some progress in the development of small molecule inhibitors 
targeting the SHH pathway of potential utility in MBSHH, no major breakthroughs have been 
made in the treatment of MBGroup3. As the genetic changes between our isogenic models is 
limited to MYC, performing a HTCS presented the opportunity to observe MYC-dependent 
drug sensitivity effects (i.e. differences in drug sensitivity according to the level of MYC 
expression)(Postel-Vinay et al., 2013). Exposing our MYC-regulable models to hundreds of 
inhibitors offered the opportunity to identify inhibitors that have a greater effect in the 
presence of MYC expression and those which have an additive effect following MYC-silencing 
with shRNA. Integration of results from the screen with data on transcriptional and biological 
MB dependencies will help the identification of targetable cellular mechanisms to optimise 












This chapter aims to use the MYC silencing isogenic models described in chapters 1 and 3 to 
investigate the MYC dependency of the response to a large panel of small molecule inhibitors, 
to identify drugs which target both MYC and which synergise with MYC knockdown. 
Identification of drugs with a greater effect on proliferation of MYC-overexpressing cells 
potentially target MYC or MYC-associated processes, whereas greater sensitivity following 






















5.3.1 High throughput drug sensitivity screening on MYC-dependent MBGroup3 cell lines  
The compound libraries used at the ICR (icr.ac.uk) for screening contain a diverse assortment 
of small molecule inhibitors that are either already established for cancer treatment or are in 
late stages of clinical development. The list of compounds of each library can be found in 
tables 5.1, 5.2 and 5.3 of the Appendix (Postel-Vinay et al., 2013)(Holme et al., 2018)(Campbell 
et al., 2016, Menon et al., 2019).  
This is of great use when assessing paediatric cancers, since most drugs are not made available 
for children until tested in adults. Therefore, the advantage of using a compound library with 
inhibitors already approved for the clinic is that any promising drugs discovered have a 
realistic chance of being directly translated into an early phase clinical trial for children (Holme 
et al., 2018).  
Additionally, a large variety of cell models of different cancers have already been screened 
with the libraries at the ICR (Chong et al., 2018, Campbell et al., 2016)(Holme et al., 2018), and 
this provides a valuable resource to compare our MYC amplified medulloblastoma cell lines 
with, potentially highlighting compounds which show increased efficacy either specifically in 
medulloblastoma cells or more broadly in all MYC amplified cancer types. 
To maximise the possibility to find positive and reproducible ‘hits’ (compounds which have a 
differential effect on MYC expressing compared to MYC downregulated cells, or vice versa), 
all three isogenic MYC-regulable cell lines were subjected to high-throughput chemosensitivity 
screening of three different compound libraries consisting of nearly 600 small molecule 
inhibitors. Library 11-12 contained 80 compounds, each one of them tested at 8 different 
concentrations (0.5, 1, 5, 10, 50, 100, 500, 1000nM). Library 13 contained a wider range of 
compounds, 397, but only tested at 4 concentrations (0.5, 5, 50 and 500nM). Library 14 
involved 120 compounds tested individually at 8 different concentrations (0.5, 1, 5, 10, 50, 
100, 500, 1000nM)(Figure 5.1).  
Each MBGroup3 cell line, with and without MYC knockdown, was subjected to each compound 
library for the identification of differences in sensitivity according to their MYC expression 






Figure 5.1. High throughput drug screening overview. Schematic summary of high throughout small 
compound chemosensitivity screen. D425, D283 and HDMB03 MBGroup3 cell lines were seeded in 384 
well plates and exposed to 3 compound libraries (plate 11-12, plate 13 and plate 14) for five days. 
Each one of the 80 compounds on library 11-12 were tested at 8 different concentrations (0.5, 1, 5, 
10, 50, 100, 500, 1000nM), the 397 contained in library 13 were tested at 4 concentrations (0.5, 5, 
50 and 500), and the 120 on library 14 at 8 different concentrations (0.5, 1, 5, 10, 50, 100, 500, 
1000nM).Cells were pre-treated with DOX 48h prior to drugging. Cell viability was estimated with 
CellTiter-Glo (CTG) reagent. Data was processed through the ICR database, and quality controls for 
each screen determined to compile data for hit identification and further analysis. Each experiment 





Is it worth to point out that our working system adds an extra degree of complexity to the 
standardised performance of a regular HTCS. Considering each cell line, shRNA constructs and 
doxycycline treatment conditions, compound libraries 11-12, 13 and 14 were performed at 
least 18 times (Figure 5.2).  
It was decided to run the screen on all conditions to enable reproducibility of drug sensitivity 
data to be assessed, and to increase robustness of the results found, since no other MB cell 
lines had been previously screened with this specific library of compounds.  
 
Figure 5.2. Complexity of the isogenic working system.Schematic representation of the isogenic 
model system. Each D425, D283 and HDMB03 MBGroup3 cell line has cloned a non-silencing (NS), 
MYC2 and MYC3 shRNA construct for silencing MYC expression. Expression of the shRNA system and 
the consequent silencing of MYC is triggered by the addition of doxycycline (DOX +) to the media. 
Constructs need to be grown separately to avoid mixing. For DOX treated conditions, cells from the 
same passage are grown in parallel with and without doxycycline in the media. 
 
 
5.3.1.1 Optimisation of drug screening  
Screening of cell sensitivity to small molecule inhibitors is performed in 384 well plates. Cell 
lines in each well are exposed to a single-dose concentration of the compounds and left to 
grow for five consecutive days. Compounds in the screen are assessed in triplicate on separate 
plates to avoid plate to plate variations. An untreated control (no compound or DMSO) 
alongside positive and negative controls (50% DMSO only or camptothecin) are included on 
every assay plate for data normalisation. Residual viability is estimated with CellTiter-Glo 
(CTG). Signal from each well is normalised to the median of the negative controls (DMSO 
treated)(for more detail, see Chapter 2). 
Maximum MYC knockdown is achieved 72h after DOX induction. With this under 
consideration, ideally cell lines would have to be pre-induced with DOX 24h prior to seeding, 
to ensure maximum efficacy of shRNA when the inhibitors hit their specific target.   
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To ensure that results seen are only representative of cell lines’ sensitivity to the drugs, prior 
optimisation of HTCS conditions were performed to determine such factors as the seeding 
density and the length of the pre-treatment with DOX to ensure MYC was knocked down prior 
to the screen. 
Firstly, the cell density recommended in the screen (500 cells/well) was assessed by growing 
cell lines cloned with each construct on 384 well plates for five days. Fast growing cell lines 
like D425 and HDMB03 reached cell confluence of around 85% by day 5, whilst D283 only 
around 60%. Having a lower doubling time, cell density of D283 was chosen to be 1000 
cells/well to ensure all cell lines were in optimal growing conditions when exposed to the 
inhibitors.  
The ability of the cells to maintain MYC knockdown for 5 days without refreshing the media 
with DOX, conditions which the cells would undergo during the screening, was further 
assessed to ensure MYC-silencing was maintained throughout the duration of the experiment. 
Due to time constraints, D425 was chosen to validate conditions for HTCS and taken as 
reference for the rest of the cell lines.  
For MYC knockdown, NS, MYC2 and MYC3 shRNA constructs were cultured in the presence of 
DOX 24 hours prior to seeding. NS, MYC2 and MYC3 cultured in the presence and absence of 
DOX, were seeded and then cultured in media without puromycin, with puromycin, grown 
without puromycin and media refreshed, grown with puromycin and media refreshed with 
DOX (Figure 5.3). After 5 days cells were harvested and protein extracted to analyse MYC 
protein expression levels with Wes after being cultured in each condition (Chapter 2). 
Wes quantification of MYC protein levels showed no major differences between conditions. 
MYC knockdown was maintained throughout the 5 days the experiment lasted. Furthermore, 
no major differences in MYC protein expression was seen between cells grown in the presence 







Results showed that puromycin did not causes differences in MYC expression and therefore it 
was decided that the best condition to run the HTCS under was to use puromycin free media 
when seeding cells into 384-well plates, and to refresh the MYC knockdown cells (which had 
been cultured in DOX 24 hours prior to seeding) with DOX at the time of plating avoiding 




Figure 5.3. MYC knockdown validation for high throughput drug screening. A)Automated Western 
Blot image of c-MYC protein levels to optimise MYC knockdown conditions for HTCS. D425 NS, MYC2 
and MYC3 shRNA constructs were cultured in the presence(dox) and absence(no dox) of DOX for 
MYC knockdown. Each condition was cultured without puromycin (N), with puromycin (P), grown 
without puromycin and media refreshed (R), grown with puromycin and media refreshed (PR), to 
check differences in expression of MYC protein. Cells were harvested and protein extracted after 5 
days of culturing. GAPDH was used as internal control. B) Wes quantification analysis of MYC protein 
expression levels of each construct grown in a particular condition (N, P, R or PR). Data is shown as 








5.3.1.2 Small molecule drug screen overview 
To reach the maximum drug diversity without prejudice on the molecular mechanism of the 
drug, D425, D283 and HDMB03 were exposed to all three compound libraries available, which 
encompass a total of 581 drugs targeting a broad range of key signalling pathways in tumour 
biology.  
HTCS at the ICR uses a 384-well screening approach where the process of liquid handling of 
inhibitor dilutions is done automatically in a Microlab STAR platform (Hamilton)(Methodology 
explained in Chapter 2). All three constructs of each MYC isogenic cell line, cultured in the 
presence and absence of DOX for MYC knockdown, were seeded in 384 well plates and 
exposed to a single-dose concentration per well of each inhibitor contained in each compound 
library (11-12, 13 and 14)(Figure 5.4). After a period of 5 days, cell viability was assessed with 
CTG reagent as explained in Chapter 2. NS, MYC2 and MYC3 shRNA constructs of each cell line 
were screened in triplicate, and data from replicate screens were combined in the final 
analysis (Campbell et al., 2016). 
Luminescence measurements of cell viability from each compound library were processed 
through the ICR database (The Institute Cancer Research, London), producing an experiment 
report for preliminary evaluation of the results (described in Chapter 2). Prior to assessment 
of drug sensitivity effects in MYC-amplified MBGroup3, quality control (QC) values generated for 
each screen were checked to ensure the quality of the data produced.  
Two measures were used as quality control metrics for replicate cell line samples: replicate 
reproducibility and a measure of overall distribution of the logged normalised luminescence 
values for the compounds (Cowley et al., 2014). The processing of the data through the ICR 
database calculates the Pearson correlation between all replicate samples, and a threshold of 
75th percentile of the correlation of all non-replicate pairs (0.6795) is used to fail individual 
replicate samples. The database uses the GenePattern module ‘ReplicatesQC’ to run these 
metrics and identify replicate samples to be removed (Campbell et al., 2018). Compound 
screen replicates are expected to be strongly correlated, therefore, pairs of replicates with 





A further quality control parameter is the Z-prime (Z) value for each screen. Z scores provide 
a measure of the separation of the positive and negative control compounds included in the 
screen, and so can be considered an estimate of how much it is possible for the individual cell-
treated wells to vary in Z-scores. Larger Z values indicate better screens. Screens with Z scores 
≥0.5 are considered excellent. Those with Z values ≤0 are considered unusable and should be 
rejected and the experiments repeated. Only screens that passed the threshold of ≥0.3 were 
used for further analysis.   
Data from reports not passing QC test, which meant screens with median Z scores ≤0.3, or 
presenting median correlation coefficients ≤0.7 between replicates, were excluded for further 




Figure 5.4. Results report from high-throughput compound screening.Example of an overview of a 
report produced by the processing of the luminescence readings through the in-house ICR data base. 
A) The report presents information about the replicate/average dynamic range, repeatability 
standard variation and calculation of the spearman rank correlation of replicates. B) visual 
representation of the dynamic range of each individual screen estimated with the Z score. C) 
Scatterplots showing correlation between replicates. 
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5.3.1.2.1 High-throughput compound screen results  
With the processed luminescence readings, percentage of control (POC) survival values were 
generated, by normalising the raw CTG readings from each plate to the median signal of the 
negative controls (cells not exposed to small molecule inhibitors, DMSO only). Results were 
expressed as a proportion of viable (metabolically active) cells relative to the DMSO control 
(as an example, 0.5 indicates that cell numbers were reduced by 50% relative to the DMSO 
only control). 
To better assess if drug sensitivity effects differed according to MYC expression levels 
(whether MYC knockdown by shRNA or not), screen analysis was focused only on data from 
D425, D283 and HDMB03 MYC2 constructs. Although drug sensitivity effects were consistent 
between MYC2 and MYC3 constructs, they were less pronounced in the MYC3 construct 
therefore in order not to generate false negatives we thought it was more appropriate to focus 
on results seen on MYC2 since it is the most efficient construct in knocking down MYC 
expression levels (see Chapter 3). Cells cloned with the NS shRNA construct were used as a 
negative control for the function of the shRNA and to determine the specific effects of the 
silencing constructs on the cell lines. Data from NS cell lines can be used to assess 
reproducibility of the data, to ensure the response to the drug was similar, if not the same, to 
those cloned with the MYC2 construct expressing high-levels of MYC.  
 
5.3.1.3 Analysis of screen results 
Remaining surviving fractions of cells after exposure to the compounds was scrutinised for 
candidate hit identification.  
The diversity of compounds tested translated into a varied range of effects on the isogenic 
models. A few inhibitors displayed inconsistent effects across the dosing range, where 
surviving fractions increased and decreased regardless of increased concentrations of the 
inhibitor. Some compounds only had a growth inhibitory effect on one of the cell lines, others 
significantly reduced cell growth of 2 of the cell lines, and the rest had a consistent growth 
inhibitory effect across D425, D283 and HDMB03. The diversity of effects seen in the screen is 







Figure 5.5. Examples of differential effects on isogenic cell line viability.Example of dose-response 
curves from surviving fractions of D425 MYC2 cells after drug exposures. Compounds tested on the 
screen elicited different effects on the cell lines; being specifically effective on MYC overexpressing 
A) or MYC knockdown cell lines D), not having a growth-inhibitory effect B), or showed inconsistent 
results C). Graphs show the different responses of D425 MYC2 expressing MYC [blue; -dox(MYC ON)] 
and with MYC knockdown [orange; +dox(MYC OFF)].  
 
Compounds that had an inconsistent growth-inhibitory dose-dependent effect were generally 
excluded from the dataset. Only those inhibitors that were contained in all three compound 
libraries and therefore repeatedly tested trice across compound libraries were considered for 
revision. If the dose-dependent growth-inhibitory effect was only inconsistent in 1 out of the 
3 libraries, the effect of the compound seen on that plate was removed, and only the effect 
on the other 2 libraries was considered. That particular compound was left for further analysis 
and the specific inconsistent effect observed in that one plate considered a mechanical 
discrepancy during robotic handling. Compounds presenting an inconsistent effect in 2 or 3 






Of 581 inhibitors tested across the 3 compound libraries, 95 drugs were repeated in different 
plates, leaving a total of 457 unique small molecule inhibitors. We then sought to perform a 
one-on-one analysis approach of the 457 compounds, plotting dose-response curves to 
establish IC50. Utilisation of the calculated IC50 to discern compound effectiveness was 
problematic. Despite some compounds causing a significant growth inhibitory effect across 
cell lines, a more resistant proportion of cells at high concentrations was seen for some of the 
constructs, translating into misleading results with each cell line having the same IC50 value 
when there was a clear difference in the proportion of surviving cells (Figure 5.6, A, B).   
On the other hand, some inhibitors had no growth-inhibitory effect on one arm of the 
experiment. The inability of the compounds to cause 50% growth inhibition prevented the 
calculation of the IC50 concentration. The same problem was seen for those compounds to 
which the cell lines were extremely sensitive. Inhibitors causing equal decrease of surviving 
cell fraction in both MYC expressing and MYC downregulated arms increased the error 
margins when trying to fit a nonlinear regression curve with Prism, resulting in ambiguous IC50 
results (Figure 5.6, C).  
To ease the automation process with a Microlab star platform (Hamilton), inhibitors contained 
in the compound libraries are all screened in the same concentration range, which does not 
account for the optimal concentration range for each individual compound. Not considering 
the pharmacokinetic properties of each particular compound translated into some of them 
not killing 50% of cells at the highest dose, indicating that the range used in the screen was 
not the correct one to determine the IC50 on our cell lines. In this regard, compounds of Library 
13 were only tested at 4 different concentrations, resulting in some cases in error margin too 
large to calculate an IC50 reliably. 
Considering all these variables that could impair the analysis, we decided that it was optimal 
not to directly use the IC50 values calculated from the surviving fractions of cells from the 
screen. To ensure to most accurate identification of compounds of interest, the remaining 
surviving fraction of cells at every concentration was considered to establish the growth 
inhibitory effect the compounds had on the cell lines. A threshold of 50% growth inhibition 
was chosen to deem compounds to have an effect, and therefore be ‘effective’, to truly 





Figure 5.6. Examples of misleading results from direct IC50 calculation.Dose-response curves of 
surviving fractions of D425, D283 and HDMB03 MYC2 cells after drug exposures from the screen. 
The graphs show the different growth inhibitory effect of A) Paclitaxel, B) R547 and C) GSK-461364 
on MYC-overexpressing (blue; -dox [MYC ON]) and MYC silenced (red; +dox [MYC OFF]) cells. A) A 
resistant proportion of cells was seen after treatment with Paclitaxel at higher doses, but IC50 
calculated between arms was the same, not reflecting the true difference between sensitivity. B) 
Treatment with R547 did inhibit the growth of D425 cells with MYC knockdown, nonetheless, a 
higher IC50 was calculated for the MYC expressing arm. C) Exposure to GSK-461364 caused an equal 
drop in surviving fractions of MYC-expressing and MYC-knockdown cells, which increased the error 
margins in Prism, preventing the calculation of reliable IC50. Curve is presented as log(concentration) 




Among all 457 drugs tested, 76.1% of compounds elicited low or no effect across cell lines 
(growth inhibition <50%). A total of 137 compounds displayed 50% growth inhibition at at 
least one concentration across D425, D283 and HDMB03 (Figure 5.7).  
 
Figure 5.7. High throughput drug screen data analysis.Schematic summary of hit identification 
process from the high-throughput small compound chemosensitivity screen. Normalised data from 
D425, D283 and HDMB03 MYC2 MBGroup3 cell lines was processed and filtered to identify drugs that 
presented a MYC-dependent effect, by causing differences in growth between cell lines 
overexpressing MYC and with MYC knockdown. Data from MYC2 constructs of each cell line was 
considered for hit identification.   
 
Drugs contained in the compound libraries are annotated with information regarding their 
main target or their inhibitory mechanism of action, which was used to classify the inhibitors 
identified. The MB cell lines displayed particular sensitivity to compounds targeting the 20S 
core particle of the proteasome (3/3 20S proteasome inhibitors screened), polo-like kinases 
(4/4 PLK inhibitors screened), WEE1 (3/3 WEE1 inhibitors screened), β-tubulin for microtubule 
formation (11/12 β-tubulin inhibitors screened) and aurora kinases (10/11 AURK inhibitors 
screened)(Figure 5.8).  
With the objective to identify inhibitors that could be used against MYC-dependent tumours, 
we focused the analysis on finding differential drug sensitivity effects depending on MYC 
expression levels. MYC-dependent effects were identified by pairing POC scores of normalised 
triplicate data of each construct according to the presence and absence of DOX in the media. 
Significant differences between MYC expressing and MYC silenced cells were established with 
student’s t-test (p≤0.05).  
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From those compounds identified to cause cell growth inhibition of 50% across the isogenic 
MB lines, 82 compounds displayed a significant difference between the surviving fractions of 
MYC expressing and MYC downregulated cell lines at two or more concentrations. These 82 
compounds were considered as potential ‘hits’ (Figure 5.7).   
The comparison of the numbers of effective compounds on the isogenic lines and those 
displaying a differential growth inhibitory effect according to MYC expression levels served to 
show that not all inhibitors tested targeting components of the cell cycle machinery displayed 
differential growth inhibition between MB cells expressing MYC and those with MYC 
knockdown. This confirmed the notion that the 82 compounds that presented a MYC-
dependent effect according to the criteria were so due to their relationship with MYC 







Figure 5.8. Percentage of effective inhibitors on medulloblastoma cell lines. The graph shows the percentage of compounds causing a growth-inhibitory effect of 50% (blue; 
GI50 across cell lines) and those having a differential effect between cells overexpressing MYC and with MYC knockdown (orange; MYC-dependent effect). Percentage of 


















Effective compounds according to class targeted




5.3.1.3.1 Mechanism of action of MYC-dependent hits  
This approach identified 82 drugs causing significantly increased growth inhibition in MYC 
expressing cells when compared to cells with MYC-silenced with shRNA. No drugs showed a 
consistent increased growth inhibition of MYC silenced cells compared to MYC expressing cell 
lines. When classified according the compounds inhibitory target, a large number of the 82 
drugs deemed as hits were found to act by inhibiting DNA synthesis or chromosomal 
replication (Figure 5.9).   
Not all compounds inhibited a single class of targets. 11 compounds had multiple targets 
belonging to different classes. Each of the classes targeted by compounds inhibiting multiple 
molecules were considered for the classification of the compounds by their mechanism of 
action. This meant that one single compound could be classified in several classes. For 
example, the compound JNJ-7706621 inhibited CDK1/2 and AURKA/B, and therefore classified 
as targeting CDKs and AURKs. With this approach, we wanted to ensure the most accurate 
accountability of all the molecules inhibited by the compounds deemed as hits, and to prevent 
overlooking specific targets.    
 
Figure 5.9. Mechanism of action/target of hits identified. Pie chart of the target/main mechanisms 
of action of the 82 compounds that met the established criteria and showed a MYC-dependent 
effect. Values shown corresponds to the number of compounds inhibiting that specific target and 






















When grouped according to the biological function of the mechanisms targeted, from the 82 
compounds, 11 targeted topoisomerases, comprising 78.6% of all drugs screened targeting 
this particular enzyme (Table 5.1). Taking into consideration specific targetable molecules, 10 
CDK and 8 microtubule inhibitors (comprising 43.5% and 66.7%, respectively, of total drugs 
targeting that particular class) had greater effect on MYC-overexpressing cell lines. In general, 
compounds targeting β-tubulin and microtubule formation had a greater effect on cells 
expressing high levels of MYC (66.7% of all microtubule inhibitors; 8/12) (Table 5.1). 
8 inhibitors targeting aurora kinases caused significant cell killing on MYC-overexpressing cells 
when compared to their counterparts with MYC knockdown (72.7% of total of compounds 
targeting AURK). A similar effect was seen with inhibitors targeting checkpoint kinases, 
comprising 71.4% of total of compounds screened inhibiting CHK. 3 out of 4 PLK inhibitors 
tested on the screen were deemed as hits, composing 75% of the total. Only 7 drugs out of 16 
targeting mTOR (43.8% of total) were found to have a MYC-dependent effect (Table 5.1). 
Within all libraries, there was only 1 inhibitor targeting each of the following molecules, 
CNDAC, farnesyltransferase, Gli, NAE, PAK and ribonucleotide reductase, that caused greater 
growth inhibition on MYC-overexpressing cells. Due to small numbers, more compounds 
inhibiting these specific components should be tested to see if the effects seen were due to 
the inhibited target or selective toxicity of the drugs. Therefore, despite their efficacy, they 
were not considered for further studies.  
As said previously, one of the advantages of using the compound libraries available at the ICR 
is the presence of conventional therapeutics in addition to targeted agents. Classification of 
the 82 compounds according to them being conventional or non-conventional therapeutics, 
gave a list of 20 compounds used in conventional cancer treatment, and 62 small molecule 
targeted agents. Inhibitors were then ranked by the number of statistically different 
concentrations between cells overexpressing MYC and with MYC knockdown (p<0.05). The 






Class n0 hits TOTAL % from total 
ALK 1 2 50 
ATM/ATR 1 6 17 
AURK 8 11 72,7 
Bcr-Abl 1 9 11 
CDK 10 23 43,5 
CHK 4 7 57,1 
CLK 1 2 50 
CNDAC 1 1 100 
DNA damaging agents 3 13 23,1 
DNA/RNA antimetabolite 4 17 23,5 
DNA-PK 1 6 16,7 
DNMT 1 4 25 
farnesyl transferase 1 1 100 
FLT3 1 5 20 
Gli 1 1 100 
HDAC 4 14 28,6 
HSP90 1 9 11 
IKK 1 3 33 
JAK 2 9 22 
kinesin spindle protein  1 2 50 
MET 1 2 50 
microtubule  8 12 66,7 
Mps1 1 2 50 
mTOR 7 16 43,8 
NAE 1 1 100 
NF-κB 1 4 25 
PAK 1 1 100 
PARP 1 9 11,1 
PDGFR 2 11 18,2 
PDK 1 2 50 
PI3K 3 17 18 
PLK 3 4 75 
Ribonucleotide reductase  1 1 100 
Src 2 6 33,3 
Topoisomerase 11 14 78,6 
Tropomyosin receptor kinase A 1 1 100 
VEGFR 2 11 18 
Wee1 2 3 67 
 
Table 5.1. Summary of total number of hits grouped according to their main mechanism of action 
or target.Hits identified to have greater growth inhibition on D425, D283 and HDMB03 MYC2 than 
their counterparts with MYC knockdown, were classified according to their mechanism of action and 
the total count (n0 hits) was compared to all compounds screened inhibiting that particular biological 






Table 5.2. Top 20 targeted agents and conventional therapeutics with a MYC-dependent growth-
inhibitory effect. The tables summarise the top 20 hits identified to have greater growth inhibition 
on D425, D283 and HDMB03 MYC2 than their counterparts with MYC knockdown, when classified 
according to their category of conventional therapeutics (table A) or targeted agents (table B). Tables 
show the name of the compound, their specific targets, and the class of molecules inhibited used 





5.3.1.3.2 Class-representative hits 
Data analysis from the screen identified 82 inhibitors exhibiting a MYC-dependent effect, 
causing a greater proportional reduction on cell growth when used on MYC overexpressing 
cell lines. When drugs were classified by their main mechanism of action, several 
representatives fitted in the same category. To narrow down the list of hits for further 
validation, one compound representative of each class was selected for the analysis of 
possible targetable molecular pathways in MBGroup3. 
For candidate selection, initially, to focus on novel targeted therapeutic avenues, standard 
chemotherapeutic drugs were excluded from the list. The remaining drugs were cross-
referenced with drug-sensitivity data of D283, DAOY and ONS-76 MB cell lines available from 
the Cancer Genome Project, which has screened thousands human cancer cell lines with 
hundreds of compounds, making publicly available the characterisation of their sensitivity and 
drug response data (https://www.cancerrxgene.org/).  
On top of the drug sensitivity data available, a compilation of evidence was performed for all 
candidate drugs. Main criteria looked for were availability of published data of the inhibitor 
being tested in MB or other brain tumours, the ability of the compounds to cross the blood-
brain barrier (BBB), their current testing in clinical trials, alongside information of potential 
mechanistic links with MYC oncogene already established, to ensure the most accurate and 
relevant choice (information summarised in Table 5.4). Some of the references used can be 
seen in the Appendix 5.4. The list of candidate drugs for each molecular target can be seen in 
Table 5.3.  
 
Table 5.3. List of candidate drugs. List of representative compounds of each drug class for further 
validation. The 82 compounds having greater cytotoxic effect on MYC over-expressing cell lines 
compared to their counterparts with MYC knockdown, were grouped by their main mechanism of 
action and a representative for each drug class was chosen considering several sources of evidence 
and published data.     
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Compound Class MB Brain BBB clinical trials combination MYC CancerRxGene 
VX-970 ATM / ATR x ✓  ✓ cisplatin   
AMG-900 AURK ✓ ✓  ✓  ✓  
Barasertib AURK ✓ ✓   ABT-737 ✓  
MLN8237 AURK ✓ ✓ ✓ ✓ WEEi / sorafenib ✓  
PF-03814735 AURK x x    ✓  
SNS-314 AURK ✓ ✓   chemo drugs   
VX-680 AURK ✓ ✓  ✓ vincristine / cyclophosphamine/ cisplatin ✓ ✓ 
PP121 Bcr-Abl / mTOR / PDGFR / Src / VEGFR x x 
     
AT7519 CDK ✓ ✓    ✓ ✓ 
BMS-265246 CDK x x      
Dinaciclib CDK ✓ ✓  ✓ anti-PD1 Ab / ABT-737   
Flavopiridol CDK ✓ ✓  ✓    
LY2835219 CDK ✓ ✓ ✓ ✓ Temozolomide   
Milciclib CDK ✓ ✓ ✓ ✓ topotecan / cytarabine ✓ ✓ 
P276-00 CDK x x  ✓ bortezomib   
Roscovitine CDK ✓ ✓ ✓ ✓ IR ✓  
SNS-032 CDK x ✓   Celecoxib / SU 5416 / GM 6001   
JNJ-7706621 CDK / AURK ✓ ✓ ✓   ✓  
AZD7762 CHK ✓ ✓  ✓ SN-38 / gemcitabine / IR ✓ ✓ 
LY2603618 CHK x x  ✓ gemcitabine / pemetrexed   
PF-00477736 CHK discontinued by Pfizer     
SAR-20106 CHK x x  x    
PD407824 CHK / Wee1 x x   cisplatin / gemcitabine   
ML167 CLK x x      
PF-02341066 c-MET / ALK x ✓ x    ✓ 
Sapacitabine CNDAC x ✓   seliciclib   
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Compound Class MB Brain BBB clinical trials combination MYC CancerRxGene 
Satraplatin DNA damaging agents ✓ ✓  ✓    
Cladribine DNA/RNA antimetabolite x x    ✓  
Clofarabine DNA/RNA antimetabolite x ✓  ✓    
Gemcitabine DNA/RNA antimetabolite ✓ ✓   pemetrexed / AZD1775 / ✓ ✓ 
Hydroxyurea DNA/RNA antimetabolite ✓    IR   
decitabine DNMT ✓  ✓  Abacavir / Phenylbutyrate / IR   
Tipifarnib Ftase x ✓    ✓ ✓ 
JK184 Gli ✓ ✓    ✓  
Belinostat HDAC ✓ ✓  ✓  ✓  
JNJ-26481585 HDAC ✓ ✓      
Mocetinostat HDAC ✓   ✓    
Vorinostat HDAC ✓ ✓ ✓   ✓ ✓ 
SNX-5422 HSP90 x ✓  ✓    
DMX_2320 IKK        
AT9283 JAK / AURK ✓ ✓  ✓ dasatinib ✓  
lestaurtinib JAK / FLT3 / TrkA ✓ ✓  ✓   ✓ 
SB 743921 kinesin spindle protein  x x  ✓    
Docetaxel microtubule ✓ ✓  ✓   ✓ 
Epothilone A microtubule        
Epothilone B microtubule ✓ ✓ ✓ ✓ IR ✓ ✓ 
Nocodazole microtubule ✓ ✓    ✓  
Paclitaxel microtubule ✓ ✓   Bazedoxifene  ✓ 
salinomycin microtubule ✓ ✓  ✓  ✓  
Vinblastine microtubule ✓ ✓   carboplatin  ✓ 
vinorelbine microtubule ✓   ✓ cyclophosphamide / bevacizumab/ temsirolimus 
 ✓ 
CCT271850 Mps1 x ✓      
AZD8055 mTOR ✓ ✓  ✓   ✓ 
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Compound Class MB Brain BBB clinical trials combination MYC CancerRxGene 
INK mTOR        
Torin 1 mTOR ✓ x   SAG   
Torin 2 mTOR ✓ ✓     ✓ 
MLN-4924 NAE x ✓  ✓ IR   
Triptolide NF-κB ✓       
PF-03758309 PAK ✓ ✓ ✓   ✓  
BMN-673 PARP x ✓  ✓ Irinotecan/temozolomide/IR  ✓ 
GSK-2334470A PDK        
PIK-75 PI3K / DNA-PK ✓ ✓    ✓  
BEZ-235 PI3K / mTOR ✓ ✓   cisplatin ✓ ✓ 
PF-04691502 PI3K / mTOR ✓ x   PF-05212384   
BI-2536 PLK ✓ ✓  ✓ IR ✓ ✓ 
BI-6727 PLK ✓ ✓  initial testing vincristine ✓  
GSK461364 PLK ✓ ✓    ✓  
Triapine RR x x  ✓ IR / cisplatin/doxorubicin   
KX2-391 Src ✓   ✓    
camptothecin Topoisomerase ✓ ✓     ✓ 
Daunorubicin Topoisomerase     idarubicin   
etoposide Topoisomerase ✓ ✓  ✓ IR  ✓ 
Idarubicin Topoisomerase ✓   ✓    
Irinotecan Topoisomerase ✓   ✓ temozolomide / Bevacizumab   
Mitoxantrone Topoisomerase ✓    cyclophosphamide  ✓ 
Pirarubicin Topoisomerase ✓ ✓   cyclophosphamide / 5'Fluoracil   
SN-38 Topoisomerase ✓ ✓ ✓   ✓ ✓ 
Topotecan Topoisomerase ✓ ✓  ✓ temozolomide / cyclophosphamide  ✓ 
Doxorubicin topoisomerase / DNA damaging agents ✓ ✓ 
  cytoxan / adriamycin / vincristine / 
MS-275 
 ✓ 
sunitinib VEGFR / PDGFR ✓    FTase inhibitors  ✓ 
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Compound Class MB Brain BBB clinical trials combination MYC CancerRxGene 
Epirubicin topoisomerase / DNA damaging agents ✓ 
     ✓ 
MK-1775 Wee1 ✓ ✓ ✓  Cisplatin / irinotecan / temozolomide ✓ ✓ 
 
Table 5.4. Information used to select class-representative hits.A thorough research on published data of all 82 compounds having a MYC-dependent effect was 
performed in order to select a compound to represent each targeting molecular mechanism. The table summarises the information looked for each compound: evidence 
of its use in medulloblastoma (MB) or other brain tumours (Brain); evidence of its ability to cross the brain blood barrier (BBB); its use in clinical trials (clinical trials) or 
if it has been tested in combination with other agents (combinational strategies); potential mechanistic links with MYC oncogene (MYC), and sensitivity of MB cell lines 
published on the CancerRxGene (cancerRxGene) website. Data availability is denoted by ✓. Compounds selected are highlighted in yellow.  IR, ionising radiation. C.D, 
chemotherapeutic drugs.  
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5.3.2 Determination of drug candidates for further validation 
5.3.2.1 Integration of RNAseq and HTCS data sets 
Through the analysis of MYC-dependent hits identified from the HTCS, a final list of 21 drugs, 
representative of each cellular mechanism, was created. To further reduce the list to specific 
candidates to validate genetically and phenotypically in our cell lines, integration of the 
results with further available in-house data sets was performed to decide which inhibitors 
would be taken forward for further validation.  
From previous studies, the group had parallel RNAseq data available for all isogenic cell lines 
with MYC-modulated by shRNA, and primary MB tumour expression data from samples of 
known subgroups and known MYC status. Dr. Janet Lindsey (PBTG) performed the RNAseq 
analysis and compared the expression data from MYC isogenic cell lines to the expression 
data from primary tumours, using Gene Set Enrichment Analysis (GSEA) and ingenuity 
pathway analysis (IPA) to identify which gene sets overlapped (shared between cell lines and 
primary data; i.e. were upregulated in human Group 3 MYC amplified cells vs human Group 3 
non-MYC amplified). 
In brief, GSEA (http://software.broadinstitute.org/gsea/index.jsp) enables to distinguish 
statistically significant differences between predetermined gene sets of two experimental 
conditions. The leading-edge subset can be interpreted as the core group of genes that 
accounts for the gene sets’ enrichment signal. For many gene sets the leading-edge genes 
overlap, therefore large changes in a relatively small number of genes give rise to most of the 
results, therefore allowing us to link changes in expression to specific regulators. In this study, 
this would allow the identification of those genes differentially expressed upon MYC 
knockdown.  
RNAseq data collected on a cohort of 250 MB patients was used to perform the GSEA analysis. 
The patient cohort consisted of 83 females and 164 males, 29 of which had tumours which 
were MBWNT, 54 MBSHH, 40 MBGroup3 and 105 MBGroup4. MBGroup3 tumours from 7 male and 2 
female patients showed evidence of MYC amplification. GSEA analysis against the Hallmark 
gene set database identified 8 gene sets that were positively enriched (FDR of <25%, 5 of 
which had a NOM (nominal) p value of <1%) in MBGroup3 versus other MB subgroups (cohort 
of 250 primary MBs with no MYC-amplified status) and 24 gene sets that were negatively 
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enriched (FDR of <25%; 10 p<0.01). Comparing MYC knockdown in the cell lines to MYC 
expressing controls this analysis identified 16 gene sets that were positively enriched (11 
p<0.01) and 15 gene sets that were negatively enriched (8 p<0.01)(analysis performed by Dr. 
Janet Lindsey; data provided by Dr. Shanel Swartz).  
Genes categorised as MYC regulated in published datasets (where MYC expression is 
regulated or altered) were used to generate a list of ‘MYC target’ genes 
(http://software.broadinstitute.org/gsea/msigdb/genesets.jsp?collection=H#). GSEA results 
showed the expected downregulation of this subgroup of genes. In contrast, the majority of 
MYC target genes were upregulated in MBGroup3 primary samples.  
Some examples of differential enrichment between gene sets, negatively enriched 
(downregulated) following MYC silencing and positively enriched (upregulated) in MBGroup3 
primary samples, were those involved in G2-M checkpoints (important for DNA replication 
and cell proliferation), E2F targets (involved in the progression of the cells cycle and DNA 
replication) and MTORC1 signalling (promoting cell growth and survival)(Figure 5.10).  
On the other hand, MYC knockdown caused the upregulation in genes with a role in IL6-JAK-
STAT3 signalling, hypoxia and epithelial to mesenchymal transition, where these gene sets 
were downregulated in MBGroup3 primary samples and upregulated in the cell lines following 
MYC silencing (detail of results found is explained in Dr. Shanel Swartz PhD thesis).  
 
Figure 5.10. Selected hallmark GSEA enrichment plots of genetic pathways associated with MYC 
expression. GSEA enrichment plots of MYC, G2-M checkpoint and DNA repair pathways positively 
or negatively enriched either in isogenic cell lines with MYC knockdown or in MBGroup3 primary 
tumour gene sets. Data kindly provided by Dr. Janet Lindsey, PBTG, Unpublished. 
172 
 
Leading Edge Analysis (LEA) reveals core genes within the gene set that account for the gene 
set's enrichment signal, as well as genes that are overlapped among gene sets. The analysis 
focused on those genes shared between primary data and the MYC-regulable lines. LEA 
highlighted key genes whose expression drives the transcriptional changes seen, therefore 
indicating a critical role in the downstream effect of MYC.  
Core genes highlighted in each differentially enriched gene set, between MYC-amplified 
MBGroup3 primary samples and MYC-silenced with shRNA, were then overlapped with the 
classes of the 82 compounds identified to have a MYC-dependent effect. The main 
overlapping genes between data sets were AURKA, AURKB, CDK4, PLK1, PLK4, CHK1, BIRC5, 
EZH2 and ODC1 (PBTG, unpublished)(Figure 5.12). 
In addition, ingenuity pathway analysis (IPA), a web-based computational software that 
analyses high throughput sequencing data to identify canonical pathways relevant to the gene 
set,  was used to infer upstream regulators of the expression changes identified 
(www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis).  
GSEA gives a good indication of the downstream effects, however many drugs target 
upstream of MYC. On the other hand, IPA infers the possible upstream transcriptional 
regulators which can explain the observed gene expression changes. IPA was performed to 
identify new targets/candidate biomarkers of biological processes related to MYC within the 
context of Group 3 medulloblastoma. For the analysis, upstream regulators that had MYC in 
their network were selected. Top upstream regulators were MYC, β-estradiol, CST5, BRD4 and 
TP53 (Figure 5.11). The top networks associated with MYC expression were biological 
networks associated with cell cycle, metabolism, nervous system development and function, 
and processes related to cell replication (analysis performed by Dr. Janet Lindsey).  
The integration of upstream regulators of the biological networks identified, with the class of 
compounds from the screen deemed as effective across the MYC-regulable cell lines, resulted 
in MYC, EGFR, BRD4, DNMT3B and mTOR as the set of upstream gene regulators targetable 




Figure 5.11. Top upstream regulators from ingenuity pathway analysis. IPA analysis of expression 
changes following MYC knockdown in our 3 cell lines of interest showed several upstream regulators 
which overlapped with primary data (MBGroup3 MYC amplified tumours compared to non-amplified 
MB).Table A) summarises the top 5 significant overlapping upstream regulators identified with IPA, 
with their p-value and predicted activation, whereas table B) shows the top 5 associated network 













 Figure 5.12. Integration of transcriptomic and high-throughput compound screen data sets. Flow 
diagram summarising the integrative approach of combining the transcriptomic (RNAseq) and 
compound screen (HTCS) data sets. 
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5.3.2.2 Medulloblastoma whole-genome CRISPR screen 
The group also had available data from a whole-genome CRISPR screen done by Dr. Matthew 
Selby (PBTG, Newcastle) on a panel of MB cell lines, consisting of MBGroup3 (D425, D283 and 
HDMB03) and non-MBGroup3 (DAOY and G401) cell lines. CRISPR was performed to identify 
genetic dependencies associated with MYC, and common dependencies specific to MBGroup3 
(Selby et al., 2017).  
In brief, the GeCKO screen (Shalem et al., 2014) consisted on infecting target cells with one 
sgRNA per cell, followed by puromycin selection and cells grown for 28 days, with genomic 
extractions at both 14 and 28 days (Figure 5.13). CRISPR screen causes gene knock outs (KO) 
rather than knockdowns, which completely removes gene expression. Gene KO was assessed 
by sequencing the sgRNA to see how the relative guide abundance alters compared to non-
targeting controls. The output of CRISPR screening is the relative guide abundance counted 
by high-throughput sequencing. From these counts, the effect that a particular guide has on 
the cell can be inferred. If the sgRNA abundance increases compared to the non-targeting 
control, this implies that loss of the corresponding gene promotes growth, whereas if the 
sgRNA count decreases or disappears this infers the targeted gene is required for normal cell 
maintenance.  
All CRISPR data must be compared to a baseline; the level of each sgRNA, following selection, 
at a point at which there has been insufficient time for a phenotypic effect. Baseline data was 
compared to day 14 and day 28. No-template controls (NTC) were present in the library as a 
control for normal growth and used to assess whether a particular sgRNA is more or less 
abundant than would be expected (whole-genome CRISPR screen and data analysis is 
described in Dr. Mathew Selby’s PhD Thesis). 
The GeCKO screen analysis was focused on MBGroup3 vs non-MBGroup3 cell lines, to identify 
MBGroup3 specific genes, pathways and biological systems that are functionally important to 
MBGroup3 (genes positively or negatively enriched when comparing MBGroup3 to a non-MYC 




Figure 5.13. MBGroup3 whole-genome CRISPR screen analysis overview.Schematic representation 
of the CRISPR screen layout. Cell lines used, MBGroup3 (Test) and other (control), separated the data 
into two experimental arms. Analysis performed following the counting of data were (i-ii) the 
comparison of relative guide abundance to identify genes and pathways that differ between the 
baseline and day 14 and day 28 (MBGroup3 and non- MBGroup3 separately); and (iii) the comparison of 
relative guide abundance between MBGroup3 and control counts on day 14 and day 28 to identify 
MBGroup3-dependent genes/pathways.) Image kindly provided by Dr. Mathew Selby (PBTG) 
 
 
MAGeCK analysis (Li et al., 2014a) was used to perform pairwise tests to identify MBGroup3-
dependent genes at days 14 and 28, by comparing positive and negative gene enrichment in 
MBGroup3 lines vs the other (non-MBGroup3). Dr. Selby performed several comparisons, MBGroup3 
vs. baseline, other vs. baseline and MBGroup3 vs. other (detail of the method can be found in 
Dr. Selby’s PhD Thesis) 
Analysis of results showed that at day 14, 1725 genes were enriched between MBGroup3 and 
the baseline (p≤0.01), 1115 between Other and the baseline (p≤0.01) and 2812 between 
MBGroup3 and the other cell lines (p≤0.01)(Figure 5.14, A). Of the genes altered, those 
highlighted in grey represent MBGroup3-dependent changes. At day 28, 1014 genes were 
enriched between MBGroup3 and the baseline (p≤0.05), 1791 between other and the baseline 
(p≤0.05), and 1614 between MBGroup3 and the other cell lines (p≤0.01). Of the genes that are 
altered those highlighted in grey represent MBGroup3-dependent changes (Figure 5.14, B)(data 




Figure 5.14. Summary of significant MBGroup3-dependent genes identified in the CRISPR 
screen.Venn diagram showing the overlap of significant genes between MBGroup3 vs. baseline, 
control vs. baseline, and MBGroup3 vs. control, at day 14 (A) and day 28 (B). Genes highlighted in grey 
are MBGroup3-dependent changes. Image and data kindly provided by Dr. Mathew Selby (PBTG) 
 
 
Dr. Selby used a simple hallmark pathway library to illustrate the form of pathway results and 
outline some broad themes observed in the data. At day 14 and 28 the gene sets MYC targets, 
DNA repair, G2-M checkpoint, E2F targets and MTORC signalling showed a reduction in guide 
abundance when compared to non-MBGroup3 cells. Protein secretion was found to be 
significantly downregulated in the MBGroup3 cell lines in a MBGroup3-dependent manner. 
Glycolysis, TGF-β signalling, IL2-STAT5 signalling and KRAS signalling were all enriched in the 
non- MBGroup3 cell lines when compared to the baseline (Figure 5.15).  In the hallmark analysis, 
the MBGroup3-dependent targets were only those that appeared significantly different in both 
arms of the screen with approximately 50% (16/35) of those pathways being identified as 




Figure 5.15. Summary of significant gene sets identified in MBGroup3 or in non-MBGroup3 of the 
CRISPR screen.Scatterplots summarising significant gene sets identified in the MB whole-genome 
CRISPR screen. A) Gene sets that are significant (p<0.05) in both MBGroup3 and control. (B) Gene sets 
that are significant (p<0.05) in only the control. (C) Gene sets that are significant (p<0.05) in only 
the MBGroup3 arm. Upregulated (blue): gene collections where knock outs cause an increase in 
relative guide abundance. Downregulated (orange): gene collections where knock outs cause a 
decrease in relative guide abundance. Pathways highlighted in bold are significant in MBGroup3 vs. 
control (MBGroup3-dependent functionally). Data, analysis and image, done and kindly provided by 





5.3.2.3 Validation of results with whole-genome CRISPR screen 
Targetable genes and signalling pathways identified through the integration of the RNAseq 
and HTCS data sets were cross-referenced with the MB CRISPR screen data to further validate 
the integrative approach taken (analysis performed with Dr. Lindsey and Dr. Selby’s data).  
MBGroup3-dependent genes identified by Dr. Selby in the CRISPR screen (genes positively or 
negatively enriched when comparing MBGroup3 to non-MYC amplified control set of cells), 
showed significant overlap with those genes identified through the integration of expression 
and compound data which showed to vary depending on MYC-expression levels.  
The same gene sets found to be negatively enriched in the CRISPR screen, mainly MYC targets, 
DNA repair, G2-M checkpoint, E2F targets and MTORC signalling, were the same pathways 
identified through the GSEA analysis of expression data. The same overlap was seen for the 
IL2-STAT5 signalling pathway, which was identified in both data sets to be positively enriched 
and upregulated according to MYC-expression. A commonality found in regards of upstream 
regulators were genes like BRD4, which is widely known to play a pivotal role on MYC 
expression. Overall, the set of genes from these gene sets identified significantly overlapped 
with the main targetable molecules predicted to be effective in MBGroup3, through the 
integration of RNAseq and HTCS data. The significant overlap in the data provides confidence 
in the potential relationship these gene have with MYC expression and emphasises the 
potential targetable molecules identified to be therapeutically relevant in this subgroup of 
tumours.   
Genes from the overlapping gene sets identified were further scrutinised by cross-referencing 
the results with the HTCS data. MBGroup3-dependent genes identified from the gene sets 
positively and negatively altered in the CRISPR screen at day 14 and 28, were cross-referenced 
with the class of compounds identified to have a MYC-dependent effect in the high-
throughput screen. The process highlighted EGFR, DNMT and mTOR as common upstream 
regulators of MYC in MBGroup3 cell lines, and PLK1, CHK1, AURKA/B and BIRC5 were the top 





Validation of the results from the integrative approach of combining RNAseq data with data 
from the high-throughput compound screen, with results from the whole-genome CRISPR 
screen, most strongly supported 6 molecular targets as potentially relevant in MBGroup3 – PLK, 
CHK, AURK, mTOR, CDK, and BIRC5 (common candidate MYC-dependent targets)(Figure 5.16). 
 
Figure 5.16. Validation of MYC-dependent results.Venn diagram summarising the 6 molecular 
targets identified through the integration of the RNAseq and HTCS data sets, that overlapped with 
the MBGroup3-dependent hits from the whole-genome MB CRISPR screen. HTCS=high-throughput 
compound screen; Transcriptomic=RNAseq; CRISPR=whole-genome CRISPR screen.  
 
 
5.3.2.4 Revision of potential molecular targets in MBGroup3 
Values of the surviving fractions from the list of 82 compounds identified to have a MYC-
dependent effect on MBGroup3 (Table 5.4) were revisited, to check the consistency of the 
findings from our integrative approach. The number of significant differences between 
treatment arms (MYC expressing and MYC silenced) of MYC2 constructs of each isogenic cell 
line was calculated to determine the ‘hit’ consistency of the inhibitors targeting the molecules 
identified by the integrative approach. All compounds targeting AURK, CDK, CHK and PLK 
showed a consistent MYC-dependent effect across cell lines, CHK and PLK inhibitors being the 
ones having greater growth-inhibitory effect on MYC-overexpressing cell lines compared to 
those with MYC knockdown. The total number of drug concentrations showing significant 
differences in the surviving fractions of D425, D283 and HDMB03 MYC2 expressing high-levels 




Compound Target Class D425 M2 D283 M2 HDMB03 M2 Total 
AMG pan-AURK (A/B/C) AURK 2 2 3 7 
AT9283 JAK2/3, AURKA/B AURK/ JAK 1 3 2 6 
Barasertib AURKB AURK 1 3 2 6 
MLN8237 AURKA AURK 1 2 2 5 
PF-03814735 AURKA/B AURK 4 2 3 9 
SNS-314 AURKA/B/C AURK 1 2 3 6 
VX-680 AURKA AURK 2 2 2 6 
AT7519 CDK1/2/4/6 CDK 2 2 2 6 
BMS-265246 CDK1/2 CDK 3 4 5 12 
Dinaciclib CDK2/5/1/9 CDK 5 6 5 16 
Flavopiridol CDK1/2/4/6/9 CDK 3 2 3 8 
JNJ-7706621 CDK1/2, AURKA/B CDK/AURK 4 1 1 6 
LY2835219 CDK4/6 CDK 1 2 1 4 
Milciclib CDK2 CDK 3 3 2 8 
P276-00 CDK1/4/9 CDK 2 2 2 6 
Roscovitine CDK1/2/5 CDK 1 1 1 3 
SNS-032 CDK2/7/9 CDK 1 3 4 8 
AZD7762 CHK1/2 CHK 4 4 5 13 
LY2603618 CHK1 CHK 2 2 2 6 
PF-00477736 CHK CHK 2 3 4 9 
SAR-20106 CHK1 CHK 1 2 3 6 
BI-2536 PLK1 PLK 7 5 6 18 
BI-6727 PLK1 PLK 3 1 2 6 
GSK461364 PLK1 PLK 2 2 2 6 
 
Table 5.5. Consistency of MYC-dependent effect of AURK, CDK, PLK and CHK inhibitors in MYC2 
MBGroup3 cell lines.Summary table of the number of drug concentrations showing significant 
differences between D425, D283 and HDMB03 MYC2 expressing high-levels of MYC versus MYC 
knockdown for each compound. The table shows the compounds’ main target and the class it 
belongs. The total number of significant drug concentrations between treatment arms (-/+dox) at a 
given concentration for each compound is summed for each cell line (D425 M2, D283 M2 and 
HDMB03 M2). The total number of significantly different concentrations between MYC2 cells 
expressing high-levels of MYC and with MYC-knockdown across cell lines is summed in the column 
total. Significant differences between HTCS treatment arms were calculated using the mean of 
triplicate data of surviving fractions (student’s t-test (p≤0.05)). 
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Plotting of the surviving fractions of cells expressing high-levels of MYC and with MYC 
knockdown of the class-representative hits, revealed the MYC-dependent effect and showed 
the expected behaviour of the compounds. Some examples can be seen in Figure 5.17.  
 
Figure 5.17. Example of growth-inhibitory curves from surviving fractions of D425, D283 and 
HDMB03 MYC2 cells.Dose-response curves of surviving fractions of D425, D283 and HDMB03 MYC2 
cells after drug exposure to A)AZD7762 (CHK1 inhibitor), B)BI2536 (PLK1 inhibitor), C)MLN8237 
(AURKA inhibitor) and D)Milciclib (CDK2 inhibitor).The graphs show the growth inhibitory effect of 
the inhibitors on D425, D283 and HDMB03 MYC2 overexpressing MYC (blue; -dox [MYC ON]) and 
with MYC silenced (red; +dox [MYC OFF]). Triplicate data of surviving fractions at each concentration 
from the screen was used to generate dose-inhibitory growth curves that fit a non-linear regression 







5.3.2.5 Candidate drug hit selection 
Integration of expression data with results from the HTCS allowed the identification of several 
targets, such as PLK, CHK, AURK, MTORC and CDK, selectively effective in MBGroup3. Genes 
identified overlapped significantly with the main MBGroup3-dependent hits from the whole-
genome CRISPR screen, which informed the decision to take compounds targeting these 
specific proteins forward for further validation.   
The main goal of this project was to identify MYC-dependent signalling pathways to inform 
the design of new effective therapeutic strategies to selectively treat high-risk MBGroup3 
patients. Before the start of a clinical trial on a drug, extensive preclinical studies are needed 
to yield preliminary efficacy, toxicity, pharmacokinetic and safety information. These involve 
in vitro and in vivo experiments.  Wide ranges of drug doses are tested in cell culture settings 
and using animal models, alongside studies of drug-target interactions and synergy studies.  
To prioritise the best suitable candidates for progression to in vivo testing, and eventually 
taking the discoveries to clinical trial, the compounds representative of the drug classes PLK 
(BI2536 inhibitor), CHK (AZD7762 inhibitor), AURK (MLN8237 inhibitor) and CDK (Milciclib 
inhibitor) were chosen to further assess their MYC-dependency in vitro. Considering that the 
targeting of the mTOR signalling pathway with inhibitors had already been studied (Chapter 
4.3), it was decided to focus further validation studies on the other molecular targets 
identified. The objective with this was to recapitulate the findings from the HTCS (MYC-
dependency of compounds) in an alternative setting, to minimise false positives and further 
prove the validity of our results. 
Through the compilation of evidence for the 82 candidate drugs, we realised that some 
compounds exhibiting a MYC-dependent effect on our cell lines, like the Wee1 inhibitor 
MK1775, had already been tested as means to target MYC in MYC-driven cancers (Restelli et 
al., 2018). Another compound exhibiting preferential sensitivity for MYC-overexpressing 
MBGroup3 in the screen, the topoisomerase inhibitor SN-38, has been shown to synergise with 
the effect of CHK1 inhibitors (Xu et al., 2011), sensitising cells to chemotherapeutic agents 
and thus promoting apoptosis (McNeely et al., 2010, Zabludoff et al., 2008). Considering the 
combinatorial therapeutic potential of the drugs stated, we also considered them to further 
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assess their effects on a panel of MB cell lines (Figure 5.17, A and B), performed in the next 
chapter.  
Since future work required the assessment of the MYC-dependent effect of the prime 
candidate inhibitors identified from the HTCS data analysis, a control drug (the BIRC5 inhibitor 
YM155) with equal effect on both arms of the HTCS experiment was also chosen (Figure 5.18, 
C). In addition, integrated analysis identified BIRC5 as a promising targetable molecule in 
MYC-driven Group 3 MB, which supports its further testing in a panel of MYC amplified/non-
amplified MB cell lines (investigated in Chapter 6).  
 
 
Figure 5.18. Example of growth-inhibitory curves from surviving fractions of D425, D283 and 
HDMB03 MYC2 cells. Dose-response curves of surviving fractions of D425, D283 and HDMB03 MYC2 
cells after drug exposure to A)MK1775 (WEE1  inhibitor), B)SN38 (topoisomerase I inhibitor) and C) 
YM155 (BIRC5 inhibitor).The graphs show the growth inhibitory effect of the inhibitors on D425, 
D283 and HDMB03 MYC2 overexpressing MYC (blue; -dox [MYC ON]) and with MYC silenced (red; 
+dox [MYC OFF]). Triplicate data of surviving fractions at each concentration from the screen was 
used to generate dose-inhibitory growth curves that fit a non-linear regression model. Curves are 






Major advances in cancer therapeutics have been achieved in the last 50 years, which has led 
to increased survival for cancer patients. Despite increased survival, most standard therapies 
still come along with severe adverse effects, majorly impairing the quality of life of survivors.  
The uniqueness of each type of cancer harbours the key for precision oncology. Tumours are 
dependent on specific genetic events that allow the acquirement of the required malignant 
biological capabilities to promote tumour progression. The existence of this burden has been 
the focus of personalised medicine to identify drugs capable to exploit these vulnerabilities 
as a therapeutic approach to treat the disease (Witkiewicz et al., 2016). 
Identification of new anticancer drugs has improved drastically over the past decades. The 
availability of laboratory robots and automated machinery in combination with advances in 
bioinformatics platforms, has allowed the routinely use of high-throughput screenings on 
well-established biological models of interest to assay hundreds of potential compounds in a 
time- and cost-efficient manner that could be exploited in the clinic (Hajare et al., 2013). 
MYC overexpression is a hallmark of MBGroup3 tumours, and a large body of evidence indicates 
that MBGroup3 tumour cells remain dependent on high levels of MYC expression to maintain 
their malignant phenotype. Several research strategies have been focusing on exploiting this 
MYC dependency for targeted therapeutic approaches (Pei et al., 2012, Weinstein and Joe, 
2008). In this regard, an unbiased high-throughput drug screen on the newly established MYC-
regulable cell models brings the unique opportunity to exploit this particular genetic 
vulnerability with the objective to better understand the role of MYC within MBGroup3 to 
develop novel therapeutic strategies.  
HTCS performed on D425, D283 and HDMB03 isogenic models enabled the interrogation of 
489 compounds in a MYC-dependent manner to identify drug sensitivity effects associated 
with MYC overexpression. Our screen identified 137 small molecule inhibitors that had 
greater growth inhibitory effect on MYC overexpressing cell lines when compared to their 
MYC-knockdown counterparts. From these 137, 82 compounds were found to be consistently 
selectively inhibiting the growth of MYC-overexpressing cell lines (consistent effect across the 
three cell lines tested). The fact that only 16.7% (82/489) of the compounds were classified 
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as MYC-dependent candidate hits demonstrates the specific sensitivity of MBGroup3 cells to the 
genes targeted.  
Other drugs causing a significant growth inhibitory effect on MYC-overexpressing cell lines 
were outliers when compared to the overall of compounds inhibiting that particular target. 
An example was the farnesyl transferase inhibitor and the CNDAC inhibitor, which only one 
inhibitor targeting each molecular feature was screened (Table 5.1). Bigger number of 
compounds with the same mechanism of action should be tested to clarify and validate the 
MYC-dependent results seen.  
Compounds identified as candidate hits showed a variety of associated mechanisms of action, 
with the vast majority inhibiting effectors of biological processes required for cell growth 
(cyclin-dependent kinases, Aurora kinases, checkpoint kinases, polo-like kinases, microtubule 
formation…etc.). Compounds identified, with their main molecular target/mechanism of 
action, is summarised in Table 5.4. MYC-addicted cell lines are characterised by high-
proliferative rates, which could explain the profound sensitivity displayed to compounds 
blocking cells ability to maintain proliferation and survival. Compounds interfering directly 
with cell proliferation, like aurora kinases or cyclin dependent kinases, were found to be less 
effective on cells with MYC silenced by shRNA, a difference in drug sensitivity that could very 
likely be a direct consequence of MYC deficiency, indicating a possible new combinational 
therapeutic avenue to target MYC-dependent tumours. 
Our results coincide with previous results from drug screens performed on MBGroup3 models. 
Pei et al. evaluated the viability of isolated cells from a mouse model of MBGroup3 which 
overexpresses MYC following their exposure to 3,642 compounds. 142 compounds were 
found to inhibit cell viability by at least 2-fold, relative to control (DMSO), and represented 
diverse drug classes, including inhibitors of histone deacetylases (HDAC), PI3K/mTOR and DNA 
topoisomerases (Pei et al., 2016). Moreover, the inhibitor BEZ-235 (dual PI3K/mTOR inhibitor) 
was previously identified by the same group to significantly inhibit viability of their cell models 
(Pei et al., 2012). Alternatively, a high-throughput screen performed by Zhang et al. also 




Another high-throughput drug screening approach performed by Endersby et al. identified 
checkpoint kinases 1 and 2 as a promising target in Group 3 medulloblastoma. Prexasertib, a 
dual CHK1/2 inhibitor show potency against multiple MB lines in addition to enhanced 
radiation-induced cytotoxicity (Endersby et al., 2018). 
In summary, our results are in line with current research and results from high-throughput 
compound screens performed on Group 3 medulloblastoma models. The same MYC-driven 
cellular dependencies are being identified by the research community, contributing to 
deciphering the cellular mechanisms that cooperate with MYC in MBGroup3 tumourigenesis.  
 
5.4.1 Limitations of the work presented  
It is important to describe the limitations of the results presented. It is exceptionally hard to 
see good responses to single doses of a particular inhibitor. Using the same broad range of 
concentrations for all the compounds supposes a limitation when determining differences in 
drug sensitivity. The largest compound library, library 13, contained 397 inhibitors that were 
only tested at 4 concentrations (0.5nM, 5nM, 50nM and 500nM), which could limit the ability 
to discern differences in sensitivity between compounds as a direct cause of MYC-
dependencies or unselected toxicity caused by the drug, since most inhibitors will cause cell 
toxicity when exposed at high (i.e. >50nM) concentrations. Testing a small number of 
concentrations, with spread concentration range, may thus reveal non-specific toxicities 
masking MYC-dependent effects.  
Chemical differences between compounds were not considered when selecting the time of 
exposure. Cell lines were exposed to all drugs for the same time, as a standard procedure for 
HTCS performance. It is possible that prolonged exposures to the compounds beyond the five 
days used here will elicit distinct effects on cell viability (Holme et al., 2018). 
Regardless of the diversity of small molecule inhibitors contained in the compound libraries 




5.4.2 Prospective validation studies  
Aware of the evident challenges of the experimentation performed, results from the HTCS 
coincide and further support the upstream and downstream regulators found through the 
integration of in house RNAseq and CRISPR datasets, that synergise with MYC causing 
significant growth inhibition in MB cell lines. The combination of RNAseq data on MYC-
regulable models and the whole genome CRISPR screen on D283 and DAOY MB cell lines 
predicted 6 targetable molecular agents to be effective on MBGroup3 – PLK, CHK, AURK, mTOR, 
EGFR and BIRC5. Compounds inhibiting PLK1 (75% of total PLK inhibitors), CHK (71.4% of total 
CHK inhibitors), CDK (43.5% of total CDK inhibitors) and AURK (72.7% of total AURK inhibitors) 
represented a huge number of the hits found from the HTCS, highlighting the hypersensitivity 
of MYC-overexpressing cell lines to these compounds.   
Our results are in line with current published studies showing the direct relationship between 
PLK1, CHK1 and AURK with MYC, supporting the use of inhibitors against these molecules to 
indirectly target MYC in MYC-amplified MB. Some examples of the common understanding 
that we have considered in order to choose candidate drugs to take forward to assess their 
individual MYC-dependent effect in MYC-amplified/regulable MB cell lines, alongside non-
amplified MBSHH models, are the following: 
 
5.4.2.1 Checkpoint kinase 1 
MYC’s ability to promote cellular proliferation is a direct cause of its control, as a transcription 
factor, over the expression of genes implicated in S-phase entry and progression of cells cycle, 
like cyclin dependent kinases (CDKs), cyclins and inhibitors of CDK. High levels of MYC are 
known to evoke replicative stress. Abnormally high cell replication rates cause the crosslink 
of lagging strands of DNA to arise which cells recognise as single-strand breaks, consequently 
triggering the DNA damage response (DDR) and holding the entry to mitosis until damage is 
repaired. Interference with DNA replication and suppression of replicative stress is triggered 
by the activation of the ATR/CHK1 signalling pathway (Figure 5.19). Activation of DNA damage 
repair by CHK1 ensures the efficient proliferation of cells and avoids detrimental genetic 
instability. Since CHK1 counteracts DNA damage, by pharmacologically inhibiting CHK1, cell 
replication is initiated bearing genetic abnormalities which triggers cell death mechanism and 
cells undergo apoptosis (Murga et al., 2011, Rohban and Campaner, 2015).  
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Another reason why CHK1 inhibitors are potentially a good therapeutic for MBGroup3 is that it 
has been shown that high levels of MYC makes MBGroup3 hypersensitive to the targeting of 
replicative stress responses when compared to other MB subgroups, like MBSHH. This 
increased sensitivity of MBGroup3 to CHK1 inhibition has been linked to its direct effect in 
decreasing MYC protein levels, through the decrease in GSK-3α phosphorylation. This is in line 
with the fact that phosphorylated GSK-3 phosphorylates c-MYC, promoting its degradation 
and affecting its regulated gene expression (Kruger et al., 2018). 
Plotting of surviving fractions of cells from the screen revealed the same MYC-dependent 
preferential effect after treatment with the CHK1 inhibitor AZD7762, which preferentially 
targeted the MYC overexpressing arm of the experiment. 
 
 
Figure 5.19. The DNA-damage response pathway.Summary of the DNA damage response pathways 
modulated by ATM, ATR, CHK1, CHK2 and WEE1 kinase. Chk1 is activated by phosphorylation on 
Ser317 and/or Ser345 by ATR after cellular DNA damage is detected by the ATM/ATR kinases. 
Downstream phosphorylation events result in G2-M- and S-phase cell cycle arrest. 




5.4.2.2 Aurora Kinases 
Another downregulated target highlighted by both data sets was Aurora kinases (AURK). Part 
of the reason why targeting them is a promising strategy is because of their downstream 
effect and key role in regulating cells mitotic progression (Figure 5.20). Inhibition of Aurora 
Kinases inevitably slows down proliferation of cells by blocking progression of cells growth 
cycle.  
AURK have an upstream and downstream MYC-dependent effect. Expression of AURKA and 
AURKB is directly mediated by MYC and at the same time, AURKA can bind onto MYC’s 
promoter and transcriptionally upregulate its expression, forming a positive regulation loop. 
In addition, AURK are also involved in stabilisation of MYC at the protein level. MYCN protein 
is stabilised through its binding with AURKA. Perturbation of this protein-protein interaction 
results in subsequent MYC degradation and promotion of cell death (Dauch et al., 2016, Chen 
et al., 2018b, Tang et al., 2017, den Hollander et al., 2010). 
Some AURKA inhibitors such as MLN8237 (Alisertib) and CD532 have been shown to 
destabilise MYCN by promoting the disassociation of the AURKA:MYCN complex, whereas 
some other Aurora-A inhibitors seem to not provoke the same effect (VX-680). The current 
hypothesis to why these differences are seen between inhibitors is that, the destabilising 
inhibitors actually alter the conformation of the kinase causing an active degradation of 
MYCN, ultimately preventing the formation of the complex. Whereas inhibitors that compete 
with ATP without producing a conformational change have no effect on the complex 
formation and stabilisation (Li et al., 2018, Otto et al., 2009). 
The potential of AURKA inhibitors as an indirect way to target MYC-amplified tumours has 
already been tested in MYCN-driven medulloblastoma and neuroblastoma models, which 
MLN8054 and MLN8237 inhibitors have been proven to be effective in promoting 
proteasomal degradation of MYCN and cell death in MYCN-amplified NB and MB (Dauch et 
al., 2016, Hill et al., 2015). 
Based on the above studies, pharmacological inhibition of AURKA by MLN8237 supposes a 
good therapeutic approach to test if a similar effect in downregulating c-MYC protein levels 




Figure 5.20. Major regulators of cells cycle progression. Schematic representation of main proteins 
involved in the regulation of the cell cycle. Entry into the cell cycle can be induced by the activation 
of transcriptional factors such as MYC in response to mitogenic signals, which induce the 
transcription of cyclins and cyclin-dependent kinases to promote cell cycle progression. Progression 
through the cell cycle is tightly regulated by CDKs, together with other proteins like Polo-like Kinase1 
(PLK1), Aurora Kinases (Aurora A and B). upon detection of DNA damage, cell cycle arrest is triggered 
via checkpoint kinase 2 (CHK2) in G1 phase, or in S/G2 phase via CHK1. Correct proliferation of cells 
is ensured by the tight regulation of proteins involved in cells division. Purple ovals denote positive 
regulators of cell cycle progression and blue ovals denote negative regulators of cell cycle 













5.4.2.3 Polo-like kinases 
Data integration also identified polo-like kinases (PLK) as a potential MYC-dependent 
targetable molecule potentially relevant in MBGroup3. PLKs comprise a family of protein kinases 
that play key regulatory roles in several biological processes. PLK1 is the most characterised 
PLK family member, due to its involvement in the regulation of multiple steps of the mitotic 
process.   
Upregulation of PLK1 expression has been reported in many cancers. Overexpression of PLK1 
can lead to mitotic defects promoting survival of cells bearing chromosomal mis-
arrangements and genetic damage that can cause aneuploidy, a premise for the degradation 
or inactivation of tumour suppressor genes like TP53. Loss of TP53 causes the DDR machinery 
to fail to detect DNA damage, allowing the entry to mitosis of those cells with high genetic 
instability which favour tumour transformation (Xiao et al., 2016, Kumar and Kim, 2015). 
Like AURK, apart from being downstream regulators of MYC expression signatures, it has been 
demonstrated that PLKs also affect MYC stabilisation, presenting again an upstream 
regulatory effect. A PLK1 and MYCN positive interconnected auto-regulatory loop has been 
described in MYCN-amplified neuroblastoma models, where PLK1 stabilises MYCN activating 
a feedforward circuit promoting mutual high expression. This sustained high expression leads 
to transcriptional amplification of MYC (Ren et al., 2018).  
This is done through the specific binding of PLK1 to the E3 ubiquitin-protein ligase Fbw7. Fbw7 
is a member of the SCF-like ubiquitin ligase complex, which targets MYC for proteasomal 
degradation. Phosphorylation of Fbw7 by PLK1 promotes its auto-polyubiquitination and its 
own proteasomal degradation, preventing the ubiquitination and subsequent degradation of 
MYC. Inhibition of PLK1 prevents Fbw7 degradation, causing stabilisation of MYCN that in turn 
directly promotes PLK1 transcription, constituting a positive feedback loop resulting in 
tumour proliferation (Sato et al., 2015, Xiao et al., 2016). 
To evaluate if PLK1 inhibition had the same impact on c-MYC expression in MYC-amplified 
MBGroup3 cell lines, the PLK1 inhibitor BI2536 tested on the screen was chosen to take forward 
for further validation. BI2536 is one of the most potent ATP-competitive inhibitors at low 
nanomolar concentrations, which has shown to downregulate expression of MYCN, induce 
apoptosis and enhance cells sensitivity to other cytotoxic agents (Chen et al., 2018b).  
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In summary, integrating our results with current published data, choosing PLK1, CHK1, CDK2 
and AURK as the major candidate MYC-dependent targets to validate from our screen hold 
great promise for the identification of new MYC-regulatory mechanisms that could be 




















































































temozolomide DNA alkylation 
vinorelbine anti-mitotic 




Appendix 5.1. Content of compound library 11-12.   
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Adrucil DNA/RNA Synthesis 
AEE788 HER1/2, VEGFR1/2 
Afatinib EGFR 
AG14361 PARP 
Altretamine DNA alkylation 























































camptothecin Topoisomerase I 
Canagliflozin SGLT 
Capecitabine anti-metabolite 
Carboplatin DNA alkylation 
Carmofur anti-metabolite 
CCT18159 HSP-90 












Cisplatin DNA alkylation 
Cladribine DNA alkylation 







CX-4945 casein kinase 2 
CYC116 AURK 
Cyclopamine hedgehog 
Cyclophosphamide DNA alkylation 
CyclosporinA calcineurin 
Cyt387 JAK 











Dexamethasone IL receptor 
DFMO ornithine decarboxylase 










Gene ID Function/Target 
E7080 VEGFR 
















Ezetimibe cholesterol absorption inhibitor 
Febuxostat Xanthine oxidase 
Fenretinide RAR 






































Hydroxyurea ribonucleotide reductase 
Ibrutinib Btk 
IC-87114 PI3K 
Idarubicin Topoisomerase II 




INK 128 mTOR 
Irinotecan Topoisomerase I 




ITX3 TrioN RhoGEF 
JK184 hedgehog 






















Lomustine DNA alkylation 
Lonidamine hexokinase 
LY2109761 TGF-β R 
LY2157299 TGF-β/Smad 
LY2228820 p38 MAPK 
LY2603618 CHK 
LY294002 PI3K 








MG149 TIP60 Histone Acetyltransferase 
Mifepristone Estrogen/progestogen 















































Pentostatin Adenosine Deaminase 
Perifosine AKT 










PH-797804 p38 MAPK 
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SB 203580 p38 MAPK 
SB 216763 GSK-3 















SK1 Sphingosine Kinase-1 
SKF91488 histamine N-methyltransferase 
SKI ll Sphingosine Kinase-1 
















TCSPIM Pim1/2 Kinase 
Telatinib VEGGFR2/3, C-KIT, PDGFR 














Triptolide RNA pol II 
















































Amonafide Topoisomerase II 
AT7519 CDK 










Camptothecin Topoisomerase I 
Carmofur Pyrimidine analog 
CCT271850 MPS1 
Cisplatin DNA alkylation 
Clofarabine anti-metabolite 
Cyclophosphamide DNA alkylation 
Dacarbazine DNA/RNA Synthesis 







Epirubicin Topoisomerase II 
EPZ6438 EZH2 
Etoposide Topoisomerase II 
Flavopiridol CDK 
FlavopiridolHCl CDK 
FludarabinePhosphate DNA/RNA Synthesis 
Fluorouracil DNA/RNA Synthesis 
Gatifloxacin DNA gyrase 
Gimeracil DPD 




Ifosfamide DNA alkylation 
Iniparib PARP 
Irinotecan Topoisomerase I 
Irinotecan trihydrate Topoisomerase I 






Lomustine DNA damaging agent 
LY2603618 CHK1 
LY2835219 CDK4/6 
Mercaptopurine Purine analog 
Methotrexate/Abitrexate DHFR 
Milciclib CDK2 
Mitoxantrone Topoisomerase II 
MK4827 PARP1/2 











Oxaliplatin DNA alkylation 
P276-00 CDK1/4/9 
Palbociclib CDK4/6 
Palbociclib Merck CDK4/6 
PD-407824 Wee1/CHK1 

















Satraplatin Platinum based 
SCR7 DNA Ligase IV 
SN-38 Topoisomerase I 
SNS-032 CDK2/7/9 
SU9516 CDK 
Temozolomide DNA alkylation 
TG003 Cdc2 like kinase 
Topotecan Topoisomerase I 
Torin ATM/ATR, mTOR 





Zebularine DNA Methyltransferase 
β-Lapachone Topoisomerase II 
 













VX-970 (M6620)  (Hall et al., 2014) (Kurmasheva et al., 2018) (Mittra et al., 2019); NCT02567422, NCT03896503 
VX-680 (Gustafson et al., 2014) (Markant et al., 2013) 
Barasertib (Diaz et al., 2015) (Helfrich et al., 2016) 
PF-03814735 (Hook et al., 2012) (Jani et al., 2010) 
AT9283 (Dasatinib) 
(Petersen et al., 2014) (Moreno et al., 2015) (Petersen et al., 2012) (Vitali et al., 2009) (Timeus et al., 2008) (Dong et al., 
2015); NCT01467986 
SNS-314 (Markant et al., 2013) (VanderPorten et al., 2009) (Arbitrario et al., 2009) (Castro-Gamero et al., 2018) 
MLN8237 (Alisertib) 
(Li et al., 2018) (Felgenhauer et al., 2018) (Otto et al., 2009) (Hill et al., 2015) (Dauch et al., 2016) (Levesley et al., 2018) 
(Kogiso et al., 2018) (Graff et al., 2016) (Nair and Schwartz, 2016) (Muscal et al., 2013) (Ahmad et al., 2015) 
CYC116 (Griffiths et al., 2008) (Hajduch et al., 2008) (Park et al., 2019) (Zhou et al., 2015) 
AMG-900 (Geron et al., 2015) (Ryu et al., 2018) (Paller et al., 2014) 
AT7519 (Dolman et al., 2015) (Norris et al., 2016) (Aleem and Arceci, 2015) 
JNJ-7706621 (Schwermer et al., 2015) (Emanuel et al., 2008) (Rødland et al., 2019) 
Dinaciclib (Bolin et al., 2018) (Kato et al., 2015) (Juric and Murphy, 2020) (Gorlick et al., 2012) 
Flavopiridol (Hanaford et al., 2015) (Shapiro et al., 1999) (Liu et al., 2019a)  
BMS-265246 (Deng and Mou, 2018) (Scott et al., 2016) 
LY2835219 (Raub et al., 2015) (Lang and Gershon, 2018) ; NCT04238819 
R547 (Berkofsky-Fessler et al., 2009) (DePinto et al., 2006) (Soldi et al., 2013) 
P276-00 (Joshi et al., 2007) (Manohar et al., 2011) 
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Roscovitine (Delehouzé et al., 2014) (Federico et al., 2010) (Le Tourneau et al., 2010) 
Milciclib (PHA-848125) (Hutter et al., 2017) (Molenaar et al., 2009) (Bolin et al., 2018) (Lubanska and Porter, 2017) (Aspeslagh et al., 2017) 
SNS-032 (Juric and Murphy, 2020) 
Cladribine (Morfouace et al., 2014) (Boyko and Boyko, 2018) 
Gemcitabine (Moreira et al., 2020) (Morfouace et al., 2014) 
Hydroxyurea (Levin et al., 1988) (Millard and De Braganca, 2016) 
Decitabine (Zwergel et al., 2018) (Gajjar et al., 2015) (Patties et al., 2016b); NCT02332889 
AZD7762 
(Yang et al., 2011) (Kruger et al., 2018) (Prince et al., 2016) (King et al., 2017) (Sausville et al., 2014) (Bartucci et al., 2012) 
(Gadhikar et al., 2013) (Zabludoff et al., 2008) (McNeely et al., 2010) (Xu et al., 2011) 
LY2603618 (Rabusertib) (Scagliotti et al., 2016) (Wehler et al., 2017) (King et al., 2015) (Burris, 2019) (Hong et al., 2016) (King et al., 2014) 
SAR-20106 (Sutton) (Jones et al., 2017) 
PD407824 (Benada and Macurek, 2015) (Bradford et al., 2019) 
PF-00477736  
Vorinostat (SAHA) (Spiller et al., 2006) (Hummel et al., 2013) (Yuan et al., 2017) (Patties et al., 2016a) (Ecker et al., 2015) (Leary et al., 2015) 
Trichostatin (Valdora et al., 2013) (Roussel and Stripay, 2018) (Unland et al., 2014) (Horing et al., 2013) 
PP121 (Che et al., 2014) 
Tipifarnib (Fouladi et al., 2007) (Kameda-Smith et al., 2018) (Haas-Kogan et al., 2011) 
JK184 (Mahindroo et al., 2009) 
Belinostat (Ecker et al., 2015) (Becher, 2019) (Gimsing et al., 2008) (Zhang et al., 2019)  
JNJ-26481585 (Carol et al., 2014) (Venugopal et al., 2013) (Arts et al., 2009)  
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Mocetinostat (Coni et al., 2017) (Eckschlager et al., 2017) (Amarante et al., 2018)  
17-DMAG (Ayrault et al., 2009) (Mellatyar et al., 2018) (Calabrese et al., 2003) 
SNX-5422 (Rajan et al., 2011) (Sun et al., 2018) 
Ispinesib (Venere et al., 2015) 
PF-02341066 (Crizotinib) (Solomon et al., 2014) (Junca et al., 2017) (Awad and Shaw, 2014) 
Sapacitabine (Lin et al., 2018) (Shapiro et al., 2013) 
Satraplatin (Akshintala et al., 2015) (Marcus et al., 2012) (Bautista et al., 2017b) 
Clofarabine (Patel et al., 2015) 
Lestaurtinib (Norris et al., 2011) (Iyer et al., 2010) (Minturn et al., 2011) 
SB-743921 (Bongero et al., 2015); NCT00136513 
Docetaxel (Zwerdling et al., 2006) (Girard et al., 2015); NCT00002825 
EpothiloneB (Oehler et al., 2011) (Peereboom et al., 2014) (Oehler et al., 2012) 
Paclitaxel (Tseng et al., 1999) (Hurwitz et al., 2001) (Bautista et al., 2017a) 
NPI-2358 (Heist et al., 2014) (Nicholson et al., 2006) 
Nocodazole (Antonucci et al., 2019) (Dasari et al., 2013) (Cherry et al., 2016) (Hong et al., 1999) 
salinomycin (Zhou et al., 2014) (Calzolari et al., 2014) (Dewangan et al., 2017) (Booth et al., 2014) 
Vinblastine (Jakacki et al., 2011) (Nobre et al., 2019) 
Vinorelbine (Kuttesch et al., 2009) (Vo et al., 2017) (Mascarenhas et al., 2019); NCT00180947 
CCT271850 (Tannous et al., 2013) (Slee et al., 2014) 
AZD8055 (Houghton et al., 2012) (Luchman et al., 2014) 
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Torin 1/2 (Thoreen et al., 2009) (Xie et al., 2016) (Wu et al., 2017)  
MLN-4924 (Hua et al., 2015) (Vanderdys et al., 2018) (Bhatia et al., 2016) 
Triptolide (Zhang et al., 2018a) 
PF-03758309 (Bondar et al., 2018) (Franovic et al., 2015) (Cosset et al., 2017) 
BMN-673 (Talazoparib) (Smith et al., 2015) (Shen et al., 2013) (Lesueur et al., 2018) 
PIK-75 (Wojtalla et al., 2012) (Guerreiro et al., 2008) (Cage et al., 2015) 
BEZ-235 (Shi et al., 2017) (Chaturvedi et al., 2018) (Pei et al., 2016) 
PF-04691502 (Yuan et al., 2011) (Singh et al., 2016) (Aldaregia et al., 2018) 
GSK461364 (Triscott et al., 2013) (Pajtler et al., 2017) (Pezuk et al., 2017) 
BI6727 (Abbou et al., 2016) (Harris et al., 2012) (Gorlick et al., 2014b) (Gorlick et al., 2014a) 
BI-2536 
(Markant et al., 2013) (Triscott et al., 2013) (Harris et al., 2012) (Julia Alejandra et al., 2017) (Czaplinski et al., 2016) (Liu 
et al., 2018) 
Triapine (Kunos et al., 2017) (Kunos and Ivy, 2018) (Kunos et al., 2019) 
Triptolide (Vispé et al., 2009) (Yan and Sun, 2018) (Kim et al., 2018) (Zhang et al., 2017) 
KX2-391 (Ahluwalia et al., 2010) (Puls et al., 2011) (Antonarakis et al., 2013) (Wei et al., 2019) 
Camptothecin (Stewart et al., 2005) (Li et al., 2008) (Li et al., 2009)  
Daunorubcin (Creutzig et al., 2013)  
Idarubicin (Dreyer et al., 2003b) (Pei et al., 2016)  
Etoposide (Ashley et al., 1996) (Xu et al., 2017); NCT00003573 
Idarubicin (Dreyer et al., 2003a) 
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Irinotecan (Grill et al., 2013) (Bomgaars et al., 2007) 
Mitoxantrone (Boon et al., 2003) (Bacolod et al., 2008) (Lian et al., 2019) 
Pirarubicin (Dhingra et al., 1995) (Iwadate et al., 2003) (Schor, 2009)  
SN-38 (Vassal et al., 1997) (Courapied et al., 2010) 
Topotecan (Blaney et al., 1996) (Wong and Berkenblit, 2004) (Shackleford et al., 2019) (Le Teuff et al., 2020) 
MK-1775 (AZD1775) 
(Matheson et al., 2016) (Harris et al., 2014) (Wright et al., 2017) (Sarcar et al., 2011) (Restelli et al., 2018) (Chen et al., 
2018a) (Sanai et al., 2018); NCT02095132 
Doxorubicin (Chamberlain et al., 1988) (Guerreiro et al., 2008) (Häcker et al., 2011) (Tjandra et al., 2020) 
Epirubicin (Hashimoto et al., 2018) 
Sunitinib (Yang et al., 2010) (Abouantoun et al., 2011) 
APO866 (Cagnetta et al., 2015) (Tateishi et al., 2016) (Olesen et al., 2010) 
YM155 (Sepantronium 
Bromide) 
(Voges et al., 2016) (Calderone et al., 2014) (Abdel-Aziz et al., 2012) (Haberler et al., 2006) (Brun et al., 2015) (Iwasa et 
al., 2008) 
 
Appendix 5.4. Published information used to prioritise compounds.    
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Chapter 6. Validation of MYC-dependent sensitivity to selected 
chemotherapeutics in Group 3 medulloblastoma isogenic cell lines 
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6.1 Introduction  
The integration of ‘omics’ techniques has been key for the identification of tumour-specific 
genetic changes for the design of targeted therapeutic strategies. Extensive profiling of 
childhood Medulloblastoma has led to its robust classification of four main subgroups and the 
identification of significant substructures within each group with distinct molecular features 
and clinicopathological outcomes (Schwalbe et al., 2017). 
Despite the wealth of molecular profiling data that describe MB, the availability of MBGroup3 
biomarkers with prognostic significance is still relatively poor, with MYC amplification or 
overexpression remaining the main biological signature. Even with the identification of critical 
genes like MYC, clinical-stage small-molecules which target MYC directly are still unavailable 
due to its structural properties, leaving indirect alternative strategies the main mechanistic 
approach to modulate MYC function in MYC-dependent tumours.  
To increase our understanding of MYC’s role in MBGroup3 biology, a high-throughput compound 
screen (HTCS) was performed (Chapter 5) on DOX-inducible MYC silencing MBGroup3 isogenic 
models developed in Chapter 3, to identify critical MYC-dependent pathways in tumour 
growth, which could potentially be exploited for novel therapeutic approaches to treat this 
specific MB subgroup.  
HTCS data was specifically interrogated to find MYC-dependent effects, where inhibition of 
specific proteins resulted in differential drug sensitivity between MYC-overexpressing and 
MYC-knockdown cell lines. This approach identified 82 small-molecule inhibitors to which 
MBGroup3 cell lines expressing MYC exhibited higher sensitivity (greater growth inhibition).  
False-positive results often occur with HTS technologies, necessitating validation of the 
results. For selection of drugs for further validation, the list of candidate hits was reduced by 
grouping the 82 compounds according to their main inhibitory target, and a representative of 
each class was selected. Criteria for selection were based on current published data of the 
compound, which involved information on the type of cancer used for, its involvement in 
clinical testing and its use for MB (summary table with the information used for selection can 




Integration of chemosensitivity data for the MYC-regulable isogenic D425, D283 and HDMB03 
MBGroup3 cell lines, with in-house generated MYC-dependent transcriptional profiles of the 
tumour cell lines and primary MB tumours, implicated four main targetable molecular 
features as being important in the growth of MYC expressing MBGroup3 cell lines: PLK, CHK, CDK 
and AURK (Chapter 5).  
To validate the findings from this integrative approach and to characterise the effect of PLK, 
CHK, CDK and AURK inhibition on MBGroup3 and its interaction with MYC expression, AZD7762 
(CHK1 inhibitor), BI2536 (PLK1 inhibitor), Milciclib (CDK2 inhibitor) and MLN8237 (AURKA 
inhibitor) inhibitors, as representatives of compound classes, were selected for further testing 
Given the accumulation of data pointing to the potential of using CHK1 inhibitors in the clinical 
setting to target MYC-dependent tumours, an additional CHK1/2 inhibitor, Prexasertib 
(LY2606368) was also selected for testing (NCT04023669) (Campagne et al., 2020, Maharaj et 
al., 2018, Endersby et al., 2018). The addition of a compound that was not previously tested 
in our screen, would also independently validate our findings indicating the potential efficacy 
of CHK1/2 inhibition in MBGroup3, and further potential for rapid clinical translation.  
Considering the future design of combinatorial therapeutic approaches for treatment of 
Group 3 medulloblastoma, and validate the MYC-dependent effect of other representative 
compounds of each drug class, SN-38 (topoisomerase inhibitor) and MK-1775 (WEE1 inhibitor) 
and YM155 (BIRC5 inhibitor) were considered for further evaluation (details of selection and 
information can be seen in section 5.3 of Chapter 5). 
To add relevance to our findings, to better characterise the chemosensitivity effects seen in 
the screen, and to assess the effects of the compounds on MYC expression, we aimed to 
validate the results in a varied panel of MB cell lines. The common thread observed after 
exposure of the isogenic cell lines to small molecule inhibitors (Chapter 4) was a reduced 
sensitivity to inhibitors upon MYC-silencing with shRNA. It was therefore important to study 
further the contribution of MYC over-expression to drug sensitivity. For this, other available 
non-MBGroup3 cell lines, DAOY (MBSHH) and UW228.2 (MBSHH) were used to assess whether drug 
sensitivity effects differed according to MB subgroup status and MYC-expression levels 
(Higdon et al., 2017). 
Apart from the original isogenic models, the parental D425, D283 and HDMB03 cell lines were 




The primary aim of this chapter is to (i) validate the MYC-dependent effect of the prime 
candidate inhibitors identified from the HTCS data analysis, (ii) investigate their direct effect 
on MYC expression to validate their suitability for the development of new indirect MYC-
targeting approaches to treat MYC-dependent MB tumours. 
• Validate the MYC-dependent effect of the inhibitors on a panel of MB cell lines 
• Investigate the effect of PLK1, CHK1/2, CDK2 and AURKA inhibition on MYC expression 




















6.3 Validation of MB cell lines’ sensitivity to small molecule inhibitors 
To verify the sensitivity results from the HTCS and validate the hits found, AZD7762 (CHK1 
inhibitor), BI2536 (PLK1 inhibitor), MLN8237 (AURKA inhibitor), Milciclib (CDK2 inhibitor), SN-
38 (topoisomerase inhibitor), MK-1775 (WEE1 inhibitor) and YM155 (BIRC5 inhibitor) 
inhibitors were assessed on a panel of MB cell lines (Table 6.1). The effect of the compounds 
on cell viability of all three MYC-regulable cell models (D425, D283 and HDMB03) and six 
parental MB cell lines (D425, D283, HDMB03, D458, DAOY, UW228.2) was examined by 
replicating the experimental conditions of the HTCS.  
INHIBITOR/TARGET CELL LINES 
BI2536 (PLK1) D425 
MK1775 (WEE1) D425 M2 
Milciclib (CDK2) D283 
MLN8237 (AURKA) D283 M2 
SN38 (TopoI) HDMB03 
YM155 (BIRC5) HDMB03 M2 
AZD7762 (CHK1) D458 
Prexasertib (CHK1/2) DAOY 
  UW228.2 
 
Table 6.1. Inhibitors and cell lines used in this study.Summary table of inhibitors and cell lines used 
in this study. Molecular target of the inhibitor enclosed in brackets. Isogenic cell lines are specified 
with ‘M2’. TopoI = topoisomerase I 
 
The validation approach replicated the experimental conditions of the HTCS to the best of our 
capabilities with the available technology. MB cells plated on 384 well plates were exposed to 
a single dose per well of 8 different concentrations of each inhibitor (0, 0.5, 1, 5, 10, 50, 100, 
500, 1000, 5000nM) for a period of five days (further details on the HTCS methodology can be 
found in Chapter 2). Isogenic cell lines were pre-induced with DOX 48h prior to drugging. After 
exposure to the drug, cell viability was assessed using CTG reagent.  
Luminescence readings were normalised to the luminescent signal of the negative control 
(DMSO only cells), and values used to generate dose-response curves with Prism from which 
IC50 values were calculated. 
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6.3.1 Validation of drug-sensitivity effects on isogenic cell lines  
The use of the MYC-regulable MBGoup3 models was aimed specifically to identify inhibitors with 
a MYC-dependent effect. Small molecule compounds chosen from the screen for in vitro 
validation selectively inhibited the growth of MYC-overexpressing cell lines over those with 
MYC-knockdown with shRNA, with the exception of YM155, which equally inhibited the 
growth of the cells regardless of MYC expression levels (Figure 6.1).  
 
 
Figure 6.1. Example of growth-inhibitory curves from surviving fractions of D425, D283 and 
HDMB03 MYC2 to YM155.The graphs show the growth inhibitory effect of YM155 on D425, D283 
and HDMB03 MYC2 overexpressing MYC (blue; -dox (MYC ON)) and with MYC silenced (red; +dox 
(MYC OFF)). Surviving fractions at each concentration from the screen (3 replicates) were used to 
generate dose-inhibitory growth curves that fit a non-linear regression model. Curves are presented 
as log(concentration)vs response. 
 
Cell lines overexpressing MYC exhibited higher sensitivity to the inhibitors when compared to 
cell lines with MYC knockdown. Treatment with the inhibitors identified to have a MYC-
dependent effect caused a significant (ratio paired students t-test, p<0.05) reduction of D425, 
D283 and HDMB03 (MYC2 construct) cells proliferation when compared to their counterparts 
expressing lower levels of MYC (Figure 6.2, 6.3 and 6.4). The same MYC-dependent growth 
inhibitory effect was seen across cell lines for MYC3 (Appendix 6.1, 6.2 and 6.3, for D425, D283 
and HDMB03, respectively). No differences in growth inhibition were seen for the NS construct 
of cell lines, when grown in the presence and absence of DOX (Appendix 6.4, 6.5, 6.6 for D425, 
D283 and HDMB03, respectively).  
In accordance with the results of the screen, treatment with the control drug YM155 (BIRC5 
inhibitor) caused greater growth inhibition of MBGroup3 cell lines compared to the effect of the 






Figure 6.2. Growth-inhibitory effect of ‘hit’ compounds from HTCS on D425 MYC2 cells.A) Concentration-dependent 
inhibitory dose-curves of D425 MYC2 MBGroup3 cells to treatment with BI2536 (PLK1 inhibitor), SN38 (topoisomerase I), 
Milciclib (CDK2 inhibitor), MLN8237 (AURKA inhibitor), YM155 (BIRC5 inhibitor), MK1775 (WEE1 inhibitor), AZD7762 (CHK1 
inhibitor) and Prexasertib (CHK1/2 inhibitor). D425 MYC2, cultured in the absence (-dox; MYC ON) and presence (+dox; MYC 
OFF) of DOX for MYC knockdown, were exposed to a single dose of 8 different concentrations of each inhibitor (0.5, 1, 5, 10, 
50, 100, 500, 1000, 5000nM) for a period of five days. After treatment, cell viability was measured with CellTiter-Glo and 
values obtained analysed with Prism8 to generate dose-response growth inhibition curves that fit a non-linear regression 
model. Curves are presented as log(concentration) vs response, and represent the percentage of cell viability of two 
independent experiments done in triplicate, relative to cells grown in the presence of DMSO. The growth inhibitory effect of 
the drug on D425 MYC2 overexpressing cell lines and with MYC knockdown was compared by paired student’s t-test 
(statistical significance denoted by *; *p<0.05). B) Table summarising the half maximal inhibitory concentration (IC50) 
calculated from the dose-response curves. Significant differences between cells expressing high (-dox: MYC ON) and low 









Figure 6.3. Growth-inhibitory effect of ‘hit’ compounds from HTCS on D283 MYC2 cells.A)Concentration-dependent 
inhibitory dose-curves of D283 MYC2 MBGroup3 cells to treatment with BI2536 (PLK1 inhibitor), SN38 (topoisomerase I), 
Milciclib (CDK2 inhibitor), MLN8237 (AURKA inhibitor), YM155 (BIRC5 inhibitor), MK1775 (WEE1 inhibitor), AZD7762 (CHK1 
inhibitor) and Prexasertib (CHK1/2 inhibitor). D283 MYC2, cultured in the absence (-dox; MYC ON) and presence (+dox; MYC 
OFF) of DOX for MYC knockdown, were exposed to a single dose of 8 different concentrations of each inhibitor (0.5, 1, 5, 10, 
50, 100, 500, 1000, 5000nM) for a period of five days. After treatment, cell viability was measured with CellTiter-Glo and 
values obtained analysed with Prism8 to generate dose-response growth inhibition curves that fit a non-linear regression 
model. Curves are presented as log(concentration) vs response, and represent the percentage of cell viability of two 
independent experiments done in triplicate, relative to cells grown in the presence of DMSO. The growth inhibitory effect of 
the drug on D283 MYC2 overexpressing cell lines and with MYC knockdown was compared by paired student’s t-test 
(statistical significance denoted by *; *p<0.05). B) Table summarising the half maximal inhibitory concentration (IC50) 
calculated from the dose response curves. Significant differences between cells expressing high (-dox: MYC ON) and low 









Figure 6.4. Growth-inhibitory effect of ‘hit’ compounds from HTCS on HDMB03 MYC2 cells. A)Concentration-dependent 
inhibitory dose-curves of HDMB03 MYC2 MBGroup3 cells to treatment with BI2536 (PLK1 inhibitor), SN38 (topoisomerase I), 
Milciclib (CDK2 inhibitor), MLN8237 (AURKA inhibitor), YM155 (BIRC5 inhibitor), MK1775 (WEE1 inhibitor), AZD7762 (CHK1 
inhibitor) and Prexasertib (CHK1/2 inhibitor). HDMB03 MYC2, cultured in the absence (-dox; MYC ON) and presence (+dox; 
MYC OFF) of DOX for MYC knockdown, were exposed to a single dose of 8 different concentrations of each inhibitor (0.5, 1, 
5, 10, 50, 100, 500, 1000, 5000nM) for a period of five days. After treatment, cell viability was measured with CellTiter-Glo 
and values obtained analysed with Prism8 to generate dose-response growth inhibition curves that fit a non-linear regression 
model. Curves are presented as log(concentration) vs response, and represent the percentage of cell viability of two 
independent experiments done in triplicate, relative to cells grown in the presence of DMSO. The growth inhibitory effect of 
the drug on HDMB03 MYC2 overexpressing cell lines and with MYC knockdown was compared by paired student’s t-test 
(statistical significance denoted by *; *p<0.05). B)Table summarising the half maximal inhibitory concentration (IC50) 
calculated from the dose-response curves. Significant differences between cells expressing high (-dox: MYC ON) and low 






Despite the differences in growth seen between isogenic cells expressing high and low levels 
of MYC, the IC50 calculated through the dose-response growth inhibition curves (summarised 
in Figure 6.2-B, 6.3-B and 6.4-B, for D425, D283 and HDMB03 respectively) did not always 
correlate with the effect seen on cell proliferation. For example, treatment of D425 MYC2 cells 
with BI2536 resulted in almost indistinguishable IC50 values between experimental arms. 
Following MYC knockdown, a stable population of drug-resistant cells was seen at higher 
concentrations of the inhibitors, therefore the IC50 values did not represent the true MYC-
dependent effect on cell proliferation.  
Concentrations above the IC50 had to be considered in order to fully appreciate the change 
seen in cells proliferative rate. Calculation of IC80 was found to better correlate with the 
differential MYC-dependent growth-inhibitory effect seen in the dose-response curves 
(Fallahi-Sichani et al., 2014). In fact, Milciclib (CDK2 inhibitor), despite having little growth 
inhibitory effect at lower doses compared to other inhibitors, showed the greatest consistent 
reduction in sensitivity of MYC-overexpressing cell lines when compared to those with MYC 
knockdown, averaging 70% reduction across cell lines (Table 6.2).  
 
 D425 D283 HDMB03  








BI2536 (PLK1) 0.82 17.9 0.49 50.7 0.31 68.7 45.8 
Milciclib (CDK2) 0.27 73.0 0.51 49.1 0.11 88.6 70.2 
MLN8237 (AURKA) 0.43 57.2 0.76 23.9 0.65 35 38.7 
MK1775 (WEE1) 0.60 39.9 0.45 55.1 0.35 65.3 53.4 
SN38 (TopoI) 0.85 15 0.22 77.8 0.19 80.8 57.9 
YM155 (BIRC5) 0.53 46.7 0.06 94.2 1.60 -60.2 26.9 
AZD7762 (CHK1) 0.53 47.0 0.56 44.2 0.51 49.3 46.8 
Prexasertib (CHK1/2) 0.38 61.8 0.44 55.9 0.32 67.9 61.9 
BI2536 IC80 0.62 38.2      
 
Table 6.2. Sensitivity of D425, D283 and HDMB03 MYC2 cells to treatment with inhibitors tested.A) Comparison of the IC50 
values calculated from the dose-response growth inhibition curves generated on D425, D283 and HDMB03 MYC2 cultured in 
the absence (-dox; MYC ON) and presence (+dox; MYC OFF) of DOX for MYC knockdown. The table shows the ratio between 
the IC50 calculated from cells expressing high levels of MYC, and those with MYC knockdown (+dox). Table summarises the 
percentage reduction in sensitivity in the presence of MYC. For D425 MYC2 treatment with BI2536, IC80 concentration was 
used to better represent the MYC-dependent growth inhibitory effect. B) Consistency in the reduction of cells sensitivity 
across cell lines is seen in the Average % reduction table. Data is presented as the % of the average of the ratio between IC50 





Through the comparison of the IC50 between D425, D283 and HDMB03 MYC2 expressing high 
and low levels of MYC, Prexasertib was found to have the most consistent MYC-dependent 
reduction in sensitivity (averaging 62% across cell lines)(Table 6.2). 
A significant difference in sensitivity was seen when comparing the effect of CHK1 inhibitors 
Prexasertib and AZD7762. Prexasertib reduced viability of MBGroup3 cell lines overexpressing 
MYC by around 62%, whereas after exposure to AZD7762 only an average of 47% was seen 
across D425, D283 and HDMB03. Prexasertib (LY2606368), apart from being a potent small 
molecule inhibitor of CHK1 protein kinase activity in vitro, also inhibits CHK2, with no apparent 
selectivity between CHK1 and CHK2 (Angius et al., 2020). On the other hand, while AZD7762 
also inhibits the expression of both CHK1 and CHK2 proteins, it has selectivity for CHK1 
(Matthews et al., 2013). 
The CHK enzymes convey the signals received from upstream DNA-damage sensing proteins, 
principally ATM and ATR, to downstream effectors of cell cycle arrest and DNA repair (Smith 
et al., 2010). There is substantial overlap in the activation and substrates of CHK1 and CHK2. 
CHK2 is particularly important in the response to double strand DNA breaks (DSB) signalled 
through activation of ATM, and controls the p53-dependent early phase G1-S checkpoint 
(Antoni et al., 2007, Garrett and Collins, 2011), although it can also contribute to S- and G2-M-
phase checkpoints. In contrast, CHK1 signalling is more important in response to single strand 
DNA breaks (SSB) and stalled DNA replication signalled by activation through ATR, and 
resulting in later S-phase and G2-M checkpoint arrest (Dai and Grant, 2010, Matthews et al., 
2013). 
Although both drugs target CHK1, MBGroup3 cell lines appeared to be extremely sensitive to 
Prexasertib, suggesting the importance of each of the signalling pathways associated with 








6.3.2 Validation of drug-sensitivity effects on parental cell lines  
To further examine the effect on growth of the candidate inhibitors in a MB subgroup-specific 
context, sensitivity to the inhibitors was investigated in MBGroup3 and MBSHH parental cell lines. 
DAOY and UW228.2 (both MBSHH) inherently express lower levels of MYC, compared to the 
MBGroup3 that are characterised by MYC amplification or overexpression (Figure 6.5). 
Comparison of the effect the inhibitors have across subgroups will bring a better 




Figure 6.5. MYC protein expression levels in parental MB cell lines.A)Automated western blot (Wes) 
of MYC protein levels expressed by D425, D283, HDMB03, D458, DAOY and UW228.2, belonging to 
MBGroup3 and MBSHH subgroups. B)densitometry analysis of MYC protein expression levels. MYC 





Comparison of the concentration-dependent growth-inhibitory curves revealed that the 
inhibitors tested markedly inhibited the growth of MBGroup3 cell lines at lower concentrations 
when compared to UW228.2 (MBSHH)(Figure 6.7). Similarities in drug sensitivity between 
DAOY and MBGroup3 cell lines was unexpected as DAOY belongs to MBSHH. However, it is 
dependent on MYC for its growth as demonstrated by our own and published CRISPR-CAS9 
experiments (Selby et al., 2017), so potentially drugs that have a growth-inhibitory MYC-
dependent effect would affect this cell line. In contrast, UW228.2 (MBSHH) showed a marked 
difference in sensitivity, where treatment with Prexasertib (CHK1/2), BI2536 (PLK1), Milciclib 
(CDK2) or MLN8237 (AURKA) had little to no inhibitory effect on this cell line (Figure 6.7).  
The lack of inhibitory effect on UW228.2 correlated with the IC50 values calculated from the 
growth-inhibitory curves (Table 6.3). Comparison of IC50s from all parental cell lines revealed 
UW228.2 had reduced sensitivity to most of the compounds, changing IC50 from the 
nanomolar concentration range to the micromolar one. UW228.2 was still sensitive to BIRC5 
(IC50=23.53nM), but not as sensitive as the other cell lines (averaging 1.87nM). Similar IC50 
values were seen across MBGroup3 cell lines, corresponding well with the growth-inhibitory 
effect seen after treatment (see section 6.3.1 of this Chapter). DAOY showed similar 
sensitivities to the compounds when compared to Group 3 cell lines, with the exception of 
Milciclib (CDK2 inhibitor) which it was comparatively resistant to. From all the inhibitors 
tested, Milciclib was the only compound that had a MYC-dependent subgroup specific growth-
inhibitory effect. 
 















D425 3.381 134.5 110.3 20.88 26.58 0.9729 68.79 4.032 
D283 7.695 144.7 105.2 36.95 2.67 6.117 33.72 2.11 
HDMB03 7.97 198 132.9 20.14 3.56 0.41 50.82 5.85 
D458 1.984 67.78 159.5 29.4 2.43 0.76 54.5 2.11 
DAOY 2.875 94.58 2669 54.61 2.75 1.12 91.02 6.39 
UW228.1 14.27 3045 6342 1664 331 23.53 2852 43.59 
 
Table 6.3. Drug sensitivity effect of MB parental cell lines to hit compounds from high throughput 
screen.Cell viability assays of D425, D283, HDMB03 and D458 for MBGroup3, and DAOY and UW228.2 
for MBSHH, after 3 days of a single exposure of 8 different inhibitor concentrations were used to 
generate dose-response growth inhibition curves with Prism, from which IC50 values (nM) were 
calculated to determine cells sensitivity to the compounds. IC50 values presented are from the mean 


































































































































































































Figure 6.6. Growth-inhibitory effect of ‘hit’ compounds from the screen on parental MB cell 
lines.Concentration-dependent dose-response inhibition curves of MBGroup3 and MBSHH cell lines to treatment 
with A)Prexasertib (CHK1/2 inhibitor), B) BI2536 (PLK1 inhibitor), C)MK1775 (WEE1 inhibitor), D)MLN8237 
(AURKA inhibitor), E)Milciclib (CDK2 inhibitor), F)SN38 (topoisomerase I), G)YM155 (BIRC5 inhibitor) and 
H)AZD7762 (CHK1 inhibitor). D425, D283, HDMB03, D458, DAOY and UW228.2 were exposed to a single dose 
of 8 different concentrations of each inhibitor (0.5, 1, 5, 10, 50, 100, 500, 1000, 5000nM) for a period of five 
days. After treatment, cell viability was measured with CellTiter-Glo and values obtained analysed with Prism8 
to generate dose-response growth inhibitory curves that fit a non-linear regression model. Curves are 
presented as log(concentration) vs response, and represent the percentage of cell viability of two 
independent experiments done in triplicate, relative to cells grown in the presence of DMSO. IC50 values (nM) 


































































Comparison of chemosensitivity displayed by the isogenic models to the sensitivity of their 
parental cell lines showed no statistically significant differences (p>0.05). The lack of 
significant differences in cell sensitivity between the MYC-regulable cells and their parental 
corroborates the suitability of the cell lines as valid models to study MBGroup3.   
To further validate these findings, the time of drug exposure in the assays was reduced from 
5 days to 3 days. To ensure cells sensitivity to the inhibitors did not change with time of drug 
exposure, dose-response curves to the inhibitors were determined with drug exposures of 72h 
instead of 120h. Comparable MYC-dependent effects of the inhibitors was seen at 72h 
exposures using MYC2 constructs in all cell lines. Since significant differences in cell growth 
inhibition was still seen at 72h mark, and conscious about time constraints to finalise 
experimentation, remaining validation experiments were performed using MYC2 constructs 

















6.4 Effect of pharmacological inhibition of PLK1, CHK1, CDK2 and AURKA on MYC 
expression and downstream pathway targets 
From the results, it was evident that the inhibitors tested had a greater effect on cell lines 
expressing high levels of MYC, when compared to those that had MYC silenced with shRNA. 
Following the validation of the MYC-dependent growth-inhibitory effect, we sought to 
determine the impact of the inhibitors on MYC expression and on downstream pathway 
targets to assess whether the effect was specific to MYC-expression.  
Following the rationale previously described, it was decided that in regards to the isogenic cell 
lines the remaining study would focus on the MYC2 shRNA constructs (MYC2). D425 MYC2, 
D283 MYC2 and HDMB03 MYC2, with and without pre-treatment with DOX for MYC 
knockdown, were exposed for 72h to a single dose of three different concentrations of each 
inhibitor; half the IC50 (0.5xIC50), IC50 (IC50), and twice the IC50 (2xIC50), previously calculated 
with the dose-response growth inhibition curves and summarised in Table 6.3. IC50 values from 
MYC-overexpressing cell lines were used to treat their corresponding counterpart with MYC 
knockdown.  
Protein analysis and quantification was done with Wes (automated western blot) 
(methodology explained in Chapter 2). To account for changes in protein expression as a 
consequence of treatment with the inhibitors, untreated cells (DMSO only) for each condition 
were used as a reference control.  
Following the same methodology, the MYC-dependent effect of the inhibitors was also tested 
in the panel of parental MB cell lines, consisting of 4 different MBGroup3 (D425, D283, HDMB03 
and D458) and two MBSHH (DAOY and UW228.2)(as described in section 6.3.2), to understand 








6.4.1 PLK1 inhibition  
When analysed at the protein level with Wes, BI2536 effectively reduced the total amount of 
PLK1, proving the effectiveness of the inhibitor on its main target. Downregulation of PLK1 
was seen both in MYC-overexpressing and in MYC knockdown cell lines. PLK1 inhibition further 
reduced protein levels of MYC, when silenced with shRNA (Figure 6.7).  
Treatment of isogenic cell lines with BI2536 caused a dose-dependent decrease in MYC 
protein levels across cell lines, both expressing high-levels of MYC and with MYC silenced. 
BI536 had the greatest effect in downregulating levels of MYC in D425, with a reduction of 
70% when exposed to IC50 concentration when compared to its untreated control (Figure 6.7, 
A). To a similar degree, when exposed to the IC50, MYC protein expression levels were reduced 
by 60% in D283 (Figure 6.7, B). PLK1 inhibition only reduced MYC protein levels by 50% in 
HDMB03 (Figure 6.7, C). 
Inhibition of PLK1 had an additive effect with MYC knockdown, which further reduced MYC 
protein levels. D283 was the only cell line that upon MYC knockdown PLK1 inhibition did not 
further reduce MYC protein levels between exposures of IC50 and 2xIC50.   
Analysis of downstream effectors of PLK1 showed evidence of the effectiveness of the 
inhibitor on MB cell lines. Downregulation of PLK1 was greater in MYC-overexpressing cell 
lines when compared to MYC-knockdown.  
Downregulation of MYC expression caused by PLK1 inhibition was accompanied with a 
reduction of levels of pCDC25 and MCL1. The regulatory effect of PLK1 on CDC25 is 
represented in Figure 6.8 (Kousholt et al., 2012). Downregulation of protein levels of PLK1 and 
downstream effectors of its signalling pathway proved the efficacy of BI2536 in inhibiting the 







Figure 6.7. Effect of PLK1 inhibition by BI2536 in isogenic D425, D283 and HDMB03 MB cell lines on MYC protein expression and downstream pathway targets. A) 
Automated western blot (Wes) of MYC protein levels expressed by D425, D283 and HDMB03 MYC2, cultured in the presence (dox) and absence (no dox) of doxycycline 
for MYC knockdown, after a single exposure with half the IC50 (0.5xIC50; 0.5),, IC50 (IC50; 1), and twice the IC50 (2xIC50; x2) concentration calculated from the growth-
inhibitory curves. Untreated cells (no drug; DMSO only) were used for each condition (+/-DOX) as controls. GAPDH was used as internal loading control. MYC protein 
expression was corrected to GAPDH protein expression levels and values normalised to the expression of untreated controls for each condition (no dox/dox). Graphs 
show the comparison of MYC protein levels between MYC overexpressing cell lines (blue: -dox; MYC ON) and those with MYC knockdown (red: +dox; MYC OFF). 





Figure 6.8. PLK1 involvement in the regulation of the cells cycle. Schematic representation of PLK1 
involvement in the progression of the cells cycle after recovery of DNA damage. A)cells arrest in G2-
M phase of the cells cycle in response to DNA damage. This is caused by the direct activation of 
CDK1 inhibitors (like WEE1) and degradation of CDK1 activators (like CDC25). B)completion of DNA-
damage repair, phosphorylation-dependent activation of PLK1 by AURKA and BORA in turn 
phosphorylates WEE1, targeting it for degradation and inducing cells entry to mitosis (Adapted from 
Kousholt et al, 2012). 
 
 
Concentration-dependent downregulation of MYC was seen in all 4 parental MBGroup3 cell lines 
after treatment with BI2536 (Figure 6.9). Densitometry analysis revealed that after treatment 
with their corresponding IC50 concentration, PLK1 inhibition with BI2536 reduced MYC protein 
levels by 50% in D425, D283 and HDMB03, when compared to untreated cells (no drug). 
Inhibition of PLK1 reduced MYC expression levels by 37.5% in D458. PLK1 inhibition with 
BI2536 reduced MYC protein levels by 26% after treatment with the highest concentration 
when compared to the untreated control. The opposite effect was seen in UW228.2, where 
MYC protein levels increased in a dose-dependent manner (Figure 6.9).  
BI2536 greatly reduced PLK1 protein levels in all parental cell lines except in UW228.2, were 
an increase in total PLK1 protein levels were seen. PLK1 inhibition caused a reduction of the 
phosphorylation of CDC25. BI2536 downregulated the MCL1 protein levels in all MBGroup3 cell 
lines, having no effect on DAOY and actually increasing its expression on UW228.2 (when 




Figure 6.9. Effect of PLK1 inhibition by BI2536 in parental MB cell lines on MYC protein expression 
and downstream pathway targets.Automated western blot (Wes) of MYC protein levels and 
downstream related proteins expressed by D425, D283, HDMB03, DAOY, UW228.2 and D458, after 
treatment with a single exposure with half the IC50 (0.5), IC50 (1), and twice the IC50 (2x) 
concentration of BI2536 calculated from the growth-inhibitory curves. Untreated cells (ctrl; DMSO 
only) were used as control. GAPDH was used as internal loading control. 
 
In summary, Wes protein quantification analysis of cells treated with BI2536 revealed a dose-
dependent downregulation of MYC protein expression. Results indicate that PLK1-regulated 








6.4.2 CDK2 inhibition 
Wes protein quantification analysis of cells treated with Milciclib showed a dose-dependent 
downregulation of MYC expression levels (Figure 6.10), when compared to untreated cells. 
CDK2 inhibition caused a reduction of D425 MYC protein levels by 60% when exposed to IC50 
(40% on cells with MYC knockdown). MYC expression levels of D283 and HDMB03 were only 
reduced by 25% and 32%, respectively (compared to around 40% with MYC knockdown by 
doxycycline in both cell lines). At the highest concentration, Milciclib reduced MYC levels by 
half on D425, D283 and HDMB03. 
Wes protein analysis showed downregulation of CDK2 in all three lines as a direct 
consequence of Milciclib treatment, most prominently in D425 (Figure 6.10, A). 
Downregulation of protein levels of MYC and CDK2, were seen with an increase in MCL1 











Figure 6.10. Effect of CDK2 inhibition by Milciclib in isogenic D425, D283 and HDMB03 MB cell lines on MYC protein expression and downstream pathway 
targets.Automated western blot (Wes) of MYC protein levels expressed by D425, D283 and HDMB03 MYC, cultured in the presence (dox) and absence (no dox) of 
doxycycline for MYC knockdown, after a single exposure with half the IC50 (0.5xIC50; 0.5), IC50 (IC50; 1), and twice the IC50 (2xIC50; x2) concentration calculated from the 
growth-inhibitory curves. Untreated cells (no drug; DMSO only) were used for each condition (+/-dox) as controls. GAPDH was used as internal loading control. MYC 
protein expression was corrected to GAPDH protein expression levels and values normalised to the expression of untreated controls for each condition (no dox/dox). 
Graphs show the comparison of MYC protein levels between MYC overexpressing cell lines (blue: -dox; MYC ON) and those with MYC knockdown (red: +dox; MYC OFF). 
Percentage reduction of MYC expression after treatment is shown relative to the corresponding untreated control. Values from one experiment.
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When studied in subgroup context, CDK2 inhibition with Milciclib caused a dose-dependent 
downregulation of MYC across MBGroup3 parental cell lines (relative to the expression of MYC 
of untreated cells).  Milciclib reduced by 50% MYC expression in D283 and HDMB03 after drug 
exposure. A 25% and 28% reduction in MYC protein levels was seen in D458 and D425 
respectively (Figure 6.11). 
A slight reduction of MYC protein expression was seen in MBSHH cell lines when treated with 
2xIC50. CDK2 inhibition reduced MYC protein levels by 15% in DAOY and was almost 
undetectable on UW228.2. As explained in section 6.3.2, MBSHH cell lines express more than 
10-fold difference in MYC expression compared to MBGroup3 cell lines (section 6.3.2, Figure 
6.5). Despite making MYC protein levels undetectable in UW228.2, it can not be said that 
Milcilcib had the most effective effect in downregulating MYC on the MBSHH cell lines, since 
the starting expression levels were already extremely lower to detect a clear decrease.  
Milciclib efficiently downregulated its main target, CDK2, across MB cell lines. A dose-
dependent increase in MCL1 protein levels was seen following CDK2 inhibition in MBGroup3 cell 
lines, whereas a reduction was seen on DAOY and UW228.2. This suggest that CDK2 inhibition 
has a subgroup specific effect on the expression of MYC and MCL1 proteins.  
PARP, an enzyme involved in DNA repair, was used as a measurement of apoptosis after 
treatment with Milciclib. During apoptosis, PARP is cleaved by the active caspase-3 (Chaitanya 
et al., 2010), therefore, a decrease in PARP total protein can indicate induction of the 
apoptotic pathway after treatment with the inhibitor. A dose-dependent decrease in total 
levels of PARP was seen after exposures to Milciclib across cell lines and regardless of 
subgroup (with the exception of D283, in which a dose-dependent increase in total levels of 




Figure 6.11. Effect of CDK2 inhibition by Milciclib in parental MB cell lines on MYC protein expression and 
downstream pathway targets.Automated western blot (Wes) of MYC protein levels and downstream related 
proteins expressed by D425, D283, HDMB03, DAOY, UW228.2 and D458, after treatment with a single 
exposure with half the IC50 (0.5), IC50 (1), and twice the IC50 (2x) concentration of Milciclib calculated from 
the growth-inhibitory curves. Untreated cells (ctrl; DMSO only) were used as control. GAPDH was used as 
internal loading control. 
 
In conclusion, CDK2 inhibition with Milciclib caused the subgroup-specific downregulation of 
MYC protein expression levels and revealed the increase of MCL1 in a subgroup-specific MYC-
dependent manner. Reduction of total levels of PARP suggests CDK9 inhibition triggers the 









6.4.3 AURKA inhibition 
On Wes analysis of protein expression levels, inhibition of AURKA caused a dose-dependent 
downregulation of MYC protein levels in all three lines, strongest in D283 (Figure 6.12). When 
compared to the untreated controls, MYC protein was reduced by 30% in D425 when treated 
at IC50, and a reduction of 25% was achieved in HDMB03. AURKA inhibition by MLN8237 
caused MYC protein levels to be reduced by 70% in D283 (Figure 6.12, B). MLN8237 treatment 
of cells with MYC-silenced with shRNA had no consistent effects on MYC protein levels. 
Alongside a decrease in MYC protein level, protein quantification analysis showed also a dose-
dependent reduction in AURKA protein levels together with its phosphorylated form across 
cell lines, regardless of MYC expression. A dose-dependent increase in MCL1 protein levels 
was seen in MYC-overexpressing cell lines, whereas levels of MCL1 did not vary with increased 






Figure 6.12. Effect of AURKA inhibition by MLN8237 in isogenic D425, D283 and HDMB03 MB cell lines on MYC protein expression and downstream pathway targets.A) 
Automated western blot (Wes) of MYC protein levels expressed by D425, D283 and HDMB03 MYC, cultured in the presence (dox) and absence (no dox) of doxycycline for MYC 
knockdown, after a single exposure with half the IC50 (0.5xIC50; 0.5), IC50 (IC50; 1), and twice the IC50 (2xIC50; x2) concentration calculated from the growth-inhibitory curves). 
Untreated cells (no drug; DMSO only) were used for each condition (+/-dox) as controls. GAPDH was used as internal loading control. MYC protein expression was corrected to 
GAPDH protein expression levels and values normalised to the expression of untreated controls for each condition (no dox/dox). Graphs show the comparison of MYC protein 
levels between MYC overexpressing cell lines (blue: -dox; MYC ON) and those with MYC knockdown (red: +dox; MYC OFF). Percentage reduction of MYC expression after 
treatment is shown relative to the corresponding untreated control. Values from one experiment. 
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Automated western blot results of parental MB cell lines after treatment showed a dose-
dependent decrease in MYC protein levels after inhibition of AURKA with MLN8237 across 
MBGroup3 cell lines, when compared to cells unexposed to the drug (Figure 6.13). Treatment 
with IC50 concentration caused a reduction of 18% in D283, 10% in D425, 30% in D458 and 
50% in HDMB03. Despite the modest reduction in MYC protein levels, the opposite effect was 
seen in the MBSHH cells, where an increase in MYC protein levels was seen with increased 
concentration of the inhibitor.    
As expected, MLN8237 caused a decrease in protein expression levels of its main target, 
AURKA, and its phosphorylated form. The effect was seen across cell lines, regardless of 
subgroup. MLN8237 treatment also caused an overall increase of the anti-apoptotic protein 
MCL1, changes in expression that were not MYC-dependent.  
 
Figure 6.13. Effect of AURKA inhibition by MLN8237 in parental MB cell lines on MYC protein expression 
and downstream pathway targets.Automated western blot (Wes) of MYC protein levels and downstream 
related proteins expressed by D425, D283, HDMB03, DAOY, UW228.2 and D458, after treatment with a single 
exposure with half the IC50 (0.5), IC50 (1), and twice the IC50 (2x) concentration of MLN8237 calculated from 
the growth-inhibitory curves. Untreated cells (ctrl; DMSO only) were used as control. GAPDH was used as 
internal loading control. 
 
In summary, AURKA inhibition with MLN8237 had a direct effect on MYC, causing a subgroup-
specific reduction of MYC-protein levels. Changes in AURKA, pAURKA and MCL1 protein levels 
were independent of MYC expression levels. 
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6.4.4 CHK1 inhibition 
6.4.4.1 AZD7762 
Analysis of AZD7762’s effect at the protein level revealed a dose-dependent decrease of MYC 
protein expression across cell lines (Figure 6.14). Treatment with IC50 concentration caused a 
34%, 17.8% and 18.8% reduction of MYC protein in D425, D283 and HDMB03 respectively, 
when compared to untreated controls. A slight reduction in MYC-protein was seen after 
treatment with AZD7762 in cells with MYC-silenced with shRNA, causing a reduction by 12%, 
10% and 0.8% in D425, D283 and HDMB03 respectively.   
Protein analysis of downstream effectors of the signalling pathway, revealed a dose-
dependent reduction of total CHK1 levels (Figure 6.14). No consistent effects were seen in 
levels of its phosphorylated form (pCHK1) at Ser345 across cell lines. This might be due to the 
lower amount of pCHK1 in the cell lines, making its chemiluminescent signal hard to detect 
and process with Wes, which results in more ambiguous results.   
Inhibition of CHK1 resulted in a dose-dependent increase of MCL1 protein in D425, D283 and 
HDMB03 cells overexpressing MYC. In comparison, cells with MYC knockdown presented with 
higher-levels of MCL1 protein, which slightly increased throughout treatment.  
PARP was used as a measurement of apoptosis after treatment with AZD7762. A dose-
dependent decrease in total levels of PARP was seen after exposures to AZD7762 across cell 
lines and regardless of MYC expression, which was markedly decreased in D425 in comparison 




Figure 6.14. Effect of CHK1 inhibition by AZD7762 in isogenic D425, D283 and HDMB03 MB cell lines on MYC protein expression and downstream pathway targets.A) 
Automated western blot (Wes) of MYC protein levels expressed by D425, D283 and HDMB03 MYC, cultured in the presence (dox) and absence (no dox) of doxycycline for MYC 
knockdown, after a single exposure with half the IC50 (0.5xIC50; 0.5), IC50 (IC50; 1), and twice the IC50 (2xIC50; x2) concentration calculated from the growth-inhibitory curves. 
Untreated cells (no drug; DMSO only) were used for each condition (+/-dox) as controls. GAPDH was used as internal loading control. MYC protein expression was corrected to 
GAPDH protein expression levels and values normalised to the expression of untreated controls for each condition (no dox/dox). Graphs show the comparison of MYC protein 
levels between MYC overexpressing cell lines (blue: -dox; MYC ON) and those with MYC knockdown (red: +dox; MYC OFF). Percentage reduction of MYC expression after 
treatment is shown relative to the corresponding untreated control. Values from one experiment.
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A dose-dependent reduction of MYC protein levels was seen across parental MBGroup3 lines 
after treatment with AZD7762 relative to untreated controls (Figure 6.15). Densitometry 
analysis of MYC protein expression following treatment with IC50 concentration of the 
inhibitor revealed a reduction of MYC protein levels by 6% in D283, 35% in D425, 34% in D458 
and by 50% in HDMB03. Conversely, a dose-dependent increase in MYC expression was seen 
in both MBSHH cell lines (Figure 6.15). 
The expected reduction in total levels of CHK1 protein was seen across cell lines (Figure 6.15). 
Treatment with AZD7762 caused a reduction of total CHK1 protein and an increase of pCHK1 
at Ser345, in all lines. Exposures to the inhibitor also increased MCL1 protein levels in a dose-
dependent manner across cell lines, regardless of subgroups.  
 
Figure 6.15. Effect of CHK1 inhibition by AZD7762 in parental MB cell lines on MYC protein expression and 
downstream pathway targets.Automated western blot (Wes) of MYC protein levels and downstream related 
proteins expressed by D425, D283, HDMB03, DAOY, UW228.2 and D458, after treatment with a single exposure with 
half the IC50 (0.5), IC50 (1), and twice the IC50 (2x) concentration of AZD7762 calculated from the growth-inhibitory 
curves. Untreated cells (ctrl; DMSO only) were used as control. GAPDH was used as internal loading control.   
 
In summary, CHK1 inhibition with AZD7762 caused a decrease in MYC protein expression in a 
MBGroup3 subgroup-specific dose-dependent manner. Changes in protein expression levels of 




Analysis of the effect of CHK1 inhibition by Prexasertib at the protein level revealed 
downregulation of MYC protein expression levels in a dose-dependent manner (Figure 6.16). 
MYC protein levels were reduced by more than 80% across cell lines regardless of subgroup, 
after exposures to the drug. MYC expression was almost reduced when tested with the 
highest concentration. D425, D283 and HDMB03 MYC expression levels only decreased by 
15%, 4% and 1% when treated at the lowest concentration tested, with a significant reduction 
when exposed to their corresponding IC50 concentration. CHK1 inhibition with Prexasertib had 
an additive effect with MYC knockdown, where further decrease in MYC protein levels was 
seen after the silencing of MYC with DOX.  
A reduction of CHK1 protein levels was seen after treatment with the inhibitor, together with 
a decrease in its phosphorylated form at Ser345, in both cells expressing high levels of MYC 
and in cells with MYC knockdown (Figure 6.16). Prexasertib also reduced levels of MCL1 in a 









Figure 6.16. Effect of CHK1 inhibition by Prexasertib in isogenic D425, D283 and HDMB03 MB cell lines on MYC protein expression and downstream pathway targets.Automated 
western blot (Wes) of MYC protein levels expressed by D425, D283 and HDMB03 MYC, cultured in the presence (dox) and absence (no dox) of doxycycline for MYC knockdown, after a 
single exposure with half the IC50 (0.5xIC50; 0.5), IC50 (IC50; 1), and twice the IC50 (2xIC50; x2) concentration calculated from the growth-inhibitory curves. Untreated cells (no drug; DMSO 
only) were used for each condition (+/-dox) as controls. GAPDH was used as internal loading control. MYC protein expression was corrected to GAPDH protein expression levels and 
values normalised to the expression of untreated controls for each condition (no dox/dox). Graphs show the comparison of MYC protein levels between MYC overexpressing cell lines 
(blue: -dox; MYC ON) and those with MYC knockdown (red: +dox; MYC OFF). Percentage reduction of MYC expression after treatment is shown relative to the corresponding untreated 
control. Values from one experiment. 
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Wes protein quantification analysis of parental MB cell lines after treatment with Prexasertib 
revealed a dose-dependent reduction of MYC protein levels across cell lines belonging to 
MBGroup3 (Figure 6.17). Exposures to its IC50 concentration caused a reduction of 40%, 80%, 
86% and 72% in D283, D425, D458 and HDMB03, respectively, when compared to their 
corresponding untreated control. The opposite effect was seen in MBSHH cell lines, where 
CHK1 inhibition with Prexasertib resulted in a dose-dependent increase of MYC protein levels.  
Prexasertib effectively downregulated CHK1 protein expression levels. CHK1 inhibition caused 
a decrease in the phosphorylation of CHK1 at Ser345 was seen in MBGroup3, whereas it 
increased in DAOY and UW228.2. As previously seen in the isogenic cell lines, Prexasertib 
downregulated MCL1 protein levels independently of MYC expression. The dose-dependent 
reduction on MCL1 was seen across cell lines regardless of subgroup.  
 
Figure 6.17. Effect of CHK1 inhibition by Prexasertib in parental MB cell lines on MYC protein expression and 
downstream pathway targets.Automated western blot (Wes) of MYC protein levels and downstream related 
proteins expressed by D425, D283, HDMB03, DAOY, UW228.2 and D458, after treatment with a single exposure with 
half the IC50 (0.5), IC50 (1), and twice the IC50 (2x) concentration of Prexasertib calculated from the growth-inhibitory 
curves. Untreated cells (ctrl; DMSO only) were used as control. GAPDH was used as internal loading control.  
 
In summary, CHK1 inhibition by Prexasertib caused downregulation of MYC protein 
expression levels in a MBGroup3 subgroup specific context. In addition, CHK1 inhibition caused 




In summary, the MYC-dependent sensitivities seen in the screen validated in all three cell lines 
in these independent experiments (Figure 6.6). When individually assessed, a MYC-
dependent growth inhibitory effect was seen across D425, D283 and HDMB03 MYC2 cell lines 
after treatment with the inhibitors. Cell lines overexpressing MYC were more sensitive to the 
inhibitors when compared to those with MYC knockdown.  
From all inhibitors tested, BI2536 (PLK1 inhibitor) and Prexasertib (CHK1/2 inhibitor) caused 
a significant reduction of MYC expression in a dose-dependent manner across isogenic 
MBGroup3 cell lines, where MYC expression was reduced by more than 50% after IC50 exposure 
to each inhibitor.  
Differences in the ability to downregulate MYC through CHK1 inhibition were seen depending 
on the inhibitors used. Exposures at IC50 to Prexasertib caused a greater reduction in MYC 
protein levels when compared to AZD7762 (averaging 82% and 24% respectively, across MYC 
overexpressing cell lines). 
As explained earlier in this chapter, both CHK1 and CHK2 are essential components in the 
DNA-damage response (DDR). CHK1 and CHK2 respectively amplify the signals from ATR and 
ATM signalling, phosphorylating a variety of downstream effectors. Depending on the severity 
of the damage, cells will either transiently arrest cell cycle progression or undergo apoptosis 
(Maréchal and Zou, 2013, Ronco et al., 2016) 
Analysis of the effect of CHK1 inhibition on MYC expression and downstream effectors of the 
CHK1 signalling pathway showed a significant difference between the phosphorylated levels 
of CHK1 at serine 345 (Ser345). Phosphorylation of CHK1 at Ser345 is a biomarker of CHK1 
inhibition, and it is mainly catalysed by ATR. Inhibition of CHK1 prevents the activation of the 
phosphatase PP2A, which normally dephosphorylates CHK1 at Ser345. Therefore, upon CHK1 
inhibition phosphorylation of at Ser345 goes up (Sancar et al., 2004, Yan et al., 2010) 
Treatment with AZD7762 caused an increase of pCHK1 at Ser345 in all lines, whereas a 
decrease was seen after exposures to Prexasertib. Differences between inhibitors could be 
explained by the sort of DNA lesions caused to the cells, either SSB or DSB, which would 
consequently activate ATR or ATM, respectively. Depending on the DDR pathway activated, 
either CHK1 or CHK2 would be primarily phosphorylated (Bartek and Lukas, 2003, Ronco et 
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al., 2016). Our results suggest that differences in growth inhibitory potency between both 
inhibitors and differential levels of pCHK1 at Ser345 might be due to the type of DNA-damage 
caused. Prexasertib, which caused a reduction of pCHK1 (Ser345), might be inhibiting CHK2 
preferentially rather than CHK1, indicating that the compound might be causing DSB and 
therefore that the ATM signalling pathway is activated. Increased growth-inhibitory effects 
displayed by Prexasertib might be indicative of a preferential dependency of MYC-
overexpressing cell lines on the ATM over the ATR signalling pathway, and the potential of 
targeting MYC-dependent MBGroup3 cell lines through CHK2 inhibition rather than CHK1.   
An easy and practical way to further study the preferential inhibition of CHK1 and CHK2, 
would be to stain the cells with an antibody for pCHK2 at threonine 68 (Thr68), a marker of 
activation of the CHK2 pathway. In response to DNA damage, ATM phosphorylates CHK2 on 
Thr68, which allows its dimerisation and auto-phosphorylation in trans at threonines 383 and 
387 resulting in full activation, and autophosphorylation in cis at serine 516 (Ser516). 
Phosphorylated Thr68 is therefore a biomarker of the upstream ATM pathway and pSer516 a 
marker of fully activated CHK2 kinase (Weber and Ryan, 2015, Ghelli Luserna Di Rorà et al., 
2016). Staining for pCHK2 at Thr68 after treatment with Prexasertib would inform of the 
mechanism of action of the compound, since phosphorylated levels of CHK2 at Thr68 should 
go down after treatment (indicating inhibition of CHK2).  
 
 Milciclib (CDK2 inhibitor) and MLN8237 (AURKA inhibitor) had the least downregulatory 
effect on MYC, compared to the other inhibitors tested. MYC protein levels where only 
reduced by 50% when treated with the highest concentration of Milciclib.  
Overall, analysis of the effect of the inhibitors at the protein level confirmed the MYC-
dependent effect to treatment with the inhibitors chosen. MYC overexpressing cell lines had 
preferential sensitivity to the compounds compared to those expressing lower levels of MYC 
as a consequence of activation of shRNA constructs by DOX. Inhibition of PLK1, CDK2, CHK1 
and AURKA caused greater reduction of MYC protein expression in MYC overexpressing cells 
than those with MYC knockdown, which was associated with a greater reduction of the cells’ 
proliferation rate.  
MYC-associated effects on drug sensitivity were also seen in a subgroup-specific context when 
parental cell lines were investigated; differential levels of MYC expression across subgroups 
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were associated with sensitivity to the inhibitors. MBSHH cell lines, expressing more than 10-
fold difference in MYC expression compared to MBGroup3 cell lines used, were less sensitive to 
CHK1, CDK2, AURKA and PLK1 inhibition.  
Treatment with the inhibitors efficiently downregulated the protein expression levels of their 
main molecular target, effect seen across the panel of MB cell lines. Treatment with 
Prexasertib (CHK1 inhibitor) and BI2536 (PLK1 inhibitor) caused the MYC-dependent 
subgroup-specific downregulation of the anti-apoptotic protein MCL1, whereas a MYC-
dependent upregulation was seen after treatment with Milciclib (CDK2 inhibitor). Regulation 
of MCL1 resulted to be independent of MYC expression after treatment with AZD7762 (CHK1 
inhibitor) and MLN8237 (AURKA inhibitor), with no subgroup specificity. The MYC-dependent 
regulation of MCL1 could explain the differences in sensitivity displayed by the inhibitors. Our 
results suggest that the dual effect of BI2536 and Prexasertib in reducing MYC and MCL1 
protein levels caused higher growth-inhibitory effect in MYC-driven MBGroup3 cell lines, 
sensitising them to the inhibitors.   
In conclusion, inhibition of CHK1, CDK2, PLK1 and AURKA had a direct downregulatory effect 
on MYC expression in MBGroup3 cell lines. The use of compounds inhibiting these main 













6.5 Effect of pharmacological inhibition of PLK1, CHK1, CDK2 and AURKA on cell cycle 
distribution  
Following the identification of a MYC-dependent growth inhibition effect on MB cell lines 
after treatment with the inhibitors, it was important to better determine the mechanism by 
which the inhibitors were causing the decrease in cell proliferation. To this end, flow 
cytometry cell cycle analysis was used on the panel of MB cell lines to examine cell cycle 
distribution after treatment with each inhibitor.  
Apoptotic cells can be detected by flow cytometry analysis by their inherent loss of DNA 
content in comparison to the otherwise ‘healthy’ population of cells. Permeabilisation of cells 
as a result of the induction of the apoptotic pathway can lead to loss of DNA, and cells with 
reduced DNA content can be detected in the sub-G1 phase of the cell cycle when stained with 
an intercalating agent like propidium iodide (PI) (Riccardi and Nicoletti, 2006, Vermes et al., 
2000). 
As a means to better understand the underlying mechanism of the MYC-dependent growth-
inhibitory effect caused by the inhibitors, flow cytometry cell cycle analysis considering sub-
G1 phase of the cell cycle as an indicator of apoptosis was performed to study the possible 
mechanism by which cells decreased their proliferative rate after treatment.   
The isogenic cell lines D425, D283 and HDMB03 MYC2, overexpressing MYC and with MYC 
silenced with shRNA, were exposed to a single dose of three different concentrations 
(0.5xIC50, IC50 and 2xIC50) of each inhibitor (IC50 determined in section 6.3 of this Chapter). NS 
cells were used as a negative control for the function and effect of the shRNA in response to 
the inhibitors. Exposures of cells to the inhibitors for cell cycle analysis were performed in 
three independent biological experiments.   
To explore the MYC-dependency of the changes seen in the cells cycle distribution after 
treatment with the inhibitors in a MB subgroup-specific context, the inhibitors were also 
tested on the panel of parental MB cell lines (D425, D283, HDMB03, D458, DAOY and 
UW228.2). Models were exposed to the inhibitors using the IC50 concentrations determined 













D425 3.381 110.3 20.88 68.79 4.032 
D283 7.695 105.2 36.95 33.72 2.11 
HDMB03 7.97 132.9 20.14 50.82 5.85 
D458 1.984 159.5 29.4 54.5 2.11 
DAOY 3.07 2669 54.61 91.02 6.39 
UW228.2 14.27 6342 1664 2852 43.59 
 
Table 6.4. IC50 values of the panel of MB cell lines used for cytometry cell cycle analysis.Cell 
viability of D425, D283, HDMB03 and D458 for MBGroup3, and DAOY and UW228.2 for MBSHH, after 
72h of exposure to a single dose of 8 different concentrations of BI2536 (PLK1 inhibitor), Milciclib 
(CDK2 inhibitor), MLN8237 (AURKA inhibitor), AZD7762 (CHK1 inhibitor) and Prexasertib (CHK1/2 
inhibitor), was used to generate dose-response curves with Prism8 (section 6.3.2). IC50 values (nM) 
generated from the curves were calculated to determine cells sensitivity to the compounds. Table 
summarises the IC50 of MB parental cell lines to each inhibitor. Values are presented as the mean 
of three independent experiments.  
 
 
72h after drug exposures, cells were harvested and samples processed for the analysis of cell 
cycle distribution as described in Chapter 2. Untreated (no DOX and no drug; DMSO only) cells 
were used as control for comparison. DOX-treated cells only (DOX, no drug) were used as 
control for the MYC-knockdown arm of the experiment.   
Cell cycle distribution of isogenic D425, D283 and HDMB03 MYC2 after treatment with the 
three different concentrations of the inhibitors can be seen in Figure 6.7 of the Appendix. Cell 
cycle distribution of MB parental cell lines after treatment with the three different 
concentrations of the inhibitors can be seen in Figure 6.8 of the Appendix.  
For comparison of changes in the cell cycle distribution after treatment with the inhibitors, 
only differences between untreated cells (no drug, DMSO only) and those treated with half-








6.5.1 PLK1 inhibition 
Treatment of D425, D283 and HDMB03 with half-maximal inhibitory concentration (IC50) of 
BI2536 significantly induced apoptosis regardless of MYC expression levels, seen by the 
accumulation of cells in the sub-G1 phase of the cell cycle at 72h (Figure 6.19). PLK1 inhibition 
by BI2536 caused a significant decrease in cells at the G1 phase of the cell cycle, regardless of 
MYC expression levels (cells overexpressing MYC and with MYC knockdown), when compared 
to the control. BI2536 treatment caused a significant increase in the number of cells in G2-M 
phase of the cell cycle of those cells expressing high levels of MYC when compared to 
untreated cells. Increase not significant in cells with MYC knockdown (Figure 6.18).  
 
Figure 6.18. Effect of BI2536 treatment on cell cycle distribution in isogenic MBGroup3 cell lines.Cell 
cycle distribution of D425, D283 and HDMB03 MYC2 cell lines after 72h of a single exposure of IC50 
concentration of the PLK1 inhibitor BI2536. Cells were stained with propidium iodide and cell cycle 
distribution analysed by flow cytometry. Graph represents the percentage (%) of cells of each cell 
cycle phase relative to total phases, of cells expressing high levels of MYC and those with MYC 
knockdown (+dox). Untreated cells (ctrl - no drug; DMSO only) were used for each condition (+/-
dox) as controls. Data is presented as the percentage of the mean (±SEM) of three independent 
experiments. Significance determined by 2-way ANOVA (*p≤0.05, **p≤0.01, ***p≤0.001, 






The same effect was seen on parental cell lines. Compared to the untreated controls, 
exposure of D283, D425, HDMB03, D458, DAOY and UW228.2 to IC50 concentrations of BI2536 
caused a significant increase in the fraction of sub-G1 cells across cell lines (indicative of 
apoptotic cells). Only a slight increase in cells at sub-G1 phase was seen in UW228.2 (the only 
line that did not reach statistical significance).  
PLK1 inhibition by BI2536 caused a significant increase in the number of cells in G2-M phase, 
together with a markedly decrease in cells at G1 phase across MB cell lines, when compared 
to their corresponding controls. In D283 and D425, a significant decrease in cells in S phase 
was seen after treatment (Figure 6.19). 
 
  
Figure 6.19. Effect of BI2536 treatment on cell cycle distribution in parental MB cell lines.Cell cycle 
distribution of D283, D425, HDMB03, D458, DAOY and UW228.2 after 72h of a single exposure of 
IC50 concentration of the PLK1 inhibitor BI2536. Cells were stained with propidium iodide and cell 
cycle distribution analysed by flow cytometry. Graph represents the percentage (%) of cells of each 
cell cycle phase relative to total phases. Untreated cells (ctrl - no drug; DMSO only) for each cell line 
were used as controls. Data is presented as the percentage of the mean (±SEM) of two independent 





6.5.2 CDK2 inhibition  
No significant changes in the population of cells at sub-G0 (apoptotic cells) were seen across 
MYC-regulable cell lines after exposure to Milciclib when compared to untreated controls 
(Figure 6.20). 
Some inconsistencies in the cell cycle distribution after treatment with Milciclib were seen 
between D425, D283 and HDMB03 MYC2 (Figure 6.20). After treatment, all cell lines exhibited 
a slight decrease in cell numbers in the G1 phase of the cell cycle. Despite the decrease 
observed, statistical significance was not reached in D425 with MYC knockdown, or in 
HDMB03 MYC2 cells expressing high levels of MYC, when compared to their corresponding 
controls.  
Milciclib caused a significant increase in the proportion of cells in G2-M phase in D283 
overexpressing MYC and in HDMB03 with MYC knockdown. A slight decrease in the 
proportion of cells in S phase was seen in D425, only statistically significant when MYC was 
knocked down (Figure 6.20).  
 
Figure 6.20. Effect of Milciclib treatment on cell cycle distribution in isogenic MBGroup3 cell 
lines.Cell cycle distribution of D425, D283 and HDMB03 MYC2 cell lines after 72h of a single 
exposure of IC50 concentration of the CDK2 inhibitor Milciclib. Cells were stained with propidium 
iodide and cell cycle distribution analysed by flow cytometry. Graph represents the percentage (%) 
of cells of each cell cycle phase relative to total phases, of cells expressing high levels of MYC and 
those with MYC knockdown (+dox). Untreated cells (ctrl-no drug; DMSO only) were used for each 
condition (+/-dox) as controls. Data is presented as the percentage of the mean (±SEM) of three 
independent experiments. Significance determined by 2-way ANOVA (*p≤0.05, **p≤0.01, 




Analysis of the effect of Milciclib treatment on cell cycle distribution in parental MB cell lines 
showed a significant increase in the sub-G1 population in MBGroup3 cell lines, compared to 
untreated controls, most markedly seen in D458 of all MBGroup3 lines (Figure 6.21). No 
significant changes in the number of cells in sub-G1 phase were seen in MBSHH cell line after 
treatment.  
A decrease in the proportion of cells in G1 phase of the cell cycle was seen across cell lines 
after treatment with the inhibitor, reaching statistical significance in D283, HDMB03, D458 
and UW228.2. As an exception, after treatment, UW228.2 exhibited a significant increase in 
the percentage of cells in S phase (Figure 6.21).  
 
 
Figure 6.21. Effect of Milciclib treatment on cell cycle distribution in parental MB cell lines.Cell 
cycle distribution of D283, D425, HDMB03, D458, DAOY and UW228.2 after 72h of a single exposure 
of IC50 concentration of the CDK2 inhibitor Milciclib. Cells were stained with propidium iodide and 
cell cycle distribution analysed by flow cytometry. Graph represents the percentage (%) of cells of 
each cell cycle phase relative to total phases. Untreated cells (ctrl-no drug; DMSO only) for each cell 
line were used as controls. Data is presented as the percentage of the mean (±SEM) of two 






6.5.3 AURKA inhibition  
All three isogenic cell lines tested showed a significant increase in the sub-G1 region (dead 
cells) of the cell cycle after treatment with IC50 concentration of MLN8237 regardless of MYC 
expression levels (Figure 6.22). Although still statistically significant, the increase in cell 
numbers in sub-G1 phase was less pronounced in cells with MYC knockdown. AURKA 
inhibition with MLN8237 caused a significant reduction of cells in G1 phase of the cell cycle 
compared to the untreated controls, regardless of MYC expression levels. A significant 
increase in the number of cells in the G2-M phase of the cell cycle was observed after 
treatment, reaching significance only in D425 with MYC silenced and in HDMB03 expressing 
high levels of MYC (Figure 6.22).  
 
Figure 6.22. Effect of MLN8237 treatment on cell cycle distribution in isogenic MBGroup3 cell 
lines.Cell cycle distribution of D425, D283 and HDMB03 MYC2 cell lines after 72h of a single 
exposure of IC50 concentration of the AURKA inhibitor MLN8237. Cells were stained with propidium 
iodide and cell cycle distribution analysed by flow cytometry. Graph represents the percentage (%) 
of cells of each cell cycle phase relative to total phases, of cells expressing high levels of MYC and 
those with MYC knockdown (+dox). Untreated cells (ctrl-no drug; DMSO only) were used for each 
condition (+/-dox) as controls. Data is presented as the percentage of the mean (±SEM) of three 
independent experiments. Significance determined by 2-way ANOVA (*p≤0.05, **p≤0.01, 






Treatment of MBGroup3 and MBSHH parental cell lines with MLN8237 also caused a significant 
increase in apoptotic cells, seen by the significant increase in sub-G1 region of the cell cycle 
(Figure 6.23). Although still statistically significant, the increase in cell numbers in sub-
G1 phase was less pronounced in DAOY and UW228.2, compared to the increase observed in 
other cell lines, which suggests a subgroup specific effect.  
AURKA inhibition with MLN8237 caused a significant reduction of cells in G1 phase of the cell 
cycle across MB cell lines, when compared to their respective untreated controls. The 
decrease in the percentage of cells in G1 phase caused by MLN8237 did not reach statistical 
significance in DAOY (Figure 6.23).  
 
 
Figure 6.23. Effect of MLN8237 treatment on cell cycle distribution in parental MB cell lines.Cell 
cycle distribution of D283, D425, HDMB03, D458, DAOY and UW228.2 after 72h of a single exposure 
of IC50 concentration of the AURKA inhibitor MLN8237. Cells were stained with propidium iodide 
and cell cycle distribution analysed by flow cytometry. Graph represents the percentage (%) of cells 
of each cell cycle phase relative to total phases. Untreated cells (ctrl-no drug; DMSO only) for each 
cell line were used as controls. Data is presented as the percentage of the mean (±SEM) of two 






6.5.4 CHK1 inhibition  
6.5.4.1 AZD7762 
A MYC-dependent increase in the number of cells in sub-G1 phase of the cell cycle was seen in 
D425, D283 and HDMB03 cloned with the MYC2 construct after exposure to AZD7762 (Figure 
6.24). Treatment of isogenic cell lines with IC50 concentration of the inhibitors caused a 
significant increase in the number of cells in sub-G1 phase in cells expressing high-levels of 
MYC, whereas no significant changes were seen in cells with MYC knockdown.  
After treatment, all three MYC-regulable cell lines tested showed a significant decrease in the 
proportion of cells at G1 phase, regardless of MYC expression levels. A significant 
accumulation of cells at G2-M phase was seen across cell lines after treatment with AZD7762, 
being D425 with MYC knockdown the only one in which significance was not reached (Figure 
6.24).  
 
Figure 6.24. Effect of AZD7762 treatment on cell cycle distribution in isogenic MBGroup3 cell 
lines.Cell cycle distribution of D425, D283 and HDMB03 MYC2 cell lines after 72h of a single 
exposure of IC50 concentration of the CHK1 inhibitor AZD7762. Cells were stained with propidium 
iodide and cell cycle distribution analysed by flow cytometry. Graph represents the percentage (%) 
of cells of each cell cycle phase relative to total phases, of cells expressing high levels of MYC and 
those with MYC knockdown (+dox). Untreated cells (ctrl-no drug; DMSO only) were used for each 
condition (+/-dox) as controls. Data is presented as the percentage of the mean (±SEM) of three 
independent experiments. Significance determined by 2-way ANOVA (*p≤0.05, **p≤0.01, 




A clear subgroup and MYC-dependent effect was seen in MB parental cell lines after 
treatment with IC50 concentration of AZD7762 (Figure 6.25). Exposure to the inhibitor caused 
a significant increase in the number of cells in sub-G1 phase of the cell cycle only in MBGroup3 
cell lines. CHK1 inhibition with AZD7762 slightly increased cell percentages in G2-M phase of 
the cell cycle, but statistical significance was not reached. After 72h of treatment, all cell lines 
exhibited a decrease in the proportion of cells at G1 phase when compared to untreated 
controls (non-significant in D425 and DAOY)(Figure 6.25).  
 
 
Figure 6.25. Effect of AZD7762 treatment on cell cycle distribution in parental MB cell lines.Cell 
cycle distribution of D283, D425, HDMB03, D458, DAOY and UW228.2 after 72h of a single exposure 
of IC50 concentration of the CHK1 inhibitor AZD7762. Cells were stained with propidium iodide and 
cell cycle distribution analysed by flow cytometry. Graph represents the percentage (%) of cells of 
each cell cycle phase relative to total phases. Untreated cells (ctrl -no drug; DMSO only) for each 
cell line were used as controls. Data is presented as the percentage of the mean (±SEM) of two 









Exposure of MYC-regulable D425, D283 and HDMB03 to IC50 concentration of Prexasertib 
significantly induced apoptosis when compared to untreated cells (Figure 6.26). This increase 
in the number of cells in sub-G1 phase of the cell cycle was seen across cells lines regardless 
of MYC expression levels.   
CHK1 inhibition with Prexasertib caused a significant decrease in cells in G1 phase of the cell 
cycle in all cell lines, when compared to untreated controls. Treatment caused a concomitant 
increase in the proportion of cells in G2-M phase of the cell cycle of D425, D283 and HDMB03 
expressing high levels of MYC (Figure 6.26).  
 
Figure 6.26. Effect of Prexasertib treatment on cell cycle distribution in isogenic MBGroup3 cell 
lines.Cell cycle distribution of D425, D283 and HDMB03 MYC2 cell lines after 72h of a single 
exposure of IC50 concentration of the CHK1 inhibitor Prexasertib. Cells were stained with propidium 
iodide and cell cycle distribution analysed by flow cytometry. Graph represents the percentage (%) 
of cells of each cell cycle phase relative to total phases, of cells expressing high levels of MYC and 
those with MYC knockdown (+dox). Untreated cells (ctrl-no drug; DMSO only) were used for each 
condition (+/-dox) as controls. Data is presented as the percentage of the mean (±SEM) of three 
independent experiments. Significance determined by 2-way ANOVA (*p≤0.05, **p≤0.01, 






Exposure of parental MB cell lines to IC50 concentration of Prexasertib significantly induced 
apoptosis when compared to untreated cells (Figure 6.27). This significant increase in the 
number of cells in sub-G1 phase of the cell cycle was seen across cells lines regardless of MYC 
expression levels (not MYC-dependent).  
In general, an increase of cells in sub-G1 phase of the cell cycle was seen together with a 
decrease in the proportion of cells in G1 phase. Although it did not reach statistical 
significance, a slight accumulation of cells in G2-M phase of the cell cycle was observed across 
cell lines after treatment (Figure 6.27).  
 
Figure 6.27. Effect of Prexasertib treatment on cell cycle distribution in parental MB cell lines.Cell 
cycle distribution of D283, D425, HDMB03, D458, DAOY and UW228.2 after 72h of a single exposure 
of IC50 concentration of the CHK1 inhibitor Prexasertib. Cells were stained with propidium iodide 
and cell cycle distribution analysed by flow cytometry. Graph represents the percentage (%) of cells 
of each cell cycle phase relative to total phases. Untreated cells (ctrl-no drug; DMSO only) for each 
cell line were used as controls. Data is presented as the percentage of the mean (±SEM) of two 









Flow cytometry analysis of MB cells’ cycle distribution after treatment with the inhibitors was 
performed on MBSHH and MBGroup3 cell lines with the aim to better characterise the growth 
inhibitory effect of the compounds.  
Analysis of the cell cycle distribution of D425, D283 and HDMB03 MYC2 cells overexpressing 
MYC and with MYC knockdown after treatment with the inhibitors, corroborated the MYC-
dependent effect seen on cell proliferation, where higher levels of MYC expression sensitised 
cells to the effect of the inhibitors.  
BI2536, Prexasertib, AZD7762 and MLN8237 caused a significant increase in the proportion 
of cells in sub-G1 phase of the cell cycle after treatment, indicating an increase in apoptotic 
cells. The increase in apoptotic cells was seen in cells overexpressing MYC in comparison to 
those with MYC-knockdown. Cell cycle arrest at G2-M phase of the cell cycle was seen in cells 
expressing lower levels of MYC. Data suggests that BI2536, Prexasertib, AZD7762 and 
MLN8237 preferentially kill MYC overexpressing cells whilst also arresting the growth of those 
with lower levels of MYC.  
Treatment with Milciclib did not result in a significant increase in apoptosis in MBGroup3 MYC2 
cells expressing high levels of MYC. Exposures to the drug caused an increase in the 
proportion of cells at G2-M phase of the cell cycle, indicating the main mechanism by which 
Milciclib inhibit MBGroup3 cells proliferation is through cell cycle arrest at G2-M phase.  
The MYC-dependent drug-sensitivity effect was also seen in the distribution of cell cycle after 
treatment in a subgroup specific context. AZD7762 and Milciclib, significantly increased the 
proportion of dead cells after treatment in MBGroup3 when compared to MBSHH cell lines. 
MLN8237 treatment caused a significant increase in the proportion of dead cells regardless 
of subgroups. BI2536 caused cell cycle arrest at G2-M phase across cell lines regardless of 
differential levels of MYC expression according to subgroup, and a significant increase in the 
proportion of cells in sub-G1 phase of the cell cycle in all MB cell lines with the exception of 
UW228.2. On the other hand, Prexasertib significantly increased the number of cells in sub-
G1 phase of the cell cycle on all MB cell lines tested, showing a clear sensitivity of MB cells to 
the compound.  
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Results from the assessment of the cell cycle distribution after treatment with the inhibitors 
showed clear differences according to levels of MYC expression and subgroup, but not 
uniformly. This information could help prioritise inhibitors that specifically induce apoptosis 
in MYC-driven MBGroup3 cell lines, like BI2536, AZD7762 and MLN8237. Overall, MBGroup3 cell 
lines exhibited increased sensitivity to PLK1, CHK1 and AURKA inhibition with the compounds 






















6.6 Cell-proliferation rescue assays 
Assessment of cell cycle distribution after drug treatment revealed an increase in the number 
of cells in sub-G1 phase of the cell cycle, which suggested that the inhibitors were inhibiting 
cells proliferation by inducing apoptosis. As preliminary experiments to assess the ability of 
cells to recover growth after exposures to the inhibitors, and whether this was MYC-
dependent, a cell-proliferation rescue assay was performed on the isogenic D425, D283 and 
HDMB03 MYC2 cell lines (methodology described in Chapter 2). Cell proliferation was 
assessed with CTG at different time points after drug exposure to study if cell growth 
(represented by metabolically active cells) could be recovered after treatment. 
D425, D283 and HDMB03 MYC2 overexpressing MYC and with MYC knockdown were exposed 
to a single dose of half IC50 (0.5xIC50), IC50 (IC50), and twice IC50 (2xIC50) concentration of each 
inhibitor, and cell viability assessed after 3 and 5 days of exposure to drug. After 5 days, 
media-containing drug was removed and plates refreshed with new media (no drug). Cells 
were left to grow for additional 5 and 9 days upon removal to check cell proliferation, 
indicative of alive metabolically active cells. Untreated cells for both conditions (-/+ DOX) 
were used as controls.   
Cell-proliferation rescue assay of isogenic D425, D283 and HDMB03 MYC2 after treatment 
with the three different concentrations of the inhibitors can be seen in figures Appendix 6.8, 
Appendix 6.9, Appendix 6.10, Appendix 6.11 and Appendix 6.12. For comparison of changes 
in metabolically active cells after exposures to the inhibitors, only differences between 









6.6.1 BI2536: PLK1 inhibition  
Inhibition of PLK1 by BI2536 caused a highly consistent reduction in cell proliferation in a time 
and dose-dependent manner across isogenic cell lines (Appendix 6.8). Treatment with the 
inhibitor caused a progressive decrease in cell proliferation after drug administration when 
compared to untreated controls, in both MYC-overexpressing and MYC knockdown cells 
across cell lines. Proliferation of cells with MYC knockdown was not as markedly reduced with 
treatment with BI2536 when compared to cells overexpressing MYC.  
When treated with IC50 concentration, a significant decrease in metabolically active cells was 
seen in MYC-overexpressing cells and with MYC knockdown after drug removal, with no 
evidence of recovery in either (Figure 6.28). A greater reduction in cell proliferation was seen 
in MYC-overexpressing cell lines when compared to their MYC-silenced counterparts (D283 
p=0,0156; D425 p<0.0001; HDMB03 p<0.0001). MYC expression sensitised the cells to the 




Figure 6.28. Effect of treatment with BI2536 on the proliferation of MYC-regulable cell lines after 
treatment with BI2536.Cell-proliferation rescue assay of D425, D283 and HDMB03 MYC2 during 
and after exposure to the PLK1 inhibitor BI2536. Cells expressing high levels of MYC (-dox; MYC ON) 
and those with MYC knockdown (+dox; MYC OFF) were exposed to IC50 concentration (green) for 5 
days. After exposure, drug was removed from the media, media changed, and cells left to grow for 
further 5 and 9 days. Cell proliferation was assessed with CTG 3, 5, 10 and 14 days after drugging. 
Untreated cells (no drug; blue) were used for each condition (+/-DOX) as controls. Data was blank-
corrected to DMSO-containing wells, and normalised to day 0. Graphs show the comparison of 
growth between untreated cells (blue) and those treated with the inhibitor (green). Data is 
presented as the mean (±SEM) of two independent experiments. Significance determined by 2-way 




6.6.2 Milciclib: CDK2 inhibition  
When compared to the growth of untreated cells, exposure to Milciclib (CDK2 inhibitor) 
caused a significant decrease in proliferation of D425, D283 and HDMB03 MYC2 cells 
overexpressing MYC and with MYC silenced with shRNA, in a time- and dose-dependent 
manner (Appendix 6.9). The decrease in cell proliferation continued after drug removal.  
A sign of growth recovery was seen in cells with MYC knockdown after treatment with IC50 of 
Miliclib, where a significant increase in proliferation was seen after drug removal (Figure 
6.29). Lower levels of MYC increased resistance to treatment with Milciclib when compared 







Figure 6.29. Proliferation of MYC-regulable cell lines after treatment with Milciclib.Cell-
proliferation rescue assay of D425, D283 and HDMB03 MYC2 during and after exposure to the CDK2 
inhibitor Milciclib. Cells expressing high levels of MYC (-dox; MYC ON) and those with MYC 
knockdown (+dox; MYC OFF) were exposed to IC50 concentration (green) for 5 days. After exposure, 
drug was removed from the media, media changed, and cells left to grow for further 5 and 9 days. 
Cell proliferation was assessed with CTG 3, 5, 10 and 14 days after drugging. Untreated cells (no 
drug; blue) were used for each condition (+/-DOX) as controls. Data was blank-corrected to DMSO-
containing wells, and normalised to day 0. Graphs show the comparison of growth between 
untreated cells (blue) and those treated with the inhibitor (green). Data is presented as the mean 
(±SEM) of two independent experiments. Significance determined by 2-way ANOVA (*p≤0.05, 




6.6.3 MLN8237: AURKA inhibition  
Exposures to MLN8237 caused a progressive decrease in D425, D283 and HDMB03 MYC2 
proliferation in a time- and dose-dependent manner when compared to untreated cells 
(Appendix 6.10). Assessment of cells proliferation after AURKA inhibition, revealed that 
treatment with MLN8237 had a higher growth-inhibitory effect in cells expressing high levels 
of MYC than in cells with MYC knockdown.  
Upon MYC silencing, a slight, but non-significant, increase in the proportion of metabolically 
active cells was seen in D425, D283 and HDMB03, indicating a possible recovery when treated 











Figure 6.30. Proliferation of MYC-regulable cell lines after treatment with MLN8237.Cell-
proliferation rescue assay of D425, D283 and HDMB03 MYC2 during and after exposure to the 
AURKA inhibitor MLN8237. Cells expressing high levels of MYC (-dox; MYC ON) and those with MYC 
knockdown (+dox; MYC OFF) were exposed to IC50 concentration (green) for 5 days. After exposure, 
drug was removed from the media, media changed, and cells left to grow for further 5 and 9 days. 
Cell proliferation was assessed with CTG 3, 5, 10 and 14 days after drugging. Untreated cells (no 
drug; blue) were used for each condition (+/-DOX) as controls. Data was blank-corrected to DMSO-
containing wells, and normalised to day 0. Graphs show the comparison of growth between 
untreated cells (blue) and those treated with the inhibitor (green). Data is presented as the mean 
(±SEM) of two independent experiments. Significance determined by 2-way ANOVA (*p≤0.05, 





6.6.4 AZD7762: CHK1 inhibition  
 AZD7762 significantly reduced cell proliferation of D425, D283 and HDMB03 in both MYC-
overexpressing and MYC knockdown cells in a time- and dose-dependent manner, when 
compared to their corresponding untreated counterparts (Appendix 6.11). Treatment with 
IC50 concentration of AZD7762 caused a significantly reduced proliferation of those cells 
expressing high-levels of MYC, in comparison to those treated with DOX for MYC knockdown. 
This effect was seen across cell lines (Figure 6.31).  
A slight time-dependent increase in the proportion of metabolically active cells was seen 
across cell lines with MYC knockdown when allowed to recover after treatment with half IC50 
concentration (Figure 6.31). Sustained time-dependent growth inhibition with no recovery 
was only seen in MYC-overexpressing cells, thus exhibiting a MYC-dependent effect. 
The cell-proliferation rescue assay thus revealed higher sensitivity of MYC-overexpressing cell 
lines to CHK1 inhibition in comparison to those with MYC knockdown; effect seen through the 













Figure 6.31. Proliferation of MYC-regulable cell lines after treatment with AZD7762.Cell-
proliferation rescue assay of D425, D283 and HDMB03 MYC2 during and after exposure to the CHK1 
inhibitor AZD7762. Cells expressing high levels of MYC (-dox; MYC ON) and those with MYC 
knockdown (+dox; MYC OFF) were exposed to IC50 concentration (green) for 5 days. After exposure, 
drug was removed from the media, media changed, and cells left to grow for further 5 and 9 days. 
Cell proliferation was assessed with CTG 3, 5, 10 and 14 days after drugging. Untreated cells (no 
drug; blue) were used for each condition (+/-DOX) as controls. Data was blank-corrected to DMSO-
containing wells, and normalised to day 0. Graphs show the comparison of growth between 
untreated cells (blue) and those treated with the inhibitor (green). Data is presented as the mean 
(±SEM) of two independent experiments. Significance determined by 2-way ANOVA (*p≤0.05, 




6.6.5 Prexasertib: CHK1 inhibition  
Treatment with the CHK1/2 inhibitor Prexasertib caused, in a time and dose-dependent 
manner, a significant reduction in D425, D283 and HDMB03 MYC2 cell proliferation, 
regardless of MYC expression levels (Appendix 6.12).  
After treatment with IC50 concentration of Prexasertib, cells overexpressing MYC exhibited a 
greater reduction in metabolically active cells after recovery time, when compared to their 
counterparts expressing lower levels of MYC (Figure 6.32).  
Following MYC knockdown, a significant decrease in cell proliferation throughout time of 
recovery was seen in D283 and HDMB03 after exposure to IC50 concentration. The decrease 





Figure 6.32. Proliferation of MYC-regulable cell lines after treatment with Prexasertib.Cell-
proliferation rescue assay of D425, D283 and HDMB03 MYC2 during and after exposure to the CHK1 
inhibitor Prexasertib. Cells expressing high levels of MYC (-dox; MYC ON) and those with MYC 
knockdown (+dox; MYC OFF) were exposed to IC50 concentration (green) for 5 days. After exposure, 
drug was removed from the media, media changed, and cells left to grow for further 5 and 9 days. 
Cell proliferation was assessed with CTG 3, 5, 10 and 14 days after drugging. Untreated cells (no 
drug; blue) were used for each condition (+/-DOX) as controls. Data was blank-corrected to DMSO-
containing wells, and normalised to day 0. Graphs show the comparison of growth between 
untreated cells (blue) and those treated with the inhibitor (green). Data is presented as the mean 
(±SEM) of two independent experiments. Significance determined by 2-way ANOVA (*p≤0.05, 




6.6.6 Conclusion  
To better understand the growth-inhibitory effect of the inhibitors on MBGroup3 cell lines and 
its associated MYC-dependency, cell-proliferation rescue assay were performed on the 
isogenic D425, D283 and HDMB03 MYC2 cell lines to assess the ability of cells to recover their 
growth after exposures to the inhibitors.  
A time- and dose-dependent decrease in cells proliferation was seen across cell lines 
expressing high levels of MYC after treatment with BI2536 (PLK1 inhibitor), AZD7762 (CHK1 
inhibitor), Milciclib (CDK2 inhibitor), MLN8237 (AURKA inhibitor) and Prexasertib (CHK1/2 
inhibitor). A MYC-dependent drug-sensitivity effect was seen in all 3 cell lines, where greater 
growth inhibition was seen in MB cell lines overexpressing MYC, when compared to cells with 
MYC knockdown, after treatment with the inhibitors.  
Cells treated with BI2536 and Prexasertib were not able to recover cell growth after drug 
removal, in both conditions, either expressing high levels of MYC or with MYC knockdown. In 
contrast, when expressing lower levels of MYC (MYC knockdown), an increase in cells 
proliferation was seen after treatment with Milciclib, AZD7762 and MLN8237, indicating a 
possible recovery.  
In summary, the ability of cells to recover their growth after treatment with the inhibitors was 
dependent on MYC expression. Treatment with Milciclib, MLN8237 and AZD7762 caused a 
MYC-dependent continued cell kill after drug removal, where recovery of cells proliferation 
was not possible when expressing high levels of MYC. On the other hand, low levels of MYC-
expression (MYC knockdown) allowed recovery of cells proliferation after treatment. No 
recovery in cell growth was seen after exposures to BI2536 and Prexasertib. 
These results could help the prioritisation of inhibitors which specifically have a MYC-








With the objective to better understand the role of MYC within MBGroup3, a high-throughput 
drug screening was performed on the MYC-regulable isogenic cell lines to identify targetable 
signalling pathways associated with MYC that could be exploited to treat MYC-driven MBGroup3 
tumours. The screen identified 82 small-molecule inhibitors which selectively inhibited the 
growth of MYC-overexpressing cell lines. As described in Chapter 5, integration of HTCS 
results with data on transcriptional MB dependencies predicted PLK1 (3.7% of hits), CHK (4.9% 
of hits), AURK (9.8% of hits) and CDK (12.2% of hits) as targetable molecules to be effective 
on MBGroup3, allowing prioritisation for further investigation.  
This chapter was set out to validate the MYC-dependency of the compounds identified from 
the screen, and investigate their direct effect on MYC protein expression, cell cycle 
distribution and cell proliferation in MYC-dependent MBGroup3 cell lines and across parental 
MB lines from different subgroups.  
 
Indeed, results presented in this chapter support the fact that pharmacological inhibition of 
CDK2, AURKA, PLK1 and CHK1 resulted in growth inhibition, downregulation of MYC protein 
levels and induction of apoptosis with preferential effect in MYC overexpressing MB cell lines, 
in comparison to those expressing lower levels of MYC, stating the MYC-dependency on these 
proteins.  
Sensitivity to AZD7762 (CHK1 inhibitor), BI2536 (PLK1 inhibitor), MLN8237 (AURKA inhibitor), 
Milciclib (CDK2 inhibitor), SN-38 (topoisomerase I inhibitor), MK-1775 (WEE1 inhibitor) and 
Prexasertib (CHK1/2 inhibitor) inhibitors was dependent on MYC expression levels, where 
exposures to the compounds had a greater growth-inhibitory effect on MYC-overexpressing 
cell lines over those with MYC-knockdown with shRNA. The MYC-dependency on these 
proteins was seen in a sub-group specific context, where MBGroup3 cell lines were more 
sensitive to the compounds identified, in comparison to the MBSHH lines DAOY and UW228.2. 
Drug-sensitivity effects seen are in accordance with differential levels of MYC expression, 




A significant difference in sensitivity was seen depending on the CHK1 inhibitor used, 
AZD7762 and Prexasertib. Prexasertib caused greater MBGroup3 cell growth inhibition when 
compared to AZD7762. The difference in drug sensitivity could be explained by the dual 
inhibition of CHK1 and CHK2 by Prexasertib, indicating the potential of targeting both 
molecules to abrogate DDR in MBGroup3 cell lines and force cells to undergo apoptosis. 
Additional experimentation studying biomarkers of CHK2 activation could shed light into the 
difference between inhibitors.  
In addition, PLK1, CDK2, CHK1 and AURKA inhibition caused downregulation of MYC at the 
protein level in MBGroup3 cell lines. Their inhibition resulted in a decrease in MYC protein 
expression in both, cells expressing high levels of MYC and in those cells with MYC knockdown. 
Results from the analysis of the effect of the inhibitors on parental MB cell lines at the protein 
level further corroborated the MYC-dependent effect of the inhibition of our main targets, 
resulting in increased levels of MYC protein in MBSHH cell lines, opposite to the decrease seen 
in MBGroup3 cell lines.  
Analysis of expression of downstream pathway targets revealed an efficient inhibition of the 
main molecular target of the compounds. Downregulation of PLK1, CHK1, CDK2 and AURKA 
after treatment with each inhibitor was seen across cell lines regardless of MYC expression 
and subgroup. Prexasertib (CHK1/2 inhibitor) and BI2536 (PLK1 inhibitor) caused the MYC-
dependent subgroup-specific downregulation of the anti-apoptotic protein MCL1, whereas a 
MYC-dependent upregulation was seen after treatment with Milciclib (CDK2 inhibitor). 
Regulation of levels of the anti-apoptotic protein MCL1 was not associated with MYC 
expression or MB subgroup after treatment with MLN8237 (AURKA inhibitor) and AZD7762 
(CHK1 inhibitor). Our findings suggest that inhibitors with a downregulatory effect on both 
MYC and MCL1 protein expression levels, would selectively inhibit the growth of MYC-driven 
MBGroup3 cell lines.  
The regulatory effect of the inhibitors on MCL1 protein levels could reveal an extra layer of 
complexity to the differences in sensitivity observed. Alternatively, differences in sensitivity 
of MBGroup3 to both CHK1 inhibitors could also be due to the fact that Prexasertib 
downregulates MCL1 protein levels.  Increased levels of MCL1 trigger anti-apoptotic signalling 
pathways, arresting cell cycle progression to prevent cells sustaining damaged DNA from 
replicating (Fujise et al., 2000, Zhang et al., 2018b). Increased MCL1 levels might occur to 
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ensure cells bearing DNA lesions do not replicate. Downregulation of MCL1 by Prexasertib 
might prevent the arrest of cells cycle and promote the apoptotic pathway. Further 
experimentation to understand the relationship between CHK1/2 inhibition and MCL1 is 
required to better explain the differences in sensitivity of MBGroup3 cell lines to the inhibitors 
used. Nevertheless, targeting components of the DDR has the potential to lead to novel 
therapeutic options for high-risk MBGroup3 patients for whom the prognosis is still 
unacceptably poor. 
Due to time constraints, only one experimental repeat was performed on each cell line. 
Despite the consistent effects seen across different MB lines, more experimental repeats 
should be performed in order to fully characterise the association between MYC and the 
expression of downstream pathway targets.   
Our findings further provide insight into the mechanism by which the small molecule 
compounds repressed MB cell proliferation. A MYC-dependent subgroup specific increase in 
the proportion of cells at sub-G1 phase of the cell cycle was seen across MBGroup3 cell lines 
after treatment with BI2536, AZD7762 and MLN8237, suggesting an increase in the 
proportion of apoptotic cells. Increase in the population of cells at sub-G1 phase correlated 
with MYC expression levels, where higher levels of apoptosis were seen in cells 
overexpressing MYC. The data suggests that utilisation of BI2536, AZD7762 and MLN8237 on 
MYC-driven MBGroup3 cell lines would highly impair their viability through the induction of 
apoptosis.  
Results from the cell-proliferation rescue assay performed on the MYC-regulable isogenic cell 
lines further supports our hypothesis that the induction of apoptosis after treatment was 
preferentially triggered on cells expressing high levels of MYC expression, in comparison to 
those with MYC knockdown. Throughout recovery time after drug treatment, a time- and 
dose-dependent decrease in cells proliferation was seen across cell lines. Cells expressing 
higher levels of MYC were unable to recover cell growth during recovery time, indicating cell 
death was induced after treatment. Increase in the proportion of metabolically active cells 
after treatment, following MYC knockdown, suggests that inhibition of PLK1, CDK2, AURKA 
and CHK1 did not result in such pronounced cell death, which allowed a slight recovery in cells 
proliferation after treatment, which was therefore MYC-dependent.    
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To further validate the MYC-dependency of the results presented, additional experiments 
using alternative backgrounds of MYC-expression could shed light into the relationship 
between MYC and the candidate targets selected. A direct way to study the MYC-dependency 
of PLK, CHK, CDK and AURK would be to engineer MBSHH cell lines to over-express MYC. If the 
effect of the inhibitors were truly dependent on MYC expression, a change in cells sensitivity 
and downstream signalling effectors would be seen following exposure to the inhibitors, 
proving the veracity of our results and the dependency of MYC on these molecules. 
Also, the MYC-dependent effect observed on MB cell lines could be studied using MYC-
amplified or MYC-overexpressing cell models of other cancer types (i.e. neuroblastoma, 
ovarian, breast). The characterisation of the effect of the inhibitors chosen on alternative 
cancer models expressing high-levels of the MYC oncogene would selectively confirm their 
MYC-dependent effect.  
 
 
Results presented strongly support the use of compounds inhibiting CHK1, PLK1 and AURKA 
as strategies for targeting MYC-amplified Group 3 medulloblastoma. Our data suggests that 
inhibition of CHK1, PLK1 and AURKA will result in a direct decrease of MYC protein expression, 
specifically impairing cell viability of MYC-dependent MBGroup3. Our data supports the 
evaluation of compounds inhibiting the targets identified within patient derived xenografts 
(PDX) and genetically engineered mouse (GEM) models to provide concluding evidence to 







Appendix 6.1. Growth-inhibitory effect of ‘hit’ compounds from HTCS on D425 MYC3 cells.Concentration-dependent 
inhibitory dose-curves of D425 MYC3 MBGroup3 cells to treatment with BI2536 (PLK1 inhibitor), SN38 (topoisomerase I), 
Milciclib (CDK2 inhibitor), MLN8237 (AURKA inhibitor), YM155 (BIRC5 inhibitor), MK1775 (WEE1 inhibitor), AZD7762 (CHK1 
inhibitor) and Prexasertib (CHK1/2 inhibitor). D425 MYC3, cultured in the absence (-dox; MYC ON) and presence (+dox; MYC 
OFF) of DOX for MYC knockdown, were exposed to a single dose of 8 different concentrations of each inhibitor (0.5, 1, 5, 10, 
50, 100, 500, 1000, 5000nM) for a period of five days. After treatment, cell viability was measured with CellTiter-Glo and 
values obtained analysed with Prism8 to generate dose-response growth inhibition curves that fit a non-linear regression 
model. Curves are presented as log(concentration) vs response, and represent the percentage of cell viability of two 
independent experiments done in triplicate, relative to cells grown in the presence of DMSO. The growth inhibitory effect of 
the drug on D425 MYC3 overexpressing cell lines and with MYC knockdown was compared by paired student’s t-test 





Appendix 6.2. Growth-inhibitory effect of ‘hit’ compounds from HTCS on D283 MYC3 cells.Concentration-dependent 
inhibitory dose-curves of D283 MYC3 MBGroup3 cells to treatment with BI2536 (PLK1 inhibitor), SN38 (topoisomerase I), 
Milciclib (CDK2 inhibitor), MLN8237 (AURKA inhibitor), YM155 (BIRC5 inhibitor), MK1775 (WEE1 inhibitor), AZD7762 (CHK1 
inhibitor) and Prexasertib (CHK1/2 inhibitor). D283 MYC3, cultured in the absence (-dox; MYC ON) and presence (+dox; MYC 
OFF) of DOX for MYC knockdown, were exposed to a single dose of 8 different concentrations of each inhibitor (0.5, 1, 5, 10, 
50, 100, 500, 1000, 5000nM) for a period of five days. After treatment, cell viability was measured with CellTiter-Glo and 
values obtained analysed with Prism8 to generate dose-response growth inhibition curves that fit a non-linear regression 
model. Curves are presented as log(concentration) vs response, and represent the percentage of cell viability of two 
independent experiments done in triplicate, relative to cells grown in the presence of DMSO. The growth inhibitory effect of 
the drug on D283 MYC3 overexpressing cell lines and with MYC knockdown was compared by paired student’s t-test 




Appendix 6.3. Growth-inhibitory effect of ‘hit’ compounds from HTCS on HDMB03 MYC3 cells.Concentration-dependent 
inhibitory dose-curves of HDMB03 MYC3 MBGroup3 cells to treatment with BI2536 (PLK1 inhibitor), SN38 (topoisomerase I), 
Milciclib (CDK2 inhibitor), MLN8237 (AURKA inhibitor), YM155 (BIRC5 inhibitor), MK1775 (WEE1 inhibitor), AZD7762 (CHK1 
inhibitor) and Prexasertib (CHK1/2 inhibitor). HDMB03 MYC3, cultured in the absence (-dox; MYC ON) and presence (+dox; 
MYC OFF) of DOX for MYC knockdown, were exposed to a single dose of 8 different concentrations of each inhibitor (0.5, 1, 
5, 10, 50, 100, 500, 1000, 5000nM) for a period of five days. After treatment, cell viability was measured with CellTiter-Glo 
and values obtained analysed with Prism8 to generate dose-response growth inhibition curves that fit a non-linear regression 
model. Curves are presented as log(concentration) vs response, and represent the percentage of cell viability of two 
independent experiments done in triplicate, relative to cells grown in the presence of DMSO. The growth inhibitory effect of 
the drug on HDMB03 MYC3 overexpressing cell lines and with MYC knockdown was compared by paired student’s t-test 




Appendix 6.4. Growth-inhibitory effect of ‘hit’ compounds from HTCS on D425 NS cells.Concentration-dependent inhibitory 
dose-curves of D425 NS MBGroup3 cells to treatment with BI2536 (PLK1 inhibitor), SN38 (topoisomerase I), Milciclib (CDK2 
inhibitor), MLN8237 (AURKA inhibitor), YM155 (BIRC5 inhibitor), MK1775 (WEE1 inhibitor), AZD7762 (CHK1 inhibitor) and 
Prexasertib (CHK1/2 inhibitor). D425 NS, cultured in the absence (-dox; MYC ON) and presence (+dox; MYC OFF) of DOX for 
MYC knockdown, were exposed to a single dose of 8 different concentrations of each inhibitor (0.5, 1, 5, 10, 50, 100, 500, 
1000, 5000nM) for a period of five days. After treatment, cell viability was measured with CellTiter-Glo and values obtained 
analysed with Prism8 to generate dose-response growth inhibition curves that fit a non-linear regression model. Curves are 
presented as log(concentration) vs response, and represent the percentage of cell viability of two independent experiments 
done in triplicate, relative to cells grown in the presence of DMSO. The growth inhibitory effect of the drug on D425 NS with 




Appendix 6.5. Growth-inhibitory effect of ‘hit’ compounds from HTCS on D283 NS cells. Concentration-dependent 
inhibitory dose-curves of D283 NS MBGroup3 cells to treatment with BI2536 (PLK1 inhibitor), SN38 (topoisomerase I), Milciclib 
(CDK2 inhibitor), MLN8237 (AURKA inhibitor), YM155 (BIRC5 inhibitor), MK1775 (WEE1 inhibitor), AZD7762 (CHK1 inhibitor) 
and Prexasertib (CHK1/2 inhibitor). D283 NS, cultured in the absence (-dox; MYC ON) and presence (+dox; MYC OFF) of DOX 
for MYC knockdown, were exposed to a single dose of 8 different concentrations of each inhibitor (0.5, 1, 5, 10, 50, 100, 500, 
1000, 5000nM) for a period of five days. After treatment, cell viability was measured with CellTiter-Glo and values obtained 
analysed with Prism8 to generate dose-response growth inhibition curves that fit a non-linear regression model. Curves are 
presented as log(concentration) vs response, and represent the percentage of cell viability of two independent experiments 
done in triplicate, relative to cells grown in the presence of DMSO. The growth inhibitory effect of the drug on D283 NS with 




Appendix 6.6. Growth-inhibitory effect of ‘hit’ compounds from HTCS on HDMB03 NS cells. Concentration-dependent 
inhibitory dose-curves of HDMB03 NS MBGroup3 cells to treatment with BI2536 (PLK1 inhibitor), SN38 (topoisomerase I), 
Milciclib (CDK2 inhibitor), MLN8237 (AURKA inhibitor), YM155 (BIRC5 inhibitor), MK1775 (WEE1 inhibitor), AZD7762 (CHK1 
inhibitor) and Prexasertib (CHK1/2 inhibitor). HDMB03 NS, cultured in the absence (-dox; MYC ON) and presence (+dox; MYC 
OFF) of DOX for MYC knockdown, were exposed to a single dose of 8 different concentrations of each inhibitor (0.5, 1, 5, 10, 
50, 100, 500, 1000, 5000nM) for a period of five days. After treatment, cell viability was measured with CellTiter-Glo and 
values obtained analysed with Prism8 to generate dose-response growth inhibition curves that fit a non-linear regression 
model. Curves are presented as log(concentration) vs response, and represent the percentage of cell viability of two 
independent experiments done in triplicate, relative to cells grown in the presence of DMSO. The growth inhibitory effect of 













Appendix 6.7. Effect of BI2536 treatment on cell cycle distribution in isogenic MBGroup3 cell lines. Cell cycle distribution of D425, D283 and HDMB03 MYC2 cell lines 
after 72h of a single exposure of half the IC50 (0.5xIC50), IC50 (1xIC50), and twice the IC50 (2xIC50) concentration of A)BI2536, B)Milciclib, C)MLN8237, D)AZD7762 and 
E)Prexasertib. Cells were stained with propidium iodide and cell cycle distribution analysed by flow cytometry. Graph represents the percentage (%) of cells of each cell 
cycle phase relative to total phases, of cells expressing high levels of MYC and those with MYC knockdown (+DOX). Untreated cells (no drug; DMSO only) were used for 







Appendix 6.8. Proliferation of isogenic MBGroup3 cell lines after treatment with BI2536.Cell-
proliferation rescue assay of D425, D283 and HDMB03 MYC2 during and after exposure to the PLK1 
inhibitor BI2536. Cells expressing high levels of MYC (-dox; MYC ON) and those with MYC knockdown 
(+dox; MYC OFF) were exposed to 0.5xIC50, IC50 and 2xIC50 concentration for 5 days. After exposure, 
drug was removed from the media, media changed, and cells left to grow for further 5 and 9 days. 
Cell proliferation was assessed with CTG at 3, 5, 10 and 14 days after drugging. Untreated cells (no 
drug) were used for each condition (+/-dox) as controls. Data was blank-corrected to DMSO-
containing wells, and normalised to day 0. Graphs show the comparison of growth between 
untreated cells (blue) and those treated with the inhibitor (red, green and purple). Data is presented 




Appendix 6.9. Proliferation of isogenic MBGroup3 cell lines after treatment with Milciclib.Cell-
proliferation rescue assay of D425, D283 and HDMB03 MYC2 during and after exposure to the CDK2 
inhibitor Milciclib. Cells expressing high levels of MYC (-dox; MYC ON) and those with MYC 
knockdown (+dox; MYC OFF) were exposed to 0.5xIC50, IC50 and 2xIC50 concentration for 5 days. After 
exposure, drug was removed from the media, media changed, and cells left to grow for further 5 
and 9 days. Cell proliferation was assessed with CTG at 3, 5, 10 and 14 days after drugging. Untreated 
cells (no drug) were used for each condition (+/-DOX) as controls. Data was blank-corrected to 
DMSO-containing wells, and normalised to day 0. Graphs show the comparison of growth between 
untreated cells (blue) and those treated with the inhibitor (red, green and purple). Data is presented 




Appendix 6.10. Proliferation of isogenic MBGroup3 cell lines after treatment with MLN8237.Cell-
proliferation rescue assay of D425, D283 and HDMB03 MYC2 during and after exposure to the 
AURKA inhibitor MLN8237. Cells expressing high levels of MYC (-dox; MYC ON) and those with MYC 
knockdown (+dox; MYC OFF) were exposed to 0.5xIC50, IC50 and 2xIC50 concentration for 5 days. After 
exposure, drug was removed from the media, media changed, and cells left to grow for further 5 
and 9 days. Cell proliferation was assessed with CTG at 3, 5, 10 and 14 days after drugging. Untreated 
cells (no drug) were used for each condition (+/-DOX) as controls. Data was blank-corrected to 
DMSO-containing wells, and normalised to day 0. Graphs show the comparison of growth between 
untreated cells (blue) and those treated with the inhibitor (red, green and purple). Data is presented 




Appendix 6.11. Proliferation of isogenic MBGroup3 cell lines after treatment with AZD7762.Cell-
proliferation rescue assay of D425, D283 and HDMB03 MYC2 during and after exposure to the CHK1 
inhibitor AZD7762. Cells expressing high levels of MYC (-dox; MYC ON) and those with MYC 
knockdown (+dox; MYC OFF) were exposed to 0.5xIC50, IC50 and 2xIC50 concentration for 5 days. After 
exposure, drug was removed from the media, media changed, and cells left to grow for further 5 
and 9 days. Cell proliferation was assessed with CTG at 3, 5, 10 and 14 days after drugging. Untreated 
cells (no drug) were used for each condition (+/-DOX) as controls. Data was blank-corrected to 
DMSO-containing wells, and normalised to day 0. Graphs show the comparison of growth between 
untreated cells (blue) and those treated with the inhibitor (red, green and purple). Data is presented 





Appendix 6.12. Proliferation of isogenic MBGroup3 cell lines after treatment with Prexasertib.Cell-
proliferation rescue assay of D425, D283 and HDMB03 MYC2 during and after exposure to the CHK1 
inhibitor Prexasertib. Cells expressing high levels of MYC (-dox; MYC ON) and those with MYC 
knockdown (+dox; MYC OFF) were exposed to 0.5xIC50, IC50 and 2xIC50 concentration for 5 days. After 
exposure, drug was removed from the media, media changed, and cells left to grow for further 5 
and 9 days. Cell proliferation was assessed with CTG at 3, 5, 10 and 14 days after drugging. Untreated 
cells (no drug) were used for each condition (+/-DOX) as controls. Data was blank-corrected to 
DMSO-containing wells, and normalised to day 0. Graphs show the comparison of growth between 
untreated cells (blue) and those treated with the inhibitor (red, green and purple). Data is presented 









Medulloblastoma is the most frequent malignant brain tumour in childhood, accounting for 
10% of all paediatric deaths from cancer. Survival rates have dramatically improved over the 
last three decades using multimodal treatment protocol of standard care, where around 80% 
of standard risk patients survive over 5 years, and between 60-65% of those with high-risk 
features (Pizer and Clifford, 2009, Packer et al., 2006, Gajjar et al., 2006, Lannering et al., 
2012). Despite reasonably high cure rates, current therapy regimes come at the expense of 
adverse treatment side effects that highly impair survivors´ quality of life (Edelstein et al., 
2011). 
Advances in molecular genomics over the past couple of decades have helped decipher the 
molecular underpinnings of this highly heterogeneous disease, providing some biologically 
and clinically relevant features. It is now recognised that MB comprises four molecular 
subgroups, Wnt (MBWNT), Shh (MBSHH), Group 3 (MBGroup3) and Group 4 (MBGroup4), 
characterised by distinct demographics, genetic, epigenetic and clinic-pathological features 
(Taylor et al., 2012, Northcott et al., 2012a). Recently, further refinement of the subgroups 
has recognised further substructures within each subgroup, suggesting between 7 and 12 MB 
subtypes (Schwalbe et al., 2017, Cavalli et al., 2017). 
MBGroup3 are highly aggressive tumours, commonly characterised by metastatic disease at 
diagnosis, with overall 5-year survival of less than 60%. Despite carrying the worst prognosis 
of all subgroups, the common driver pathway of this subgroup of tumours has not yet been 
identified. MYC oncogene amplification or overexpression is the most common recurring 
alteration (accounting for 17% of MBGroup3 cases), which has become the hallmark of this 
subgroup of tumours (Kool et al., 2012, Northcott et al., 2012a). 
The molecular characterisation of MB has already been used to guide the development of new 
clinical trials. Stratification of the disease incorporating pathological variants, subgroup 
information and molecular characteristics, has enabled adjustment of therapeutic regimes 
according to patients’ prognosis. In this regard, SMO inhibitors have been incorporated into 
the treatment for MBSHH patients and reduced intensity are being used for MBWNT patients 
presenting with low-risk features (Lee et al., 2019). Unfortunately, no major changes have 
proceeded to enhance outcomes for MBGroup3 patients. Despite incorporating subgroup-
specific treatment stratification, substantial biological and survival differences are still 
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apparent within subgroups (Mack and Northcott, 2017, Schwalbe et al., 2017, Cavalli et al., 
2017).  
There is thus an urgent need to develop new therapeutic strategies for high-risk MB patients 
within Group 3. The fact that MYC depletion causes growth arrest and tumour regression in 
MYC-driven murine MB models, indicating the essentiality of MYC in MBGroup3 tumour biology 
(Pei et al., 2012, Roussel and Robinson, 2013), has stimulated interest in developing strategies 
to disrupt MYC function to treat this specific subgroup of tumours.  
MYC is a multifunctional transcriptional factor determining the expression of a large number 
of genes involved cellular processes including cell-cycle progression, metabolism, apoptosis, 
ribosome biogenesis and protein synthesis (Tansey, 2014). Deregulation of the MYC oncogene 
occurs in most cancers, where sustained high levels of MYC have a dramatic impact on a wide 
range of cellular processes facilitating the acquisition of the set of genetic changes required 
to maintain the hallmarks of malignancy (Jain et al., 2002, Hanahan and Weinberg, 2000). 
Upregulation of MYC expression alone is incapable of driving neoplastic transformation. This 
has led to increased interest in elucidating the biological context-specific role of MYC in 
tumorigenesis, and its complex interacting network of genes to identify those who synergise 
with MYC to promote malignant transformation and could be targeted to develop clinically 
relevant strategies to treat MYC-driven cancers (Gabay et al., 2014, Meyer and Penn, 2008, 
Whitfield et al., 2017) 
The ever-growing knowledge regarding MYC biology and function from research done on all 
types of human cancers, an array of direct and indirect targeting strategies have been 
developed to abrogate MYC function and to manipulate MYC-dependent signalling pathways 
as a therapeutic strategy to treat MYC-driven cancers (Grotzer et al., 2009, Whitfield et al., 
2017, Juraschka and Taylor, 2019). The feasibility of targeting MYC or its dependent expression 
programs are particularly attractive strategies to treat high-risk patients with MBGroup3, aiming 
at more biologically relevant approaches to improve standard treatment and survival rates of 





7.2 Summary of findings  
Deregulation of MYC activity in most cancers has been associated with tumour aggressiveness 
and poorer survival, with most of them showing a clear dependence on it. Research on MYC 
in the context of medulloblastoma has previously been conducted, with studies reporting 
growth arrest and tumour regression following depletion of MYC in MYC-driven cell and 
murine MB models. (Stearns et al., 2006, von Bueren et al., 2009, Pei et al., 2012, Roussel and 
Robinson, 2013, Li et al., 2014b).  
MYC-dependent transcriptional signatures are cell specific, and the study of its function and 
biology must be done accordingly. To date, the cell-specific MYC-dependent expression 
program in MBGroup3 has not been studied. Therefore, the current study was conceived and 
undertaken to provide a better understanding of MYC´s role in MB tumour biology by 
exploring it in a MBGroup3 context-specific MYC-dependent manner, with the aim to provide 
evidence of the MYC-dependency of Group 3 medulloblastoma tumours and to identify MYC-
associated pathways that could be ultimately exploited in the clinic to improve survival of MB 
patients with this specific subgroup.  
To accomplish this, newly generated D425, D283 and HDMB03 isogenic MBGroup3 cell lines with 
a DOX-inducible system for MYC knockdown, generated by the PBTG, were used to investigate 
the nature and extent of MYC dependency and involvement in MBGroup3 pathogenesis.  
Firstly, the effectiveness of MYC knockdown achieved with the inducible shRNA system was 
validated at the protein and mRNA level in all three sets of cell lines. Moreover, the MYC-
dependent cancer phenotypes of the models were established and characterised, where 
reduction of MYC expression significantly decreased cells proliferation and apoptotic markers. 
Reduction in MYC-expression levels results in a G1 cell cycle arrest, leaving cells in a 
metabolically activate state but without being actively growing. 
Sensitisation of MYC-overexpressing MBGroup3 isogenic cells to ionising radiation further 
exemplified the appropriateness of using the newly generated MYC-regulable cell lines as 
models to study MYC’s dependent biology and therapeutic response within human MBGroup3 




Following establishment of the MYC-dependent phenotype, the role of MYC-
amplification/gain in drug sensitivity/resistance was investigated using the MYC-regulable 
isogenic models. The therapeutic potential of the pharmacological targeting of signalling 
pathways associated with MYC was assessed in a MYC-dependent manner with the newly 
generated models, undertaking three indirect pharmacological anti-MYC strategies (targeting 
MYC transcription through BRD4 and CDK9 inhibition, and MYC mRNA translation through 
mTOR inhibition), previously shown to downregulate MYC transcriptional signature in other 
MYC-driven cancers.  
A MYC-dependent drug-sensitivity effect was observed following mTOR inhibition with 
AZD2014 (Vistusertib) and INK128 (Sapanisertib), BRD4 inhibition with JQ1 and CDK9 
inhibition with CYC065; greater growth-inhibition following treatment with the inhibitors was 
seen in MBGroup3 cells overexpressing MYC when compared to their counterparts with MYC 
knockdown, highlighting the potential interconnection of these molecular features with MYC 
expression in Group 3 medulloblastoma.  
Notably, targeting MYC mRNA translation through mTOR inhibition, a downstream target of 
the PI3K/AKT signalling pathway, did not have a downregulatory effect on MYC expression. 
On the other hand, targeting MYC transcription through CDK9 and BRD4 inhibition resulted in 
reduced MYC protein levels, with growth arrest and apoptosis induction, highlighting the 
potential of BRD4 and CDK9 inhibition as a therapeutic strategy to treat MYC overexpressing 
MBGroup3 tumours (Chapter 4). 
Based on the current availability of multiple pharmacological approaches to indirectly target 
MYC at different levels, and the potential MYC-dependency of established chemo-
therapeutics, a high-throughput compound screening (HTCS) was performed on the MYC-
regulable isogenic cell lines to investigate the MYC dependency of the response of MYC 
overexpressing cells and with MYC knockdown to a large panel of conventional chemo-
therapeutics and small molecule inhibitors. The HTCS, which covered most of the targetable 
molecules previously associated with a MYC-downregulatory effect, was used to identify drugs 
exhibiting a MYC-dependent effect (i.e. causing greater growth-inhibition of cells 




Scrutinisation of HTCS data identified 82 small molecule inhibitors which selectively inhibited 
the growth of MYC-overexpressing cell lines. Compounds identified showed a variety of 
associated mechanisms of action, with the vast majority inhibiting effectors of biological 
processes required for cell growth (cyclin-dependent kinases, aurora kinases, checkpoint 
kinases, polo-like kinases, microtubule formation…etc.). As described in Chapter 5, integration 
of HTCS results with data on transcriptional MB primary samples and MYC-regulable cell 
models predicted PLK1 (3.7% of hits), CHK1 (4.9% of hits), AURK (9.8% of hits) and CDK (12.2% 
of hits) as targetable molecular agents to be effective on MBGroup3. Molecules identified 
through the integration of data sets overlapped significantly with results from a MB whole-
genome CRISPR screen, validating our experiments and approach, and allowing prioritisation 
for further investigation.  
A compound representative of each cellular mechanism, and considering published data on 
its properties (i.e. previous testing in MB or brain tumours, use in clinical trials and potential 
mechanistic associations with MYC oncogene already established), was prioritised to take 
forward for validation of findings from Chapter 5, and to further assess their MYC-dependent 
effect in a wider varied panel of MB cell lines (MYC-amplified/regulable MBGroup3 and non-
amplified MBSHH cell lines). Reasoning behind studying the effect of the inhibitors on other MB 
cell lines with different backgrounds of MYC-expression, was to study further the MYC-
dependency of the molecules identified and their specific relationship with MYC. The use of 
available non-MYC amplified MBSHH (DAOY and UW228.2) cell lines would help to study the 
reproducibility of the MYC-dependent sensitivities observed, and to demonstrate that the 
susceptibility observed were not a direct result of MYC downregulation with shRNA.  
Additionally, a small molecule compound not previously tested in the screen, Prexasertib 
(LY2606368; CHK1 inhibitor), was taken forward to test on MB cell lines to independently 
confirm target-dependent results from the screen (Chapter 5).    
The effect of prioritised compounds inhibiting CHK1 (AZD7762, Prexasertib), PLK1 (BI2536), 
CDK2 (Milciclib), AURKA (MLN8237), WEE1 (MK1775), BIRC5 (YM155), and TOP1 (SN38) was 
individually assessed in MYC-amplified/regulable MBGroup3 and non-MYC amplified MBSHH cell 
lines, broadly validating the MYC-dependent growth inhibitory effects seen from the HTCS 
after exposure to the inhibitors, with the exception of BIRC5 inhibition by YM155, a control 
drug which inhibited cell growth regardless of MYC expression levels (Chapter 6).  
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Further analysis of downstream pathway targets was prioritised to genes overlapping 
between datasets. Evaluation of changes in pharmacodynamic endpoints indicative of CHK1, 
PLK1, CDK2 and AURKA inhibition was performed to assess the mechanistic effects of the 
compounds and their effect on MYC expression. Inhibition of the main targetable molecules 
resulted in a time- and dose-dependent decrease of MYC protein levels across cell lines, with 
specificity of target inhibition for Group 3 compared to MBSHH cell lines.  
Importantly, the inhibitors exhibited a downregulatory effect of their main target protein 
across cell lines regardless of subgroup and MYC expression. In addition, analysis of expression 
of downstream pathway targets revealed a downregulation of the anti-apoptotic protein 
MCL1 in a MYC-dependent subgroup-specific manner after treatment with Prexasertib 
(CHK1/2 inhibitor) and BI2536 (PLK1 inhibitor). In comparison, Milciclib (CDK2 inhibitor) 
caused the MBGroup3 subgroup-specific MYC-dependent upregulation of the protein, in 
comparison to the downregulatory effect it had on MBSHH cell lines. No association with MYC 
expression or subgroup was seen after treatment with MLN8237 (AURKA inhibitor) and 
AZD7762 (CHK1 inhibitor), where a common observation of increased MCL1 protein levels was 
seen (Chapter 6).  
As previously discussed in Chapter 6, differences in the growth inhibitory effect and inhibition 
of downstream pathway targets between both CHK1 inhibitors, AZD7762 and Prexasertib, 
could be a direct consequence of preferential inhibition of CHK2 over CHK1 by Prexasertib. 
Interference with the ATM signalling pathway through CHK2 inhibition appears to be more 
detrimental to MBGroup3 cells expressing high-levels of MYC. Future experiments should 
include an extensive assessment of biomarkers of CHK1 and CHK2 inhibition, and a 
comprehensive study on how the inhibitors affect both DDR pathways. These studies could 
help understand why MBGroup3 lines presented increased sensitivity to Prexasertib, and how 
this could be used to target this subgroup of tumours.  
As reported in Chapter 6, the effect of PLK1, AURKA, CDK2 and CHK1 on MYC-overexpressing 
MBGroup3 cell survival was MYC-dependent and linked to apoptosis, whereas at lower levels of 
MYC expression, the compounds caused G2-M cell cycle arrest. Induction of apoptosis was 
confirmed by the inability of cells to recover growth after treatment with the compounds. A 
MYC-dependent time and dose-dependent decrease in cell viability after treatment further 
supports the notion that MBGroup3 cells depend on the expression of PLK1, AURKA, CDK2 and 
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CHK1, and their inhibition causes downregulation of MYC with a direct impact on cell survival 
(Chapter 6). 
In summary, this study provides the first direct and extensive investigation of therapeutic 
MYC-dependencies in Group 3 medulloblastoma, identifying CDK9, BRD4, PLK1, CDK2, AURKA 
and CHK1 as new MYC-regulatory mechanisms that could be therapeutically exploited against 
MYC-driven high-risk MBGroup3. The significance of our findings and how these could be 
advanced and translated into patient benefit are discussed below.   
 
7.3 Relevance of results presented 
For the appropriate development of tailored therapeutic approaches, a better understanding 
of disease biology in a subgroup specific context is essential. The lack of identified driver 
pathways in MBGroup3 has placed efforts on targeting its most recurrent genetic alteration, MYC 
amplification/overexpression. So far, studies of MBGroup3 tumour biology have utilised MYC-
amplified cell lines and mouse models resembling MYC-activated MB, but elevated MYC-
expression is a characteristic feature of only a subset of MBGroup3 tumours (Ivanov et al., 2016) 
(Robinson et al., 2012, Venkataraman et al., 2014, Menyhárt et al., 2019, Kawauchi et al., 
2017) 
This study presented the validation of the newly generated MYC-regulable MBGroup3 cell lines 
as new models to study MBGroup3 biology with better resemblance to the nature of the disease, 
which could provide better insight into MBGroup3 pathogenesis and MYC’s involvement in it. 
Generation of the lines was focused to enable the modulation of MYC to specifically study the 
true requirement of MBGroup3 cell lines on MYC and to reveal MYC-associated genetic and 
therapeutic dependencies.  
Furthermore, testing of already established indirect anti-MYC approaches in a MYC-
dependent manner in MBGroup3 highlighted the potential of BRD4 and CDK9 inhibition to 
specifically downregulate MYC expression and its oncogenic transcriptional program in MYC-
driven MBGroup3. Results presented in this thesis are in accordance with current studies 
supporting the hypothesis of using BRD4 and CDK9 inhibitors to downregulate MYC 
transcription (Lu et al., 2015, Bolin et al., 2018, Delmore et al., 2011). These results provide 
new evidence of the MYC-dependency of these proteins in MBGroup3, further supporting the 
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use of BRD4 and CDK9 inhibitors as potential new avenues against the most aggressive form 
of MB.  
The present study provides a valuable resource of drug-sensitivity data of Group 3 MB cell 
lines to almost 500 cancer therapeutics and small molecule inhibitors targeting a broad range 
of key signalling pathways in tumour biology. Results from the high-throughput compound 
screen on MYC-regulable lines not only enabled the specific identification of differences in 
sensitivity according to MYC expression levels, but permitted the characterisation of the 
response to several compounds. Such compounds, with many of them already established for 
cancer treatment (i.e. Gemcitabine, Paclitaxel, Docetaxel, etc.) or are in late stages of clinical 
development (for easier and faster translation to the clinic) have never been tested in MB, 
which could reveal better chemotherapeutic approaches for MBGroup3.  
Most importantly, screen data showed that current conventional therapies may be MYC-
dependent. Classification of the 82 inhibitors with a MYC-dependent effect according to them 
being conventional or non-conventional therapeutics, identified increased sensitivity of MYC-
overexpressing MBGroup3 cell lines to inhibitors targeting β-tubulin for microtubule formation 
and topoisomerases (i.e. Paclitaxel, SN-38, Camptothecin, Docetaxel; Table 5.2 of Chapter 5). 
The analysis of differences in growth inhibition between MYC-overexpressing MBGroup3 lines 
and MYC-silenced with shRNA revealed that current chemotherapeutic agents used in MB 
treatment, such as Vincristine and Cyclophosphamide, had no consistent effect on our models. 
Our findings can potentially explain the poor responsiveness of Group 3 medulloblastoma to 
current therapies, emphasising the need for alternative chemotherapeutic agents for patients 
with MBGroup3. Results from the screen suggest the use of inhibitors targeting microtubule 
formation and topoisomerases to be extremely effective in MBGroup3, identifying alternative, 
specific, and more potent chemotherapeutic agents that could improve current 
chemotherapeutic regimens for patients with Group 3 medulloblastoma.   
An advantage of the approach taken with the high-throughput compound screen is the fact 
that it allowed us to study the response to the compounds across a range of drug 
concentrations, avoiding possible artefactual effects seen by other high-throughput screening 
methodologies, where only a single-concertation of each compound is tested, which can mask 
MYC-dependent effects (Rieken et al., 2015, Ricci* et al., 2018, Clare et al., 2019). 
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The key to interpreting functional screening is the ability to define ‘high-confidence’ hits. The 
opportunity to integrate data from MYC-dependent transcriptional profiles of the tumour cell 
lines and primary MB tumour with the results from the screen, and the cross-validation of 
results with data from genetic dependencies from CRISPR in MB lines (Selby et al., 2017), 
enabled a more robust and confident definition of PLK1, CHK, CDK, and AURK as relevant 
molecular targets in MBGroup3. Integrative approach allowed the specific prioritisation of 
compounds targeting these molecules for new effective targetable approaches for this MB 
subgroup.   
As a master transcriptional regulator, MYC drives the transcription of several cell cycle 
proteins, including CDKs (CDK2, CDK4 and CDK6), PLK1 and AURK (Aurora A and Aurora B) to 
stimulate cell cycle progression (Otto and Sicinski, 2017). It is well established that MYC 
amplified tumours depend on MYC’s growth-regulatory signal for enhanced and uncontrolled 
cell proliferation, which requires a highly regulated cell cycle process to ensure genomic 
integrity for cell survival and consequent tumour progression (Murga et al., 2011). By 
dysregulating key cell cycle regulatory proteins, cells are able to enter mitosis with a greater 
load of genetic instability, which eventually triggers the apoptotic signalling cascade. This 
could explain why cells overexpressing MYC presented higher sensitivity to the inhibition of 
these molecules, with the inhibitors having a greater growth inhibitory effect on cells 
overexpressing MYC.  
The importance of such proteins has led researchers to pursue their inhibition to indirectly 
target MYC activity in MYC-driven cancers, including medulloblastoma. (Muscal et al., 2013, 
Hill et al., 2015, Otto and Sicinski, 2017, Ferrao et al., 2012, Ando et al., 2019, Balakrishnan et 
al., 2017, Bolin et al., 2018, Campaner et al., 2010). This study presents the first-ever 
phenotypic and molecular characterisation of the inhibitory effect of PLK1 (BI2536), CHK1 
(AZD7762; Prexasertib), CDK2 (Milciclib) and AURKA (MLN8237) on the expression of MYC and 
downstream pharmacodynamic endpoints of the signalling pathway in the specific context of 
MBGroup3, which could guide the establishment of new combinational approaches to most 
effectively manipulate the MYC-dependent expression signature in MYC-driven high-risk 
MBGroup3 as a therapeutic avenue to treat patients with this tumours.  
Data presented highlights the most effective way to target MYC-dependent MBGroup3 tumours. 
Since lower MYC expression levels result in downregulation of proliferation and apoptosis, 
and seems to protect tumours from the effect of inhibitors, the targeting of genes and 
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molecular features required for MYC-overexpressing cell lines to survive is the most powerful 
approach to affect tumour cells viability.  
Current literature on components of the MYC-interactome (Balakrishnan et al., 2017, Xiao et 
al., 2016, Triscott et al., 2013, Han et al., 2019b, Harris et al., 2012), in combination with the 
data generated from this study indicate PLK1 as the most promising target to effectively 
achieve growth arrest and tumour regression in MYC-driven MBGroup3 tumours by 
compromising MYC expression PLK1 inhibition with BI2536 showed the most consistent MYC 
downregulatory effect, in addition to downregulating PLK1 signalling pathway, across MBGroup3 
cell lines. We provided evidence of the specific dependency of MBGroup3 lines to PLK1, outlining 
the promising clinical application of PLK1 inhibitors to treat patients with Group 3 MB.  
In summary, this study presents the first most extensive investigation of MYC-dependencies 
in Group 3 medulloblastoma using newly established MYC-regulable cell lines with the aim to 
provide enough evidence to develop new clinically relevant therapeutic approaches to treat 
patients with high-risk MBGroup3. This study provides a valuable resource of MYC-dependent 
drug-sensitivity data of MBGroup3 cell lines to hundreds of small molecule compounds, 
providing the basis for the robust identification of molecular targets associated with MYC 
expression that could specifically be used for novel targeted therapeutic avenues to treat 













7.4 Study limitations  
Some of the potential limitations of the results presented are outlined below. 
This study used MYC-silencing isogenic models to regulate MYC expression to identify MYC-
dependencies in MBGroup3. The use of cell models presents in itself the limitation that they fail 
to adequately recapitulate the heterogeneity of the disease. Despite being a useful tool to 
study primary tumours, they do not completely replicate primary cells and therefore might 
provide slightly different results. Also, cell lines may have acquired additional changes in long-
term culture. Therefore, validation on patient derived xenograft (PDX) models is needed for 
further validation of the results.  
As with any other high-throughput technology, the experimental and automated design come 
with some impediments that need awareness. The HTCS performed used the same broad 
range of concentrations for all the compounds contained in the libraries, which can limit the 
ability to discern differences in sensitivity between compounds as a direct result of MYC-
dependencies or off-target toxicity caused by the drug, since most inhibitors will cause cell 
toxicity when exposed at high (i.e. >50nM) concentrations. Therefore, MYC-dependent effects 
identified from library 13, with the compounds only tested at four different concentrations 
(0.5, 5, 50 and 500nM), should be reinforced by testing the compounds at a smaller range of 
concentrations to better assess the MYC-dependency of the results.    
Chemical differences between compounds were not considered when selecting the time of 
exposure. Cell lines were exposed to all drugs for the same time, as a standard procedure for 
comparison with the main HTCS database. It is possible that prolonged exposures to the 
compounds beyond the five days used here will elicit distinct effects on cell viability, since cell 
inhibitory properties of some agents are amplified over multiple cell cycles (Holme et al., 
2018). 
Regardless of the diversity of small molecule inhibitors contained in the compound libraries 
used, most drugs have been extensively studied and established for cancer treatment. One of 
the up-sides of the broad characterisation of the compounds is that related toxicities have 
already been described from clinical trials and second generations of those compounds can 
be further developed to amend related secondary effects (Rollins et al., 2004, Macarulla et al., 
2010, Asghar et al., 2015, Canella et al., 2017). Although some inhibitors tested might not be 
suitable for clinical purposes, results from the screen should point us to the main signalling 
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pathways that synergise with MYC, to guide drug development for better and newer 
compounds targeting that specific avenue.  
Selection of compounds representative of each class was performed based on current 
published data, rather than functional MB drug-sensitivity data, due to time constraints and 
expenses of experimentation. The information used for choosing compounds as class-
representative of hits lacked functional relevance. It might be possible that by prioritising 
compounds based on published data on MB, some potent compounds against MYC-driven 
MBGroup3 tumours might have been missed. Inhibitors to which the cells were sensitive to, but 
with no prior reports on them being tested on MB models were disregarded. To accurately 
choose the most effective compounds from the screen targeting each class, each one of the 
inhibitors belonging to a class should have been tested independently from the screen, and 
their effect in MBGroup3 cell lines assessed. A more functional approach would have allowed a 
more considered selection of compounds representative of each targeted class. 
The main objective of the project was to assess the MYC-dependency of Group 3 
medulloblastoma using the newly established MYC-inducible isogenic cell lines. After the 
characterisation of the cancer phenotypes of the models, it was established that reduction of 
MYC expression significantly decreased cells proliferation and apoptotic markers. Reduction 
in MYC-expression levels results in a G1 cell cycle arrest, leaving cells in a metabolically 
activated state but without being actively growing. This raises the question whether the 
inducible shRNA system truly reflects MYC-dependent sensitivities or solely identifies reduced 
susceptibility to the inhibitors when proliferation and cell cycle are down-regulated by MYC 
knockdown.  
The common pattern observed after treatment of MBGroup3 cells with most of the inhibitors 
tested in this thesis was the increased resistance of MB cells with MYC-silenced with shRNA. 
Reduction of MYC expression levels in MYC-addicted MBGroup3 lines appears to protect them 
from the effects of the inhibitors, by stopping cell cycle and reducing apoptosis. Additional 
experiments that would expose the actual contribution of MYC-overexpression to the drug 
sensitivity are the testing of candidate inhibitors in other Group 3 cell lines without high-levels 
of MYC expression. Alternatively, performing clonogenic assays after exposure to the 
inhibitors would directly enable the assessment of cell viability.   
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Virtually, all of the Group 3 model cell lines harbour MYC amplifications, a characteristic of 
only 17% of Group 3 tumours (Roussel and Robinson, 2013). Therefore, in order to represent 
the full heterogeneity of patient tumours and understand MYC’s contribution to the high-risk 
aggressive Group 3 phenotype, cell line models of Group 3 tumours without MYC amplification 
should be established. As reported by Ivanov et al., several MB cell lines are still poorly 
characterised, where over half of all available MB cell lines have not been subtyped or 
characterised to the standards of the molecular era of MB research (Ivanov et al., 2016). A 
better characterisation of their genetic features and subtyping could broaden the repertoire 
of models of MBGroup3 disease, which would help in the identification of relevant cells to use 
to answer MYC-related questions in a Group 3 specific context.  
 
Another limitation of the data presented in this study was that cell proliferation was the main 
parameter used to assess cells susceptibility to the inhibitors. CTG assay was used to 
determine the number of viable cells in culture based on quantitation of the ATP present, as 
an indicator of metabolically active cells (the amount of ATP is directly proportional to the 
number of cells present in culture). To provide evidence that the effects of MYC-dependency 
observed are not simply due to the in vitro drug sensitivity assay bias towards cell 
proliferation, cells capacity to divide unlimitedly could be assessed by performing alternative 
in vitro experiments, such as colony formation assays. Clonogenic assays are widely used to 
determine the effectiveness of treatment with cytotoxic agents by assessing cells reproductive 
death (Franken et al., 2006). The addition of colony formation assays to the repertoire of 
experiments performed on the drug candidates, would bring an extra layer of validation of the 
cell’s susceptibility to the inhibitors.  
 
Overall, validation of results was done in a small panel of MB cell lines. Due to the lack of 
Group 3 cell lines without MYC amplification, other MB cell lines available in the PBTG 
belonging to the SHH subgroup were used instead, DAOY and UW228.2.  
MBSHH subgroup is most frequently associated with inactivating mutations of PTCH1 (the SHH 
receptor) or SUFU (a downstream signal transducer). By binding to its receptor, SHH directly 
upregulates MYCN transcription via GLI family transcription factors (Kenney et al. 2003). In 
addition to having uniformly high MYCN expression levels, MYCN amplification can occur in 
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MBSHH, which is a marker of poor prognosis (Ellison et al., 2011, Northcott et al., 2012a).  
Overexpression of MYCN is sufficient to promote proliferation, and MYCN activity is necessary 
for SHH-induced proliferation. 
MYCN is therefore both a marker of enhanced SHH activity; MYCN is a critical mediator of SHH 
signals in granule neuronal precursors (GNPs) (Kenney et al., 2003) and is absolutely required 
for normal cerebellar development. On the other hand, c-MYC is not normally expressed in 
GNPs, and its overexpression is mutually exclusive to MYCN. Despite the fact that MYCN and 
c-MYC genes are differentially expressed in the hindbrain, and that MYCN, but not c-MYC, is a 
target of SHH signalling, it has been reported that MYCN can functionally replace c-MYC in 
mouse development, proliferation and differentiation implying many interchangeable 
functions (Kawauchi et al., 2012)(Malynn et al., 2000)(Kenney et al., 2003)(Zindy et al., 2006).  
Upregulation of MYCN through the SHH signalling pathway in MBSHH might be affecting c-MYC 
expression and interfering with the MYC-dependent drug sensitivities identified. Despite 
probably not being the most relevant cell models to study MYC-dependencies, their inherent 
lower expression of c-MYC makes them an invaluable resource to compare to MYC-
overexpressing MBGroup3 cell lines. Although there are clear differences between the signalling 
pathways that define each subgroup, variation in response to the inhibitors according to MYC 
expression levels was studied to provide insight into MYC’s role in the pathology of MB 
disease, and to identify targetable pathways associated with MYC expression.  
The use of only 2 non-MYC amplified MB cell lines limited the characterisation of differences 
in the response of non-Group 3 cell lines to the compounds (Ivanov et al., 2016). 
Implementation of a larger set of non-MYC amplified medulloblastoma cell lines would bring 
more genetic heterogeneity of the disease, and could help best determine the subgroup 







7.5 Future lines of investigation 
This study validated the newly established isogenic MYC-regulable cell lines as new models to 
investigate the MYC-dependent biology of MBGroup3 tumours, as a means to identify and 
develop novel therapeutic strategies to bring into the clinic for high-risk patients with MBGroup3 
tumours. Some future lines of investigation to exploit our findings and to establish the 
required evidence to support new clinical trials for patients with Group 3 MB are discussed 
below.  
7.5.1 Combinational therapeutic approaches  
Given the highly adaptative nature of MYC-driven MB, emergence of resistance following 
exposures to standard chemotherapeutic agents or small molecule compounds used as single 
agents it is widely established, limiting their therapeutic effectiveness (Othman et al., 2014, 
Bertrand et al., 2018, Dean et al., 2005). Given the complex regulation of the MYC-expression 
program, a MYC-inhibitory strategy should not be limited to a single agent approach, but 
rather a combinational strategy using different compounds targeting unique aspects of MYC 
oncogenicity to help achieve better responses.   
Results presented in this study show that MYC-dependent Group 3 MB tumours are more 
susceptible to perturbation of cell cycle proteins and proteins involved in the control of the 
DNA-damage pathway. Therefore, we provide enough evidence to direct future strategies to 
include the combined use of PLK1 and BRD4 inhibitors, to efficiently downregulate MYC-
expression signatures to sensitise cells to standard chemotherapy. Inhibition of PLK1 with 
BI2536 in addition to MYC knockdown had an additive effect on the isogenic cell lines. In 
principle, a decrease in MYC expression and destabilisation of MYC protein through the 
combinational inhibition of PLK1 and BRD4, can achieve a MYC-dependent tumour regression 
whilst triggering cell death for prolonged responses (Han et al., 2019b, Tontsch-Grunt et al., 
2018).  
An alternative potentially promising approach is the use of AURK and CHK1 inhibitors in 
combination with standard chemotherapy to downregulate MYC-expression to enhance the 
susceptibility of MYC-driven MBGroup3 to DNA-damaging agents, promoting genomic instability 
and to eventually trigger the MYC-dependent apoptotic signalling pathway (Dammert et al., 
2019). As reported in this study, inhibition of AURKA and CHK1 causes cell cycle arrest at G2-
M phase and induces apoptosis in MYC-overexpressing cell lines. The combined inhibition of 
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these key regulators of the cell cycle would preferentially kill MYC-overexpressing cell lines 
over those cells with a normal cell cycle activity and ability to repair damaged DNA caused by 
chemotherapeutic agents.  
Treatment of GTML2 MB xenografts with a combination of CDK2 inhibitors with BRD4 has 
been reported to supress tumour growth in vivo (Bolin et al., 2018). This combination states 
the synergy of both proteins in efficiently downregulating MYC-dependent pathways in MYC-
driven MB. A MYC-dependent growth inhibitory effect was seen after treatment with BRD4 
and CDK2, which was linked with downregulation of MYC protein expression levels. Combined 
inhibition of both proteins should result in a synergistic effect in efficiently inhibiting MYC-
dependent pathways, specifically supressing tumour growth of MYC-overexpressing MBGroup3 
tumours. This approach could have the potential to generate clinically relevant therapeutic 
effects against MYC-driven high-risk MBGroup3 tumours.  
Despite the increasing number of successful drug combination studies to treat MYC-driven 
cancers, discovery of such combinations are mostly based on studies on other types of cancer. 
As stated in this thesis, it is of crucial importance to study MYC in a cell-specific context. In this 
regard, a small-scale drug-combination high-throughput screen could be designed to study 
the combinational inhibitory effect of the molecular targets identified to have a MYC-
dependent effect in our cell lines (Liu et al., 2019b).  
Following the assessment of the activity of each compound as a single agent, a good way to 
bring drug candidates further into clinical testing would be to perform a pairwise combination 
screen with the inhibitors tested in this thesis. The activity of each of the compounds would 
be assessed against the rest of compounds to identify effective combinations. This approach 
would not only allow the assessment of the combinatorial effect of the dual targeting of 
essential molecules for Group 3 MB tumours, but also their relationship and differential effect 
according to MYC expression levels (with and without MYC silenced with shRNA).   
However, clinical applications of combination therapy are often limited by tolerable dose 
ranges, and, therefore, it is desirable to identify combinations that enable dose reduction (i.e. 
synergistic potency)(Tallarida, 2011). Additionally, combining drugs does not necessarily 
translate into an increase in efficacy over the single agents, and, therefore, it is desirable to 
identify combinations with effects greater than what is achievable with either drug alone (i.e., 
synergistic efficacy)(Foucquier and Guedj, 2015, Meyer et al., 2019).  
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To assess a combination’s performance having these two goals in mind, several drug 
quantitative synergy methods have been developed (Chou and Talalay, 1983, Yadav et al., 
2015, Foucquier and Guedj, 2015, Twarog et al., 2016, Zimmer et al., 2016, Schindler, 2017). 
Current methods to quantify drug synergy are based on either Loewe additivity or Bliss 
independence principles. Loewe advanced the dose additivity principle (Loewe and 
Muischnek, 1926), and Bliss first described the multiplicative survival principle (BLISS, 1939). 
The goal of using synergistic drugs is to achieve more with less. Finding such combinations is 
vital for optimizing therapeutic windows, as there exists a fine line between clinical efficacy 
and tolerable doses.  
One of the benefits of combination drug studies is that newly identified targeted compounds 
can be assessed alongside current chemotherapeutic agents used in MB treatment. It is not 
only important to find compounds to which cell lines are sensitive to, but to find how these 
new treatments could be combined with current standard of care chemotherapies, including 
radiation (Zhang and Yang, 2016).  
An interesting approach to take with small-scale combinational studies would be, in one 
instance, to test inhibitors targeting PLK1, CDK2/9, CHK1, AURKA and JQ1 after exposures to 
IR. Assessment of cells’ viability after treatment could help identify synergistic effects between 
targeting these molecules and radiation. Identification of inhibitors with an additive effect to 
radiation could be used to eradicate remaining viable cells after IR treatment, and decrease 
disease recurrence. On the other hand, another promising approach would be to assess the 
synergy of candidate inhibitors with current chemotherapeutic agents, like cisplatin, 
vincristine, cyclophosphamide or lomustine.  
The insufficient efficacy of treatment for patients with MBGorup3 highlights a pressing need for 
synergistically efficacious combinations in order to improve the depth and durability of 
response (Meyer et al., 2019). Finding effective combinational approaches of targeted 
compounds with chemotherapeutic agents could improve responsiveness of high-risk 




7.5.2 Genetic validation of targets with siRNA 
Following the identification of MYC-dependent targets identified from the HTCS and their 
pharmacological validation, the genetic validation of PLK1, CHK1, AURKA and CDK2 inhibition 
should be pursued as an additional approach for target validation (Perwitasari et al., 2013) . 
The evaluation of MYC expression and changes in cell proliferation following the genetic 
attenuation of the expression of our genes of interest by small interfering RNA (siRNA) using 
the MYC-regulable cell lines, would further validate the interconnection of the molecules with 
MYC and establish target-dependency of this specific subgroup of tumours to these proteins, 
providing confidence of their therapeutic inhibitory-value and their potential use in clinical 
settings to target MYC-dependent MB tumours (von Bueren et al., 2009, Jain, 2004) 
 
7.5.3 In vivo assessment of candidate molecular targets  
Mouse models of MB have been instrumental in understanding the disease and the role of 
molecular drivers, and to establish appropriate preclinical pipelines. To date, the research 
community has developed accurate murine models that recapitulate all MB subgroups, each 
of which has been critical for the identification and development of new therapeutic 
approaches (Roussel and Stripay, 2020).  
Mouse models have to closely resemble and recapitulate human tumours, representing 
disease heterogeneity and mimicking molecular, epigenetic and genetic landscapes. 
Conventional knock-out technology has been the pivotal approach to generate some of the 
most accurate genetically engineered mouse models (GEMM) of MB. One example is the 
widely used Patched 1 model of SHH MB, which has enabled the assessment of genes that 
drive MBSHH tumourigenesis (Goodrich et al., 1997).  
The lack of molecular drivers defining Group 3 medulloblastoma delayed the development of 
GEMMs for this specific subgroup. Initially, lentiviral or retroviral vectors that conditionally 
express or repress potential MBGroup3 drivers, including MYC and GIF1, were used to modify 
purified GNPs or neural stem cells to assess the role of these potential MBGroup3 drivers. 
Modified progenitors were then implanted into the cerebella of immune-compromised mice, 
which gave rise to tumours with histopathological and molecular characteristics consistent 
with Group 3. (Kawauchi et al., 2012, Pei et al., 2012, Roussel and Stripay, 2020). 
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MYC-overexpression is the hallmark of MBGroup3. While tumours in this subgroup rarely display 
MYCN amplification, the first mouse model of Group 3 developed had MYCN expression driven 
by the glutamate transporter 1 (Glt1) promoter in hindbrain progenitors (GTML) (Swartling et 
al., 2010). Tumours from this model resembled the phenotype and molecular profile of 
MBGroup3. Despite the histological relevance of the GTML model, MYCN amplification is less 
common than MYC amplification in this subgroup, which has driven the development of a 
derivative model, GMYC, in which MYC is driven by the hindbrain Glt1 promoter (Roussel and 
Stripay, 2020). Alternatively, other models with enforced MYC expression have been 
developed through retroviral gene transfer and the loss of Trp53 function to reprogram GNPs 
or NSC (Kawauchi et al., 2012, Vo et al., 2018, Huang et al., 2019).   
GEMMs of MBGroup3 are a valuable tool for in vitro and in vivo testing, but the whole 
heterogeneity or microenvironment of the tumour can not be fully captured. An increasingly 
prevalent model in MB preclinical research are patient-derived xenograft (PDX) models, which 
address the limitations of GEM models (Roussel and Stripay, 2020). PDXs are generated by 
implanting tissue from a patient’s tumour into mice, amplifying tumours intracranially in vivo 
(Shu et al., 2008). The presence of stromal environmental components and the heterogeneity 
of the tumour cell population provide a significant advantage in regard to a more accurate 
interrogation of disease mechanism and therapeutic response (Hovestadt et al., 2019). Since 
PDXs enable a more accurate recapitulation of the disease, they are becoming the gold 
standard for preclinical testing (Sandén et al., 2017, Brabetz et al., 2018). 
The ability of MBGroup3 mouse models to grow as spheres in vitro, have become instrumental 
for conducting high-throughput drug screens to identify novel therapies. Using the MYC-
driven, Trp53−/− mouse model, Pei and collaborators performed a drug screen which 
identified a cooperative effect between HDAC and PI3K inhibitors (Pei et al., 2016), while 
Morfouace and collaborators demonstrated a new combination approach of pemetrexed and 
gemcitabine (Morfouace et al., 2014). From these preclinical studies have emerged early stage 
clinical trials including SJMB12 (Pemetrexed and Gemcitabine for Newly diagnosed patients 
with Non-WNT, Non-SHH, MB)(NCT0187861). A more recent St. Jude clinical trial (SJDAWN) 
include the use of a CDK4/6 inhibitor (ribociclib) in combination with gemcitabine for 
recurrent MBGroup3 (NCT03434262). Survival of mice harbouring the MYC-amplified MBGroup3 
patient-derived Med-311FH orthotopic xenograft, was significantly extended by the inhibition 
of CDK4/6 with Palbociclib (Cook Sangar et al., 2017). These studies stimulated a phase 1 study 
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with Palbociclib in children with recurrent, progressive or refractory CNS tumours including 
medulloblastoma (PBTC-042). Recently, inhibitors of CHK1 and CHK2 were found to efficiently 
suppress the proliferation of mouse and human MBGroup3, with or without TP53 mutation, in 
combination with gemcitabine or cyclophosphamide (Roussel and Stripay, 2020). The clinical 
trial SJELiOT, designed based on this work, was recently approved by the FDA and began 
enrolling in July 2019 (NCT04023669). 
Most of the preclinical work in MB has focused on SHH and Group 3, due in part to the need 
for improved therapies for the high-risk subsets of these groups (Roussel and Stripay, 2020).. 
Major challenges are the blood-brain and blood-tumour barriers (Fortin, 2012). These have 
limited the number of drugs that can be used to treat MB patients. While several drugs and 
small molecules have been tested in mouse models and found to be efficacious in suppressing 
medulloblastoma proliferation, most used established cell lines. Thus, ideally preclinical trials 
should be performed in multiple mouse models in vitro and in vivo and should require that all 
drugs be investigated for their brain and tumour penetration (Picha et al., 2012, Lee, 2014). 
Based on previous work performed on in vivo models of Group 3 MB and considering the data 
presented in this thesis, there is a strong argument to further explore the role of CDK9, BRD4, 
PLK1, AURKA, and CHK1 inhibition in GEMM and PDX models of MBGroup3. Drug combinational 
and synergy studies would enable the prioritisation of those inhibitors with a synergistic effect 
with MYC expression for testing in relevant MBGroup3 in vivo models. Experimentation in vivo 
is the key next step in the clinical development of the findings presented in this thesis, to 
support their use in the clinic.  
Assessment of pharmacodynamic markers, dosing schedules, with special consideration to the 
ability of the inhibitor to penetrate the blood-brain barrier (BBB) in different GEMM and PDXs 
of MBGroup3, will provide the essential pre-clinical evidence to support the development of 








7.5.4 Alternative MYC-targeting strategies 
For decades, MYC-mediated tumourigenesis was thought to occur mainly through tumour 
cell-intrinsic mechanisms, but several lines of investigation have demonstrated that 
manipulation of the MYC-signalling pathway does not only have a direct impact on tumour 
cells through proliferative and apoptotic mechanisms, but also through an influence on the 
host immune response(Casey et al., 2014b, Casey et al., 2014a, Bachireddy et al., 2012, Tran 
et al., 2011). 
The MYC oncogene regulates the transcription of multiple components of the immune 
response, like CD47 and the programmed death-ligand 1 (PD-L1) (Majeti et al., 2009) (Atsaves 
et al., 2017, Casey et al., 2016). CD47 and PD-L1 are required to remodel the tumour 
microenvironment to recruit CD4+ T cells and macrophages, associated with reduction of 
angiogenesis and induction of cellular senescence (Mina et al., 2015, Rakhra et al., 2010). MYC 
overexpression has been linked to upregulation of the expression of such immune 
checkpoints, which supresses the immune system and allow cancer cells to bypass the 
surveillance of the immune system (McCracken et al., 2015, Casey et al., 2016, Soucek et al., 
2007, Sodir et al., 2011). 
Recently, some studies have identified the requirement of a properly functioning host immune 
system for the effective elimination of tumour cells following inactivation of MYC activity 
(Gabay et al., 2014, Rakhra et al., 2010, Helm et al., 2013). Downregulation of MYC expression 
has been found to result in reduced expression of CD47 and PD-L1 both in vitro and in vivo 
studies, resulting in the recruitment of the necessary immune effectors for the complete 
elimination of tumours cells (Casey et al., 2016, Spranger et al., 2016). 
It will be of interest to interrogate changes in expression of components of the immune 
response following MYC modulation with shRNA using the MYC-regulable cell models, to shed 
light on the mechanism by which MYC oncogene specifically regulates the immune response 
in Group 3 medulloblastoma and identify MYC-dependent neo-antigens which could be 





So far, BRD4 inhibition by JQ1 inhibitor has been reported to downregulate PD-L1 and CD47 
in certain MYC-driven tumours, which was associated with recruitment of T cells (Zhu et al., 
2016, Melaiu et al., 2017, Hogg et al., 2017). Therefore, identification of the MYC-dependent 
regulatory mechanisms of the immune signalling response in MYC-driven MB could help direct 
combinational therapeutic strategies to downregulate the oncogenic activity of MYC and also 
activate the immune system MYC-driven MBGroup3 tumours for most efficacious tumour 






















In conclusion, this study was undertaken to investigate the role and involvement of MYC in 
MBGroup3 pathogenesis, to identify biological signalling pathways associated with MYC-
expression and essential for the maintenance of the malignant phenotype and viability of the 
tumour, to aid in the development of clinically relevant therapeutic strategies for patients 
with this highly-lethal MB subgroup. 
The MYC-dependency of MBGroup3 was exploited using the new MYC-regulable isogenic cell 
lines, identifying several specific Group 3 druggable dependencies (e.g. cell cycle regulators, 
DNA-damage response controllers, mitotic control machinery, epigenetic modifiers) with 
direct clinical implications for the development of personalised treatment against MBGroup3.  
Our findings provide evidence that supports in vivo preclinical studies using PLK1, CHK1, 
AURKA and CDK2 inhibitors for treating patients with MYC-driven MB, paving the way for 
improving MB treatment, through the development of targeted therapies to implement in 
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